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A. INTRODUCTION 
 
3 
1. OVERVIEW 
“In the 21st century, the field of chemistry will face more than just academic 
challenges. Indeed, our ability to devise straightforward and practical chemical 
syntheses is indispensable to the survival of our species.”1  
With this statement, Ryoji Noyori precisely summarizes the rising challenges chemical 
and pharmaceutical industry has to face nowadays. Increasing concerns about climate 
change, resource depletion, and environmental degradation has created new targets for 
the scientific community.2 Advanced chemical processes must be economical, safe, 
environmentally benign, and resource- and energy-saving.3 Thus, production of the 
myriad of substances that are required to serve the needs of society, stretching from the 
world of material science to health care, must address synthetic efficiency not only in 
terms of selectivity (chemo-, regio-, diastereo- and enantioselectivity) but increasingly in 
terms of atom economy, that is, in terms of maximizing the number of atoms of all raw 
materials that end up in the product.4 Organometallic chemistry has already proven its 
potential to play an important role in the development of green chemistry.2 A plethora of 
very versatile reagents and synthetic transformations are provided and synthetic organic 
chemists can choose from an ever growing toolbox of organometallic derivatives, each 
possessing a unique reactivity and selectivity depending on the nature of the metal used.5 
The reactivity of organometallic reagents is strongly determined by the polarity of the 
incorporated carbon-metal bond. An appropriate selection of the metal atom and the 
organic moiety creates versatile tools for specific synthetic applications.5 Due to their 
strongly polarized carbon-metal bond, organolithium reagents represent a highly reactive 
class of organometallics but are incompatible with sensitive functional groups.6 In 
contrast, organoboron reagents have been established as air- and moisture-stable building 
blocks with a high functional group tolerance. However, their almost covalent carbon-
boron bond enforces harsh conditions and highly developed catalytic systems for the 
reaction with electrophiles.7 Organomagnesium, -copper and -zinc reagents can be 
considered as a compromise between these two extremes. Although Grignard reagents 
                                                 
1
 R. Noyori, Chem. Commun. 2005, 1807. 
2
 R. H. Crabtree, Organometallics 2011, 30, 17. 
3
 R. Noyori, Green Chem. 2003, 5, G37. 
4
 a) B. M. Trost, Angew. Chem. Int. Ed. 1995, 34, 259. b) B. M. Trost, Science 1991, 254, 1471. 
5
 a) Handbook of Functionalized Oganometallics (Ed.: P. Knochel), Wiley-VCH, Weinheim, 2005.  
b) Metal-Catalyzed Cross-Coupling Reactions, 2nd Ed. (Eds.: A. de Meijere, F. Diederich), Wiley-VCH, 
Weinheim, 2004. c) A. Boudier, L. O. Bromm, M. Lotz, P. Knochel, Angew. Chem. Int. Ed. 2000, 39, 
4414.   
6
 G. Wu, M. Huang, Chem. Rev. 2006, 106, 2596. 
7
 N. Miyaura, A. Suzuki, Chem. Rev. 1995, 95, 2457.  
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are highly reactive towards electrophiles, they show an excellent functional group 
tolerance at appropriate low temperatures.8 Also organocopper reagents possess a well-
balanced reactivity. They undergo smoothly reactions with various electrophilic 
substrates but still tolerate various versatile functional groups.9 A main drawback is the 
thermal instability as well as the need of the preparation from other organometallic 
species such as organolithium or organomagnesium reagents.10 The big advantages of 
organozinc reagents are their stability at elevated temperatures8 and the outstanding 
functional group tolerance.11 The slightly lower reactivity compared to other 
organometallic reagents can readily be overcome by suitable transition metal catalysts 
readily facilitating reactions with electrophiles.12 The availability of empty low-energy p-
orbitals in organozinc reagents enables readily the interaction with d-orbitals of transition 
metals and thus leads to smooth transmetalation reactions.5a,11a For this reason, Pd-
catalyzed Negishi coupling reactions usually proceed much faster and under milder 
conditions than the corresponding Stille or Suzuki cross-coupling reactions.5b,13 
An elegant example for the utility of the Negishi cross-coupling is demonstrated with 
the stereoselective synthesis of β-carotene (Scheme 1). The key feature of this approach 
is the regio- and stereoselective zirconium-catalyzed methylalumination of terminal 
alkyne precursors, followed by transmetalation with ZnCl2 and subsequent Negishi cross-
coupling of the resulting vinylzinc intermediates with the appropriate vinyl halide 
electrophiles furnishing β-carotene in >99% stereoisomeric purity.14 
                                                 
8
 P. Knochel, W. Dohle, N. Gommermann, F. F. Kneisel, F. Kopp, T. Korn, I. Sapountzis, V. A. Vu, 
Angew. Chem. Int. Ed. 2003, 42, 4302. 
9
 a) P. Knochel, M. J. Rozema, C. E. Tucker, Preparation of Highly Functionalized Copper Reagents in 
Practical Approach Series in Chemistry - Organocopper Reagents, (Ed.: R. J. K. Taylor), Oxford 
University Press, 1993, 348. b) Modern Organocopper Chemistry (Ed.: N. Krause), Wiley-VCH, 
Weinheim, 2002. 
10
 a) Organometallics in Organic Synthesis (Ed.: E.-i. Negishi), Wiley, New York, 1980. b) For halogen-
copper exchange reactions, see: i) X. Yang, T. Rotter, C. Piazza, P. Knochel, Org. Lett. 2003, 8, 1229.  
ii) X. Yang, P. Knochel, Synlett 2004, 1, 81. iii) M. I. Calaza, X. Yang, D. Soorukram, P. Knochel, Org. 
Lett. 2004, 8, 1229. iv) X. Yang, A. Althammer, P. Knochel, Org. Lett. 2004, 6, 1665. c) For direct 
insertion of highly reactive copper, see: i) G. W. Ebert, R. D. Rieke, J. Org. Chem. 1984, 49, 5280.  
ii) R. M. Wehmeyer, R. D. Rieke, J. Org. Chem. 1987, 52, 5056. iii) G. W. Ebert, R. D. Rieke, J. Org. 
Chem. 1988, 53, 4482. 
11
 a) P. Knochel, N. Millot, A. L. Rodriguez, Org. React. 2001, 58, 417. b) Organozinc Reagents 
 (Eds.: P. Knochel, P. Jones), Oxford University Press, New York, 1999. 
12
 a) Metal-Catalyzed Cross-Coupling Reactions 2nd Ed. (Eds.: A. de Meijere, F. Diederich), Wiley-VCH, 
Weinheim, 2004. b) Handbook of Organopalladium Chemistry for Organic Synthesis (Ed.: E.-i. Negishi), 
Wiley-VCH, New York, 2002. c) Transition Metals for Organic Synthesis 2nd Ed. (Eds.: M. Beller,  
C. Bolm), Wiley-VCH, Weinheim, 2002. 
13
 a) E. Negishi, Angew. Chem Int. Ed. 2011, 50, 673. b) C. C. C. Johansson Seechurn, M. O. Kitching,  
T. J. Colacot, V. Snieckus, Angew. Chem Int. Ed. 2012, 51, 5062. c) V. F. Slagt, A. H. M. de Vries,  
J. G. de Vries, R. M. Kellog, Org. Process Res. Dev. 2010, 14, 30.   
14
 F. Xeng, E.-i. Negishi, Org. Lett. 2001, 3, 719. 
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Scheme 1: Total synthesis of β-carotene using Negishi cross-couplings. 
 
An impressive industrial application of a Negishi cross-coupling reaction is the 
synthesis of the HIV-reverse transcriptase inhibitor MIV-150 (Scheme 2) by the Chiron 
Corporation.15 The reaction of the aryl zinc reagent with the enantiopure cyclopropyl 
iodide affords stereoselectively the key intermediate in 85 % yield. 
 
Scheme 2: Negishi cross-coupling in the synthesis of HIV-reverse trancriptase inhibitor  
MIV-150. 
 
 
 
 
 
                                                 
15
 S. Cai, M. Dimitroff, T. McKennon, M. Reider, L. Robarge, D. Ryckman, X. Shang, J. Therrien, Org. 
Process Res. Dev. 2004, 8, 353. 
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2. ORGANOMAGNESIUM REAGENTS 
More than 100 years ago, Victor Grignard prepared organomagnesium compounds for 
the very first time.16 These so called Grignard reagents turned out to be exceptionally 
versatile nucleophiles and are nowadays widely used in chemical laboratories and have 
even found their way into chemical industry.17  
The direct insertion of magnesium metal into carbon-halogen bonds is still the most 
straightforward approach for the preparation of organomagnesium compounds.17 The 
exact mechanism of this reaction is still not entirely elucidated, but radical pathways are 
generally accepted.18 Despite the efficiency of the magnesium insertion in terms of atom 
economy4 the reaction suffers from a limited functional group tolerance since the 
standard protocol for the insertion is highly exothermic and normaly performed at the 
boiling point of the solvent (e.g. Et2O or THF). Therefore the preparation in plant scale is 
accompanied with serious safety risks.19  
These drawbacks have been elegantly bypassed by Rieke and coworkers using highly 
reactive magnesium powder (Mg*) prepared by the reduction of magnesium salts with 
lithium naphthalide. This methodology allowed the preparation of the organomagnesium 
reagents at very low temperatures and thus enabled the tolerance of very sensitive groups 
like nitriles and esters (Scheme 3).20 
 
Scheme 3: Preparation and reactivity of a functionalized Grignard reagent using highly reactive 
Rieke-Mg (Mg*). 
 
In order to avoid the drawback of the prior preparation of the highly active 
magnesium, Knochel and coworkers developed a methodology applying stoichiometric 
amounts of LiCl in the insertion reaction (Scheme 4).21 This gives access to a range of 
                                                 
16
 V. Grignard, Compt. Rend. Acad. Sci. Paris, 1900, 130, 1322.   
17
 a) Handbook of Grignard Reagents (Eds.: G. S. Silverman, P. E. Rakita), Marcel Dekker, New York, 
2000. b) Grignard Reagents, New Developments (Ed.: H. G. Richey Jr.), Wiley-VCH, New York, 2000.  
c) J. Wiss, M. Länzlinger, M. Wermuth, Org. Proc. Res. Dev. 2005, 9, 365. 
18
 a) H. M. Walborksy, Acc. Chem. Res. 1990, 23, 286. b) J. F. Garst, Acc. Chem. Res. 1991, 24, 95.  
c) J. F. Garst, M. P. Soriaga, Coord. Chem. Rev. 2004, 248, 623.   
19
 M. C. Jones, Plant and Operations Progress 1989, 8, 200. 
20
 a) R. D. Rieke, Science 1989, 246, 1260. b) R. D. Rieke, M. V. Hanson, Tetrahedron 1997, 53, 1925.  
b) J. Lee, R. Verlade-Ortiz, A. Guijarro, J. R. Wurst, R. D. Rieke, J. Org. Chem. 2000, 65, 5428.  
d) R. D. Rieke, Aldrichchim. Acta 2000, 33, 52.   
21
 a) F. M. Piller, P. Appukkuttan, A. Gavryushin, M. Helm, P. Knochel, Angew. Chem. Int. Ed. 2008, 47, 
6802. b) F. M. Piller, A. Metzger, M. A. Schade, B. A. Haag, A. Gavryushin, P. Knochel, Chem. Eur. J. 
2009, 15, 7192. 
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new functionalized aryl and heteroaryl magnesium species from the corresponding 
chlorides and bromides under mild reaction conditions.  
Scheme 4: Preparation of functionalized organomagnesium reagents using Mg in the presence of 
LiCl. 
 
A more convenient preparation of organomagnesium compounds with high functional 
group tolerance, avoiding many of the flaws of the direct insertion, is the halogen-
magnesium exchange reaction. The driving force for this reaction class is the formation 
of an organometallic reagent possessing a higher stability than the exchange reagent itself 
(?? > ???????? 	> ???????  > ???????  > ?????? ).22 Based on the preliminary work of Prévost23 
and Villieras,24 Knochel could impressively demonstrate the potential of the iodine-
magnesium exchange with iPrMgBr and PhMgCl on substrates bearing sensitive 
functionalities (Scheme 5).25 
                                                 
22
 D. Hauk, S. Lang, A. Murso, Org. Process Res. Dev. 2006, 10, 733. 
23
 C. Prévost, Bull. Soc. Chim. Fr. 1931, 49, 1372. 
24
 a) J. Villiéras, Bull. Chem. Soc. Fr. 1967, 5, 1520. b) J. Villiéras, B. Kirschleger, R. Tarhouni,  
M. Rambaud, Bull. Chem. Soc. Fr. 1986, 24, 470. 
25
 a) L. Boymond, M. Rottländer, G. Cahiez, P. Knochel, Angew. Chem. Int. Ed. 1998, 37, 1701.  
b) I. Sapountzis, P. Knochel, Angew. Chem. Int. Ed. 2002, 41, 1610. 
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Scheme 5: Preparation and reactivity of functionalized Grignard reagents by iodine-magnesium 
exchange using iPrMgBr or PhMgCl. 
 
This method could further be improved by the addition of stoichiometric amounts of 
LiCl to the exchange reagent iPrMgCl resulting in the formation of an organomagnesium 
species with the formal composition iPrMgCl·LiCl. Noteworthy, this so called Turbo-
Grignard reagent shows a remarkably higher reactivity, broadening the scope of the 
exchange reaction. A huge variety of aromatic and heteroaromatic bromides could now 
be converted into the corresponding magnesium reagents. However, the increased 
reactivity does not limitate the functional group tolerance (Scheme 6).26  
Scheme 6: Preparation and reactivity of functionalized Grignard reagents by bromine-
magnesium exchange using the Turbo-Grignard reagent (iPrMgCl·LiCl). 
 
The formation of a magnesium-lithium ate complex as intermediate of the Turbo-
Grignard reagent leads to deaggregation of the organometal species and is assumed to be 
responsible for the higher solubility and the enhanced reactivity of the Grignard reagent 
(Scheme 7).26  
 
Scheme 7: Effect of LiCl on Grignard reagents. 
                                                 
26
 a) A. Krasovskiy, P. Knochel, Angew. Chem. Int. Ed. 2004, 41, 1610. b) A. Krasovskiy, B. F. Straub,  
P. Knochel, Angew. Chem. Int. Ed. 2006, 45, 159. c) H. Ren, P. Knochel, Chem. Commun. 2006, 726.  
d) C.-Y. Liu, P. Knochel, Org. Lett. 2005, 7, 2543. e) F. Kopp, A. Krasovskiy, P. Knochel, Chem. 
Commun. 2004, 2288. 
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Since electron-rich aromatic compounds resisted to undergo a bromine-magnesium 
exchange, reagents of type RMg2·LiCl had been developed.26b Quantum calculations on 
exchange reactions indicated that the reaction becomes more likely when the exchange 
reagent’s ate character is increased. Thus, bis-magnesium reagents of type RMg2·LiCl 
complete the exchange reaction methodology on substrates where iPrMgCl·LiCl fails.26b 
Besides these two halogen-metal interconversions, a direct metalation using 
magnesium amide bases is the third major pathway to magnesium organometallics.27 The 
recently developed mixed lithium-magnesium amide bases TMPMgCl·LiCl and 
TMP2Mg·2LiCl (Turbo-Hauser bases) give access to a large number of functionalized 
aromatic, heteroaromatic and vinylic organomagnesium reagents (Scheme 8).28,29 
Scheme 8: Direct magnesiation using Turbo-Hauser bases TMPMgCl·LiCl and TMP2Mg·2LiCl. 
                                                 
27
 a) L. Meunier, C. R. Hebd. Seances Acad. Sci. 1903, 136, 758. b) C. R. Hauser, H. G. Walker, J. Am. 
Chem. Soc. 1947, 69, 295. c) C. R. Hauser, F. C. Frostick, J. Am. Chem. Soc. 1949, 71, 1350.  
d) A. Schlecker, A. Huth, E. Ottow, J. Mulzer, J. Org. Chem. 1995, 60, 8414. 
28
 a) A. Krasovskiy, V. Krasovskaya, P. Knochel, Angew. Chem. Int. Ed. 2006, 45, 2958. b) N. Boudet,  
J. R. Lachs, P. Knochel, Org. Lett. 2007, 9, 5525. c) M. Mosrin, P. Knochel, Org. Lett. 2008, 10, 2497.  
d) A. H. Stoll, P. Knochel, Org. Lett. 2008, 10, 113. e) G. C. Clososki, C. J. Rohbogner, P. Knochel, 
Angew. Chem. Int. Ed. 2007, 46, 7681. f) C. J. Rohbogner, A. J. Wagner, G. C. Clososki, P. Knochel,  
Org. Synth. 2009, 86, 374. g) C. J. Rohbogner, G. C. Clososki, P. Knochel, Angew. Chem. Int. Ed. 2009, 
47, 1503. 
29
 For a recent review article about metalation reactions using hindered amide bases, see: B. A. Haag,  
M. Mosrin, H. Ila, V. Malakhov, P Knochel, Angew. Chem. Int. Ed. 2011, 50, 9794.   
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3. ORGANOBORON REAGENTS 
From the first isolation of an organoboron compound by Frankland in 186030 to the 
report of their palladium-catalyzed cross-coupling reactions with organic halides by 
Suzuki and Miyaura in 1979,31 the chemistry of organoboron compounds has experienced 
a tremendous development. Brown and coworkers intensively explored the preparation 
and application of boron-containing compounds in organic synthesis.32 For his pioneering 
work in this field, Brown received the Nobel Prize in 1979. 
One of the most significant reasons for the success and the extensive use of 
organoboron compounds in modern organic synthesis is the highly covalent character of 
the carbon-boron bond and their high compatibility with a broad range of functional 
groups,33 their water stability as well as their relatively low toxicity.32 Hence, these 
reagents have emerged to a versatile class of synthons in organic chemistry.7,32,34  
The most general route for the generation of organoboron reagents is the 
transmetalation reaction of various metalorganic species with trihalogenboranes or 
trialkoxyboranes like BCl3 or B(OMe)3.35,36 Organoboron compounds with all kinds of 
organic groups, whether alkyl, aryl, alkenyl, or alkynyl can be obtained in this way. The 
first preparation of an organoborane by Frankland over a century ago used 
triethoxyborane and diethylzinc,30,32 which was later superseded by the more readily 
prepared Grignard reagents. For metals significantly more electropositive than boron, the 
equilibrium of the transmetalation reactions lies entirely on the side of the organoborane 
                                                 
30
 a) E. Frankland, B. Duppa, Proc. Royal Soc. 1860, 10, 568. b) E. Frankland, J. Chem. Soc. 1862, 15, 
363. 
31
 N. Miyaura, A. Suzuki, J. Chem. Soc., Chem. Commun. 1979, 866. b) N. Miyaura, K. Yamada,  
A. Suzuki, Tetrahedron Lett. 1979, 20, 3437. 
32
 a) H. C. Brown, in Boranes in Organic Chemistry, Cornell University Press, New York, 1972.  
b) A. Pelter, K. Smith, H. C. Brown, in Borane Reagents, Academic Press, New York, 1988.  
c) D. S. Matteson, in Stereodirected Synthesis with Organoboranes, Springer, New York, 1995.  
d) V. Snieckus, Chem. Rev. 1990, 90, 879. e) T. Ishiyama, N. Miyaura, J. Organomet. Chem. 2000, 611, 
392. f) E. Tyrell, P. Brookes, Synthesis 2003, 469. g) T. Ishiyama, N. Miyaura, J. Organomet. Chem. 2003, 
680, 3. 
33
 a) S. Darses, T. Jeffery, J.-P. Gênet, J.-L. Brayer, J.-P. Demoute, Tetrahedron Lett. 1996, 37, 3857.  
b) D. Willis, R. M. Strongin, Tetrahedron Lett. 2000, 41, 6271. c) G. Manickam, A. D. Schluter, Synthesis 
2000, 442. d) J. W. Goodby, M. Hird, R. A. Lewis, K. J. Toyne, Chem. Commun. 1996, 2719.  
e) B. U. Maes, R. Lemiere, R. Dommisse, K. Augustyns, A. Haemers, Tetrahedron 2000, 56, 1777.  
f) D. Ren, R. A. McClelland, Can. J. Chem. 1998, 76, 78. 
34
 a) A. Suzuki, in Metal-Catalyzed Cross-Coupling Reactions (Eds.: F. Diederich, P. J. Stang), Wiley-
VCH, Weinheim, 1998, 49. b) S. P. Stanforth, Tetrahedron 1998, 54, 263. c) A. Suzuki, J. Organomet. 
Chem. 1999, 576, 147. d) S. R. Chemler, D. Trauner, S. J. Danishefsky, Angew. Chem. Int. Ed. 2001, 40, 
4544. e) A. F. Littke, G. C. Fu, Angew. Chem. Int. Ed. 2002, 41, 4176. f) S. Kotha, K. Lahiri, D. Kashinath, 
Tetrahedron 2002, 58, 9633. g) A. Suzuki, J. Organomet. Chem. 2002, 653, 83. h) S. V. Ley,  
A. W. Thomas, Angew. Chem. Int. Ed. 2003, 42, 5400. 
35
 J. Kristensen, M. Lysén, P. Vedsø, M. Begtrup, Org. Lett. 2001, 3, 1435. 
36
 a) A. Michaelis, P. Becker, Chem. Ber. 1880, 13, 59. b) E. Krause, R. Nitsche, Chem. Ber. 1921, 54, 
2784. 
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and the metal halide (order of reactivity: K, Na > Li > Mg > Al > Zn, Cd > Pb, Hg, Sn).37 
The ease of displacement of various groups X of BX3 follows the order Hal > OR > 
NR2.38 Recently, Vedsø and Begtrup reported an efficient method for the synthesis of 
ortho-substituted arylboronic esters via ortho-lithiation and in situ trapping of the 
corresponding lithium species with triisopropyl borate (Scheme 9).35 
 
Scheme 9: Preparation of organoboron reagents via transmetalation. 
 
A very efficient method for the preparation of organoboron reagents is the 
hydroboration of unsaturated compounds.39 The first hydroboration was reported by 
Brown et al. using diborane (B2H6) generated from BF3 and NaBH4.40 With the years the 
hydroboration proved to be one of the most important transformations for the synthesis of 
complex molecules due to its high regioselectivity and the excellent functional group 
tolerance. The syn-addition of hydroboranes to unsaturated compounds occurs with 
predictable selectivity, wherein the boron adds preferentially to the least hindered carbon. 
This selectivity is enhanced if sterically demanding boranes like pinacolborane or  
9-borabicyclo[3.3.1]nonane (9-BBN) are used. Combining the hydroboration with a 
subsequent oxidation of the newly formed borane gives readily access to anti-
Markovnikov alcohols. The hydroboration/oxidation sequence constitutes a powerful 
method for the regio- and stereoselective synthesis of alcohols (Scheme 10).41  
 
Scheme 10: Hydroboration and subsequent oxidation for the regio- and stereoselective synthesis 
of alcohols. 
 
                                                 
37
 G. E. Coates, M. L. H. Green, P. Powell, K. Wade, in Principles of Organometallic Chemistry, Methuen, 
London, 1968. 
38
 M. F. Lappert, M. K. Majumdar, J. Organometallic Chem., 1966, 6, 316. 
39
 H. C. Brown, Organoboran Compounds in Organic Synthesis, in Comprehensive Organometallic 
Chemistry (Ed.: G. Wilkinson), Pergamon Press, Oxford, 1982, 111. 
40
 a) H. C. Brown, B. C. Subba Rao, J. Am. Chem. Soc. 1956, 78, 5694. b) H. C. Brown, B. C. Subba Rao, 
J. Org. Chem. 1957, 22, 1136. 
41
 G. W. Kabalka, T. M. Shoup, N. M. Goudgaon, J. Org. Chem. 1989, 5930. 
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For the synthesis of chiral, enantiomerically enriched stereocenters in organoboron 
species, hydroboration is by far the most general method.42 In the early days of 
organoboron chemistry, chirality was introduced via chiral auxiliaries obtained from the 
chiral pool.43 Isopinene for instance can be converted into a chiral hydroborating reagent 
IpcBH2 by addition of BH3. A drawback of this methodology is the attachment of the 
chiral auxiliary via a boron-carbon bond, complicating its recycling. The chiral auxiliary 
needs to be removed prior subsequent carbon-carbon bond forming chemistry limitating 
this otherwise elegant chemistry (Scheme 11).  
 
Scheme 11: Preparation and application of IpcBH2. 
 
Soderquist and coworkers developed an improved stoichiometric chiral auxiliary 
derived from 9-BBN-related derivatives for the hydroboration of a broad variety of 
olefins proceeding with extremely high selectivity.44 Most importantly, transformation of 
the resulting boron-carbon bond can be accomplished without removal of the chiral 
auxiliary (Scheme 12).  
 
Scheme 12: Stereoselective hydroboration with Soderquist’s chiral borane and subsequent 
oxidation. 
 
In terms of a catalytic enantioselective process, Hayashi et al. described the use of 
catechol borane (1,3,2-benzodioxaborole, HBCat) as achiral hydroborating reagent in 
combination with a rhodium catalyst and the chiral ligand BINAP.45 
Another convenient approach for the preparation of organoboron reagents is the 
transition metal-catalyzed borylation of aryl halides and triflates. The cross-coupling 
                                                 
42
 a) I. Beletskaya, A. Pelter, Tetrahedron 1997, 53, 4957. b) K. Burgess, M. J. Ohlmeyer, Chem. Rev. 
1991, 91, 1179. c) A. M. Carroll, T. P. O’Sullivan, P. J. Guiry, Adv. Synth. Catal. 2005, 347, 609.  
d) H. C. Brown, in Organic Syntheses via Boranes, Wiley-VCH, London, 1975. 
43
 H. C. Brown, P. V. Ramachandran, J. Organomet. Chem. 1995, 500, 1. 
44
 A. Z. Gonzalez, J. G. Roman, E. Gonzalez, J. Martinez, J. R. Medina, K. Matos, J. A. Soderquist, J. Am. 
Chem. Soc. 2008, 130, 9218. 
45
 a) T. Hayashi, Y. Matsumoto, Y. Ito, J. Am. Chem. Soc. 1989, 111, 3426. b) T. Hayashi, Y. Matsumoto, 
Y. Ito, Tetrahedron: Asymmetry 1991, 2, 601. 
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reaction of these aryl derivatives with pinacolborane46 or bis(pinacolato)diboron47 in the 
presence of a palladium catalyst and a base enables readily the synthesis of highly 
functionalized arylboron compounds containing sensitive groups such as carbonyl, cyano 
or nitro (Scheme 13). By using more active catalytic systems Miyaura and Fürstner 
could also employ aryl chlorides as precursors.48 
 
Scheme 13: Preparation of organoboron reagents via Pd-catalysed borylation of aryl halides and 
triflates. 
 
Since Suzuki and Miyaura introduced in 1979 organoboron reagents into the realm of 
cross-coupling chemistry by demonstrating a palladium-catalysed reaction of 1-alkenyl-
boranes with aryl and alkynyl halides in presence of a base,31 this reaction has seen 
significant advancement and has become one of the most powerful carbon-carbon bond 
forming methods in organic synthesis (Scheme 14).7,34,49 The availability of the reagents 
and the mild reaction conditions all contribute to the versatility of this reaction. The 
coupling reaction offers several additional advantages, such as being largely unaffected 
by the presence of water, tolerating a broad range of functional groups and proceeding 
generally regio- and stereoselective. Moreover, the inorganic by-product of the reaction 
is non-toxic and easily removed from the reaction mixture thereby making this reaction 
suitable not only for laboratories but also for industrial processes.50 For instance, the 
                                                 
46
 a) M. Murata, S. Watanabe, Y. Masuda, J. Org. Chem. 1997, 62, 6458. b) M. Murata, T. Oyama,  
S. Watanabe, Y. Masuda, J. Org. Chem. 2000, 65, 164. 
47
 a) T. Ishiyama, M. Murata, N. Miyaura, J. Org. Chem. 1995, 60, 7508. b) T. Ishiyama, Y. Itoh,  
T. Kitano, N. Miyaura, Tetrahedron Lett. 1997, 38, 3447. 
48
 a) T. Ishiyama, K. Ishida, N. Miyaura, Tetrahedron 2001, 57, 9813. b) A. Fürstner, G. Seidel, Org. Lett. 
2002, 4, 541. 
49
 a) N. Miyaura, Top. Curr. Chem. 2002, 219, 11. b) F.-X. Felpin, T. Ayad, S. Mitra, Eur. J. Org. Chem. 
2006, 2679. c) A. Suzuki, Heterocycles 2010, 80, 15. d) Cross-Coupling Reactions – A Practical Guide 
(Ed.: N. Miyaura), Springer, New York, 2002. e) C. Torborg, M. Beller, Adv. Synth.Catal. 2009, 351, 
3027. f) L. Ackermann, R. Born, Angew. Chem. Int. Ed. 2005, 44, 2444. g) L. Ackermann, Synlett 2007, 4, 
507.  
50
 A. Suzuki, J. Organomet. Chem. 1999, 576, 147. 
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Suzuki-Miyaura coupling has been used in the total synthesis of Caparratriene, a natural 
product that is highly active against leukemia (Scheme 14).51 
 
Scheme 14: Standard Suzuki-Miyaura cross-coupling and its application in the total synthesis of 
Capparatriene. 
 
Until now, organoboronic acids52 are the most frequently used reagents in the Suzuki-
Miyaura cross-coupling reaction although they are far from ideal. For example, though 
there are currently over 450 boronic acids commercially available, many of these 
reagents are difficult to purify due to their waxy constitution. Moreover, boronic acids 
tend to form trimeric cyclic anhydrides (boroxines) which can influence the reaction 
stoichiometry. Thus, it is difficult to determine the concentration of boronic acid versus 
boroxine in a mixture. Consequently, many literature protocols for Suzuki-Miyaura cross-
couplings employ excess of the boronic acid to ensure a complete conversion of the 
electrophilic component in the reaction.53 Therefore, various boronic derivatives, such as 
trifluoroborates,53,54 MIDA boronates55 or DAN reagents56 have been developed to 
overcome these drawbacks. The reagents exist as monomeric complexes with defined 
structures aiding for precise adjustment of stoichiometry.  
                                                 
51
 J. R. Vyvyan, E. A. Peterson, M. L. Stephan, Tetrahedron Lett. 1999, 40, 4947. 
52
 a) N. Miyaura, A. Suzuki, Synth. Commun. 1981, 11, 513. b) T. Ohe, N. Miyaura, A. Suzuki, J. Org. 
Chem. 1993, 58, 2201. c) D. Badone, M. Baroni, R. Cardamone, A. Ielmini, U. Guzzi, J. Org. Chem. 
1997, 62, 7170. d) A. Zapf, M. Beller, Chem. Eur. J. 2000, 6, 1830. 
53
 G. A. Molander, N. Ellis, Acc. Chem. Res. 2007, 40, 275. 
54
 a) G. A. Molander, B. Canturk, Angew. Chem. Int. Ed. 2009, 48, 9240. b) A. Darses, J.-P. Genet, Chem. 
Rev. 2008, 108, 288. 
55
 a) D. M. Knapp, E. P. Gillis, M. D. Burke, J. Am. Chem. Soc. 2009, 131, 6961. b) E. P. Gillis,  
M. D. Burke. Aldrichimica Acta, 2009, 42, 17. c) E. P. Gillis, M. D. Burke, J. Am. Chem. Soc. 2007, 129, 
6716. 
56
 a) H. Noguchi, K. Hojo, M. Suginome, J. Am. Chem. Soc. 2007, 129, 758. b) H. Noguchi, T. Shioda,  
C.-M. Chou, M. Suginome, Org. Lett. 2008, 10, 377. c) N. Iwadate, M. Suginome, Org. Lett. 2009, 11, 
1899. 
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An impressive demonstration of biaryl synthesis employing trifluoroborates was 
disclosed with the preparation of Trityrosine.57 The analogous boronic acid gave none of 
the double coupling product while the aryltrifluoroborate afforded the desired product in 
74% overall yield (Scheme 15). 
 
Scheme 15: Synthesis of Trityrosine employing trifluoroborates as nucleophile. 
 
 
4. ORGANOZINC REAGENTS 
In the first years after the discovery of the carbon-zinc bond by Frankland,58 
organozinc reagents found only little attention due to the excellent accessibility of 
organolithium compounds and the well-established procedures for the preparation of 
organomagnesium reagents described by Grignard.16,59 Since organozinc compounds 
possess an intrinsically lower reactivity compared to the aforementioned analogs, they 
found only few applications in organic synthesis, such as the Simmons-Smith 
cyclopropanation reaction60 or the Reformatsky reaction of zinc enolates.61 However, one 
of the main advantages of organozinc reagents is the significantly higher tolerance of 
functional groups present in both the organometallic substrate and the electrophile. This 
can be explained by the higher covalent character of the carbon-zinc bond in comparison 
to the carbon-magnesium or carbon-lithium bond. For this reason, organozinc reagents 
can be handled at elevated temperatures not tolerated by the corresponding Grignard or 
organolithium reagents.5a,11,62  
                                                 
57
 O. Skaff, K. A. Jollioffe, C. A. Hutton, J. Org. Chem. 2005, 70, 7353. 
58
 a) E. Frankland, Liebigs Ann. Chem. 1848, 71, 171. b) E. Frankland, J. Chem. Soc. 1848, 2, 263. 
59
 V. Grignard, Ann. Chim. 1901, 24, 433. 
60
 a) H. E. Simmons, T. L. Cairns, A. Vladiuchick, C. M. Hoiness, Org. React. 1972, 20, 1.  
b) H. E. Simmons, R. D. Smith, J. Am. Chem. Soc. 1958, 80, 5323. c) H. E. Simmons, R. D. Smith, J. Am. 
Chem. Soc. 1959, 81, 5323. d) H. Lebel, J.-F. Marcoux, C. Molinaro, A. B. Charette, Chem. Rev. 2003, 
103, 977. 
61
 a) S. Reformatsky, Chem. Ber. 1887, 20, 1210, b) S. Reformatsky, Chem. Ber. 1895, 28, 2842.  
c) R. Ocampo, Tetrahedron 2004, 60, 9325. d) A, Fürstner, Angew. Chem. Int. Ed. 1993, 32, 164. 
62
 a) P. Knochel, F. Langer, M. Rottländer, T. Stüdemann, Chem. Ber. 1997, 130, 387. b) P. Knochel,  
J. J. Almena Perea, P. Jones, P. Tetrahedron 1998, 54, 8275.  
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Similarly to organomagnesium compounds, the most common method for the direct 
synthesis of organozinc reagents is the insertion of zinc powder into organic halides.11,62c 
However, the reaction suffers from the use of expensive organic iodides and elevated 
reaction temperatures. To avoid these drawbacks, Rieke et al. used highly active zinc 
(Zn*), prepared by reduction of ZnCl2 with lithium naphthalide to obtain functionalized 
organozinc reagents from less reactive arylbromides (Scheme 16).20b-d,63 
  
Scheme 16: Preparation and reactivity of a functionalized organozinc reagent using highly 
reactive Rieke-Zn (Zn*). 
 
In 2006, Knochel and coworkers reported a LiCl-facilitated insertion of zinc metal 
into organic halides.64 Besides aromatic and heteroaromatic bromides and iodides, the 
presence of stoichiometric amounts of LiCl enabled also the use of alkyl bromides and 
benzyl chlorides in insertion reactions (Scheme 17).  
Scheme 17: Preparation of functionalized organozinc reagents using Zn in the presence of LiCl. 
                                                 
63
 a) R. D. Rieke, P. T.-J. Li, T. P. Burns, S. T. Uhm, J. Org. Chem. 1981, 46, 4324. b) L. Zhu,  
R. M. Wehmeyer, R. D. Rieke, J. Org. Chem. 1991, 56, 1445.   
64
 a) A. Krasovskiy, V. Malakhov, A. Gavryushin, P. Knochel, Angew. Chem. Int. Ed. 2006, 45, 6040.  
b) A. Metzger, M. A. Schade, P. Knochel, Org. Lett. 2008, 10, 1107. c) N. Boudet, S. Sase, P. Sinha,  
C.-Y. Liu, A. Krasovskiy, P. Knochel, J. Am. Chem. Soc. 2007, 129, 12358.   
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By using a LiCl-mediated magnesium insertion in the presence of ZnCl2  
Knochel et al. were able to further improve the aforementioned insertion reaction.21,65 
Due to the higher reduction potential of magnesium, the insertion times could be 
shortened and aryl bromides as well as heteroaryl bromides and chlorides replaced  
the corresponding iodides as cheaper starting materials. Furthermore, by using  
only 0.5 equivalents of ZnCl2 more reactive diorganozinc reagents could be obtained  
(Scheme 18). 
Mg, LiCl
THF
RFG X RFG MgX LiCl
R = alkyl, aryl, heteroaryl, benzyl
X = Cl, Br
FG = CO2R, COR, CHO, CN, Hal, CF3, OR
91% 90% 91% 83% 69%
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Scheme 18: Preparation and reactivity of functionalized organozinc reagents using LiCl-
mediated Mg-insertion in the presence of ZnCl2. 
 
Another convenient approach for the preparation of diorganozinc reagents is the 
iodine-zinc exchange reaction using dialkylzinc species such as diethylzinc or 
diisopropylzinc. A range of alkyl iodides reacted with diethylzinc in the presence of 
Cu(I) salts to the corresponding dialkylzinc reagents.66 Moreover, this methodology 
could be improved by using Li(acac) as catalytic additive. Thus, highly functionalized 
aryl and heteroaryl iodides could be converted into the corresponding diorgano zinc 
species and trapped with a broad range of electrophiles (Scheme 19).67 
                                                 
65
 a) A. Metzger, F. M. Piller, P. Knochel, Chem. Commun. 2008, 5824. b) T. D. Blümke, F. M. Piller,  
P. Knochel, Chem. Commun. 2010, 46, 4082.   
66
 a) M. J. Rozema, A. Sidduri, P. Knochel, J. Org. Chem. 1992, 57, 1956. b) M. J. Rozema, C. Eisenberg, 
H. Lütjens, R. Ostwald, K. Belyk, P. Knochel, Tetrahedron Lett. 1993, 34, 3115.   
67
 F. F. Kneisel, M. Dochnahl, P. Knochel, Angew. Chem. Int. Ed. 2004, 43, 1017. 
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Scheme 19: Preparation and reactivity of functionalized zinc reagents by iodine-zinc exchange 
using iPr2Zn. 
 
Inspired by the work on the Turbo-Hauser bases, Knochel et al. developed the mild 
and chemoselective bases TMP2Zn·2MgCl2·2LiCl and TMPZnCl·LiCl for hydrogen-
metal interconversion on sensitive substrates. A variety of sensitive aromatic and 
heteroaromatic compounds could be smoothly zincated and subsequently functionalized.  
(Scheme 20).29,68 
 
Scheme 20: Direct zincation using TMPZnCl·LiCl and TMP2Zn·2MgCl2·2LiCl. 
                                                 
68
 a) S. H. Wunderlich, P. Knochel, Angew. Chem. Int. Ed. 2007, 46, 7685. b) M. Mosrin, P. Knochel, Org. 
Lett. 2009, 11, 1837. c) M. Mosrin, T. Bresser, P. Knochel, Org. Lett. 2009, 11, 3406. d) A. Unsinn,  
P. Knochel, Chem. Commun. 2012, 48, 2680.   
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5. ADAMANTANE AND ITS CHEMISTRY 
The originality of adamantane structure showing also in the properties of its 
derivatives is the main factor governing the constant interest to the chemistry of this 
compound.69 The development of the adamantane chemistry makes it possible both to 
solve a series of theoretical problems and to design molecules of substances promising 
for the practical application in the fields of medicine, supramolecular chemistry, 
nanotechnologies, etc.70 Thus, adamantane derivatives found numerous applications in 
medicinal chemistry and drug development. No other singular hydrocarbon moiety (apart 
from the methyl group) is as successful as adamantane in improving or providing 
pharmacological activity for pharmaceuticals. Having the “lipophilic bullet” (adamantane 
is assumed to provide the critical lipophilicity) readily available as an “add-on” for 
known pharmacophors, it was used for example in the modification of hypoglycemic 
sulfonylureas,71 anabolic steroids,72 and nucleosides.73 The adamantane modifications 
were chosen to enhance lipophilicity and stability of the drugs, thereby improving their 
pharmacokinetics. Aminoadamantanes, such as Amantadine,74 Rimantadine,75 or 
Tromantadine,76 are anti-Influenza A agents and were among the first compounds on the 
pharmaceutical market containing an adamantyl moiety (Figure 1).77  
 
Figure 1: Pharmaceutical active substances containing an adamantyl moiety. 
 
The aminoadamantanes are synthetic drugs that have not been inspired by natural 
products like numerous other drugs. There are, however, also natural products that 
incorporate the adamantane skeleton, showing interesting biological properties  
(Figure 2).  
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Figure 2: Naturally occurring substrates bearing an adamantyl moiety. 
 
Plukenetione A for example was first isolated from Clusia plukenetii in 199678 and 
displayed cytotoxicity in a panel of cell lines for different cancer entities.79 Also 
Sampsonione I, isolated from Hypericum sampsonii, showed cytotoxicity toward a P388 
cell line.80 However, Hyperibone K, isolated from the Uzbek medicinal plant Hypericum 
scrabum, provided only moderate cytotoxicity in two human cancer cell lines,81 and no 
anti-HIV activity. 
Noteworthy, the addition of adamantane moieties increases the permeability of the 
modified compounds through the blood-brain barrier.82 Therefore, targets of the central 
nervous system are today most promising both academically and commercially. With the 
discovery that Amantadine gives symptomatic benefits in Parkinson disease83 and the 
application of Memantine for the treatment of Alzheimer disease,84 two 
neurodegenerative diseases of increasing importance in the aging society are being 
addressed with structurally remarkably simple adamantane derivatives (Figure 3).  
 
Figure 3: Simple adamantane derivatives as pharmaceuticals against Parkinson and Alzheimer 
disease. 
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An emerging field with respect to the application of adamantane derivatives is the 
inhibition of enzymes using adamantane based scaffolds. Most important are the DPP-IV 
inhibitors Vildagliptin and Saxagliptin,85 that currently enter the multibillion dollar 
market of diabetes management (Figure 4).  
 
Figure 4: Adamantane derivatives as pharmaceuticals against diabetes. 
 
Moreover, there are three classes of adamantane derivatives of relevance in cancer 
research. The add-on strategy is followed by adamantane derivatives of cisplatin (e.g. 
LA-12) and Adaphostin. Adamantyl retinoids (e.g. CD437) however represent an 
alternative strategy to fight cancer cell proliferation (Figure 5).  
 
Figure 5: Adamantane derivatives as pharmaceutically active substrates against cancer. 
 
LA-12 was found to provide a higher degree of cytotoxicity against both cisplatin-
sensitive and cisplatin-resistant ovarian cancer cells compared to other cisplatin-
analogous substrates.86 Furthermore, Adaphostin is the adamantyl ester of the protein 
tyrosine kinase inhibitor AG957.87 Both AG957 and Adaphostin are classified as 
tyrphostins (tyrosine phosphorylation inhibitors) and were shown to induce chronic 
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myelogenous leukemia cell death.88 The adamantyl-based retinoid CD437 shows high 
activity against a broad spectrum of cancers, including lung, prostate, ovarian, breast, 
melanoma and leukemia.89  
The synthesis of adamantane derivatives is commonly based on the application of well 
known efficient procedures of selective monofunctionalization of adamantane and on the 
availability of its polyfunctional derivatives with the same substituents at the bridgehead 
positions.90 The synhesis of adamantyl derivatives includes mainly two approaches: 
selective functionalization of tertiary C–H bonds in mono- and polysubstituted 
adamantanes and the selective modification of functional groups on adamantane 
derivatives.  
Among the methods of activation of the tertiary C–H bond in substituted adamantane 
derivatives with the use of nitric acid, the application of the nitrating mixture 
HNO3/H2SO4 found the widest spread. In this mixture an efficient single-electron oxidant 
NO2+ is generated in situ. The reaction most probably proceeds via a single-electron 
transfer mechanism (SET mechanism) with the formation of adamantyl cation-radicals 
that can be trapped by various nucleophiles. Thus, the use of 1,1-dichloroethene as a 
nucleophile introduces a fragment of the acetic acid onto the bridgehead position of the 
adamantane frame in almost quantitative yield (Scheme 21).91 
 
Scheme 21: Functionalization of 1-adamantlyacetic acid via SET and subsequent trapping with 
1,1-dichloroethene as electrophile. 
 
Under similar conditions, 1-adamantanecarboxylic acid can be converted to the 
corresponding acetylamino derivative by using acetonitrile as nucleophile in the HNO3–
H2SO4 medium. The bifunctional derivative has been obtained in 77% yield  
(Scheme 22).92 
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Scheme 22: Functionalization of 1-adamantanecarboxylic acid via SET and subsequent trapping 
with acetonitrile as electrophile. 
 
Moreover, the treatment of 1-bromoadamantane with 1,2-diethoxy-1,2-bis(trimethyl-
siloxy)ethene in dry CH2Cl2 in the presence of catalytic amounts of ZnCl2 gives the 
desired α,α-dichloroester in excellent yield (Scheme 23). 
 
Scheme 23: ZnCl2-promoted addition of 1,2-diethoxy-1,2-bis(trimethylsiloxy)ethene to 1-bromo-
adamantane. 
 
Adamantane is readily brominated at elevated temperatures with liquid bromine 
forming 1-bromoadamantane.93 The major drawback of this methodology is the poor 
functional group tolerance. The bromination of functionalized adamantane derivatives 
succeded without catalysts only with a few compounds such as 1-adamantylacetic acid,94  
1-(4-nitrophenyl)adamantane,95 or 1-(α-acetylamino)ethyladamantane96 (Scheme 24). 
 
Scheme 24: Bromination of 1-(4-nitrophenyl)adamantane. 
 
However, bromination of the 1-adamantanecarboxylic acid requires already a catalyst 
to furnish the corresponding bromo-derivative in good yield. 3-Bromo-1-adamantane-
carboxylic acid has been obtained in 68% yield by treating 1-adamantane-carboxylic acid 
with anhydrous bromine in the presence of AlBr3.97 
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Furthermore, by treating adamantane derivatives with fluorooxytrifluoromethane 
(CF3OF) under conditions preventing radical processes (in the dark or in the presence of 
radical inhibitors) the tertiary position of the adamantane framework undergoes a 
selective fluorination.98 Besides CF3OF, also IF5 proved to be an effective fluorinating 
agent.99 Substituted adamantane derivatives are only monofluorinated, whereas the 
unsubstituted adamantane reacts with IF5 to both mono- and difluoro derivatives 
depending on the amount of the fluorinating reagent (Scheme 25). 
 
Scheme 25: Fluorination of adamantane derivatives using CF3OF, and IF5. 
 
The hydroxylation of the tertiary C–H bonds in functionalized adamantane derivatives 
can be performed with oxidation systems containing metal complexes or salts. Thus, 
potassium permanganate in a 2% NaOH solution converts 3,5-difluoroadamantane-1-
carboxylic acid to the corresponding hydroxyl derivative in 83% yield (Scheme 26).94 
 
Scheme 26: Hydroxylation of adamantane derivatives using KMnO4/NaOH. 
 
Recently an efficient procedure has been developed for the selective hydroxylation of 
tertiary C–H bonds applying RuO4 as oxidant.100 The latter is generated in situ under the 
reaction conditions and is responsible for the selectivity of the process. The generation of 
RuO4 from catalytic amounts of RuCl3 is performed by stoichiometric amounts of the 
cheap oxidant KBrO3. The procedure permits the hydroxylation of substrates with 
various functional groups like ester, oxazolidine, carbamate or sulfamate (Scheme 27). 
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Scheme 27: Hydroxylation of adamantane derivatives using RuO4. 
 
An efficient system for the preparation adamantylacetamides proved to be a mixture 
of cerium ammonium nitrate (CAN) with sodium azide in acetonitrile (Scheme 28).101 
The corresponding alcohols are formed as side products. 
 
Scheme 28: Amidation of adamantane derivatives using CAN/NaN3. 
 
Friedel-Crafts alkylation of aromatics with diverse alkylating agents including tertiary 
alkyl halides has been extensively investigated.102 Also the related adamantylation of 
aromatics is of great interest since an increasing variety of pharmaceuticals containing 
the phenyladamantane moiety have been discovered.  
De Meijere et al. for instance use Pd/C as catalyst for Friedel-Crafts type arylation 
reactions of adamantane. The reaction of 1-bromoadamantane with different arenes in the 
presence of Pd/C furnishes the corresponding 1-aryladamantane derivatives in excellent 
yields (Scheme 29).103 Noteworthy, Stetter et al. have discovered earlier that donor-
substituted arenes like toluene and acetanilide can be easily adamantylated by heating 
with 1-bromoadamantane in the presence of water.104 
 
Scheme 29: Friedel-Crafts type arylation of 1-bromoadamantane. 
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Furthermore, the arylation of 1-bromoadamantane with the use of substoichiometric 
(35 mol%) or even stoichiometric amounts of FeCl3105 or AlCl3106 has been known much 
longer, and is well documented. However, recently Nakamura and coworkers developed 
an efficient cross-coupling reaction of 1-chloroadamantane with aryl Grignard reagents 
using catalytic amounts of an N-heterocyclic carbene ligand (NHC-ligand) and FeCl3 
(Scheme 30).107 
 
Scheme 30: FeCl3-catalyzed cross-coupling reaction of 1-chloroadamantane and an aryl 
Grignard reagent. 
 
Also the silver-catalysed reaction of tertiary alkyl bromides with aryl Grignard 
reagents in dichloromethane affords the corresponding cross-coupling products in 
reasonable yields (Scheme 31).108  
 
Scheme 31: Silver-catalyzed phenylation of 1-bromoadamantane. 
 
Hafnium(IV) trifluoromethanesulfonate has been found to be an efficient catalyst for 
Friedel-Crafts alkylation. The adamantylation of toluene with 1-chloroadamantane in the 
presence of 5 mol% Hf(OTf)4 furnishes the corresponding product in 92% yield  
(Scheme 32).109 
 
Scheme 32: Hf(OTf)4-catalyzed Friedel-Crafts arylation of 1-chloroadamantane. 
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Furthermore, Laali et al. have reported a TfOH-promoted adamantylation of aromatic 
substrates using the ionic liquid n-butylmethylimidazolium triflate ([BMIM][OTf]) as 
solvent (Scheme 33).110 
 
Scheme 33: TfOH-promoted adamantylation of anisol in the ionic liquid n-butylmethyl-
imidazolium triflate ([BMIM][OTf]). 
 
Recently, a method for Suzuki-Miyaura cross-coupling reactions of tertiary alkyl 
bromides, using the commercially available catalyst components NiBr2·diglyme and  
4,4′-di-tert-butyl-2,2′-bipyridine, was disclosed.111 Thus, the reaction of 1-iodo-
adamantane with the isopropylphenyl-substituted 9-borabicyclo[3.3.1]nonane (9-BBN) 
furnished the desired product in 61% yield (Scheme 34).  
 
Scheme 34: Susuzki-Miyaura cross-coupling of 1-iodoadamantane with the isopropylphenyl-
substituted 9-borabicyclo[3.3.1]nonane. 
 
 
6. IMIDAZOLE AND ITS CHEMISTRY 
The imidazole ring is a constituent of several important natural products, including 
purine, histamine, histidine or nucleic acid. Due to its polarity and its ionisable aromatic 
character, it leads to improved pharmacokinetic characteristics of lead molecules and is 
therefore used as a remedy to optimize solubility and bioavailability parameters of 
proposed poorly soluble molecules.112  
Marine sponges produce a plethora of structurally diverse secondary metabolites 
usually containing both imidazole and pyrrole moieties.113 Since the discovery in 1971 of 
the first alkaloid of this family, Oroidin,114 many hundreds of such compounds have been 
isolated. Members of this family range from relatively simple compounds containing 
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intact imidazole systems such as Hymenidine, Parazoanthoxanthin A and Cribrostatin 6 
to considerably more complex metabolites such as Palau’amine or Axinellamine A 
(Figure 6). 
 
Figure 6: Natural products occurring in marine sponges containing the imidazole moiety. 
 
However, the most important natural product derived from imidazole is the proteino-
genic amino acid histidine. With its physiological pH value of 7.4, the histidine acts in 
protein building blocks as a free base and as a conjugated acid (pKa = 7.00) due to a 
regulating acid-base equilibrium. Especially in enzymes, imidazole acts as Brønsted base 
or Brønsted acid. Moreover it also has the possibility to form complexes with metal ions. 
These properties are unique among the proteinogenic amino acids (Figure 7).115 
Histamine is formed by enzymatic decarboxylation of histidine. It acts as a vasodilator 
and thus lowers the blood pressure. Moreover, it can contract smooth muscles and 
regulate the gastric acid secretion. Too high histamine level in the blood can cause 
allergic reactions like hay fever, which can be surpressed by antihistamines blocking the 
allergy-causing histamine receptors (H1 receptors).116 Cimetidine is used for treatment of 
duodenal and gastric ulcers. By blocking the histamine receptors stimulating the gastric 
acid secretion (H2 receptors), it reduces the gastric acid production (Figure 7).116 
 
Figure 7: Natural products containing the imidazole moiety. 
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Among imidazole derivatives a huge variety of pharmacological activite molecules 
can be found.112 Metronidazole is a nitroimidazole antibiotic medication used particularly 
for anaerobic bacteria and protozoa. Metronidazole is an antibiotic, amebicide, and 
antiprotozoal and the drug of choice for first episodes of mild-to-moderate Clostridium 
difficile infection.117 Bifonazole shows antifungal activity. It has dual mode of action. It 
blocks transformation of 24-methylendihydrolanosterol to desmethylsterol in fungi 
together with inhibition of HMG-CoA. This enables fungicidal properties against 
dermatophytes and distinguishes bifonazole from other antifungal drugs.116 Eprosartan is 
an Angiotensin II receptor antagonist used for the treatment of high blood pressure. It 
blocks the binding of Angiotensin II to AT1 receptors in vascular smooth muscle, causing 
vascular dilatation and inhibits sympathetic norepinephrine production (Figure 8).116 
 
Figure 8: Pharmaceutically relevant imidazole derivatives. 
 
Ionic liquids have received attention in recent years for their various desirable 
properties. Imidazolium-based ionic liquids and ionic liquid monomers are becoming 
increasingly popular in a variety of areas including biphasic reaction catalysis,118 
electromechanical actuator membranes and diluents,119 separation science membranes,120 
as well as water purification agents121 or green solvents (Figure 9).122 Imidazole was 
targeted for its ability to form cationic compounds, which are molten salts at low molar 
mass. Ionic liquids offer several beneficial attributes including fixed charge, potential as 
green solvents, and relatively high thermal stability. The imidazole ring has gained much 
attention for its ability to tune the properties of the resulting ionic liquid. The type of 
substituents on any of the positions in the ring and exchange of the counteranion 
influences many physical properties such as the melting point, the boiling point, and the 
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viscosity. Furthermore, imidazolium ionic liquids utilize two of their unique properties in 
biphasic catalysis, i.e. their ability to coordinate transition metals and their hydrophilic 
ionic nature. Several imidazolium-based ionic liquid molecules have displayed the ability 
to catalyze atom transfer radical polymerization and facilitate the synthesis of polymers 
with a narrow molecular weight distribution.123  
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Figure 9: Imidazole-based ionic liquids. 
 
Imidazoles react with electrophilic reagents like halogenoalkanes via the nucleophilic 
pyridine-like N-atom to give quarternary salts as primary products. These salts readily 
undergo deprotonation and react with a second halogenoalkane to afford 1,3-
dialkylimidazolium salts (Scheme 35).116  
 
Scheme 35: Reaction with electrophilic reagents. 
 
In the presence of strong bases, imidazoles form the corresponding imidazolyl anion 
and easily undergo 1-alkylation with halogenoalkanes and dialkyl sulfates.124 Due to the 
ambient character of unsymmetrical imidazolyl anions, base-induced alkylation of 
substituted imidazoles furnishes product mixtures (Scheme 36). Imidazolyl anions also 
react with acid chlorides, sulfonyl chlorides and trialkylchlorosilanes to give the 
corresponding 1-substituted imidazoles.125 
 
Scheme 36: Base-induced reaction with electrophilic reagents leading to product mixtures. 
 
SEAr reactions like halogenations or azo couplings are mostly performed in neutral or 
basic medium. Chlorination with SO2Cl2 furnishes 4,5-dichloroimidazole116 whereas 
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bromination with Br2 in water or HOAc/NaOAc126 and iodination with I2 in 
H2O/NaOH127 produce the corresponding 2,4,5-trihalogenated imidazoles. Azo couplings 
in aqueous alkaline solution lead to 2-substituted products, since the negative charge of 
the intermediate imidazolyl anion is delocalized over positions 1-3 of the ring  
(Scheme 37).128  
 
Scheme 37: Azo coupling of imidazole in basic medium. 
 
Reactions of N-substituted imidazole derivatives with nucleophiles occur rather 
slowly and demand vigorous conditions. For instance, the SNAr reaction of 2-halogeno-1-
alkylimidazoles require high temperatures (Scheme 38).129 
 
Scheme 38: SNAr reaction of N-substituted imidazol derivatives. 
 
The treatment of 1,3-dialkylimidazolium salts with strong bases leads to deprotonation 
at position 2 generating 1,3-dialkylimidazolium ylides. Due to their electronic 
distribution, these ylides exhibit the behavior of nucleophilic carbenes and undergo 
electrophilic reactions like alkylation, acylation, halogenations, etc. at position 2 
(Scheme 39).130 
 
Scheme 39: Preparation of 1,3-dialkylimidazolium ylides and there subsequent reaction with 
electrophiles. 
 
1,3-dialkyl- and 1,3-diacylimidazolium ions show high reactivity against OH-ions, 
usually with addition at position 2 followed by ring-cleavage. For instance, the reaction 
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of imidazole with PhCOCl in NaOH/H2O leads to the cleaved product 1,2-
(dibenzoylamido)ethane and formate (Scheme 40).131 
 
Scheme 40: Ring cleavage of 1,3-diacylimidazolium ions under basic conditions. 
 
  
                                                 
131
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7. OBJECTIVES 
As functionalized five- and six-membered heterocycles are highly important building 
blocks for the synthesis of pharmaceuticals, agrochemicals and materials (e.g. regio-
regular polymers), a simple and general method for the regioselective preparation of 
metalated heterocycles would be highly desirable. Hence, a selective Br/Mg-exchange 
reaction of unsymmetrically substituted five- and six-membered dibromo-heterocycles 
should be developed (Scheme 41).132 
 
 
Scheme 41: Regioselective Br/Mg-exchange on unsymmetrically substituted dibromohetero-
cycles and subsequent functionalization. 
 
Arylboron derivatives have found broad applications for the performance of Suzuki-
Miyaura cross-couplings. In general, most arylboronic compounds are prepared via 
lithium or magnesium organometallics in a two-step process. The aim of the project lay 
on the development of a convenient, general and atom-economical method for the one-
pot preparation of boronic derivatives using inexpensive starting materials with little 
toxicity and their subsequent use in Suzuki-Miyaura cross-coupling reactions  
(Scheme 42).133 
 
 
Scheme 42: One-pot preparation and subsequent cross-coupling of magnesium diarylboronates. 
 
β,γ-Unsaturated ketones and esters are versatile building blocks in organic chemistry. 
Although a number of synthetic methods for β,γ-unsaturated ketones have been 
disclosed, only a few have been proven practical and useful. Moreover, the direct 
preparation of β,γ-unsaturated esters is entirely unknown in literature. Therefore, a 
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procedure involving the reaction of substituted allylic zinc reagents, prepared via direct 
metal insertion into substituted allylic halides, with a broad range of acid chlorides and 
chloroformates was envisioned to furnish the corresponding α-substituted  
β,γ-unsaturated ketones and esters (Scheme 43). 
 
 
Scheme 43: Preparation of α-substituted β,γ-unsaturated ketones and esters via addition of allylic 
zinc reagents to various acid chlorides and chloroformates. 
 
Functionalized alkenes bearing aldehyde, keto or ester functions are found in a 
plethora of naturally occurring products as well as in pharmaceutically active substances. 
This makes functionalized alkenyl organometallics bearing such sensitive carbonyl 
groups important intermediates in organic synthesis. Since the addition of LiCl to various 
insertion reactions allows the simple preparation of alkyl, aryl, and benzylic zinc 
reagents, this method should be extended to alkenyl zinc reagents starting from their 
corresponding unsaturated bromides (Scheme 44).134 
 
 
Scheme 44: Preparation of alkenylzinc reagents and subsequent functionalization. 
 
Adamantane derivatives found numerous applications in medicinal chemistry and 
drug development. The development of the adamantane chemistry allows it to design 
molecules of substances promising for the practical application in the fields of medicine, 
supramolecular chemistry, nanotechnologies, etc. Until now, no general methodology has 
been reported for the selective synthesis of adamantyl organometalic reagents. Hence, a 
mild and convenient procedure for the selective synthesis of adamantyl organometallics 
was envisioned also tolerating functional groups on the adamantyl scaffold  
(Scheme 45).135 
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Scheme 45: Preparation of adamantylzinc reagents and subsequent functionalization. 
 
The imidazole scaffold can be found in a plethora of naturally occuring products. 
Moreover, among imidazole derivatives a huge variety of pharmacological active 
molecules can be found and are therefore important targets in pharmaceutical industry. 
For this reason, a methodology for the selective and predictable functionalization of all 
positions of the imidazole ring starting from simple imidazole by directed metalation and 
sulfoxide/magnesium exchange is highly desirable (Scheme 46).136 
 
Scheme 46: Fully functionalization of imidazole scaffold starting from plain N-protected 
imidazole. 
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1. HIGHLY REGIOSELECTIVE PREPARATION OF HETEROARYL-
MAGNESIUM REAGENTS USING A Br/Mg-EXCHANGE 
1.1 INTRODUCTION 
The functionalization of heterocycles is of key importance for the preparation of 
pharmaceuticals, agrochemicals and materials (regioregular polymers) and has attracted a 
lot of attention in recent years.137 Especially important is the regioselective preparation of 
metalated five- and six-membered heterocycles. Substituted pyridines react with a variety 
of metallic bases leading to the corresponding metalated intermediates. Using a proper 
set of reaction conditions and an appropriate metal base enables the performance of a 
range of selective metalations. The nature of the substituents attached to the pyridine 
scaffold deeply influences the regioselectivity and the rate of the metalation. The 
deprotonation of 5-bromonicotinic acid with lithium 2,2,6,6-tetramethylpiperidide 
(TMPLi)138 for example proceeds smoothly leading regioselectively after iodolysis to the 
desired product with the iodo-substituent in position 4 (Scheme 47).139 
 
Scheme 47: Regioselective deprotonation on 5-bromonicotinic acid with TMPLi. 
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Another way of controlling the regioselectivity in metalation reactions of pyridine 
derivatives is the addition of strong Lewis acids such as BF3·OEt2. It turns out that the 
sterically hindered base TMPMgCl·LiCl reacts reversibly with BF3·OEt2 at temperatures 
below -20 °C leading to the frustrated Lewis pair TMPMgCl·BF3.140 This adduct 
decomposes only at temperatures above -10 °C.141 Through a coordination of the BF3 
group at the N-heterocyclic nitrogen the acidity of the pyridyl hydrogens increases and 
the deprotonation of even electron-rich pyridines such as 2-methoxypyridine proceeds 
readily. Moreover, the addition of BF3·OEt2 also changes dramatically the direction of 
the deprotonation. Thus, 3-bromoisonicotinonitrile is magnesiated with TMPMgCl·LiCl 
in position 2 providing the corresponding 2-allylated pyridine in 65% yield after Cu(I)-
catalyzed allylation. In the presence of BF3·OEt2, a complete switch of regioselectivity is 
observed and the 4-allylated pyridine is obtained after a Cu(I)-catalyzed allylation in 63% 
yield (Scheme 48).142 
 
Scheme 48: Effect of BF3·OEt2 on the deprotonation of 3-bromoisonicotinonitrile with 
TMPMgCl·LiCl. 
 
The presence of a bromo or an iodo substituent attached to the pyridine ring allows the 
performance of halogen/metal exchange. The use of alkyllithium reagents leads to fast 
exchange reactions. However, the reaction conditions and the nature of the lithium 
reagent used are of special importance since lithiation of the pyridine ring may be a 
competitive process.  
In the reaction with 5-bromo-2-chloropyridine tBuLi plays the role of a base and the 
ortho-lithiation leads selectively after addition of TMSCl to the trisubstituted product  
5-bromo-2-chloro-4-(trimethylsilyl)pyridine in 92% yield. In contrast, nBuLi selectively 
exchanges the bromine of 5-bromo-2-chloropyridine and furnishes, after addition of 
TMSCl, selectively the disubstituted heterocycle 2-chloro-5-(trimethylsilyl)pyridine in 
90% yield (Scheme 49).143 
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Scheme 49: Br/Li exchange versus ortho-lithiation depending on the nature of the lithium 
reagent. 
 
Furthermore, Knochel et al. found that a tosyloxy substituent in position 2 of  
3,5-dibromopyridine allows a highly regioselective Br/Mg exchange reaction using 
iPrMgCl·LiCl.26c The bromine substituent in position 3 undergoes a Br/Mg exchange 
with 99:1 regioselectivity, showing the strong influence of the tosyloxy group. The 
reaction of the pyridylmagnesium reagent with DMF affords the corresponding 
pyridylaldehyde in 88% yield (Scheme 50). 
 
Scheme 50: Regioselective Br/Mg exchange on 3,5-dibromopyridin-2-yl 4-tosylate with 
iPrMgCl·LiCl. 
 
Based on these results, we envisioned a convenient and general regioselective Br/Mg-
exchange reaction for unsymmetrically substituted dibromoheterocycles allowing the 
preparation of various thienyl-, furyl- and pyridyl-magnesium derivatives.  
 
1.2 REGIOSELECTIVE Br/Mg-EXCHANGE ON UNSYMMETRICAL DIBROMO-
HETEROCYCLES USING iPrMgCl·LiCl 
Preliminary experiments have shown that the treatment of unsymmetrically substituted 
dibromo-heterocycles like 2,5-dibromo-3-(methylthio)thiophene (2a) with iPrMgCl·LiCl 
(1a) (1.05 equiv) in THF at 0 °C leads within 1 h to the corresponding magnesium 
reagent 3a in >95% yield and with a regioselectivity of >99:1. Its addition to 3-chloro-4-
methoxybenzaldehyde (4a, 0.9 equiv) at -20 °C provides the corresponding alcohol 5a in 
74% yield (Scheme 51). With these conditions in hand, several unsymmetrically 
substituted dibromo-thiophenes and -benzo[b]thiophenes have been converted into their 
corresponding magnesium species (Table 1) and subsequently functionalized using a 
broad range of electrophiles, such as aldehydes, aryl iodides or acyl chlorides in the 
presence of an appropriate catalyst.  
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Scheme 51: Regioselective Br/Mg-exchange on unsymmetrical 2,5-dibromothiophene 2a using 
iPrMgCl·LiCl (1a). 
 
This regioselective exchange has been performed with a number of unsymmetrically 
substituted dibromothiophenes in excellent regioselectivities. Thio-substituents such as 
MeS, PhS or PyrS on the dibromothiophene direct the Br/Mg-exchange in position 5 with 
a regioselectivity of >99:1 (Table 1).144 Subsequent functionalization reactions furnish 
the corresponding products in excellent yields. Hence, (5-bromo-4-(methylthio)thiophen-
2-yl)magnesium bromide (3a) has been transmetalated with ZnCl2 and submitted to a Pd-
catalysed Negishi cross-coupling145 with electrophiles 4b and 4c furnishing the highly 
functionalized products 5b and 5c in 82% and 84% yield respectively (entries 1 and 2). 
The reaction of organomagnesium compound 3a with di-tert-butyl dicarbonate (4d) 
produces the ester-substituted thiophene 5d in 82% yield (entry 3). Furthermore, the 
magnesium reagent 3b of the PhS-substituted dibromothiophene smoothly adds to 
anisaldehyde (4e) furnishing the corresponding alcohol in 91% yield (entry 4). Also Pd-
catalyzed Negishi cross-couplings of 3b after transmetalation with an electron-poor as 
well as an electron-rich electrophile (4f and 4g) proceed well and lead to the desired 
products 5f and 5g in high yields (entries 5 and 6). Noteworthy, the exchange reaction as 
well as the subsequent cross-coupling with 4g has been carried out in a 15 mmol scale 
without any loss in regioselectivity or yield. Finally, also Mg-species 3c of the PyrS-
substituted dibromothiophene has been successfully submitted to a Negishi cross-
coupling with ethyl 4-iodobenzoate (4h) producing thiophene 5h in 92% yield (entry 7). 
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Table 1: Preparation of functionalized thiophenes via regioselectively generated heteroaryl-
magnesium reagents of type 3. 
Entry Mg-Reagent[a] Electrophile Product, Yield[b] 
 
 
 
 
1 3a: >99:1 4b 5b: 82%[c] 
 
 
 
 
2 3a: >99:1 4c 5c: 84%[c] 
 
 (tBuO2C)2O 
 
3 3a: >99:1 4d 5d: 82% 
 
 
MeO
CHO
 
 
4 3b: >99:1 4e 5e: 91% 
  
 
 
5 3b: >99:1 4f 5f: 86%[c] 
  
 
 
6 3b: >99:1 4g 5g: 96%[c],[d] 
 
 
 
 
7 3c: >99:1 4h 5h: 92%[c] 
[a] Obtained after exchange reaction with iPrMgCl·LiCl (1a; 1.05 equiv) in THF at 0 °C in 1 h. Ratio of 
regioisomers determined by 1H NMR analysis of the quenched crude reaction mixture (HOAc, 10 equiv). 
[b] Yield of analytically pure isolated product as determined by 1H NMR analysis. [c] Obtained after a 
Negishi cross-coupling (ZnCl2 (1 equiv); then 4% Pd(PPh3)4) with ArI (0.9 or 1.1 equiv). [d] Reaction was 
performed on a 15 mmol scale.  
 
 
 
B. RESULTS AND DISCUSSION 
 
44 
Also the TMS-substituted dibromothiophene 2d undergoes readily the Br/Mg-
exchange with iPrMgCl·LiCl (1a) (1.05 equiv) in THF at 0 °C and leads within 1 h to the 
corresponding magnesium reagent 3d in >95% yield and with a regioselectivity of >99:1. 
Its addition to 2,3-dichlorobenzaldehyde (4i, 0.9 equiv) at -20 °C provides the 
corresponding alcohol 5i in 86% yield (Scheme 52). 
 
Scheme 52: Regioselective Br/Mg-exchange on unsymmetrical 2,5-dibromothiophene 2d using 
iPrMgCl·LiCl (1a). 
 
After transmetalation with ZnCl2 (1 equiv), the Negishi cross-coupling reaction of 
magnesium species 3d with 4-iodoanisol (4g) using 4% Pd(PPh3)4 as catalyst furnishes 
the corresponding arylated thiophene 5j in 87% yield (Table 2, entry 1). Moreover, 
transmetalation of 3d with ZnCl2 (1 equiv) followed by a Cu(I)-catalyzed146 acylation 
(10% CuCN·2LiCl) with furan-3-carbonyl chloride (4j) gives access to the 
functionalized ketone 5k in 72% yield (entry 2). Since benzo[b]thiophenes are important 
building blocks for the preparation of organic materials,147 regioselective 
functionalizations of this scaffold have been performed with iPrMgCl·LiCl (1a). The 
Br/Mg-exchange of dibromo-thienothiophene 2e leads to the corresponding magnesium 
reagent 3e in >95% and >99:1 regioselectivity. Its subsequent addition to anisaldehyde 
(4e) proceeds readily and furnishes the expected alcohol 5l in 81% yield (entry 3). The 
arylated thienothiophene 5m has been obtained in almost quantitative yield after Pd-
catalysed cross-coupling of magnesium reagent 3e with 4-iodoanisol (4g). 
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Table 2: Preparation of functionalized thiophenes and benzo[b]thiophenes via regioselectively 
generated heteroarylmagnesium reagents of type 3. 
Entry Mg-Reagent[a] Electrophile Product, Yield[b] 
 
 
 
 
1 3d: >99:1 4g 5j: 87%[c],[d] 
 
 
 
 
2 3d: >99:1 4j 5k: 72%[e] 
 
 
MeO
CHO
 
 
3 3e: >99:1 4e 5l: 81% 
 
 
 
 
4 3e: >99:1 4g 5m: 96%[c] 
[a] Obtained after exchange reaction with iPrMgCl·LiCl (1a; 1.05 equiv) in THF at 0 °C in 1 h. Ratio of 
regioisomers determined by 1H NMR analysis of the quenched crude reaction mixture (HOAc, 10 equiv). 
[b] Yield of analytically pure isolated product as determined by 1H NMR analysis. [c] Obtained after a 
Negishi cross-coupling (ZnCl2 (1 equiv); then 4% Pd(PPh3)4) with ArI (0.9 or 1.1 equiv). [d] Reaction was 
performed on a 10 mmol scale. [e] Obtained after acylation (ZnCl2 (1 equiv); then 10% CuCN·2LiCl) with 
ArCOCl (0.9 equiv). 
 
Besides thio- and TMS-substituted thiophenes, also other substituents on the 
dibromothiophene have been tested. Interestingly, by using 2,5-dibromo-3-phenyl-
thiophene, no regioselective Br/Mg-exchange could be achieved under various 
conditions. However by introducing a substituent at the ortho position of the phenyl 
group like Me, MeO or Me2N selectivities from 20:1 up to >99:1 could be obtained. This 
effect may be explained by assuming a conformation change by moving the aryl group 
out of plane due to the substituent on position 2’ of the aryl ring and therefore shielding 
the bromine at position 2.  
The Br/Mg-exchange of 2,5-dibromo-3-(o-tolyl)thiophene (2f) with iPrMgCl·LiCl 
(1a) (1.05 equiv) in THF at 0 °C leads within 1 h to the corresponding magnesium 
reagent (3f) in >95% yield and with a regioselectivity of 22:1. After transmetalation with 
ZnCl2, the Negishi cross-coupling with 4-iodoanisol (4g) furnishes the highly 
functionalized thiophene 5n in almost quantitative yield (Scheme 53).  
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Scheme 53: Regioselective Br/Mg-exchange on unsymmetrical 2,5-dibromothiophene 2f using 
iPrMgCl·LiCl (1a). 
 
Employing 2-N,N-dimethylaniline as substituent on the dibromothiophene, the ratio of 
the regioisomers of the Br/Mg-exchange could be increased and the corresponding 
magnesium reagent 3g has been obtained in a regioselectivity of 39:1 (Table 3, entry 1). 
The subsequent Negishi cross-coupling with 4-iodobenzonitrile (4k) furnished the 
desired bisarylated bromothiophene 5o in 91% yield. Furthermore, a 2-anisyl-substituent 
on the dibromothiophene directs the Br/Mg-exchange in position 5 with a regioselectivity 
of >99:1 (entry 2). The cross-coupling product 5p is obtained after a Negishi cross-
coupling of the magnesium species 3h with 4-iodobenzonitrile (4k) in 90% yield. 
Noteworthy, a satisfactory regioselectivity of 20:1 has also been achieved with 
heterocyclic substituents like a 2-pyridyl or a 2-thienyl group (entries 3 and 4). The 
subsequent cross-coupling reactions of the magnesium reagents 3i and 3j with the 
electrophiles 4h and 4l lead to the expected products 5q and 5r in 89% and 83% yield 
respectively. It is worth mentioning, that no chelating effect with the MeO- or Me2N-
substituent of the phenyl ring as well as with the pyridyl- or the thienyl-substituent could 
be observed. It is assumed that this might be a result of the too long distance between the 
bromine in position 2 of the thiophene ring and the heteroatom of the MeO- or Me2N-
group of the phenyl ring or the pyridyl- and the thienyl-substituent caused by the almost 
perpendicular orientation of the thiophene ring and the substituents in position 3.  
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Table 3: Preparation of functionalized thiophenes via regioselectively generated heteroaryl-
magnesium reagents of type 3. 
Entry Mg-Reagent[a] Electrophile Product, Yield[b] 
 
 
 SBr
CN
Me2N
 
1 3g: 39:1 4k 5o: 91%[c] 
 
 
 
 
2 3h: >99:1 4k 5p: 90%[c] 
 
 
 
 
3 3i: 20:1 4h 5q: 89%[c] 
 
 
 
 
4 3j:[d] 20:1 4l 5r: 83%[c] 
[a] Obtained after exchange reaction with iPrMgCl·LiCl (1a; 1.05 equiv) in THF at 0 °C in 1 h. Ratio of 
regioisomers determined by 1H NMR analysis of the quenched crude reaction mixture (HOAc, 10 equiv). 
[b] Yield of analytically pure isolated product as determined by 1H NMR analysis. [c] Obtained after a 
Negishi cross-coupling (ZnCl2 (1 equiv); then 4% Pd(PPh3)4) with ArI (0.9 or 1.1 equiv). [d] Exchange 
reaction performed at -20 °C in 1 h.  
 
1.2.1 TUNABLE REACTIVITY OF THIENYLMAGNESIUM REAGENTS TOWARDS CARBONYL 
DERIVATIVES 
By the reaction of magnesium species like 3h with formyl-substituted heterocyclic 
iodides, it has been possible to either perform an addition to the aldehyde-group or a 
Negishi cross-coupling using the iodide substituent (Scheme 54). After transmetalation 
with ZnCl2 (0.5 equiv), the reaction with 5-iodofuran-2-carbaldehyde (4m) produces 
rapidly the corresponding alcohol 5s in 60% yield.148 By the addition of 4% Pd(PPh3)4 
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the formyl group remains untouched and the Negishi cross-coupling takes place leading 
to 5t in 76% yield (Scheme 2).  
 
Scheme 54: Tuneable reactivity of heteroarylmagnesium reagent 3h towards 4m by the presence 
or absence of Pd(PPh3)4. 
 
1.2.2 FURTHER FUNCTIONALIZATION OF MONOBROMOTHIOPHENES 
In order to exemplify the further functionalization of monobromo-thiophenes of type 5 
obtained after the selective Br/Mg-exchange, the previously prepared monobromo-
thiophene 5g has been submitted to a second Br/Mg-exchange reaction using 
iPrMgCl·LiCl (1a; 1.1 equiv) at ambient temperature. The resulting magnesium reagent 6 
was readily used in different types of functionalization reactions (Scheme 55 and  
Table 4). 
 
Scheme 55: Further functionalization of cross-couling product 5g via Br/Mg-exchange and 
subsequent reactions with different electrophiles. 
 
Thus, thienylmagnesium reagent 6 easily adds to aldehyde 4n providing the 
corresponding alcohol 7a in 77% yield (Table 4, entry 1). After transmetalation with 
ZnCl2 (1 equiv), a Negishi cross-coupling reaction with aryl iodide 4h using 5% 
Pd(PPh3)4 as catalyst leads to the expected product 7b in 73% yield (entry 2). Moreover, 
transmetalation with ZnCl2 (1 equiv) followed by a Cu(I)-catalyzed acylation  
(10% CuCN·2LiCl) with the acyl chloride 4o gives the functionalized ketone 7c in 70% 
yield (entry 3). 
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Table 4: Preparation of functionalized thiophenes of type 7 via regioselectively generated 
heteroarylmagnesium reagent 6. 
Entry Mg-Reagent[a] Electrophile Product, Yield[b] 
 
 
 
 
 
1 6 4n 7a: 77% 
 
 
 
 
2 6 4h 7b: 73%[c] 
 
 
 
 
3 6 4o 7c: 70%[d] 
[a] Obtained after exchange reaction with iPrMgCl·LiCl (1a; 1.1 equiv) in THF at 25 °C in 1 h. [b] Yield 
of analytically pure isolated product as determined by 1H NMR analysis. [c] Obtained after a Negishi cross-
coupling (ZnCl2 (1 equiv); then 5% Pd(PPh3)4) with ArI (0.9 equiv). [d] Obtained after acylation (ZnCl2  
(1 equiv); then 10% CuCN·2LiCl) with ArCOCl (0.9 equiv). 
 
1.3 REGIOSELECTIVE Br/Mg-EXCHANGE ON UNSYMMETRICAL 3,5-DIBROMO-
PYRIDINES USING iPrMgCl·LiCl 
The regioselective Br/Mg-exchange has also been extended to various 3,5-dibromo-
pyridine derivatives (Scheme 56). The corresponding magnesium-species 9a-d have been 
obtained in satisfactory regioselectivities up to 28:1 (Table 5). Subsequent Negishi cross-
coupling reactions after transmetalation with ZnCl2 lead to trisubstituted pyridine 
derivatives 10a-d in good yields (60-88%, entries 1-4). Both electron-poor and electron-
rich aryl iodides have been used successfully. The cross-coupling reactions are usually 
completed within 1 h reaction time at 25 °C. 
 
Scheme 56: Regioselective Br/Mg-exchange on unsymmetrical 2,5-dibromo pyridines of type 8 
using iPrMgCl·LiCl (1a). 
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Table 5: Preparation of functionalized pyridines of type 10 via regioselectively generated 
heteroarylmagnesium reagents of type 9. 
Entry Mg-Reagent  (Conditions [T, t])[a] Electrophile Product, Yield
[b] 
 
 
 
 
1 9a (-55 °C, 2 h): 27:1 4h 10a: 88%[c] 
 
 
 
 
2 9b (-78 °C, 2 h): 13:1 4h 10b: 64%[c] 
 
 
 
 
3 9c (0 °C, 1 h): 28:1 4k 10c: 74%[c] 
 
 
 
 
4 9d (-65 °C, 1 h):[d] 17:1 4g 10d: 60%[c] 
[a] Obtained after exchange reaction with iPrMgCl·LiCl (1a; 1.05 equiv) in THF. Ratio of regioisomers 
determined by 1H NMR analysis of the quenched crude reaction mixture (HOAc, 10 equiv). [b] Yield of 
analytically pure isolated product as determined by 1H NMR analysis. [c] Obtained after a Negishi cross-
coupling (ZnCl2 (1 equiv); then 4% Pd(PPh3)4) with ArI (0.9 equiv). [d] Exchange reaction was performed 
using iPr2Mg·LiCl (0.55 equiv). 
 
1.4 REGIOSELECTIVE Br/Mg-EXCHANGE ON UNSYMMETRICAL DIBROMO-
HETEROCYCLES USING IsitylMgBr·LiCl 
Preliminary experiments showed that the regioselectivity of the Br/Mg-exchange 
reaction with iPrMgCl·LiCl (1a) on 2,5-dibromothiophenes with an alkyl substituent in 
position 3 resulted only in poor regioselectivities. Therefore, we envisioned that by 
increasing the steric hindrance of the Grignard reagent R1MgX·LiCl of type 1 as well as 
its aggregation in solution by adding typical chelating amines as ligand (L1 or L2) would 
allow to improve the regioselectivity of the Br/Mg-exchange reaction (Scheme 57).  
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Scheme 57: Regioselective Br/Mg-exchange on unsymmetrical 2,5-dibromoheterocycles of  
type 11.149 
 
Thus, treatment of 2,5-dibromo-3-methylthiophene (11a) with iPrMgCl·LiCl (1a;  
1.05 equiv) furnishes a regioisomeric mixture of the thienylmagnesium chlorides 12a and 
13a in a ratio of 80:20 (Table 6, entry 1). However, the addition of  tridentate ligands like 
N-[2-(dimethylamino)ethyl]-N,N’,N’-trimethylethane-1,2-diamine (L1; 1.05 equiv) or 
2,2’-oxy-bis(N,N-dimethylethaneamine)150 (L2; 1.05 equiv) leading to the sterically more 
hindered complexes 1a·L1 and 1a·L2 significantly improves the regioisomeric ratio of the 
resulting magnesium reagents in favour of 12a (85:15 and 87:13; entries 2-3). Moreover, 
lower temperatures (-60 °C, 1 h) further increase the regioisomeric ratio up to 90:10 
favouring the formation of 12a (entry 4). In comparison to secondary alkylmagnesium 
reagents like 1a, arylmagnesium bromides, such as mesitylmagnesium bromide (1b) or 
isitylmagnesium bromide (1c), displayed lower exchange reaction rates, but lead to a 
regioselectivity increase from 84:16 to 96:4 (compare entry 1 with entries 5 and 7). 
Remarkably, the addition of 2,2’-oxy-bis(N,N-dimethylethan-amine) (L2; 1.05 equiv) to 
LiCl-solubilized mesitylmagnesium bromide (1b; 1.05 equiv) convertes 11a (-20 °C, 12 
h) predominantly into the Grignard species 12a with a regioisomeric ratio of 97:3 (entry 
6). The even more sterically hindered exchange reagent isitylmagnesium bromide (1c) 
furnishes with 2,2’-oxy-bis(N,N-dimethylethanamine) (L2, 1.05 equiv) at -10 °C in 16 h 
now a perfect regioselectivity ratio of  >99:1 for 12a:13a (entry 8).151  
                                                 
149
 a) S. Schröter, C. Stock, T. Bach Tetrahedron 2005, 61, 2245. b) Y. Garcia, F. Schoenebeck,  
C. Y. Legault, C. A. Merlic, K. N. Houk, J. Am. Chem. Soc. 2009, 131, 6632. 
150
 a) X.-J. Wang, L. Zhang, X. Sun, Y. Xu, D. Krishnamurthy, C. Senanayake, Org. Lett. 2005, 7, 5593.  
b) C.-S. Da, J.-R. Wang, X.-G. Yin, X.-Y. Fan, Y. Liu, S.-L. Yu, Org. Lett. 2009, 11, 5578. c) Y. Liu,  
C.-S. Da, S.-L. Yu, X.-G. Yin, J.-R. Wang, X.-Y. Fan, W.-P. Li, R. Wang, J. Org. Chem. 2010, 75, 6869. 
d) X.-Y. Fan, Y.-X. Yang, F.-F. Zhuo, S.-L. Yu, X. Li, Q.-P. Guo, Z.-X. Du, Z.-S. Da, Chem. Eur. J. 2010, 
16, 7988. 
151
 The regioisomer 13a was not observed in 1H NMR measurements of the hydrolyzed crude reaction 
mixture (HOAc, 10 equiv, -20 to 25 °C). 
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These results were extended to various 2,5-dibromo-heterocycles (11b-d; entries 9-
14). In each case the use of the sterically hindered Grignard reagent 1c in combination 
with (Me2NCH2CH2)2O (L2; 1.05 equiv) gives the best results (compare entries 9, 11, 13 
with 10, 12 and 14). However, the use of the bulky reagent 1c·L2 lead to significantly 
lower exchange rates and the Br/Mg-exchanges requires ca. 16 h compared to 1-6 h. 
 
Table 6: Regioselective Br/Mg-exchange on unsymmetrical 2,5-dibromoheterocycles bearing 
alkyl substituents using various complexed and uncomplexed Grignard reagents of type 1. 
Entry R1MgX·LiCl Ligand Conditions  [T, t][a] 
Product of Type 10,  
Ratio Regioisomers[b] 
 
 
  
 
1 1a - -20 °C, 20 min 12a: 80:20 
2 1a L1   -20 °C, 20 min              12a: 85:15 
3 1a L2   -20 °C, 20 min              12a: 87:13 
4 1a L2   -60 °C, 1 h              12a: 90:10 
5 1b -   -20 °C, 12 h              12a: 84:16 
6 1b L2   -20 °C, 12 h              12a: 97:3 
7 1c -   -10 °C, 12 h              12a: 96:4 
8 1c L2   -10 °C, 16 h              12a: >99:1c 
 
 
  
 
9 1a L2   -10 °C, 20 min              12b: 85:15 
10 1c L2   -10 °C, 16 h              12b: >99:1[c] 
 
 
  
 
11 1a L2   -10 °C, 6 h              12c: 80:20 
12 1c L2   -10 °C, 16 h              12c: >99:1 
 
 
  
 
13 1a L2   -10 °C, 6 h              12d: 75:25 
14 1c L2   -10 °C, 16 h              12d: 91:9 
[a] Complete conversion as determined by GC analysis of an iodolyzed reaction aliquot. [b] Determined by 
1H NMR anaylsis of the quenched crude reaction mixture (HOAc, 10 equiv). [c] The regioisomer of type 
13 was not observed in 1H NMR analysis of the hydrolyzed crude reaction mixture (HOAc, 10 equiv,  
-20 to 25 °C). 
B. RESULTS AND DISCUSSION 
53 
With these conditions in hand (1c·L2, -10 °C, 16 h) various five-membered 
heterocyclic species have been selectively magnesiated with a regioselectivity of >99:1. 
Thus, 2,5-dibromo-3-methylthiophene (11a) undergoes readily the Br/Mg-exchange with 
isitylmagnesium bromide (1c, 1.05 equiv) in combination with 2,2’-oxy-bis(N,N-
dimethylethanamine) (L2, 1.05 equiv) at -10 °C in 16 h in perfect regioselectivity of  
>99:1. The reaction of the corresponding organomagnesium reagent 12a with di-tert-
butyl dicarbonate (4d) leads to the ester-substituted thiophene derivative 14a in 83% 
yield (Scheme 58). 
 
Scheme 58: Regioselective Br/Mg-exchange on unsymmetrical 2,5-dibromothiophene 11a using 
isitylMgBr·LiCl (1c) in combination with ligand L2. 
 
After transmetalation with ZnCl2 (1 equiv), the Negishi cross-coupling reaction of 
magnesium species 12a with ethyl 4-iodobenzoate (4h) using 4% Pd(PPh3)4 as catalyst 
furnishes the corresponding arylated thiophene 14b in 86% yield (Table 7, entry 1). 
Moreover, transmetalation of 12a with ZnCl2 (1 equiv) followed by a Cu(I)-catalyzed 
acylation (10% CuCN·2LiCl) with thiophene-2-carbonyl chloride (4p) produces the 
functionalized ketone 14c in 85% yield (entry 2). Similarly, the transmetalation of 12a 
with ZnCl2 (0.5 equiv) followed by CuCN·2LiCl (0.5 equiv) and the addition of chloranil 
(1.5 equiv) generates the substituted thiophenyl dimer 14d in 87% yield (entry 3).152 
Furthermore, also the n-hexyl-substituted dibromothiophene 11b can be converted to the 
corresponding magnesium reagent 12b in perfect regioselectivity by applying this 
methodology. The addition of 12b to anisaldehyde (4e) leads to the expected alcohol 14e 
in 71% yield (entry 4). Moreover, the direct reaction of 4-methoxybenzenesulfinyl 
chloride (4q) with the heterocyclic magnesium-species 12b furnishes sulfoxide 14f in 
70% yield (entry 5).153 Besides alkyl-substituted dibromothiophenes, also the methyl-
substituted furan 11c has been regioselectively converted to its magnesium species 12c. 
Through transmetalation of 12c with ZnCl2 (1 equiv) followed by a Cu(I)-catalyzed 
acylation (10% CuCN·2LiCl) with acyl chloride 4p the functionalized ketone 14g has 
been obtained in 79% yield (entry 6). The Pd-catalyzed cross-coupling of 12c with  
                                                 
152
 A. Krasovskiy, A. Tishkov, V. Del Almo, H. Mayr, P. Knochel, Angew. Chem. Int. Ed. 2006, 45, 5010. 
153
 a) C. B. Rauhut, L. Melzig, P. Knochel, Org. Lett. 2008, 10, 3891. b) L. Melzig, C. B. Rauhut,  
P. Knochel, Synthesis 2009, 6, 1041. c) L. Melzig, C. B. Rauhut, N. Naredi-Rainer, P. Knochel, Chem.  
Eur. J. 2011, 17, 5362. 
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4-iodobenzonitril (4k) furnishes after transmetalation with ZnCl2 the desired product 14h 
in 78% yield (entry 7). Finally, alcohol 14i has been obtained in 73% yield by addition of 
magnesium species 12c to pivalaldehyde (4r) (entry 8). 
 
Table 7: Preparation of functionalized five-membered heterocycles of type 14 via 
regioselectively generated heteroarylmagnesium reagents of type 12. 
Entry Mg-Reagent[a] Electrophile Product, Yield[b] 
 
 
  
1 12a: >99:1 4h 14b: 86%[c] 
 
 
 
 
2 12a: >99:1 4p 14c: 85%[d] 
 
 
 
 
3 12a: >99:1 - 14d: 87%[e] 
 
 
 
 
4 12b: >99:1 4e 14e: 71% 
  
 
 
5 12b: >99:1 4q 14f: 70% 
 
 
 
 
6 12c: >99:1 4p 14g:79%[d] 
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7 12c: >99:1 4k 14h: 78%[c] 
  tBuCHO 
 
8 12c: >99:1 4r 14i: 73% 
[a] Obtained after exchange reaction with 1c (1.05 equiv) and L2 (1.05 equiv) in THF at -10 °C in 16 h. 
Ratio of regioisomers determined by 1H NMR analysis of the quenched crude reaction mixture (HOAc,  
10 equiv). [b] Yield of analytically pure isolated product as determined by 1H NMR analysis. [c] Obtained 
after a Negishi cross-coupling (ZnCl2 (1 equiv); then 4% Pd(PPh3)4) with ArI (0.9 or 1.2 equiv).  
[d] Obtained after acylation (ZnCl2 (1 equiv); then 10% CuCN·2LiCl) with ArCOCl (0.9 or 1.2 equiv).  
[e] Obtained after transmetalation with ZnCl2 (0.5 equiv) and a copper-mediated oxidative dimerization 
(CuCN·2LiCl (0.5 equiv); then addition of chloranil (1.5 equiv)).  
 
Remarkably, also the tribromothiophene 11e undergoes a smooth Br/Mg-exchange 
with perfect regioselectivity. The reaction of 11e with isitylmagnesium bromide (1c,  
1.05 equiv) in combination with 2,2’-oxy-bis(N,N-dimethylethanamine) (L2, 1.05 equiv) 
proceeds at 0 °C within 1 h furnishing the magnesium species 12e in >99:1 regioselectity 
(Scheme 59). In this case, the exchange reaction is faster compared to the dibromo-
analogon 11a due to the inductive effect of the additional bromine atom in position 3 of 
the thiophene ring. After transmetalation of 12e with ZnCl2 a Pd-catalyzed cross-coupling 
with 4-iodobenzonitril (4k) furnishes the tetrasubstituted thiophene 14j in 77% yield. 
 
Scheme 59: Regioselective Br/Mg-exchange on unsymmetrical 2,3,5-tribromothiophene 11e 
using isitylMgBr·LiCl (1c) in combination with ligand L2. 
 
Moreover, transmetalation of 12e with ZnCl2 (1 equiv) followed by a Cu(I)-catalyzed 
acylation (10% CuCN·2LiCl) with the acyl chloride 4s gives the functionalized ketone 
14k in 86% yield (Table 8, entry 1). The addition reaction of 12e and anisaldehyde (4e) 
produces the desired alcohol 14l in 88% yield (entry 2). Finally, the direct reaction of  
4-methoxybenzenesulfinyl chloride (4q) with the heterocyclic magnesium-species 12e 
furnishes sulfoxide 14m in 94% yield (entry 3). 
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Table 8: Preparation of functionalized five-membered heterocycles of type 14 via 
regioselectively generated heteroarylmagnesium reagents of type 12. 
Entry Mg-Reagent[a] Electrophile Product, Yield[b] 
 
 
 
 
1 12e: >99:1 4s 14k: 86%[c] 
 
 
 
 
2 12e: >99:1 4e 14l: 88% 
 
 
 
 
3 12e: >99:1 4q 14m: 94% 
[a] Obtained after exchange reaction with 1c (1.05 equiv) and L2 (1.05 equiv) in THF at 0 °C in 1 h. Ratio 
of regioisomers determined by 1H NMR analysis of the quenched crude reaction mixture (HOAc,  
10 equiv). [b] Yield of analytically pure isolated product as determined by 1H NMR analysis. [c] Obtained 
after acylation (ZnCl2 (1 equiv); then 10% CuCN·2LiCl) with ArCOCl (0.9 or 1.2 equiv).  
 
Interestingly, the Br/Mg-exchange reaction of 2,5-dibromo-3-methoxythiophene with 
isitylmagnesium bromide (1c) in combination with 2,2’-oxy-bis(N,N-imethylethan-
amine) leads to the 2-magnesiated thiophene 12f (Scheme 60) and not to the  
5-magnesiated one (as for the other dibromo-thiophene derivatives 11a-c and 11e). It is 
assumed that this selectivity resulted from a preliminary coordination of the bulky 
magnesium reagent to the oxygen of the methoxy substituent. This complexation seems 
to be essential for the Br/Mg-exchange reaction to proceed. In contrast, by using 
iPrMgCl·LiCl (1a) in the exchange reaction, the opposite selectivity has been observed 
(4:1 ratio in favour of the 5-magnesiated thiophene).154 This might be a result of the high 
reactivity of iPrMgCl·LiCl (1a) that allows the exchange reaction to proceed without 
prior chelation in an etheral solvent like THF.  
                                                 
154
 The exchange reaction was carried out under the same conditions as described in Scheme 58 and  
Table 7 but at -78 °C. Higher temperatures deteriorated the ratio. At ambient temperature, the observed 
ratio was 2.4:1 in favour of the 5-magnesiated derivative. 
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Scheme 60: Regioselective Br/Mg-exchange on 2,5-dibromo-3-methoxythiophene 11f using 
isitylMgBr·LiCl (1c) in combination with ligand L2. 
 
Thus, thienylmagnesium reagent 12f easily adds to aldehyde 4a providing the 
corresponding alcohol 14n in 73% yield (Table 9, entry 1). After transmetalation with 
ZnCl2 (1 equiv), a Negishi cross-coupling reaction with aryl iodide 4k using 5% 
Pd(PPh3)4 as catalyst leads to the expected product 14o in 69% yield (entry 2). Moreover, 
transmetalation with ZnCl2 (1 equiv) followed by a Cu(I)-catalyzed acylation  
(10% CuCN·2LiCl) with the acyl chloride 4o gives the functionalized ketone 14p in 66% 
yield (entry 3). 
 
Table 9: Preparation of functionalized five-membered heterocycles of type 14 via 
regioselectively generated heteroarylmagnesium reagents of type 12. 
Entry Mg-Reagent[a] Electrophile Product, Yield[b] 
 
 
 
 
1 12f: >99:1 4a 14n: 73% 
 
 
 
 
2 12f: >99:1 4k 14o: 69%[c] 
 
 
 
 
3 12f: >99:1 4o 14p: 66%[d] 
[a] Obtained after exchange reaction with 1c (1.05 equiv) and L2 (1.05 equiv) in THF at -10 °C in 16 h. 
Ratio of regioisomers determined by 1H NMR analysis of the quenched crude reaction mixture (HOAc,  
10 equiv). [b] Yield of analytically pure isolated product as determined by 1H NMR analysis. [c] Obtained 
after a Negishi cross-coupling (ZnCl2 (1 equiv); then 4% Pd(PPh3)4) with ArI (0.9 or 1.2 equiv).  
[d] Obtained after acylation (ZnCl2 (1 equiv); then 10% CuCN·2LiCl) with ArCOCl (0.9 or 1.2 equiv).  
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The regioselective Br/Mg-exchange with 1c·L2 has also been extended to 3,5-
dibromo-2-(trimethylsilyl)pyridine (15) leading to the corresponding magnesium reagent 
16 at -25 °C within 2 h (Scheme 61). The subsequent Negishi cross-coupling reactions 
after transmetalation with ZnCl2 led to trisubstituted pyridine derivatives 17a-b in 
satisfactory yields (60-61%, Scheme 61).  
 
Scheme 61: Preparation of functionalized pyridines of type 17 via regioselectively generated 
heteroarylmagnesium reagent 16. 
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2. ONE-POT PREPARATION OF MAGNESIUM DI(HETERO)ARYL- AND 
DIALKENYLBORONATES FOR SUZUKI-MIYAURA CROSS-COUPLINGS 
2.1 INTRODUCTION 
Organoboron derivatives have found broad applications for the performance of 
Suzuki-Miyaura cross-couplings.7,49 In particular, various boronic acids,52 esters46-48 and 
their derivatives, such as trifluoroborates,53,54 MIDA boronates55 or DAN reagents56 have 
been used very successfully as synthetic tools in the preparation of natural products and 
pharmaceutically active compounds. Shultz et al. for example described a convenient 
synthetic route for the preparation of a Bradykinin B1 antagonist including a Suzuki-
Miyaura cross-coupling as key step (Scheme 62).155 Bradykinin B1 is a kinin responsible 
for the mediation of physiological processes accompanying acute and chronic pain and 
inflammation.156 
 
Scheme 62: Suzuki-Miyaura cross-coupling as key step in the synthesis of a Bradykinin B1 
antagonist. 
 
However, the known methods for preparation of the aforementioned organoboron 
reagents suffer from major drawbacks, such as multi-step syntheses, low atom-economy, 
expensive transition-metal catalysis or low tolerance towards functional groups. In 
general, most arylboronic compounds are prepared via Li- or Mg-organometallics in a 
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 P. D. O’Shea, D. Gauvreau, F. Gosselin, G. Hughes, C. Nadeau, A. Roy, C. S. Shultz, J. Org. Chem. 
2009, 74, 4547. 
156
 M. G. Bock, J. Longmore, Curr. Opin. Chem. Biol. 2000, 4, 401. 
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two-step process,32a-c,35,36,157 although direct transition metal-catalyzed borylations can be 
realized (Scheme 63).46-48,158  
 
Scheme 63: Common syntheses of arylboronate esters and acids. 
 
In the search of a convenient, general and atom-economical4 method for the 
preparation of boronic derivatives suitable for cross-coupling reactions, we investigated a 
one-pot procedure using inexpensive aryl bromides, magnesium as a low-cost reducing 
agent with little toxicity and a trialkylborate as cheap boron source. Thus, we utilized the 
accelerating effect of LiCl as additive in direct metal insertions allowing the presence of 
a broad range of sensitive functional groups in organometallic reagents recently reported 
by Knochel et al.21,64,159 2-bromo-4-fluorobenzonitrile for instance undergoes smoothly a 
direct Mg-insertion in the presence of LiCl furnishing the corresponding organo-
magnesium compound at room temperature tolerating the nitril-group (Scheme 64). 
 
Scheme 64: LiCl-mediated preparation of (2-cyano-5-fluorophenyl)magnesium bromide and 
subsequent Negishi cross-coupling. 
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 a) D. D. Winkle, K. M. Schaab, Org. Process Res. Dev. 2001, 5, 450. b) M. Vaultier, B. Carboni, in 
Comprehensive Organometallic Chemistry (Eds.: G. Wilkinson, F. G. Stone, E. W. Abel), Pergamon, New 
York, 1995, Vol. 11, 191. c) K. Smith, A. Pelter, in Comprehensive Organic Synthesis, (Eds.: B. M. Trost, 
I. Fleming), Pergamon, New York, 1991, Vol. 8, 703. d) M. Zaidlewicz, M. Krzeminski, Science of 
Synthesis, 2004, 6, 1097. e) M. M. Midland, Chem. Rev. 1989, 89, 1553. f) C. Ollivier, P. Renaud, Chem. 
Rev. 2001, 101, 3415. g) V. Darmency, P. Renaud, Top. Curr. Chem. 2006, 263, 71. 
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 a) I. A. I. Mkhalid, J. H. Barnard, T. B. Marder, J. M. Murphy, J. F. Hartwig, Chem. Rev. 2010, 110, 
890. b)  C. Kleeberg, L. Dang, Z. Lin, T. B. Marder, Angew. Chem. Int. Ed. 2009, 48, 5350. c) L. Dang, Z. 
Lin, T. B. Marder, Chem. Commun., 2009, 3987. 
159
 a) Y.-H. Chen, P. Knochel, Angew. Chem. Int. Ed. 2008, 47, 7648. b) Y.-H. Chen, M. Sun, P. Knochel, 
Angew. Chem. Int. Ed. 2009, 48, 7648. 
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Based on this methodology, we explored various borate sources for the in situ trapping 
of the generated organomagnesium intermediate. The treatment of methyl  
2-bromobenzoate (18a) with commercially available Mg turnings (1.6 equiv), B(OBu)3 
(1.0 equiv) and LiCl (1.1 equiv) furnishes within 1 h the magnesium arylboronate 19a in 
full conversion at ambient temperature. Its cross-coupling with 4-bromobenzonitrile 
(22a) using 4% Pd(dppf)Cl160 and Cs2CO3 (2 equiv) in a 1:1 THF/EtOH mixture 
provides the desired cross-coupling product 21a in 65% yield (Scheme 65).  
CO2Me
Br B(OBu)3, Mg, LiCl
CO2Me
B(OBu)3MgBr
Br
CN
(22a, 0.8 equiv)
21a: 65%
Pd(dppf)Cl2
Cs2CO3,THF/EtOH
65 °C, 12 h
CNMeO2C
19a: >85%18a (1 equiv)
THF, 25 °C, 1 h
 
Scheme 65: Preparation of magnesium arylboronate 19a and subsequent Suzuki-Miyaura cross-
coupling. 
 
Interestingly, the alternative conversion of 18a to the corresponding zinc reagent using 
Mg turnings (1.6 equiv), ZnCl2 (1.0 equiv) and LiCl (1.1 equiv) in THF21 requires 3 h 
reaction time showing that the presence of B(OBu)3 significantly accelerates the Mg-
insertion. Besides B(OBu)3 also other boron compounds such as B(OMe)3, B(OEt)3, 
B(OiPr)3, B(OAc)3, and even NaB(OMe)4 or LiB(OMe)4, proved to be feasible for in situ 
trapping of the magnesium reagent. However B(OBu)3 was found to be the most 
promising boron source since no transesterification reactions with sensitive substrates 
like methyl 2-bromobenzoate (18a) were observed. 
 
2.2 PREPARATION OF MAGNESIUM DIARYLBORONATES VIA MAGNESIUM-
INSERTION FOR SUZUKI-MIYAURA CROSS-COUPLINGS  
With these results in hands, the methodolody has been optimized considering both 
sufficiently fast reaction times while using only minimal amounts of the boron source. A 
better atom economy can be achieved without a loss of yield by using 0.5 equiv of 
B(OBu)3 and forming therefore magnesium diarylboronates of type 20 (Scheme 66).161 
Remarkably, both aryl groups (Ar1) are transferred under typical Suzuki-Miyaura cross-
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 a) R.-S. Gan, T. S. Hor, in Ferrocenes (Eds.: A. Togni, T. Hayashi), Wiley-VCH, Weinheim, 1995.  
b) G. A. Molander, M. R. Rivero, Org. Lett. 2002, 4, 107. c) G. A. Molander, C.-S. Yun, M. Ribagorda,  
B. Biolatto, J. Org. Chem. 2003, 68, 5534. 
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 NMR-experiments indicate that several arylboronates like ArB(OBu)3MgX, Ar2B(OBu)2MgX and 
Ar3B(OBu)MgX are in fact formed and that the formula Ar2B(OBu)2MgX reflects only the stoichiometry 
used. 
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coupling conditions using various aryl halides or pseudo-halides of type Ar2-X (22-24,  
X = Cl, Br, I, ONf,162 OTs,163 OTf164). 
B(OBu)3, Mg, LiCl
(22-24, 0.8 equiv)
21: 70-95%
THF/EtOH/DMF
65 °C, 2-12 h
20: >85%18 (1 equiv)
Ar1 Br (Ar1)2B(OBu)2MgBrTHF, 25 °C, 1 h
Ar2 X
Ar1 Ar2
X = Cl, Br, I, ONf, OTs, OTf
Pd(dppf)Cl2, Cs2CO31
2
 
Scheme 66: General equation for the synthesis and cross-coupling of magnesium diarylboronates 
of type 20. 
 
Thus, under typical reaction conditions, the sensitive Boc-protected bromophenol 18b 
reacted with B(OBu)3 (0.5 equiv), Mg (1.6 equiv) and LiCl (1.1 equiv) in THF within 1 h 
at 25 °C providing the magnesium diarylboronate 20a (>85% yield, Scheme 67). Its Pd-
cross-coupling with the bromobenzamide 22b proceeds within 3 h at 65 °C using 4% 
Pd(dppf)Cl2 and Cs2CO3 (2 equiv) in a 4:4:1 THF/EtOH/DMF mixture and leads to the 
functionalized biphenyl 21b in 91% yield clearly demonstrating that both aryl groups of 
20a are available for the cross-coupling.  
 
Scheme 67: Preparation and subsequent cross-coupling of magnesium diarylboronate 20a. 
 
This behaviour was general and a wide range of diarylboronates of type 20 bearing 
various functional groups (ester, cyanid, Boc-, (thio)methoxy-, amino- or silyl-group)  
were prepared conveniently at 25 °C within 15 min to 1 h. The subsequent cross-
coupling reactions of the magnesium diarylboronates 20b-i with a broad variety of aryl 
and heteroaryl bromides as electrophiles produce under standard conditions the desired 
products 21c-k in excellent yields (Table 10). In particular, 1-bromo-
bis(trifluoromethyl)-benzene (18c) was efficiently converted into the corresponding 
diarylboronate 20b via the direct magnesium insertion (Mg (1.6 equiv), LiCl (1.1 equiv)) 
                                                 
162
 a) J. Hoegermeier, H.-U. Reissig, Chem. Eur. J. 2007, 13, 2410. b) J. Dash, T. Lechel, H.-U. Reissig, 
Org. Lett. 2007, 9, 5541. c) J. B. Grimm, K. J. Wilson, D. J. Witter, J. Org. Chem. 2009, 74, 6390. 
163
 a) B. Bhayana, B. P. Fors, S. L. Buchwald, Org. Lett. 2009, 11, 3954. b) L . Zhang, T. Meng, J. Wu, J. 
Org. Chem. 2007, 72, 9346. c) D. Zim, V. R. Lando, J. Dupont, A. L. Monteiro, Org. Lett. 2001, 3, 3049. 
164
 a) A. F. Littke, C. Dai, G. C. Fu, J. Am. Chem. Soc. 2000, 122, 4020. b) G. A. Molander, C. R. Bernardi, 
J. Org. Chem. 2002, 67, 8424. c) G. A. Molander, C.-S. Yun, Tetrahedron 2002, 58, 1465. 
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in the presence of trisbutylborate (B(OBu)3 (0.5 equiv)). Subsequent Suzuki-Miyaura 
cross-coupling with 5-bromovanillin (22c) bearing an aldehyde-, a methoxy- and a 
hydroxy-function furnishes successfully the substituted vanillin 21c in 83% yield  
(entry 1). The diarylboronate 20c bearing a nitril group has been prepared under standard 
conditions and undergoes smoothly the cross-coupling reaction with 4-bromo-
acetophenone (22d) leading to the functionalized biphenyl 21d in 82% yield (entry 2). 
Furthermore, using the same conditions, the dithioanisylboronate 20d readily furnishes 
after the Pd-catalyzed cross-coupling the desired products 21e and 21f in 87-92% yield 
(entries 3 and 4). Noteworthy, the unprotected 5-bromoindole (22e) could be used as 
electrophile without hempering the cross-coupling. Moreover, also the corresponding 
diarylboronate 20e of 3-bromophenyl diethylcarbamate (18f) has been successfully cross-
coupled with the secondary amide 22b bearing an acidic proton. The desired product 21g 
has been obtained in 90% yield (entry 5). Also the ester-substituted bromopyridine 22f 
could be successfully applied as electrophile. The fluoro- and amino-substituted 
diarylboronates 20f and 20g react readily in the cross-coupling reaction furnishing the 
corresponding products 21h and 21i in 79% and 90% yield respectively (entries 6 and 7). 
The cross-coupling reactions of the diarylboronates 20h and 20i with the electron-poor 
electrophiles 22g and 22h proceed well under standard conditions and the highly 
substituted biphenyls 21j and 21k have been optained in high yields (entries 8 and 9). 
 
Table 10: Suzuki-Miyaura cross-couplings performed with magnesium diarylboronates of  
type 20 and aryl bromides of type 22 as electrophiles.  
Entry Ar2B(OBu)2MgBr (conditions [T, t]) Electrophile 
Product 
(t, Yield[a]) 
1 
F3C CF3
B(OBu)2MgBr
2
 
 
20b (25 °C, 15 min) 
 
Br
OH
OMe
CHO
 
22c 
F3C
CF3
CHO
OH
OMe
 
21c (12 h, 83%) 
2 
B(OBu)2MgBr
CN
2
 
20c (25 °C, 1 h) 
 
22d 
NC
Me
O
 
21d (12 h, 82%) 
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3 
B(OBu)2MgBr
SMe
2
 
20d (25 °C, 1 h) 
Br
OH
OMe
CHO
 
22c 
CHO
OH
OMe
MeS
 
21e (6 h, 87%) 
4 
B(OBu)2MgBr
SMe
2
 
20d (25 °C, 1 h) 
 
22e 
 
N
H
MeS
 
21f (6 h, 92%) 
5 
B(OBu)2MgBr
2
O NEt2
O
 
 
20e (25 °C, 1 h) 
Br
NHtBu
O
 
 
22b 
O
NEt2
O
O
NHtBu
 
21g (7 h, 90%) 
6 
B(OBu)2MgBr
2F
 
20f (25 °C, 1 h) 
N
CO2EtBr
 
22f 
N
CO2Et
F
 
21h (3 h, 79%) 
7 
B(OBu)2MgBr
NMe2
2
 
20g (25 °C, 1 h) 
N
CO2EtBr
 
22f 
N
CO2Et
Me2N
 
21i (2 h, 90%) 
8 
B(OBu)2MgBr
2Cl
OMe
 
20h (25 °C, 1 h) 
Br
EtO2C CO2Et
 
22g 
EtO2C
Cl
CO2Et
MeO
 
21j (6 h, 81%) 
9 
 
20i (25 °C, 1 h) 
 
Br
CN
F
 
22h 
 
21k (3 h, 70%) 
[a] Yield of isolated, analytically pure product.  
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As shown in Scheme 68, also alkenyl bromides can be used as electrophiles in the 
Suzuki-Miyaura cross-coupling. Thus, the highly functionalized styrene derivative 21l 
has been obtained via the Pd-catalyzed cross-coupling of dithioanisylboronate 20d and 
alkenyl bromide 22i in 75% yield. 
 
Scheme 68: Preparation and subsequent cross-coupling of magnesium diarylboronate 20d with 
the alkenyl bromide 22i. 
 
Although aryl bromides have been used mostly as electrophiles (Table 10), also 
heteroaryl chlorides readily undergo the Suzuki-Miyaura cross-coupling with diaryl-
boronates of type 20 without any further optimization (Scheme 69). Thus, 
dianisylboronate 20j readily furnishes after the Pd-catalyzed cross-coupling with  
2-chloronicotinonitrile (23a) the desired product 21m in 78% yield. Moreover, the highly 
functionalized pyridine derivative 21n could be synthesized in high yield via the Pd-
catalyzed reaction of the trimethylsilyl-substituted diarylboronate 20k with the 
chloropyridine 23b. 
 
Scheme 69: Preparation and subsequent cross-coupling of magnesium diarylboronates 20j and 
20k with aryl chlorides of type 23 as electrophiles. 
 
Furthermore, also aryl pseudo-halides proved to be versatile electrophiles for the 
cross-coupling reaction with diarylboronates of type 20 (Table 11). The diarylboronate 
20a prepared from the corresponding Boc-protected bromophenol 18b undergoes 
smoothly the Pd-catalyzed cross-coupling with nonaflate 24a and furnishes the desired 
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product 21o in 78% yield (entry 1). Also the tosylate 24b has been successfully 
employed in the cross-coupling reaction with the trifluoromethyl-substituted 
diarylboronate 20l leading to the functionalized quinoline derivative 21p in 70% yield 
(entry 2). Finally, dithioanisyl-boronate 20d readily reacts in the Pd-catalyzed cross-
coupling with the triflate 24c to the functionalized biphenyl 21q in 81% yield (entry 3). 
 
Table 11: Suzuki-Miyaura cross-couplings performed with magnesium diarylboronates of type 
20 and aryl pseudo-halides of type 24 as electrophiles.  
Entry Ar2B(OBu)2MgBr (conditions [T, t]) Electrophile 
Product 
(t, Yield[a]) 
1 
 
B(OBu)2MgBr
2
OBoc
 
 
20a (25 °C, 1 h) 
N Me
ONf
 
 
24a 
N Me
OBoc
 
21o (3 h, 78%) 
2 
 
B(OBu)2MgBr
CF3
2
 
 
20l (25 °C, 1 h) 
N Me
OTs
 
 
24b 
 
21p (12 h, 70%) 
3 
B(OBu)2MgBr
SMe
2
 
20d (25 °C, 1 h) 
OTf
MeO
 
24c 
MeS
MeO
 
21q (12 h, 81%) 
[a] Yield of isolated, analytically pure product. 
 
In some cases, when the aryl bromide is sterically hindered (18n) or strongly electron-
deficient (18o and 18p), the preparation of the mono-arylboronate (ArB(OBu)3MgBr) 
was preferable165 leading to a significant yield improvement in the subsequent Suzuki-
Miyaura cross-coupling (Table 12). Thus, mono-arylboronate 19b, containing the 
sterically demanding Boc-protected alcohol in meta-position of the aryl, furnishes after 
the Pd-catalyzed cross-coupling with the unprotected bromoaniline 22j the highly 
                                                 
165
 This proved to be necessary in less than 10% of all cases studied. 
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functionalized biphenyl 21r in 86% yield (entry 1). Noteworthy, the alcohol group gets 
unprotected during the cross-coupling reaction leading to the free phenol derivative. The 
mono-arylboronate 19c of the highly electron-deficient aryl bromide 18o undergoes a 
smooth cross-coupling reaction with ethyl 4-bromobenzoate (22k) leading to the desired 
product 21s in 72% yield (entry 2). Analogously, also for tert-butyl 4-bromobenzoate 
(18p) the mono-arylboronate 19d reacts more efficiently than the corresponding 
diarylboronate with the electrophiles 22l and 22m in the cross-coupling reaction. For this 
reason, the resulting functionalized biphenyl derivates 21t and 21u could be obtained in 
excellent yields (entries 3 and 4).  
 
Table 12: Suzuki-Miyaura cross-couplings performed with magnesium mono-arylboronates of  
type 19 and aryl bromides of type 22 as electrophiles.  
Entry ArB(OBu)3MgBr (conditions [T, t]) Electrophile 
Product 
(t, Yield[a]) 
1 
 
B(OBu)3MgBr
BocO
 
19b (25 °C, 1 h)[b] 
NH2
ClBr
 
22j 
NH2
Cl
OH
 
21r (6 h, 86%) 
2 
B(OBu)3MgBr
CN
F
 
19c (25 °C, 1 h)[b] 
 
 
22k 
CO2Et
NC
F
 
21s (12 h, 72%) 
3 
 
19d (25 °C, 1 h)[b] 
Br
OMe
 
 
22l 
 
21t (12 h, 89%) 
4 
 
19d (25 °C, 1 h)[b] 
 
22m 
 
21u (4 h, 78%) 
[a] Yield of isolated, analytically pure product. [b] 1 equiv of B(OBu)3 was used. 
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2.3 PREPARATION OF MAGNESIUM DIALKENYLBORONATES VIA MAGNESIUM-
INSERTION FOR SUZUKI-MIYAURA CROSS-COUPLINGS 
The method described above also proved to be suitable for alkenyl halides. Suzuki-
Miyaura cross-coupling reactions with mono- and dialkenylboronic derivatives such as 
19e-f and 20m proceed in high yields. Thus, the treatment of cyclohexenyl iodide (25a) 
with B(OBu)3 (1 equiv), Mg (1.6 equiv) and LiCl (1.1 equiv) in THF at 25 °C produces 
within 1 h the corresponding magnesium alkenyl-boronate 19e in >85% yield  
(Scheme 70). Similarly, the reaction of 2-iodostyrene (25b) furnishes under the same 
conditions the desired alkenylboronate 19f (>85% yield). Cross-coupling of 6a-b with 4-
bromo-benzonitrile (22a) furnishes the functionalized alkenes 26a-b in 71% and 95% 
yield respectively. 
 
Scheme 70: Preparation and subsequent cross-coupling of magnesium alkenylboronates 19e and 
19f with aryl bromide 22a as electrophile. 
 
The magnesium dialkenylboronate 20m was prepared from 1-bromostyrene (25c), 
B(OBu)3 (0.5 equiv), Mg (1.6 equiv) and LiCl (1.1 equiv). Pd-catalyzed cross-coupling 
with ethyl 4-bromobenzoate (22k) under standard conditions gives the diaryl ethylene 
26c in 95% yield (Scheme 71). 
 
Scheme 71: Preparation and subsequent cross-coupling of magnesium alkenylboronate 20m with 
aryl bromide 22k as electrophile. 
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2.4 PREPARATION OF MAGNESIUM DIHETEROARYLBORONATES VIA MAGNESIUM-
INSERTION FOR SUZUKI-MIYAURA CROSS-COUPLINGS 
Remarkably, the aforementioned method could also be applied in the synthesis of 
functionalized diheteroarylboronates without any further optimization. Thus, 3-bromo-
benzofuran (27a) readily reacts with Mg (1.6 equiv) and LiCl (1.1 equiv) in the presence 
of B(OBu)3 (0.5 equiv) in THF within 1 h at room temperature to the diheterocyclic 
magnesium boronate 20n in >85% yield (Scheme 72). A subsequent Suzuki-Miyaura 
cross-coupling reaction with the aryl bromide 22n furnishes the corresponding 
heterocyclic product 28a in 84% yield. As expected, the unprotected amine did not 
hamper the cross-coupling reaction.  
 
Scheme 72: Preparation and subsequent cross-coupling of diheterocyclic boronate 28a with aryl 
bromide 22n as electrophile. 
 
Furthermore, the reaction of diheteroarylboronate 20n with aryl bromide 22o leads to 
the desired substituted benzofuran 28bf in 86% yield (Table 13, entry 1). The related 
diheterocyclic magnesium boronates 20o and 20p have been obtained in an analogous 
approach. 3-bromothiophene (27b) and 3-bromobenzothiophene (27c) provide after LiCl-
mediated Mg-insertion with magnesium turnings (1.6 equiv) and in situ borylation with 
B(OBu)3 (0.5 equiv) the corresponding diheteroarylboronates 20o and 20p in >85% 
yield. The Suzuki-Miyaura cross-coupling reaction of 20o with the aryl bromides 22g and 
22p furnish the highly functionalized heterocycles 28c and 28d in 72% and 79% yield, 
respectively (entries 2 and 3). Finally, also diheteroarylboronate 20p undergoes readily a 
Pd-catalysed reaction with the aryl bromide 22b and produces the substituted 
benzothiophene 28e in 72% yield (entry 4).  
 
 
 
 
 
 
B. RESULTS AND DISCUSSION 
 
70 
Table 13: Suzuki-Miyaura cross-couplings performed with magnesium diheteroarylboronates of 
type 20 and aryl bromides of type 22 as electrophiles.   
Entry Het2B(OBu)2MgBr (conditions [T, t]) Electrophile 
Product 
(t, Yield[a]) 
1 
 
20n (25 °C, 30 min) 
 
22o 
O
O NEt2
O
 
28b (3 h, 86%[b]) 
2 
 
 
20o (0 °C, 30 min) 
 
22g 
S
EtO2C CO2Et
 
28c (3 h, 72%[b]) 
3 
 
20o (0 °C, 30 min) 
 
22p 
N
N
S
MeS
 
28d (12 h, 79%[b]) 
4 
 
20p (0 °C, 1 h) 
 
22b 
S
O
NHtBu
 
28e (12 h, 77%[b]) 
[a] Yield of isolated, analytically pure product. [b] Obtained after Pd-catalyzed cross-coupling  
(4% Pd(dppf)Cl2, Cs2CO3 (2 equiv), THF/EtOH/DMF (4:4:1), 65 °C).  
 
For 4-bromo-3-methylisoxazole (27d) the corresponding diheteroarylboronate showed 
only poor reactivity in the Suzuki-Miyaura cross-coupling. Therefore, the mono-
heteroarylboronate 19g has been synthesized using magnesium turnings (1.6 equiv), 
B(OBu)3 (1.0 equiv) and LiCl (1.1 equiv) and has been submitted to the Pd-catalysed 
cross-coupling reaction. The functionalized heterocyclic derivate 28f could then be 
obtained in a good yield (Scheme 73). 
 
Scheme 73: Preparation and subsequent cross-coupling of magnesium mono-heteroarylboronate 
19g and subsequent cross-coupling with aryl bromide 22k as electrophile. 
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Remarkably, not only heterocyclic bromides can be converted to their corresponding 
diheteroarylboronates, also 2-chlorothiophene (27e) provides after LiCl-mediated Mg-
insertion with magnesium turning (1.6 equiv) and in situ borylation with B(OBu)3  
(0.5 equiv) the corresponding dithienylboronate 20q in >85% yield (Scheme 74). The 
subsequent Suzuki-Miyaura cross-coupling with the chloropyridine derivative 23c 
furnishes the highly functionalized thiophene 28g in 86% yield.  
 
Scheme 74: Preparation and subsequent cross-coupling of magnesium dithienylboronate 20q and 
subsequent cross-coupling with aryl chloride 23c as electrophile. 
 
Furthermore, under typical reaction conditions, also bromopyridine derivatives react 
effectively to the corresponding dipyridylboronates. Thus, 3-bromopyridine 27f is 
converted to its dipyridylboronate 20r in >85% yield within 1 h by using B(OBu)3  
(0.5 equiv), magnesium turnings (1.6 equiv) and LiCl (1.1 equiv) in THF at ambient 
temperature (Table 14, entry 1). The Suzuki-Miyaura cross-coupling employing the 
substituted 2-bromo-furan 22q as electrophile leads to the corresponding cross-coupling 
product 28h in 82% yield. The related dipyridyl magnesium boronates 20s and 20t have 
been obtained in an analogous approach. 5-bromo-2-methoxypyridine (27g) and  
5-bromo-2-chloropyridine (27h) provided after LiCl-mediated Mg-insertion with 
magnesium turnings (1.6 equiv) and in situ borylation with B(OBu)3 (0.5 equiv) the 
functionalzied dipyridylboronates 20s and 20t in >85% yield. The subsequent Suzuki-
Miyaura cross-coupling reaction of 20s with the aryl bromide 22r furnishes the highly 
functionalized pyridine derivative 28i 85% yield (entry 2). The dipyridylboronate 20t 
undergoes readily a Pd-catalysed reaction with the heteroaryl bromide 22s and produces 
the substituted pyridine 28j in 72% yield (entry 3). 
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Table 14: Suzuki-Miyaura cross-couplings performed with magnesium dipyridylboronates of  
type 20 and aryl bromides of type 22 as electrophiles.   
Entry Het2B(OBu)2MgBr (conditions [T, t]) Electrophile 
Product 
(t, Yield[a]) 
1 
N
B(OBu)2MgBr
2
 
20r (25 °C, 1 h) 
 
22q[b] 
N
O
CO2Et
 
28h (24 h, 82%[c]) 
2 
 
20s (25 °C, 1 h) 
 
22r 
NMeO
NO2
 
28i (12 h, 85%[d]) 
3 
 
20t (25 °C, 1 h) 
 
 
22s[b] 
 
28j (12 h, 72%[e]) 
[a] Yield of isolated, analytically pure product. [b] 0.7 equiv of electrophile were used. [c] Obtained after 
Pd-catalyzed cross-coupling (4% (Pd(PPh3)4, Na2CO3·10H2O (1.3 equiv), THF/dioxane/H2O (4:4:1),  
110 °C). [d] Obtained after Pd-catalyzed cross-coupling (4% Pd(dppf)Cl2, Cs2CO3 (2 equiv), 
THF/EtOH/DMF (4:4:1), 65 °C). [e] Obtained after Pd-catalyzed cross-coupling (4% Pd(PPh3)4, Cs2CO3 
(2 equiv), THF/EtOH (1:1), 65 °C). 
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3. PREPARATION OF α-SUBSTITUTED β,γ-UNSATURATED KETONES 
AND ESTERS VIA THE DIRECT ADDITION OF SUBSTITUTED ALLYLIC 
ZINC REAGENTS  
3.1 INTRODUCTION 
The reaction of allylic organometallic reagents with carbonyl derivatives is of high 
importance in synthetic organic chemistry.166 Since allylic moieties can be found in a 
plethora of natural occurring products, allylic organometallics play a significant role in 
their total synthesis (Figure 10).167 Psymberin for example has been isolated from the sea 
sponge Psammocinia sp. and shows a high and selective cytotoxic activity against 
different human cancer cell lines.168 In 2005 De Brabander and coworkers described its 
first total synthesis.169  
Me
HO
OH
O
O
OH
MeO
N
H
OH
Me
Me
OMe
OH
OMeOMe
Psymberin ( )-Strictifolione
H
NO
O
O
Me
Cl
OH
H
Salinosporamide A
OH OH O
O
 
Figure 10: Naturally occurring substrates bearing allylic moieties. 
 
Cossy et al. used a stereoselective allyltitanation as key step in the synthesis of  
(+)-Strictifolione, which was isolated from the stem bark of Cryptocaria strictifolia 
growing in Indonesian tropical rainforests.170,171 (+)-Strictifolione exhibits a potent 
antifungal activity. Salinosporamide A was found in the marine actinomycete 
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 For allylmetal additions, see: a) S. R. Chemler, W. R. Roush, in Modern Carbonyl Chemistry 
 (Ed.: J. Otera), Wiley-VCH, Weinheim, 2000. b) S. E. Denmark, N. G. Almstead, in Modern Carbonyl 
Chemistry (Ed.: J. Otera), Wiley-VCH, Weinheim, 2000. c) Stereoselective Synthesis, Methods of Organic 
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e) A. N. Thadani, R. A. Batey, Org. Lett. 2002, 4, 3827. f) S. W. Li, R. A. Batey, Chem. Commun. 2004, 
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Salinospora tropica distributed in ocean sediments around the Bahamas.172 It is a potent 
proteasome inhibitor and is currently being tested as an anticancer drug candidate to treat 
patients with multiple myeloma.173 One of the key steps of its synthesis reported by 
Corey and coworkers was the reaction of 2-cyclohexenylzinc chloride with a chiral 
aldehyde bearing three stereogenic centers. In this process, two stereogenic centers were 
formed stereoselectively (20:1 dr) with the right configuration.174 
Especially allylic zinc reagents are very versatile organometallic species since their 
behaviour is much more predictable than the behaviour of the corresponding allylic 
magnesium or lithium reagents.175 Moreover, the magnesium and lithium compounds 
suffer from their instability as well as from their difficult and inconvenient preparation.176  
Cyclohexenylzinc bromide for instance is readily prepared from zinc foil and the 
corresponding bromide at -15 °C in 60% yield (Scheme 75).177 However, higher yields 
are prevented by accompanying side reactions such as homocoupling and hydrolysis. 
 
Scheme 75: Preparation of cyclohexenylzinc bromide from zinc and its corresponding bromide. 
 
Recently Knochel and coworkers have reported the use of commercially available zinc 
powder in the presence of lithium chloride in THF as a cheap and convenient method for 
the synthesis of substituted allylic zinc reagents from allyl halides or phosphonates 
reducing unwanted side reactions on a minimum.178 Thus, the LiCl-mediated zinc 
insertion provided cyclohexenylzinc chloride in 84% yield (Scheme 76).    
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 R. H. Feling, G. O. Buchanan, T. J. Mincer, C. A. Kauffman, P. R. Jensen, W. Fenical, Angew. Chem. 
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Scheme 76: LiCl-medidated preparation of cyclohexenylzinc chloride. 
 
β,γ-Unsaturated ketones and esters are versatile building blocks in organic 
chemistry.179 Although a number of synthetic methods have been disclosed, only a few 
have been proven practical and useful. The acylation of olefins for example allows the 
synthesis of β,γ-unsaturated ketones, but generates α,β-unsaturated ketones as side-
products and suffers from poor functional group tolerance (Scheme 77).180  
 
Scheme 77: Praparation of β,γ-unsaturated ketones via acylation of olefines. 
 
The reaction of various allylic organometallics with acyl halides has also been 
reported in literature. Silicon,181 tin,182 copper,183 rhodium,184 manganese,185 titanium,186 
mercury,187 cadmium,188 and indium189 are some of the metal powders used in the 
synthesis of β,γ-unsaturated ketones. But these protocols are mostly neither simple nor 
straightforward and are therefore of limited application. Since the reaction of allylic zinc 
reagents with acid chlorides190 or nitriles191 seemed to be a promising approach, our focus 
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lay on the investigation of addition reactions using the now readily available substituted 
allylic zinc reagents. This led finally to the development of a simple and flexible method 
for the synthesis of α-substituted β,γ-unsaturated ketones and esters through the addition 
of substituted allylic zinc reagents to a broad range of acid chlorides and chloroformates. 
 
3.2 PREPARATION OF SUBSTITUTED ALLYLIC ZINC REAGENTS 
As preliminary experiments had shown, the LiCl-mediated zinc insertion into allylic 
halides provided the corresponding allylic zinc reagents almost without formation of 
homocoupling products (Scheme 78).  
 
Scheme 78: Preparation of allylic zinc reagents 30 from allylic halides 29 via LiCl-mediated zinc 
insertion. 
 
Thus, under optimized conditions but-2-en-1-ylzinc bromide (30a) is formed within  
1 h at 25 °C in 83% yield by dropwise addition of 1-bromobut-2-ene (29a, 1 equiv) to a 
suspension of commercially available zinc powder (2.0 equiv) and dry lithium chloride 
(1.1 equiv) in THF (Scheme 79).  
 
Scheme 79: LiCl-mediated preparation of the substituted allylic zinc organometallics 30 by 
direct insertion of zinc powder (yields determined by iodometric titration192) 
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This procedure has been successfully extended to other allylic halides leading to 
cinnamylzinc chloride (30b, 86%), (3-methylbut-2-en-1-yl)zinc bromide (30c, 92%),  
(3,7-dimethylocta-2,6-dien-1-yl)zinc bromide (30e, 83%) and cyclohex-2-en-1-ylzinc 
bromide (30f, 89%). Especially the preparation of zinc reagent 30b is remarkable, since 
cinnamyl chloride is known to readily undergo extensive homocoupling reaction during 
the synthesis of the corresponding zinc reagent. It is noteworthy, that also functional 
groups like an ester or a nitrile are tolerated in this insertion reaction. Hence,  
2-enecarboxylic acid ethyl ester-6-cyclohexenylzinc chloride (30h) and 2-cyano-5-
cyclopentenylzinc chloride (30i) have been obtained from their corresponding chlorides 
in 90% and 69% yield, respectively. Starting from 2-chloromethyl-6,6-dimethyl-
bicyclo[3.1.1]hept-2-ene (29g), also zinc reagent 30g could be synthesized in 73% yield  
(25 °C, 30 h).178a (2-(Trimethylsilyl)but-2-en-1-yl)zinc chloride (30d) has been generated 
from its chloride in the presence of zinc powder (10 equiv) and lithium chloride (3 equiv) 
in 18 h at 25 °C in 81% yield.178b  
 
3.3 PREPARATION OF α-SUBSTITUTED β,γ-UNSATURATED KETONES 
We then decided to concentrate our studies on the addition of these highly reactive 
allylic zinc reagents to a broad range of acid chlorides. It turned out that this reaction 
proceeds under exceedingly mild conditions (-78 °C, 1-2 h) and furnishes selectively β,γ-
unsaturated ketones 32 without any traces of the α,β-unsaturated isomers (Scheme 80).  
 
Scheme 80: Preparation of α-substituted β,γ-unsaturated ketones of type 32 via addition of 
allylic zinc reagents 30 to various acid chlorides of type 31. 
 
Thus, the addition of but-2-en-1-ylzinc bromide (30a) to 4-(tert-butyl)benzoyl 
chloride (31a) leads selectively to the corresponding α-substituted β,γ-unsaturated ketone 
32a in 85% yield (Scheme 81).  
 
Scheme 81: Preparation of α-substituted β,γ-unsaturated ketone 32a from disubstituted allylic 
zinc reagent 30a. 
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Moreover, also addition of organozinc reagent 30a to the (hetero)aromatic acid 
chlorides 31b and 31c furnishes selectively the corresponding α-substituted  
β,γ-unsaturated ketones 32b-c in high yields (Table 15, entries 1-2). Regardless of the 
substitution pattern of the (hetero)aromatic acid chloride, the reaction proceeds within  
1 h at -78 °C. Noteworthy, the configuration of the double bond in the zinc reagent does 
not affect the reaction course, allowing the use of E- and Z-isomeric mixtures.  
 
Table 15: Preparation of α-substituted β,γ-unsaturated ketones 32b-g from disubstituted allylic 
zinc reagents 30a-b.  
Entry Substrate Acid Chloride Product, Yield[a] Conditions  (T, t) 
 
 
 
 
 
1 30a 31b 32b: 71% 
-78 °C, 1 h 
  
 
 
 
2 30a 31c 32c: 65% 
-78 °C, 1 h 
 
 
 
 
 
3 30b 31a 32d: 90% 
-78 °C, 1 h 
  
  
 
4 30b 31b 32e: 77% 
-78 °C, 1 h 
  
  
 
5 30b 31d 32f: 84% 
-78 °C, 1 h 
  
 
 
 
6 30b 31e 32g: 72% -20 to 25 °C,  
2 h 
[a] Yield of analytically pure isolated product as determined by 1H NMR analysis. 
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Cinnamylzinc chloride (30b) reacts in a similar manner. The α-substituted  
β,γ-unsaturated ketones 32d-f are obtained by addition to the corresponding 
(hetero)aromatic acid chlorides 31a, 31b and 31d in excellent yields (entries 3-5). 
Interestingly, also with aliphatic acid chloride 31e the addition proceeds smoothly (-20 to 
25 °C, 2 h) and leads to ketone 32g in 72% yield (entry 6). 
This procedure could also be successfully applied to trisubstituted allylic zinc 
derivatives. Thus, (3-methylbut-2-en-1-yl)zinc bromide (30c) reacted selectively in 1 h at 
-78 °C with 4-(tert-butyl)benzoyl chloride (31a) to afford the corresponding α,α-
disubstituted β,γ-unsaturated ketone 32h in 93% yield (Scheme 82).  
 
Scheme 82: Preparation of α,α-substituted β,γ-unsaturated ketone 32h from trisubstituted allylic 
zinc reagent 30c. 
 
Remarkably, the addition of (2-(trimethylsilyl)but-2-en-1-yl)zinc chloride (30d) to the 
acid chlorides 31a and 31b furnishes the corresponding ketones 32i and 32j in the almost 
quantitative yield of 98% and 99%, respectively (Table 16, entries 1 and 2). Also the 
trisubstituted allylic zinc reagent 30e, containing another double bond besides the allylic 
one, could be employed in the addition reaction. (Hetero)aromatic acid chlorides (31a 
and 31d) as well as an aliphatic one (31e) have been used to synthesize the corres-
ponding ketones 32k-m leaving the non-allylic double bond untouched (entries 3-5).  
 
Table 16: Preparation of α- and α,α-substituted β,γ-unsaturated ketones 32i-m from 
trisubstituted allylic zinc reagents 30d-e. 
Entry Substrate Acid Chloride Product, Yield[a] Conditions  (T, t) 
 
 
 
O
tBu Me
TMS
 
 
1 30d 31a 32i: 98% 25 °C, ovn 
  
  
 
2 30d 31b 32j: 99% 
-78 °C, 1 h 
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O
tBu
Me
Me
Me
 
 
3 30e 31a 32k: 70% 
-78 °C, 1 h 
  
 
 
 
4 30e 31d 32l: 79% 
-78 °C, 1 h 
  
 
 
 
5 30e 31e 32m: 74% 
-78 °C, 1 h 
[a] Yield of analytically pure isolated product as determined by 1H NMR analysis. 
 
The cyclic allylic zinc reagents 30f-i show an analogous behaviour. The addition of 
cyclohey-2-en-1-ylzinc bromide (30f) to acid chloride 31f affords selectively the 
corresponding α-substituted β,γ-unsaturated ketone 32n in 75% yield (Scheme 83). 
 
Scheme 83: Preparation of α-substituted β,γ-unsaturated ketone 32n from cyclic allylic zinc 
reagent 30f. 
 
Furthermore, the allylic zinc reagent 30f smoothly adds to acid chloride 31a affording 
selectively the corresponding α-substituted β,γ-unsaturated ketone 32o in 83% yield 
(Table 17, entry 1). Moreover, the cyclic zinc reagent 30g reacts readily with the 
(hetero)aromatic acid chlorides 31a and 31b to the ketones 32p and 32q in 67% and 89% 
yield, containing a terminal double bond (entries 2 and 3). Also, zinc reagent 30h 
undergoes the addition reaction with the (hetero)aromatic acid chlorides 31d and 32g 
smoothly and furnishes the corresponding ketones 32r and 32s in high yields (90% and 
80%, entries 4 and 5). The addition of 2-cyano-5-cyclopentenylzinc chloride (30i) to acid 
chloride 31g leads to the α-substituted β,γ-unsaturated ketone 32t (70% yield, entry 6). 
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Table 17: Preparation of α-substituted β,γ-unsaturated ketones 32o-t from cyclic allylic zinc 
reagents 30f-i.  
Entry Substrate Acid Chloride Product, Yield[a] Conditions  (T, t) 
 
 
  
 
1 30f 31a 32o: 83% 
-78 °C, 1 h 
 
 
 
 
 
2 30g 31a 32p: 67% 
-78 °C, 1 h 
  
 
 
 
3 30g 31b 32q: 89% -78 to 25 °C,  
2 h 
 
 
 
 
 
4 30h 31d 32r: 90% -78 to 25 °C, 
ovn 
 
 
 
 
 
5 30h 31g 32s: 80% -78 to 25 °C, 
ovn 
 
 
  
 
6 30i 31g 32t: 70% -78 to 25 °C, 
ovn 
[a] Yield of analytically pure isolated product as determined by 1H NMR analysis. 
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3.3.1 FURTHER FUNCTIONALIZATION OF α-SUBSTITUTED β,γ-UNSATURATED KETONES 
Ring-closing metathesis (RCM) represents one of the most powerful and versatile 
tools in organic synthesis for the formation of carbon-carbon double bonds193 and has 
proven to be highly important for natural product synthesis.194 With the α-substituted 
β,γ-unsaturated ketones in hands, the diene-precursor 33 for a RCM has readily been 
synthesized in only one step via the diastereoselective addition166 of allyl magnesium 
chloride to the carbonyl moiety of 32d in almost quantitative yield (Scheme 84). The 
subsequent RCM using the second generation of Grubbs’ catalyst195 furnishes 
diastereoselectively cyclopentene derivative 34 in 97% yield.  
 
Scheme 84: Diastereoselective addition of allyl magnesium chloride to 32d and subsequent ring-
closing metathesis forming the cyclopentene derivative 34. 
 
3.4 PREPARATION OF α-SUBSTITUTED β,γ-UNSATURATED ESTERS 
Due to the lack of a convenient and practical direct synthesis for α-substituted β,γ-
unsaturated esters in the literature, we extended our method to this direction. As shown in 
Scheme 85, the allylic zinc reagent 30b reacts readily under the optimized conditions 
with chloroformate 35a and forms selectively the desired α-substituted β,γ-unsaturated 
ester 36a in 64% yield.  
 
Scheme 85: Preparation of α-substituted β,γ-unsaturated ester 36a from disubstituted allylic zinc 
reagent 30b. 
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Furthermore, cinnamylzinc chloride (30b) adds to aromatic (35b) as well as to allylic 
chloroformates (35c) affording the corresponding α-substituted β,γ-unsaturated esters 
36b and 36c in 78% and 82% yield, respectively (Table 18, entries 1 and 2). The 
trisubstituted allylic zinc reagent 30c shows a similar behaviour and furnishes ester 36d 
in 70% yield (entry 3). 
 
Table 18: Preparation of α-substituted β,γ-unsaturated esters of type 36. 
Entry Substrate Chloroformate Product, Yield[a] Conditions (T, t) 
 
 
 
 
 
1 30b 35b 36b: 78% -78 to 25 °C, 
2 h 
  
 
 
 
2 30b 35c 36c: 82% -78 to 25 °C, 
2 h 
 
 
 
 
 
3 30c 35b 36d: 70% -20 to 25 °C, 
2 h 
[a] Yield of analytically pure isolated product as determined by 1H NMR analysis. 
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4. PREPARATION OF FUNCTIONALIZED ALKENYLZINC REAGENTS 
BEARING CARBONYL GROUPS VIA DIRECT METAL INSERTION 
4.1 INTRODUCTION 
Functionalized alkenes bearing aldehyde, keto or ester functions are found in a 
plethora of naturally occurring products as well as in pharmaceutically active substances 
(Figure 11). Thuggacin A, for example, has been isolated from the myxobacterium 
Sorangium cellulosum196 and shows strong antibiotic activity against Mycobacterium 
tuberculosis by targeting the bacterial respiratory chain.197 Moreover, Rapamycin, found 
in Streptomyces hygroscopicus,198 is a known immunosuppressant drug used to prevent 
rejection in organ transplantations (especially for kidney transplants). Its first total 
synthesis was reported by Nicolaou et al. in 1993.199 Upenamide is a macrocyclic marine 
natural product from a branching sponge of the genus Echinochalina, containing an all-
trans triene chain system.200  
 
Figure 11: Naturally occurring substrates bearing funcionalized alkene moieties. 
 
Olefin metathesis is one of the most important methods in organic synthesis for the 
formation of carbon-carbon double bonds and has proven to be highly useful for natural 
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product synthesis.201 However, for the synthesis of highly functionalized double bonds an 
approach via cross-coupling reactions of alkenyl organometallics derived from the 
corresponding alkenyl halides seems to be more promising.202 The synthesis of 
Rapamycin for instance contains as key step a Stille-coupling of two alkenyl iodides with 
vinylenedistannane for the stereoselective ring closure and the introduction of the 
conjugated double bond system (Scheme 86).199  
Scheme 86: Stille-coupling as key step in the total synthesis of Rapamycin. 
 
For this reason a simple and efficient method for the preparation of functionalized 
alkenyl organometallics bearing sensitive groups is highly desirable. Especially 
alkenylzinc halides are useful targets due to their high functional group tolerance and 
their excellent reactivity in the presence of an appropriate catalyst.5,62,64c,203 In general, 
functionalized alkenyl organometallic compounds are mostly prepared via halogen-metal 
exchange reactions of the corresponding iodoalkenes. Thus, an iodine-lithium exchange 
with n-butyllithium at -80 °C on 5-chloro-1-iodopent-1-ene combinded with a subsequent 
transmetalation allows the synthesis of the corresponding alkenyl zinc reagent  
(Scheme 87).204 Moreover, Knochel et al. described the use of iPrMgCl·LiCl as exchange 
reagent for the formation of alkenyl magnesium reagents. 6-(Ethoxymethoxy)-1-
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iodocyclo-hex-1-ene, for example, could readily be converted into its corresponding 
magnesium reagent (Scheme 87).205 
 
Scheme 87: Preparation of alkenyl organometallics via iodine-metal exchange reactions. 
 
The major drawbacks of this method are the low reaction temperatures required and 
the use of expensive and unstable alkenyl iodides as starting materials. To avoid these 
drawbacks, direct insertion reactions could be used. However, up to now, only 
unfunctionalized alkenyl organometallics could be employed in direct insertion 
reactions.206 Rieke et al. for instance described the use of highly active zinc (Zn*) 
prepared via reduction of ZnCl2 with lithium naphthalide for the synthesis of styrylzinc 
or (1-phenylvinyl)zinc bromide (Scheme 88).63  
 
Scheme 88: Preparation of (1-phenylvinyl)zinc bromide from its corresponding bromide using 
Rieke-Zn (Zn*). 
 
Recently, Knochel and coworkers have developed a practical and useful method for 
the synthesis of alkyl-,64a,65b aryl-,21,64b and benzylzinc64b,65a,207 halides via LiCl-mediated 
metal-insertion into the corresponding chlorides and bromides. Based on these results, we 
searched for a convenient, mild and atom economical4 methodology for the preparation 
of highly functionalized alkenylzinc reagents starting from readily available alkenyl 
bromides bearing for the first time sensitive functional moieties. 
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4.2 DIRECT INSERTION OF ZINC INTO ACTIVATED ALKENYL BROMIDES 
Since the addition of LiCl enables a smooth zinc insertion into alkyl bromides, 
aromatic halides as well as benzylic chlorides, this method has been applied to activated 
alkenyl bromides for the effective preparation of functionalized alkenyl zinc reagents 
(Scheme 89). 
 
Scheme 89: Preparation of alkenylzinc reagents 38 from activated alkenyl bromides 37 via dirct 
zinc insertion and subsequent functionalization. 
 
Thus, 2-bromocyclohex-1-encarbaldehyde (37a) undergoes a smooth zinc insertion 
using commercially available zinc powder (1.5 equiv, 25 °C, 1 h) in the presence of LiCl 
(1.5 equiv) leading to the zinc reagent 38a (86% yield, Scheme 90). A Pd-catalyzed 
Negishi cross-coupling reaction145,208 with 4-bromobenzonitrile (39a) using 2% 
Pd(PPh3)4 affords the highly functionalized benzonitrile 40a in 82% yield. The presence 
of the electron-withdrawing formyl group on the double bond accelerates the electron-
transfer from the zinc to the organic halide through conjugation and therefore enables this 
exceptionally fast insertion reaction. 
 
Scheme 90: LiCl-mediated zinc insertion in alkenyl bromide 37a leading to zinc reagent 38a and 
subsequent cross-coupling. 
 
Moreover, a Cu(I)-catalyzed allylation reaction146 with ethyl 2-(bromomethyl)acrylate 
(39b) leads to the desired product 40b in 94% yield (Table 19, entry 1).  The copper-
catalyzed alkynylation reaction11a,146 of 38a with the bromoacetylene 39c209 affords the 
highly functionalized acetylene 40c in 80% yield (entry 2). Furthermore, the acylation 
reaction146 using 2-bromobenzoyl chloride (39d) affords ketone 40d in 51% yield (entry 
3). Additionally, Pd-catalyzed cross-coupling reactions with 5-bromo-3-cyanopyridine 
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(39e) and 4-bromobenzotrifluoride (39f) produce the highly functionalized cyclohexenyl 
derivatives 40e and 40f in 65-73% yield (entries 4 and 5). Finally, the reaction of 38a 
with the Tietze immonium reagent 39g210 leads to the aminoaldehyde 40g (68% yield, 
entry 6).  
 
Table 19: Reactions of alkenylzinc reagent 38a with electrophiles. 
Entry Zinc Reagent (Yield [%])[a] Electrophile Product Yield [%]
[b]
 
 
 
 
 
 
1 38a (86) 39b 40b 94[c] 
  
 
 
 
2 38a 39c 40c 80[d] 
  
 
 
 
3 38a 39d 40d 51[d] 
  
 
 
 
4 38a 39e 40e 65[e] 
  
 
 
 
5 38a 39f 40f 73[e] 
  
 
 
 
6 38a 39g 40g 68 
[a] Determined via titration with I2. [b] Isolated yield of analytically pure product. [c] 3% CuCN·2LiCl was 
used. [d] 1 equiv CuCN·2LiCl was used. [e] 2% Pd(PPh3)4 was used and the reaction was performed at  
50 °C. 
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Analogous to aldehyde 38a, the heterocyclic dihydropyranylzinc derivative 38b has 
been prepared by a direct zinc insertion using zinc powder (1.5 equiv) in the presence of 
LiCl (1.5 equiv, 25 °C, 1 h, 77% yield). After reaction with immonium salt 39g, the  
N,N-dimethyl-aminomethyl substituted dihydropyran derivative 40h was isolated in 88% 
yield (Scheme 91).  
 
Scheme 91: LiCl-mediated zinc insertion in 37b leading to 38b and subsequent functionalization. 
 
A direct insertion of zinc dust in 3-iodocyclohex-2-en-1-one and related structures is 
also possible.211 However, the corresponding iodides are often unstable at room 
temperature which makes a synthesis starting from the corresponding bromide highly 
desireable. Hence, applying the method described above to 3-bromo-cyclohex-2-en-1-
one (37c), a smooth insertion reaction occurs furnishing the 3-zincated cyclohexenone 
38c in 86% yield (Scheme 92). A Pd-catalyzed cross-coupling reaction with 4-bromo-
benzonitrile (39a) affords the 3-substituted cyclohexenone derivative 40i in 88% yield. 
 
Scheme 92: LiCl-mediated zinc insertion in 37c leading to 38c and subsequent cross-coupling. 
 
The Pd-catalyzed cross-coupling of 38c with ethyl 4-iodobenzoate (39h) affords the 3-
substituted cyclohexenone derivative 40j in 76% yield (Table 20, entry 1). Cu(I)-
mediated reactions of 38c with 3-bromocyclohexene (39i) or the bromoacetylene 39c 
produce the unsaturated ketones 40k and 40l in 71-76% yield (entries 2 and 3). 
Analogously, 3-bromo-cyclopentenone (37d) is converted to the corresponding 
alkenylzinc reagent 38d in 94% yield (25 °C, 5 h). Pd-catalyzed cross-coupling with 
4-(trifluoromethyl)bromobenzene (39f) leads to the substituted cyclopentenone 40m in 
74% yield (entry 4).  
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Table 20: Reactions of alkenylzinc reagents 38c and 38d with electrophiles. 
Entry Zinc Reagent (Yield [%])[a] Electrophile Product Yield [%]
[b]
 
 
 
 
 
 
1 38c (86) 39h 40j 76[c] 
 
 
 
 
 
2 38c 39i 40k 76[e] 
  
 
 
 
3 38c 39c 40l 71[e] 
 
 
 
 
 
4 38d (94) 39f 40m 74[c] 
[a] Determined via titration with I2. [b] Isolated yield of analytically pure product. [c] 2% Pd(PPh3)4 was 
used and the reaction was performed at 50 °C. [d] 3% CuCN·2LiCl was used. [e] 1 equiv CuCN·2LiCl was 
used.  
 
Furthermore, also alkenyl bromides bearing a keto function can be directly converted 
into the corresponding zinc reagents via LiCl-mediated zinc insertion. Thus  
(2-bromocyclopent-1-en-1-yl)(phenyl)methan-one (37e) reacts readily with zinc powder 
(1.5 equiv) and LiCl (1.5 equiv) at 25 °C within 1 h to the corresponding organozinc 
compound 38e in 62 % yield (Scheme 93). A Pd-catalyzed cross-coupling of 38e with 
ethyl 4-bromobenzoate (393j) leads to 40n in 70% yield. A Cu(I)-catalyzed allylation 
reaction with ethyl 2-(bromomethyl)acrylate (39b) furnishes the desired product 40o in 
79% yield. 
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Scheme 93: LiCl-mediated Zn-insertion in 37e leading to 38e and subsequent functionalizations. 
 
Due to chelation of the zinc center with the carbonyl group, acyclic alkenylzinc 
reagents bearing a vicinal aldehyde have been prepared without loosing the 
stereochemical information of the alkenyl precursors. In general, the formation of a five-
membered ring chelate stabilizes the corresponding organometallic compound by several 
kcal/mol212 and reduces the nucleophilicity of the carbonyl group. Thus, (Z)-3-bromo-4,4-
dimethylpent-2-enal (37f) reacts with zinc powder (1.5 equiv) in the presence of LiCl  
(1.5 equiv) leading to the alkenylzinc reagent 38f  in 67% yield (Scheme 94). A Pd-
catalyzed cross-coupling with 2-bromobenzaldehyde (39k) furnishes the unsaturated 
aldehyde 40p in 92% yield and with a Z:E-selectivity of >99:1. 
 
Scheme 94: LiCl-mediated Zn-insertion in 37f leading to 38f and subsequent cross-coupling. 
 
A Cu(I)-catalyzed allylation of 38f with 3-bromocyclohexene (39i) leads to the desired 
unsaturated product 40q in 96% yield (Table 21, entry 1). Moreover, also the  
4-fluoro and the 4-methoxy substituted derivatives 37g and 37h of (Z)-3-bromo-3-
phenylprop-2-enal react to the corresponding zinc species 38g and 38h in 35-41% yield. 
The following Cu(I)-catalyzed allylation reaction with ethyl 2-(bromomethyl)-acrylate 
(3b) furnishes the cinnamyl-aldehydes 40r and 40s in 89-95% yield (Z:E >99:1, entries 2 
and 3).  
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Table 21: Reactions of acyclic alkenylzinc reagents 38f-h with electrophiles. 
Entry Zinc Reagent (Yield [%])[a] Electrophile Product Yield [%]
[b]
 
 
 
 
 
 
1 38f (67) 39i 40q 96[c],[e] 
 
 
 
 
 
2 38g (35) 39b 40r 95[d],[e] 
 
 
 
 
 
3 38h (41) 39b 40s 89[d],[e] 
[a] Determined via titration with I2. [b] Isolated yield of analytically pure product. [c] 3% CuCN·2LiCl was 
used. [d] 1 equiv CuCN·2LiCl was used. [e] Ratio of Z:E >99:1. 
 
Noteworthy, the developed method has also been applied on an acyclic alkenyl 
bromide bearing an ester function. Hence, (Z)-ethyl 3-bromo-3-phenylacrylate (37i) has 
been converted into the corresponding zinc reagent 38i with zinc powder (1.5 equiv) and 
LiCl (1.5 equiv; 25 °C, 1 h) in 62% yield (Scheme 95). The copper-mediated reaction of 
38i with 4-chlorobenzoyl chloride (39l) and ethyl 2-(bromomethyl)acrylate (39b) affords 
the highly functionalized cinnamyl esters 40t and 40u in 79-85% yield with a  
Z:E-selectivity of  >99:1. 
Scheme 95: LiCl-mediated zinc insertion in 37i leading to 38i and subsequent functionalizations. 
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4.2.1 PREPARATION OF 1-SUBSTITUTED TETRAHYDROPHTHALAZINES 
Unsaturated 1,4-dicarbonyl compounds are highly reactive and undergo condensation 
reactions with hydrazine providing tetrahydrophthalazines.213 Thus, zinc reagent 38a was 
acylated with benzoyl chloride using 3% CuCN·2LiCl as catalyst affording the  
1,4-dicarbonyl derivative 40v. After aqueous workup, the crude 40v undergoes without 
further purification a smooth condensation reaction with hydrazine hydrate 
(NH2NH2·H2O) in methanol to afford the 1-substituted tetrahydrophthalazine 41a in 54% 
yield (Scheme 96). Following this protocol, compounds 41b and 41c, bearing a  
3-chlorophenyl- and a 2-thienyl-substituent, respectively, have been prepared (49-54% 
yield, Scheme 96). 
 
Scheme 96: Synthesis of substituted tetrahydrophthalazines of type 41. 
 
4.3 MAGNESIUM INSERTION IN THE PRESENCE OF ZnCl2 INTO LESS ACTIVATED 
ALKENYL BROMIDES 
The direct insertion of zinc into alkenyl bromides requires the presence of adjacent 
electron-withdrawing groups. Alkenyl bromides without such electronic activation either 
do not undergo an insertion reaction or react only at elevated temperatures and require 
long reaction times. To avoid these drawbacks, we have used the stronger reducing metal 
magnesium. The LiCl-mediated Mg insertion in the presence of ZnCl2 allows an efficient 
synthesis of alkenylzinc halides starting from weakly activated alkenyl bromides 
(Scheme 97).  
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Scheme 97: Preparation of alkenylzinc reagents 43 from less activated alkenyl bromides 42 via 
magnesium insertion in presence of ZnCl2 and subsequent functionalization. 
 
Whereas a vicinal ethyl ester does not sufficiently activate the alkenyl bromide 42a 
for a LiCl-mediated zinc insertion, it undergoes a selective magnesium insertion in the 
presence of ZnCl2 and LiCl furnishing the alkenylzinc reagent 43a in 70% yield  
(Scheme 98). Its Pd-catalyzed cross-coupling with (5-bromothiophen-2-yl)trimethyl-
silane (39m) leads to the substituted thiophene 44a in 71% yield.  
 
 
Scheme 98: Selective insertion of Mg in the presence of ZnCl2 and LiCl in the ester-substituted 
alkenyl bromides 42a and subsequent cross-coupling. 
 
In an analogous way to 42a, the ester-substituted cyclopentene derivative 42b has 
been converted to its corresponding zinc reagent 43b and submitted to a Pd-catalyzed 
cross-coupling with bromothiophene 39n furnishing the substituted thiophene 44b in 
86% yield. The Cu(I)-mediated allylation with 39b afforded the unsaturated product 44c 
in 77% yield (Scheme 99). 
Scheme 99: Selective insertion of Mg in the presence of ZnCl2 and LiCl in the ester-substituted 
alkenyl bromide 42b and subsequent functionalizations (additional complexed salts are omitted 
for the sake of clarity). 
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Remarkably, the zinc insertion proceeds also well with the acyclic unsaturated 
bromoester 42c. The LiCl-mediated Mg insertion in the presence of ZnCl2 furnishes the 
corresponding zinc reagent 43c in 50% yield without any loss of stereochemical 
information due to the chelation of the zinc center with the carbonyl group. The 
subsequent copper-catalyzed reaction of 43c with 4-chlorobenzoyl chloride (39l) and 
ethyl 2-(bromomethyl)acrylate (39b) produces the functionalized acyclic compounds 44d 
and 44e in 77-86% yield (Z:E >99:1, Scheme 100). 
Scheme 100: Selective insertion of Mg in the presence of ZnCl2 and LiCl in the ester-substituted 
alkenyl bromide 42c and subsequent functionalizations (additional complexed salts are omitted 
for the sake of clarity). 
 
Although 1,2-dibromocyclopentene (42d) can be converted to the corresponding 
magnesium reagent by a Br/Mg-exchange with iPrMgCl·LiCl,214 a more atom 
economical approach using Mg/ZnCl2/LiCl is possible. Thus, the treatment of 42d with 
magnesium in the presence of ZnCl2 and LiCl leads to the desired alkenylzinc reagent 
43d in quantitative yield (Scheme 101). Its Cu(I)-catalyzed reaction with 3-bromo-
cyclohexene (39i) affords 44f in 86% yield.  
 
Scheme 101: Selective mono-insertion of Mg in the presence of ZnCl2 and LiCl into alkenyl 
dibromide 42d and subsequent allylation (additional complexed salts are omitted for the sake of 
clarity). 
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Furthermore, an acylation reaction of 43d using 2-bromobenzoyl chloride (39d) 
affords the unsaturated ketone 44g in 64% yield (Table 22, entry 1). Additional Cu(I)-
mediated reactions with cyclohexenone (39o), 3-iodocyclo-hexenone (39p) and 
bromoacetylene 39c lead to the expected products  44h-j in 65-78% yield (entries 2-4). 
Finally, the Pd-catalyzed cross-coupling reaction of 43d with 3-bromo-5-cyanopyridine 
(3e) furnishes the substituted pyridine 44k in 54% yield (entry 5).  
 
 Table 22: Reactions of alkenylzinc reagent 43d with electrophiles. 
Entry 
Zinc Reagent[a] 
(Yield [%])[b] Electrophile Product Yield [%]
[c]
 
 
 
  
 
1 43d (98) 39d 44g 64[d] 
  
 
 
 
2 43d 39o 44h 70[d] 
  
 
 
 
3 43d 39p 44i 65[d] 
  
 
 
 
4 43d 39c 44j 78[e] 
  
 
 
 
5 43d 39e 44k 54[f] 
[a] Additional complexed salts are omitted for the sake of clarity. [b] Determined via titration with I2.  
[c] Isolated yield of analytically pure product. [d] 1 equiv of CuCN·2LiCl was used. [e] 2% CuCN·2LiCl 
was used. [f] 2% Pd(PPh3)4 was used and the reaction was performed at 50 °C. 
 
A functionalization of the related 1,2-dibromocyclohexene employing this method has 
not been possible. Since the 6-membered ring has a smaller ring strain, the initially 
formed organomagnesium reagent presumably eliminates MgBr2 leading to cyclohexyne 
which undergoes fast side reactions such as trimerisation (Scheme 102).  
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Scheme 102: Reaction of 1,2-dibromocyclohexene with Mg in the presence of ZnCl2 and LiCl 
leading to elimination and subsequent trimerisation. 
 
However, the increased ring strain in the dibromo-norbornadiene derivative 42e 
prevents this elimination reaction and the corresponding zinc reagent 43e is obtained 
within 1 h in 70% yield using Mg (2.5 equiv) in the presence of LiCl (1.5 equiv) and 
ZnCl2 (1.1 equiv) (Scheme 103). A Pd-catalyzed cross-coupling of 43e with ethyl 4-
iodobenzoate (39h) produces the arylated norbornadiene 44l in 60% yield. A Cu(I)-
catalyzed allylation reaction with ethyl 2-(bromomethyl)acrylate (39b) leads to the 
desired product 44m in 61% yield. 
Scheme 103: Selective insertion of Mg in the presence of ZnCl2 and LiCl in the alkenyl 
dibromide 42e and subsequent functionalizations (additional complexed salts are omitted for the 
sake of clarity). 
 
 As expected, alkenyl bromides bearing an electron-donating substituent such as  
(2-bromocyclopent-1-en-1-yl)(phenyl)sulfane (42f) do not undergo a direct zinc 
insertion. However, using Mg (2.5 equiv) in the presence of LiCl (1.5 equiv) and ZnCl2 
(1.1 equiv) furnishes 43f within 1 h in 69% yield (Scheme 104). A subsequent Pd-
catalyzed cross-coupling reaction with ethyl 4-iodobenzoate (39h) leads to the arylated 
cyclopentene 44n in 81% yield. A Cu(I)-mediated acylation of 43f with 4-chlorobenzoyl 
chloride (39l) furnishes the unsaturated ketone 44o in 86% yield. 
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Scheme 104: Selective insertion of Mg in the presence of ZnCl2 and LiCl in the alkenyl bromide 
42f and subsequent functionalizations (additional complexed salts are omitted for the sake of 
clarity). 
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5. SYNTHESIS OF FUNCTIONALIZED ADAMANTYLZINC REAGENTS 
USING A Br/Mg-INSERTION IN THE PRESENCE OF ZnCl2 
5.1 INTRODUCTION 
Synthesis of organomagnesium reagents is known for many years.16-21 Nevertheless, 
none of these many studies provides an explanation for the systematic failures 
encountered in attempts at synthesizing cage-structure organomagnesium compounds. 
Thus, at no time does 1- or 2-adamantyl bromide yield an organometallic compound, 
whereas secondary or tertiary halides such as isopropyl chloride, tert-butyl chloride, and 
3-chloro-3-ethylpentane give excellent yields of organomagnesium compounds.215 The 
reaction of 1-adamantylmagnesium bromide with highly reactive magnesium (Mg*) 
obtained in situ by the standard method of Rieke and coworkers216 could not furnish any 
trace of organomagnesium compound. Instead, a 60% yield of hydrolysed adamantane 
and a 30% yield of homocoupling product can be isolated (Scheme 105).215 
 
Scheme 105: Reaction of adamantyl bromide with Rieke-Mg (Mg*). 
 
However, Dubois et al. develop a so-called "static" method whereby the entire 
reaction was conducted without any stirring of the reaction medium leading to 58% yield 
of 1-adamantylmagnesium bromide (Scheme 106).217 When this process was extended to 
2-AdBr, the yield of 2-adamantylmagnesium bromide lay at 60%.  
 
Scheme 106: Successful synthesis of adamantylmagnesium bromide. 
 
It was shown, that the success of this “static” method lay in the preservation of the 
surface state of the magnesium. The formation of organomagnesium compounds is a 
typical surface reaction, whereas the side reactions occur in the medium. Competition 
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between these two reaction pathways is depending on the degree of adsorption of the 
transient species at the metal surface. Since the volume of cage-structure adamantane has 
a steric effect on the degree of adsorption of the transient species, the reactions in the 
medium are favoured. This explains the failures to obtain an organometallic compound 
with stirring. In contrast, with less hindered molecules, surface reactions are favored, and 
the organometallic compounds are formed readily.215 
Until 1983, all attempts for the direct synthesis of organolithium compounds218 had 
failed, and only the halogene/lithium exchange reactions furnished a few cage-structure 
organolithium compounds.219 The syntheses using secondary or tertiary adamantyl 
halides and methyl or tert-butyllithium, tertiary220 and secondary220d,221 adamantyl 
organolithium compounds could be obtained only when an excess of tert-butyllithium 
was used. Extension of the previously described method used for magnesium 
compounds215 to organolithium compounds was unsuccessful since tertiary 
organolithium compounds are known to attack diethyl ether at a temperature above  
-30 °C. Moreover, in the absence of stirring, lithium chloride slowly coats the metal with 
a film rapidly inhibiting the attack by the halogenated derivative.222 By using a 2% 
sodium lithium alloy in an apolar solvent, Dubois and coworker prevented scouring the 
metal surface during synthesis and limited solvent-attack side reactions. Under these 
conditions, 1-adamantyllithium could be obtained for the first time in a high yield 
(Scheme 107).222 
 
Scheme 107: Synthesis of adamantyllithium using a 2% sodium lithium alloy. 
 
In 1973, Rieke and coworkers reported a general approach for the preparation of 
highly reactive zinc (Zn*) allowing for the first time the oxidative addition to primary 
alkyl bromides as well as to aryl iodides and bromides.223 In 1991, they published an 
improved method which was not only safer but also furnished a more reactive zinc 
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enabling the synthesis of secondary and tertiary alkyl bromides to yield the 
corresponding organozinc reagents in good yields under mild conditions.224 Thus,  
1-adamantyl bromide reacts within 2 h under reflux with Zn* furnishing the 
corresponding organozinc species in 65% yield (Scheme 108). 
Scheme 108: Synthesis of adamantylzinc chloride using Rieke-Zn (Zn*). 
 
The trimethylstannylation of 1-bromo- and 1-iodoadamantanes as well as of 2-bromo-
adamantane has been shown to occur by free radical intermediates in an SRN1 like 
reaction.225 Also 1,3-dihaloadamantane derivatives undergo the trimethylstannylation 
exclusively in a SRN1 like manner (Scheme 109).226  
 
Scheme 109: Trimethylstannylation of 1-bromo-3-chloroadamantane. 
 
Noteworthy, the photostimulated reaction of Me3Sn- anions with 1-chloro- and 1-
bromoadamantane in liquid ammonia afforded within a few minutes the corresponding 
stannylated products in good yields.225b  
Recently, Knochel and coworkers have developed a practical and useful method for 
the synthesis of alkyl-,64a,65b aryl-,21,64b and benzylzinc64b,65a,207 halides via LiCl-mediated 
metal-insertion into the corresponding chlorides and bromides. Based on these results, we 
searched for a convenient, mild and atom economical4 methodology for the preparation 
of functionalized adamantylzinc reagents starting from readily available adamantyl 
bromides bearing for the first time sensitive functional moieties. 
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5.2 PREPARATION OF FUNCTIONALIZED ADAMANTYLZINC REAGENTS 
Preliminary experiments have shown that only the use of the highly reactive Rieke-
zinc (Zn*) provides a direct zinc insertion. Since we wanted to avoid the use of 
stochiometric amounts of lithium naphthalide, the main focus lay on the use of a stronger 
reducing metal than zinc. Thus, the LiCl-mediated Mg insertion in the presence of ZnCl2 
allowed an efficient synthesis of adamantylzinc reagents 46 starting from the 
corresponding tertiary bromides 45 (Scheme 110). 
+ Mg + LiCl
THF
0 to 25 °C
2-3 h
+ ZnCl2Br
R
ZnCl MgBrCl LiCl
R
(2 equiv) (1.1 equiv)(1.1 equiv)
ZnX
46a: 85%
ZnX
46b: 63%
ZnX
46c: 57%
CO2Et O
O
45 46
Scheme 110: Preparation of functionalized adamantylzinc reagents 46 via the LiCl-mediated 
Mg-insertion in the presence of ZnCl2 (additional complexed salts are omitted for the sake of 
clarity). 
  
As illustrated in Scheme 110, the zinc species 46a was obtained from 1-bromo-
adamantane 45a within 2 h at ambient temperature in 85% yield using Mg (2 equiv) in 
the presence of LiCl (1.1 equiv) and ZnCl2 (1.1 equiv). Remarkably, also the 
functionalized adamantylzinc reagents 46b and 46c have been obtained for the very first 
time in 63% and 57% yield, following this procedure. Noteworthy, the acetal protection 
of the keto-function of 5-bromoadamantan-2-one was compulsory since the preparation 
of the zinc reagent from the unprotected ketone caused the cleavage of the cage structure. 
 
5.3 FUNCTIONALIZATION OF ADAMANTYLZINC REAGENTS 
The obtained adamantylzinc reagents 46a-c have proven to be highly reactive and 
readily undergo a broad variety of functionalization reactions in the presence of an 
appropriate catalyst. Thus, zinc reagent 46a smoothly reacts in a Pd-catalyzed Negishi 
cross-coupling reaction145,208 with aryl halides 47a-m. Using 1% Pd(OAc)2 and  
2% SPhos227 as catalytic system, zinc reagent 46a reacts within 2 h at 50 °C with the 
ester substituted aryl iodide 47a, aryl bromide 47b and even the aryl chloride 47c to the 
corresponding cross-coupling product 48a in excellent yields (Scheme 111). 
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Scheme 111: Negishi cross-coupling reaction of adamantylzinc reagent 46a with aryl halides of 
type 47 (additional complexed salts are omitted for the sake of clarity). 
 
Various electron-rich and electron-poor electrophiles (0.9 equiv) are used in the cross-
coupling reaction at 50 °C affording the corresponding arylated adamantyl derivatives 
48b-i in good to excellent yields, tolerating functional groups like nitril, aldehyde, ketone 
or carbamate (Table 23, entries 1-8). Noteworthy, also double cross-coupling could be 
achieved under these reaction conditions (entries 9 and 10), furnishing the corresponding 
products 48l and 48m in 82% and 55% yield, respectively. 
 
Table 23: Negishi cross-coupling reactions of adamantylzinc reagent 46a with aryl bromides of 
type 47. 
Entry Zn-Reagent Electrophile Product, Yield[a] 
 ZnX
 
 
 
1 46a  47d 48b: 88%[b] 
 
 
 
 
2 46a 47e 48c: 84%[b] 
 
 
 
 
3 46a 47f 48d: 94%[b] 
 
 
  
4 46a 47g 48e: 62%[b] 
  
 
 
5 46a 47h 48f: 80%[b] 
  
 
 
6 46a 47i 48g: 88%[b] 
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7 46a 47j 48h: 70%[b] 
 
 
 
 
8 46a 47k 48i: 95%[b] 
 
 
 
 
9 46a 47l 48j: 82%[c] 
 
 
 
 
10 46a 47m 48k: 55%[d] 
[a] Yield of analytically pure isolated product as determined by 1H NMR analysis. [b] Obtained after a 
Negishi cross-coupling (Pd(OAc)2 (1 mol%) and SPhos (2 mol%)) with ArBr (0.9 equiv). [c] Obtained 
after a Negishi cross-coupling (Pd(OAc)2 (1 mol%) and SPhos (2 mol%)) with 2,7-dibromo-fluorene  
(0.45 equiv). [d] Obtained after a Negishi cross-coupling (Pd(OAc)2 (2 mol%) and SPhos (4 mol%)) with 
4,4'-dibromo-1,1'-biphenyl (0.4 equiv). 
 
As illustrated in Scheme 112, also heteroaryl bromides have been employed in the 
Negishi cross-coupling reactions. Adamantyl zinc reagent 46a reacts smoothly with   
3-bromobenzothiophene (49a, 0.9 equiv) at 50 °C within 2 h to the corresponding 
substituted adamantane 48l in 84% yield. 
 
Scheme 112: Negishi cross-coupling reaction of adamantylzinc reagent 46a with 3-bromobenzo-
thiophene (49a) (additional complexed salts are omitted for the sake of clarity). 
 
A broad variety of heteroaryl bromides as electrophiles produce under standard 
conditions the desired products 48m-r in excellent yields (Table 24). In particular, 
benzofuran, benzothiazol, protected indol or different thiophene derivatives have 
successfully been employed in the cross-coupling reaction furnishing the corresponding 
heteroarylated adamantan compounds 48m-r in good to excellent yields. 
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Table 24: Negishi cross-coupling reactions of adamantylzinc reagent 46a with heteroaryl 
bromides of type 49. 
Entry Zn-Reagent Electrophile Product, Yield[a] 
 
 
 
 
1 46a  49b 48m: 57%[b] 
 
 
 
 
2 46a 49c 48n: 91%[b] 
 
 
 
 
3 46a 49d 48o: 71%[b] 
 
 
 
 
4 46a 49e 48p: 61%[b] 
 
 
 
 
5 46a 49f 48q: 53%[b] 
 
 
 
S S
 
6 46a 49g 48r: 58%[b] 
[a] Yield of analytically pure isolated product as determined by 1H NMR analysis. [b] Obtained after a 
Negishi cross-coupling (Pd(OAc)2 (1 mol%) and SPhos (2 mol%)) with heteroaryl bromide (0.9 equiv). 
 
Adamantylzinc reagent 46a also undergoes Cu(I)-catalyzed acylation reactions leading 
to the desired ketone derivatives 51a-d in good to excellent yields (Scheme 113 and 
Table 25). 46a reacted with 4-fluorobenzoyl chloride (50a, 0.9 equiv) and 20% 
CuCN·2LiCl to the corresponding ketone 51a in 89% yield (Scheme 113).  
+
CuCN 2LiCl (0.2 equiv)
THF, -40 to 25 °C, ovn
51a: 89%
50a (0.9 equiv)
ZnX
46a
O
Cl
F
O
F
 
Scheme 113: Cu(I)-catalyzed acylation reaction of adamantylzinc reagent 46a with 4-fluoro-
benzoyl chloride (50a) (additional complexed salts are omitted for the sake of clarity). 
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Under the same reaction conditions, also other acid chlorides 50b-d have been 
employed in the Cu(I)-catalyzed acylation reaction. Not only the substituted benzoyl 
chlorides 5b-c undergo the acylation reaction with adamantylzinc species 46a in good 
yields (Table 25, entries 1 and 2), also the heteroaromatic 6-chloronicotinoyl chloride 
(50d) furnished the corresponding ketone 51d in the acceptable yield of 44% (entry 3). 
 
Table 25: Cu(I)-catalyzed acylation reactions of adamantylzinc reagent 46a with acid chlorides 
of type 50. 
Entry Zn-Reagent Electrophile Product, Yield[a] 
 ZnX
 
Cl
O
Cl
 
 
1 46a  50b 51b: 70%[b] 
 
 
 
 
2 46a 50c 51c: 80%[b] 
 
 
 
 
3 46a 50d 51d: 44%[b] 
[a] Yield of analytically pure isolated product as determined by 1H NMR analysis. [b] Obtained after a 
acylation reaction (CuCN·2LiCl (0.2 equiv)) with acid chloride (0.9 equiv). 
 
Besides Pd-catalyzed Negishi cross-coupling reactions and Cu(I)-catalyzed acylation 
reactions the highly reactive adamantylzinc reagent 46a also reacts in a a Cu(I)-catalyzed 
allylation reaction146 with ethyl 2-(bromomethyl)acrylate (52a, 0.9 equiv) leading to the 
desired product 53a in 91% yield (Table 26, entry 1).  Moreover, the copper-catalyzed 
reaction11a,146 of 46a with the bromoacetylene 52b209 (0.9 equiv) affords the highly 
functionalized acetylene 53b in 66% yield (entry 2). Furthermore, the adamantylzinc 
reagent 46a also reacts smoothly with S-phenyl benzenesulfonothioate (52c, 0.9 equiv) 
affording thioether 9c in almost quantitative yield (entry 3). Additionally, the Cu(I)-
mediated reaction with cyclohex-2-enone (52d, 0.9 equiv) furnishes the desired 1,4-
addition product 53d in 91% yield (entry 4). 
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Table 26: Further functionalization reactions of adamantylzinc reagent 46a with various 
electrophiles. 
Entry Zn-Reagent Electrophile Product, Yield[a] 
 ZnX
 
 
 
1 46a  52a 53a: 91%[b] 
 
 
 
 
2 46a 52b 53b: 66%[c] 
 
 
 
 
3 46a 52c 53c: 98%[d] 
 
 
 
 
4 46a 52d 53d: 91%[e] 
[a] Yield of analytically pure isolated product as determined by 1H NMR analysis. [b] Obtained after 
allylation reaction (CuCN·2LiCl
 
(0.2 equiv)) with ethyl 2-(bromomethyl)acrylate (0.9 equiv). [c] Obtained 
after alkynylation reaction (CuCN·2LiCl
 
(0.2 equiv)) with ethyl 3-bromopropiolate (0.9 equiv). [d] 
Obtained after addition to S-aryl benzenethiosulfonate (0.9 equiv). [e] Obtained after 1,4-addition 
(CuCN·2LiCl (1.1 equiv) and TMSCl (2.0 equiv))
 
with cyclohex-2-enone (0.9 equiv). 
 
Amination reactions are well known in literature.228 Recently, several Pd(0)-229 and 
Cu(I)-catalyzed230 reactions between aromatic halides and various amines have been 
reported. Moreover, Knochel and coworkers found that this synthetic transformation can 
also be realized by reacting various arylmagnesium species with nitroarenes leading after 
a reductive workup to polyfunctional amines.231 In order to avoid the use of 2 equivalents 
of arylmagnesium species, they employed nitrosoarenes for the amination reaction.232  
It turned out that also the adamantylzinc reagent 46a readily reacts at ambient 
temperature within 2 h with nitroarenes of type 54. After reductive workup, the 
substituted amino derivatives 55a and 55b could be obtained in 89% and 71% yield, 
respectively (Scheme 114). 
                                                 
228
 Modern Amination Methods (Ed.: A. Ricci) Wiley-VCH, Weinheim, 2000. 
229
 a) B. H. Yang, S. L. Buchwald, J. Organomet. Chem. 1999, 576, 125. b) J. P. Wolfe, S. Wagan,  
J.-F. Marcoux, S. L. Buchwald, Acc. Chem. Res. 1998, 31, 805. c) J. F. Hartwig, Angew. Chem. Int. Ed. 
1998, 37, 2046. d) L. M. Alcazar-Roman, J. F. Hartwig, A. L. Rheingold, L. M. Liable-Sands, I. A. Guzei, 
J. Am. Chem. Soc. 2000, 122, 4618. 
230
 a) A. Klapars, J. C. Antilla, X. Huang, S. L. Buchwald, J. Am. Chem. Soc. 2001, 123, 7727.  
b) M. Wolter, A. Klapars, S. L. Buchwald, Org. Lett. 2001, 3, 3803. c) R. Shen, J. A. Porco, Org. Lett. 
2000, 2, 1333. d) A. V. Kalinin, J. F. Bower, P. Riebel, V. Snieckus, J. Org. Chem. 1999, 64, 2986. 
231
 I. Sapountzis, P. Knochel, J. Am. Chem. Soc. 2002, 124, 9390. 
232
 F. Kopp, I. Sapountzis, P. Knochel Synlett 2003, 6, 885. 
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Scheme 114: Addition of adamantylzinc reagent 46a aryl nitroso compounds 54 and subsequent 
reduction to amines of type 55 (additional complexed salts are omitted for the sake of clarity). 
 
Analogous to the unfunctionalized adamantylzinc reagent 46a, the ester-substituted 
adamantylzinc derivative 46b readily reacts in a Pd-catalyzed Negishi cross-coupling 
with 4-bromothioanisole (47f, 0.9 equiv) at 50 °C within 2 h to the highly functionalized 
adamantyl derivate 56a in 87% yield (Scheme 115).  
 
Scheme 115: Negishi cross-coupling reaction of adamantylzinc reagent 46b with 4-bromothio-
anisole (47f) (additional complexed salts are omitted for the sake of clarity). 
 
Under the same reaction conditions, also ethyl 4-bromobenzoate (47b, 0.9 equiv) and  
5-bromo-2-methylbenzothiazole (49c, 0.9 equiv) have been employed in the Pd-catalyzed 
Negishi reaction with the ester-substituted adamantylzinc species 46b. The corresponding 
cross-coupling products 56b and 56c have been obtained in 84% and 70%, respectively 
(Table 27, entries 1 and 2). Moreover, adamantylzinc reagent 46b also undergoes 
smoothly Cu(I)-catalyzed acylation reactions with 4-chlorobenzoyl chloride (50b,  
0.9 equiv)  and 2-furoyl chloride (50e, 0.9 equiv) leading to the desired ketone 
derivatives 57a and 57b in good to excellent yields (entries 3 and 4).  
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Table 27: Functionalization reactions of adamantylzinc reagent 46b with various electrophiles. 
Entry Zn-Reagent Electrophile Product, Yield[a] 
 
 
 
 
1 46b  47b 56b: 84%[b] 
 
 
 
 
2 46b 49c 56c: 70%[b] 
 
 
Cl
Cl
O
 
 
3 46b 50b 57a: 82%[c] 
 
 
 
 
4 46b 50e 57b: 54%[c] 
[a] Yield of analytically pure isolated product as determined by 1H NMR analysis. [b] Obtained after a 
Negishi cross-coupling (Pd(OAc)2 (1 mol%) and SPhos (2 mol%)) with (hetero)aryl bromide (0.9 equiv). 
[c] Obtained after a acylation reaction (CuCN·2LiCl (0.2 equiv)) with acid chloride (0.9 equiv). 
 
Also the adamantylzinc reagent 46c could easily be functionalized by Pd-catalyzed 
Negishi cross-coupling reactions with both electron-poor and electron-rich aryl bromides. 
The highly functionalized cross-coupling products 58a-c have been obtain in high yields 
(Scheme 116). 
 
Scheme 116: Negishi cross-coupling reactions of adamantylzinc reagent 46c with aryl bromides 
of type 47 (additional complexed salts are omitted for the sake of clarity). 
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5.4 APPLICATION OF ADAMANTYLZINC REAGENTS 
The synthesis and investigation of well-defined model oligomers has recently become 
useful to gain insight into the structural and electronic properties of the corresponding 
polymers. Depending on their size and substitution pattern the oligothiophenes are 
usually more soluble than polymers allowing the precise characterization of the 
electronic and geometric structure both in solution and in solid state.233  
In analogy to the polymers, the solubility of oligothiophenes decreases dramatically 
with increasing chain length, which is due to the stiffness of the conjugated pi-system and 
the strong interactions between the chains. The problem of low solubility can be solved 
by the synthesis of corresponding oligothiophenes bearing alkyl substituents.234 Several 
α-alkyl and α,α'-dialkyl-substituted oligothiophenes were synthesized and characterized 
by different research groups. Especially, monosubstituted derivatives are attractive 
candidates since they offer the possibility of dimerizing them to the corresponding α,α’-
disubstituted oligothiophenes with doubled conjugated chain length.233  
Following this idea, adamantylzinc reagent 46a has been submitted to a Negishi cross-
coulpling reaction with the 5-bromo-terthiophene 49h furnishing the corresponding α-
substituted oligothiophene 48s in 64% yield (Scheme 117). 
Scheme 117: Negishi cross-coupling reactions of adamantylzinc reagent 46a with 5-bromo-
2,2':5',2''-terthiophene (49h) (additional complexed salts are omitted for the sake of clarity). 
 
Subsequently, the adamantyl-substituted oligothiophene 48s has been selectively 
brominated at the α-position of the oligothiophene with NBS leading to the 
corresponding product 59 in an almost quantitative manner (Scheme 118). 
 
Scheme 118: Selective bromination of the adamantyl-substituted oligothiophene 4s using N-
bromosuccinimide. 
 
The Kumada cross-coupling reaction together with the homocoupling of thienyl-
Grignard reagents have become the most frequently used methods in the synthesis of 
                                                 
233
 P. Bäuerle, The Synythesis of Oligothiophenes in Handbook of Oligo- and Polythiophenes (Ed.:  
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234
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various oligothiophenes.235 From the large variety of catalysts examined for thiophene 
synthesis, Ni(dppp)Cl2,236 Ni(dppf)C12,237 and Ni(dppe)C12236 turned out to be the  
most effective.  
Thus, the α,α’-diadamantyl-sexithiophene 60 could be synthesized in 77% yield by 
the reaction of the corresponding Grignard reagent of the brominated adamantyl-
substituted oligiothiophene 59 by using Ni(dppp)Cl2 as catalyst in the homocoupling 
(Scheme 119). 
Scheme 119: Synthesis of α,α’-diadamantyl-sexithiophene 60 via Ni-catalyzed dimerisation  
of 59. 
 
Since the solubility of unsubstituted sexithiophene is lower than 50 mg/l chloroform234 
and even the α,α’-di-n-hexyl-substituted sexithiophene shows only a low solubility, it is 
noteworthy that the α,α’-diadamantyl-sexithiophene 60 is excellent soluble in all 
common organic solvents. The high solubility arises most probably from two reasons; on 
one hand, the apolar adamantyl-moiety is known to strongly increase the lipophilicity of 
molecules and on the other hand its bulkiness should prevent the pi-stacking of the 
oligothiophenes.  
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6. FULL FUNCTIONALIZATION OF THE IMIDAZOLE SCAFFOLD BY 
SELECTIVE METALATION AND SULFOXIDE/MAGNESIUM 
EXCHANGE 
6.1 INTRODUCTION 
Among functionalized imidazole derivatives a huge variety of compounds are known 
to possess a broad range of significant biological properties or are important templates in 
medicinal chemistry238 (e.g. as antibacterial,239 anticancer240 or anti-inflammatory241 
pharmaceuticals). Due to their importance a number of methods has been described in the 
literature allowing the construction of the heteroaromatic core of these substances by 
cyclization protocols.242 However, recently much more attention lay on the design and 
development of efficient protocols that are based on the selective functionalization of the 
imidazole ring via transition metal-catalyzed reactions. This enabled the synthesis of 
imidazole derivatives, including bioactive and/or naturally occurring compounds, which 
cannot be accessed by other means.238 
Rossi et al. described in 2007 a attractive, convenient and practical procedure243 for 
the synthesis of free (NH)-2-arylimidazoles. Free (NH)-imidazoles were reacted with  
2 equivalents of electron-deficient, electron-rich or electron-neutral aryl iodides in DMF 
in the presence of a catalytic amount of Pd(OAc)2 and 2 equivalents of CuI under base-
free and ligandless conditions to give the required 2-arylimidazoles in satisfactory yields 
and with excellent regioselectivity (Scheme 120).  
 
Scheme 120: Pd-catalyzed Cu-mediated arylation at position 2 with aryl iodides. 
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 For reviews, see: a) F. Bellina, R. Rossia, Adv. Synth. Catal. 2010, 352, 1223. b) T. Satoh, M. Miura, 
Chem. Lett. 2007, 36, 200. c) M. Schnürch, R. Flasik, A. F. Khan, M. Spina, M. D. Mihovilovic,  
P. Stanetty,  Eur. J. Org. Chem. 2006, 328. d) H. Du, Y. He, R. Sivappa, C. J. Lovely, Synlett 2006, 7, 965. 
239
 M. Antolini, A. Bozzoli, C. Ghiron, G. Kennedy, T. Rossi, A. Ursini, Bioorg. Med. Chem. Lett. 1999, 9, 
1023. 
240
 L. Wang, K. W. Woods, Q. Li, K. J. Barr, R. W. McCroskey, S. M. Hannick, L. Gherke, R. B. Credo, 
Y.-H. Hui, K. Marsh, R. Warner, J. Y. Lee, N. Zielinski-Mozng, D. Frost, S. H. Rosenberg, H. L. Sham,  
J. Med. Chem. 2002, 45, 1697. 
241
 J. C. Lee, J. T. Laydon, P. C. McDonnell, T. F. Gallagher, S. Kumar, D. Green, D. McNulty,  
M. J. Blumenthal, J. R. Heys, S. W. Landvatter, J. E. Strickler, M. M. McLaughlin, I. R. Siemens,  
S. M. Fisher, G. P. Livi, J. R. White, J. L. Adams, P. R. Young, Nature 1994, 372, 739. 
242
 For review, see: B. E. Maryanoff, H.-C. Zhang, J. H. Cohen, I. J. Turchi, C. A. Maryanoff, Chem. Rev. 
2004, 104, 1431. 
243
 a) F. Bellina, C. Calandri, S. Cauteruccio, R. Rossi, Tetrahedron 2007, 63, 1970. b) F. Bellina,  
S. Cauteruccio, R. Rossi, Eur. J. Org. Chem. 2006, 1379. 
B. RESULTS AND DISCUSSION 
113 
Sessler and coworkers reported a procedure for the synthesis of 2,2’-biimidazoles via 
a Pd-catalyzed homocoupling of 2-iodoimidazoles in toluene in the presence of Et3N 
(Scheme 121).244  These 2-iodo derivatives were synthesized by treatment of the 
corresponding 2-unsubstituted imidazoles with N-iodosuccinimide (NIS) in refluxing 
THF (Scheme 121).244  
 
Scheme 121: Synthesis of free (NH)-2,2’-biimidazole derivatives. 
 
Starting from 1987, Stille-type reactions have frequently been used to introduce 
organic groups at the 2-position of 1-methylimidazole derivatives.245 1-Methyl-2-
tributylstannylimidazole, commercially available but also readily accessible in high yield 
by C-2 lithiation of 1-methylimidazole followed by treatment with tributyltin chloride, 
has been used in Pd-catalyzed reactions.245 Wasserscheid et al. used catalytic amounts of 
PdCl2(PPh3)2 in a Stille-type reaction of 1-methyl-2-tributylstannylimidazole with 4-
fluoroiodobenzene in THF under reflux to synthesize 2-(4-fluorophenyl)-1-
methylimidazole in 70% yield (Scheme 122).245d 
 
Scheme 122: Stille-type reaction of 1-methyl-2-tributylstannylimidazole. 
 
In 2003, Sudhçlter and coworkers prepared a 2,6-diimidazol-2-ylpyridine derivative in 
79% yield via Pd(PPh3)4-catalyzed double cross-coupling reaction of 1-methyl-2-
tributylstannylimidazole with 2,6-dibromo-4-ethoxycarbonylpyridine in toluene under 
reflux (Scheme 123).245e 
                                                 
244
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Scheme 123: Stille-type reaction of 1-methyl-2-tributylstannylimidazole. 
 
Also Suzuki-Miyaura cross-coupling reactions have been employed successfully to 
introduce aryl and alkenyl groups into the 2-position of imidazole derivatives. In 2005, 
Langhammer and Erker reported the Pd(PPh3)4-catalyzed reaction of 2-iodo-1-[(4-
methylthio)phenyl]imidazole with 3-methoxyphenylboronic acid in the presence of 
K2CO3 as the base to give  the arylated imidazole in 78% yield (Scheme 124). 2-iodo-1-
[(4-methylthio)phenyl]imidazole, which was employed as the electrophile, was obtained 
by C-2 lithiation of 1-[(4-methylthio)phenyl)]-imidazole and subsequent quenching with 
iodine.246  
 
Scheme 124: Suzuki-Miyaura cross-coupling reaction of 2-iodo-1-[(4-methylthio)phenyl]-
imidazole. 
 
Stille-type cross-couplings have also frequently been used to efficiently introduce 
organic groups into the 4-position of 1-substituted imidazoles. In 1996, Cliff and Pyne 
described a Pd2(dba)3/AsPh3/CuI-catalyzed reaction of 1-ethoxymethyl-4-trimethyl-
stannylimidazole with β-bromostyrene (E/Z=10:1) furnishing (E)- and (Z)-1-ethoxy-
methyl-4-(2-phenylethenyl)imidazole in 68% and 12% yield, respectively (Scheme 125). 
The 1-substituted 4-trialkylstannylimidazole was prepared by treatment of the 
corresponding iodo-imidazole derivative with EtMgBr in CH2Cl2 followed by quenching 
with Me3SnCl (Scheme 125).247 
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Scheme 125: Stille-type reaction for the functionalization of position 4 on the imidazole ring.  
 
In 2000, Wrobel et al. developed a three-step synthesis for the selective arylation in 
position 5 of the imidazole ring. The iodoimidazole was prepared by C-2 lithiation of  
1-methylimidazole followed by treatment with diphenyl disulfide. The resulting 
compound was then sequentially treated with nBuLi in THF at -78 °C and iodine to give 
5-iodo-1-methyl-2-phenylsulfonylimidazole in 80% yield (Scheme 126).248 
Subsequently, a Suzuki-Miyaura reaction of 5-iodo-1-methyl-2-phenylsulfonylimidazole 
with phenylboronic acid furnished the arylated imidazole in 73% yield (Scheme 126). It 
should be mentioned that the PdCl2(PPh3)2-catalyzed Stille-type reaction of the iodo-
imidazole derivative with phenyltrimethylstannane in DMF led to the cross-coupling 
product in less yield (62%) than in the Suzuki-Miyaura reaction with phenylboronic acid 
under the conditions shown in Scheme 126.249 
Scheme 126: Three-step synthesis for the selective functionalization of position 5 on the 
imidazole ring. 
 
 
In 2010, Sames and coworkers reported a general and comprehensive approach for the 
synthesis of complex aryl imidazoles, in which all three C–H bonds of the imidazole core 
have been arylated in a regioselective and sequential manner.250 To circumvent the low 
reactivity of the C-4 position, a transfer from the protecting group on N-1 to N-3 nitrogen 
was introduced. This enabled the preparation of 4-arylimidazoles and sequential C4-C5-
arylation of the imidazole core (Scheme 127), providing rapid access to all regioisomers 
of mono-, di-, and triarylimidazoles.250 
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Scheme 127: Selective arylation of position 2, 4 and 5 on the imidazole ring via Heck-type cross-
coupling reactions. 
 
There are a number of established protocols for the synthesis of substituted imidazoles 
where the imidazole ring is constructed via cyclo-condensation as well as via direct 
arylation reactions. Although these approaches have been improved over the past decade, 
each method has its scope and efficiency limitations like generation of isomers or 
unselective functionalization reactions.250,251 In contrast to conventional condensation 
and arylation methods, selective metalation reactions would enable the derivatization and 
elaboration of the imidazole ring in a regioselective manner and provide new possibilities 
for the synthesis of complex imidazole derivatives. Hence, we were looking for a mild 
and general metalation protocol allowing the flexible synthesis of individually substituted 
imidazole derivatives. 
 
6.2 OVERVIEW 
TMP-bases like TMPMgCl·LiCl or TMPZnCl·LiCl are known as mild and 
chemoselective metalating reagents for hydrogen-metal interconversion on sensitive 
substrates. A variety of sensitive aromatic and heteroaromatic compounds could be 
smoothly metalated and subsequently functionalized.27,28,29,68 Hence, we decided in the 
search for a general, selective and flexible methodology for the full functionalization of 
the imidazole scaffold to focus on metalation reactions using these type of bases.  
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Scheme 128 illustrates a general overview for the fully functionalization of the imidazole 
scaffold starting from the double protected imidazole 61.  
Scheme 128: Selective fully functionalization of the imidazole ring in a regioselective manner. 
 
The protected imidazole 61 was regioselective metalated in position 5 by using 
TMPMgCl·LiCl (62). The subsequent sulfinylation employing 4-methoxy-3,5-dimethyl-
benzenesulfinyl chloride153c,252,253,254 (68a) led to imidazole 67. The sulfoxide group on 
position 5 was found to be essential for the full functionalization procedure, since it 
allows both the direct metalation in ortho position and its replacement by a 
sulfoxide/magnesium exchange. Hence, the sulfoxide substituent enabled the subsequent 
metalation with TMPMgCl·LiCl (62) in position 4. After functionalization of the 
magnesium species 69 imidazoles of type 70 were obtained. The next functionalization 
step was performed in position 5 by means of a sulfoxide/magnesium exchange. Thus, 
treatment of imidazole derivatives 70 with iPrMgCl·LiCl (63) led to the corresponding 
magnesium intermediates 71 which could readily be functionalized leading to imidazoles 
of type 72. The protecting group in position 2 was then selectively removed followed by 
metalation using either TMPMgCl·LiCl (62) or TMP2Zn·2MgCl·2LiCl (65). The 
metalated imidazole derivatives 74 and 75 were then functionalized to give imidazoles of 
type 76. In the final step, the N-3 nitrogen was selectively alkylated by using Meerwein’s 
reagent (66, triethyloxonium tetrafluoroborate) furnishing the corresponding imidazolium 
salts 77. Afterwards, nitrogen N-1 was deprotected and the alkylated imidazoles of type 
78 were obtained. Using this protocol, all positions of the imidazole scaffold could be 
functionalized in a selective manner. 
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6.3 SELECTIVE FUNCTIONALIZATION ON POSITION 4 OF THE IMIDAZOLE RING 
Preliminary experiments have shown that the best combination of protecting groups 
for the use of TMP-bases in the full functionalization of the imidazole scaffold is a 
TBDMS-group in position 2 and a N,N-dimethylsulfamoyl group at nitrogen N-1 
(position 1). The TBDMS-group has proven to be stable under the metalation conditions 
but is also easily removeable by treatment with TBAF.255 
Since the main challenge faced by the regioselective functionalization of imidazoles is 
the differentiation of positions 4 and 5 we envisioned an elegant way to solve this issue 
by introduction of a protecting group on the N-1 nitrogen directing the metalation to 
position 5.256 When positioned on an aromatic ring, the N,N-dimethylsulfamoyl group is 
known to direct lithiation in the ortho position.257 Moreover, if position 2 of the 
imidazole is already substituted, the presence of this sulfamoyl group on N-1 enables 
highly selective deprotonation in position 5.256,258  
Thus, metalation of the protected imidazole 61259 with the highly chemoselective base 
TMPMgCl·LiCl (62, 1.1 equiv, 25 °C, 1 h) leads to magnesiation in position 5, directed 
by the sulfamoyl group on nitrogen N-1. Subsequent sulfinylation employing 4-methoxy-
3,5-dimethyl-benzenesulfinyl chloride254 (68a, 0.9 equiv, -20 to 25 °C, 4 h) furnishes 
imidazole 67 in 86% yield (Scheme 129). 
 
Scheme 129: Selective metalation in position 5 of the imidazole ring with TMPMgCl·LiCl (62) 
and subsequent sulfoxide synthesis. 
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 M. Gianotti, C. Corti, S. Delle Fratte, R. Di Fabio, C. P. Leslie, F. Pavone, L. Piccoli, L. Stasi,  
M. J. Wigglesworth, Bioorg. Med. Chem. Lett. 2010, 20, 5069. 
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As mentioned before, the sulfoxide group on position 5 was found to be essential for 
the full functionalization procedure, since it allows the direct metalation in ortho position 
(position 4). Hence, the sulfoxide substituent enables the selective metalation of 
imidazole 67 in position 4 with TMPMgCl·LiCl (62, 1.1 equiv, -30 °C, 1 h) in an almost 
quantitative manner. The resulting magnesium reagent 69 was readily used in different 
types of functionalization reactions furnishing the corresponding 4-substituted imidazoles 
of type 70 (Schemes 130-133 and Table 28). 
Scheme 130: Selective metalation in position 4 of the imidazole ring with TMPMgCl·LiCl (62) 
and subsequent functionalization (additional complexed salts are omitted for the sake of clarity). 
 
Thus, after transmetalation with ZnCl2 (1.1 equiv, -30 °C, 15 min), the magnesium 
reagent 69 undergoes smooth Pd-catalyzed Negishi cross-coupling reactions.145,208 Using 
5% Pd(PPh3)4 as catalyst, various electron-rich and electron-poor electrophiles  
(0.9 equiv) are used in the cross-coupling at 50 °C affording the 4-substituted imidazole 
derivatives 70a-f in good to excellent yields (Table 28, entries 1-6). Noteworthy, not only 
the simple aryl iodides 68b-e could be used in the cross-coupling reactions (entries 1-4), 
also a pyridyl (68f, entry 5) and a vinylic iodide (68g, entry 6) lead to good results. 
 
Table 28: Selective metalation in position 4 of the imidazole 67 with TMPMgCl·LiCl (62) and 
subsequent Negishi cross-coupling reactions. 
Entry Mg-Reagent[a] Electrophile Product, Yield[b] 
 
 
 
 
1 69 68b 70a: 84%[c] 
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2 69 68c 70b: 72%[c] 
 
 
 
 
3 69 68d 70c: 71%[c] 
 
 
 
 
4 69 68e 70d: 60%[c] 
  
 
 
5 69 68f 70e: 60%[c] 
  
 
 
6 69 68g 70f: 83%[c] 
[a] Obtained after metalation with TMPMgCl·LiCl (1.1 equiv) in THF at -30 °C in 1 h. [b] Yield of 
analytically pure isolated product as determined by 1H NMR analysis. [c] Obtained after a Negishi cross-
coupling (ZnCl2 (1.1 equiv); then 5% Pd(PPh3)4) with R–I (0.9 equiv).  
B. RESULTS AND DISCUSSION 
121 
Moreover, magnesium reagent 69 also undergoes after transmetalation with ZnCl2  
(1.1 equiv) a Cu(I)-catalyzed allylation reaction146 with ethyl 2-(bromomethyl)acrylate 
(68h, 0.9 equiv) leading to the desired product 70g in 98% yield (Scheme 131).   
 
Scheme 131: Selective metalation in position 4 of the imidazole ring with TMPMgCl·LiCl (62) 
and subsequent Cu-catalyzed allylation (additional complexed salts are omitted for the sake of 
clarity). 
 
Furthermore, the Cu(I)-catalyzed acylation reaction146 of magnesium reagent 69 using 
4-chlorobenzoyl chloride (68i, 0.9 equiv) affords the corresponding ketone 70h in 82% 
yield (Scheme 132). 
 
Scheme 132: Selective metalation in position 4 of the imidazole ring with TMPMgCl·LiCl (62) 
and subsequent Cu-catalyzed acylation (additional complexed salts are omitted for the sake of 
clarity). 
 
The Cu(I)-catalyzed reaction11a,146 of magnesium reagent 69 with the bromoacetylene 
68j260 (0.9 equiv) affords the highly functionalized acetylene 70i in 53% yield  
(Scheme 133). 
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 M. C. P. Yeh, P. Knochel, Tetrahedron Lett. 1989, 30, 4799. 
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Scheme 133: Selective metalation in position 4 of the imidazole ring with TMPMgCl·LiCl (62) 
and subsequent Cu-catalyzed alkynylation (additional complexed salts are omitted for the sake of 
clarity). 
 
6.4 SELECTIVE FUNCTIONALIZATION ON POSITION 5 OF THE IMIDAZOLE RING 
The next functionalization was performed in position 5 by means of a 
sulfoxide/magnesium exchange.153c,252,253 Thus, treatment of imidazole derivatives of 
type 70 with iPrMgCl·LiCl (63, 1.2 equiv) at -78 °C leads within 1 h to the 
corresponding magnesium intermediates of type 71 in almost quantitative yield (Scheme 
134). Subsequently, different types of functionalization reactions have been carried out 
furnishing the corresponding 4- and 5-substituted imidazoles of type 72 (Schemes 134-
136 and Table 29). 
Scheme 134: Selective sulfoxide/Mg exchange in position 5 of the imidazole ring with 
iPrMgCl·LiCl (63) and subsequent functionalization (additional complexed salts are omitted for 
the sake of clarity). 
 
After transmetalation with ZnCl2 (1.2 equiv, -78 °C, 15 min), the magnesium reagents 
of type 71 readily undergo Pd-catalyzed Negishi cross-coupling reactions. Thus, the allyl-
substituted imidazole derivative 71a reacts with 5% of Pd(PPh3)4 as catalyst at  
50 °C and ethyl 4-iodobenzoate (68b, 0.9 equiv) and 4-iodobenzonitrile (68k, 0.9 equiv) 
to the corresponding cross-coupling products 72a-b in good to excellent yields (Table 29, 
entries 1and 2). Also the vinylic substituted imidazole derivative 70f readily undergoes 
after the sulfoxide/magnesium exchange and transmetalation with ZnCl2 (1.2 equiv,  
-78 °C, 15 min) Pd-catalyzed Negishi cross-coupling reactions (entries 3 and 4). 
Noteworthy, the double bond stays untouched and no isomerisation occurs. The 
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magnesium species 71c-e of the arylated imidazole derivatives have also been submitted 
to Pd-catalyzed Negishi reactions furnishing the corresponding cross-coupling products 
72e-i in high yields (entries 5-9).  
 
Table 29: Selective sulfoxide/Mg exchange in position 5 of imidazole derivatives of type 70 with 
iPrMgCl·LiCl (63) and subsequent Negishi cross-coupling reactions. 
Entry Mg-Reagent[a] Electrophile Product, Yield[b] 
 
 
 
 
1 71a  68b 72a: 71%[c] 
 
 
 
 
2 71a 68k 72b: 90%[c] 
 
 
 
 
3 71b 68g 72c: 88%[c] 
 
 
 
 
4 71b 68l 72d: 100%[c] 
 
 
 
 
5 71c 68g 72e: 60%[c] 
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6 71c 68d 72f: 70%[c] 
 
 
 
 
7 71d 68b 72g: 85%[c] 
 
 
 
 
8 71d 68d 72h: 80%[c] 
 
 
 
 
9 71e 68c 72i: 68%[c] 
[a] Obtained after sulfoxide/Mg exchange with TMPMgCl·LiCl (1.2 equiv) in THF at -78 °C in 1 h.  
[b] Yield of analytically pure isolated product as determined by 1H NMR analysis. [c] Obtained after a 
Negishi cross-coupling (ZnCl2 (1.1 equiv); then 5% Pd(PPh3)4) with R–I (0.9 or 1.1 equiv). 
 
In order to prove the existence of the magnesium species and to clarify whether the 
cross-coupling is a Negishi reaction and not a Heck-type reaction, the magnesium species 
71c of imidazole derivative 70a has been submitted to a reaction with  
4-fluorobenzaldehyde (68m, 0.9 equiv) after the sulfoxide/magnesium exchange. The 
obtained alcohol 72j clearly demonstrated the availability of magnesium species 71c 
(Scheme 135). 
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Scheme 135: Selective sulfoxide/Mg exchange in position 5 of the imidazole ring with 
iPrMgCl·LiCl (63) and subsequent addition to aldehyde 68m (additional complexed salts are 
omitted for the sake of clarity). 
 
Cu(I)-catalyzed acylation reactions of magnesium reagents of type 71 furnished only 
hydrolyzed species. Hence, a Pd-catalyzed acylation reaction261 has been employed 
leading to the desired ketone derivatives in good to excellent yields (Scheme 136). The 
vinylic substituted imidazole 70f reacted with 4-chlorobenzoyl chloride (68i, 0.9 equiv) 
and 5% Pd(PPh3)4 after sulfoxide/magnesium exchange and transmetalation with ZnCl2  
(1.2 equiv, -78 °C, 15 min) to the corresponding ketone 72k in 79% yield. Also the 
arylated imidazole 70a furnishes under the same reaction conditions the corresponding 
ketone 72l in 66% yield (Scheme 136). 
 
Scheme 136: Selective sulfoxide/Mg exchange in position 5 of the imidazole ring with 
iPrMgCl·LiCl (63) and subsequent Pd-catalyzed acylation (additional complexed salts are 
omitted for the sake of clarity). 
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6.5 SELECTIVE FUNCTIONALIZATION ON POSITION 2 OF THE IMIDAZOLE RING 
6.5.1 SELECTIVE DEPROTECTION ON POSITION 2 
In order to be able to functionalize in position 2, the TBDMS-group had to be 
selectively removed from the imidazole ring. As illustrated in Scheme 137 imidazole 
derivatives of type 72 have been treated with tetra-n-butylammonium fluoride (64,  
1 equiv) at 0 °C to cleave the C–Si-bond and furnish the unprotected imidazoles 73 in 
quantitative yield while leaving the N,N-dimethylsulfamoyl group at the N-1 untouched. 
 
Scheme 137: Selective deprotection with TBAF·3H2O (64) in position 2 of the imidazole ring. 
 
Thus, the double functionalized imidazole derivatives 72f and 72h-i could selectively 
deprotected leading to the corresponding imidazoles 73a-c in excellent yields (Table 30). 
 
Table 30: Selective deprotection with TBAF·3H2O (64) at position 2 of imidazoles of type 72. 
Entry Imidazole Derivative Deprotection 
Reagent 
Product, Yield[a] 
 
 
 
 
1 72f  64 73a: 93%[b] 
 
 
 
 
2 72h 64 73b: 94%[b] 
 
 
 
 
3 72i 64 73c: 100%[b] 
[a] Yield of analytically pure isolated product as determined by 1H NMR analysis. [b] Obtained after 
addition of tetra-n-butylammonium fluoride (1 equiv). 
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6.5.2 SELECTIVE FUNCTIONALIZATION ON POSITION 2 
For the metalation of position 2 of the imidazole scaffold two pathways were 
developed. Preliminary experiments have shown that either TMP2Zn·2MgCl·2LiCl (65) 
or TMPMgCl·LiCl (65) could be employed as metalating reagents.  
Due to the mild and chemoselective properties of TMP2Zn·2MgCl·2LiCl (65), the 
metalating reaction of imidazoles derivatives of type 73 can be carried out at -20 °C 
furnishing the corresponding diimidazolylzinc derivatives 74 in almost quantitative yield 
within 1 h (Scheme 138). Subsequent functionalization reactions lead to the fully 
functionalized imidazole derivatives 76 (Table 31). 
 
Scheme 138: Selective metalation in position 2 of the imidazole ring TMP2Zn·2MgCl·2LiCl (65) 
and subsequent functionalization (additional complexed salts are omitted for the sake of clarity). 
 
The Cu(I)-catalyzed allylation reaction of the imidazole zinc reagent 74a with ethyl 2-
(bromomethyl)acrylate (68h, 1.1 equiv) leads to the desired full functionalized imidazole 
76a in 81% yield (Table 31, entry 1). Additionally, a Pd-catalyzed Negishi cross-
coupling reaction with 1-iodo-4-nitrobenzene (68l, 0.9 equiv) produces the highly 
functionalized imidazole derivative 76b in 76% yield (entry 2). Furthermore, also the 
imidazole zinc reagent 74b undergoes smoothly a Cu(I)-catalyzed allylation with ethyl 2-
(bromomethyl)acrylate (68h, 0.9 equiv) furnishing imidazole 76c in 86% yield (entry 3). 
The Pd-catalyzed Negishi cross-coupling reactions with ethyl 4-iodobenzoate (68b, 1.1 
equiv) and 4-iodobenzonitrile (68k, 0.9 equiv) produces the highly functionalized 
imidazole derivatives 76d and 76e in 72% and 95% yield (entries 4 and 5). 
 
Table 31: Selective metalation in position 2 of imidazole derivatives of type 73 with 
TMP2Zn·2MgCl·2LiCl (65) and subsequent functionalization. 
Entry Zn-Reagent[a] Electrophile Product, Yield[b] 
 
 
 
 
1 74a  68h 76a: 81%[c] 
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2 74a 68l 76b: 76%[d] 
 
 
 
 
3 74b 68h 76c: 86%[c] 
 
 
 
 
4 74b 68b 76d: 72%[d] 
  
 
 
5 74b 68k 76e: 95%[d] 
[a] Obtained after metalation with TMP2Zn·2MgCl·2LiCl (0.55 equiv) in THF at -20 °C in 1 h. [b] Yield 
of analytically pure isolated product as determined by 1H NMR analysis. [c] Obtained after allylation 
reaction (1 equiv. CuCN·2LiCl
 
with ethyl 2-(bromomethyl)acrylate (0.9 or 1.1 equiv)). [d] Obtained after a 
Negishi cross-coupling (5% Pd(PPh3)4) with Ar–I (0.9 or 1.1 equiv). 
 
As illustrated in Scheme 139, position 2 of the imidazole scaffold could also be 
metalated using TMPMgCl·LiCl (62, 1.2 equiv) at -78 °C. Within 1 h, the reaction 
furnished the imidazol magnesium derivatives 75 in an almost quantitative manner. 
Functionalization reactions lead to the highly substituted imidazoles 76 (Table 32). 
 
Scheme 139: Selective metalation in position 2 of the imidazole ring with TMPMgCl·LiCl (62) 
and subsequent functionalization (additional complexed salts are omitted for the sake of clarity). 
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In order to demonstrate the higher reactivity of the magnesium reagents of type 75 
compared to the diimidazolylzinc reagents of type 74, imidazole derivative 75a has been 
submitted to an addition reaction with 4-fluorobenzaldehyde (68m, 1.1 equiv) furnishing 
the corresponding alcohol 76f in 92% yield (Table 32, entry 1). Moreover, the 
magnesium reagent 75a also reacts smoothly with S-(3,4-dichlorophenyl) 
benzenesulfonothioate (68n, 0.9 equiv) affording thioether 76g in 93% yield (entry 2). 
The corresponding diimidazolylzinc reagent 74b could not undergo these two reactions 
and led only to the hydrolyzed species. Since Cu(I)-catalyzed acylation reaction does not 
proceed, a Pd-catalyzed acylation reaction has been employed leading to the desired 
ketone derivative in a good yield. The magnesium derivative 75a reacts with 4-
chlorobenzoyl chloride (68i, 1.1 equiv) and 5% Pd(PPh3)4 after transmetalation with 
ZnCl2 (1.2 equiv, -78 °C, 15 min) to the corresponding ketone 76h in 58% yield (entry 
3). Furthermore, after transmetalation with ZnCl2 (1.2 equiv, -78 °C, 15 min), the 
magnesium species 75b successfully undergoes a Pd-catalyzed Negishi cross-coupling 
reaction furnishing imidazol 76i in 75% yield (entry 4). Moreover, the magnesium 
reagent 75b also reacts readily with S-(3,4-dichlorophenyl) benzenesulfonothioate (68n, 
0.9 equiv) affording the corresponding thioether 76j in 70% yield (entry 5). 
 
Table 32: Selective metalation in position 2 of imidazole derivatives of type 73 with 
TMPMgCl·LiCl (62) and subsequent functionalization. 
Entry Mg-Reagent[a] Electrophile Product, Yield[b] 
 
 
 
 
1 75a  68m 76f: 92%[c] 
 
 
 
 
2 75a 68n 76g: 93%[e] 
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3 75a 68i 76h: 58%[d] 
 
 
 
 
4 75b 68k 76i: 75%[f] 
  
 
 
5 75c 68n 76j: 70%[e] 
[a] Obtained after metalation with TMPMgCl·LiCl (1.2 equiv) in THF at -78 °C in 1 h. [b] Yield of 
analytically pure isolated product as determined by 1H NMR analysis. [c] Obtained after addition to  
4-fluorobenzaldehyde (1.1 equiv). [d] Obtained after a Negishi acylation (ZnCl2 (1.1 equiv); then 5% 
Pd(PPh3)4 with 4-chlorobenzyol chloride (1.1 equiv)). [e] Obtained after addition to S-aryl benzenethio-
sulfonate (0.9 equiv). [f] Obtained after a Negishi cross-coupling (ZnCl2 (1.2 equiv); then 5% Pd(PPh3)4) 
with 4-iodobenzonitrile (0.9 equiv)). 
 
6.6 SELECTIVE N-3-ALKYLATION AND SUBSEQUENT N-1-DEPROTECTION 
Depending on the substitution pattern, N-protected imidazoles have shown the 
tendency to tautomerize leading to mixtures of isomers after deprotection (due to steric 
factors).262 N-sulfamoylimidazoles are known to react with alkylating reagents 
exclusively via their nonsubstituted nitrogen atom since alkylation on N-1 is 
hampered.263 Moreover, the formation of an imidazolium salt by N-3-alkylation increases 
the lability of the dimethylsulfamoyl group allowing its removal via the addition of 
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 a) C. J. Lovely, H. Du, R. Sivappa, M. R. Bhandari, Y. He, H. V. R. Dias, J. Org. Chem. 2007, 72, 
3741. b) Y. He, Y. Chen, H. Du, L. A. Schmid, C. J. Lovely, Tetrahedron Lett. 2004, 45, 5529. 
263
 a) H. K. Lee, M. Bang, C. S. Pak, Tetrahedron Lett. 2005, 46, 7139. b) S. Beaudoin, K. E. Kinsey,  
J. F. Burns, J. Org. Chem. 2003, 68, 115. 
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concentrated HCl.264 The outcome of this procedure is thus the N-alkylation of the 
imidazole ring selectively at the previously nonsubstituted nitrogen atom.265  
Hence, the fully functionalized imidazole derivatives of type 76 have been treated 
with Meerwein’s reagent (66, trimethyloxonium tetrafluoroborate, 1 equiv) generating 
the corresponding imidazolium salts 77. The N,N-dimethylsulfamoyl group at the N-1 is 
then cleaved by addition of concentrated HCl furnishing the alkylated imidazoles of type 
78 in good yields (Scheme 140). 
 
Scheme 140: Selective methylation with Meerwein’s reagent (66) at position N-3 of the 
imidazole ring and subsequent deprotection at position N-1. 
 
Thus, the fully functionalized imidazol 76e undergoes smoothly the described 
alkylation/deprotection procedure leading to the methylated imidazole 78a in 72% yield 
as the only isomer (Table 33, entry 1). By using regioisomer 76i of imidazole 76e, the 
corresponding alkylated isomer 78b could be obtained (entry 2). Additionally, also the 
thioether-substituted isomeric imidazoles 76g and 76j have been alkylated successfully 
furnishing the regioisomeric imidazoles 78c and 78d in 65% and 72% yield, respectively 
(entries 3 and 4). 
 
Table 33: Selective methylation with Meerwein’s reagent (66) at position N-3 of imidazole 
derivatives of type 76 and subsequent deprotection at position N-1. 
Entry Imidazole Derivative Methylating 
Reagent 
Product, Yield[a] 
 
 
 
 
1 76e  66 78a: 72%[b] 
                                                 
264
 N. Jacobi, T. Lindel, Eur. J. Org. Chem. 2010, 5415. 
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2 76i 66 78b: 74%[b] 
 
N
N
Cl
S
F3C
Me2NO2S
Cl
Cl
 
 
 
3 76g 66 78c: 65%[b] 
 
N
N
F3C
S
Cl
Me2NO2S
Cl
Cl
 
 
 
4 76j 66 78d: 72%[b] 
[a] Yield of analytically pure isolated product as determined by 1H NMR analysis. [b] Obtained after 
addition of trimethyloxonium tetrafluoroborate (1 equiv) and subsequent treatment with HCl (excess). 
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7. SUMMARY AND OUTLOOK 
This work focused on the development of a convenient and general regioselective 
Br/Mg-exchange reaction for unsymmetrically substituted dibromoheterocycles allowing 
the preparation of various thienyl-, furyl- and pyridyl-magnesium derivatives. Further-
more, in the search of a general and atom-economical method for preparing boronic 
derivatives suitable for cross-coupling reactions, a one-pot procedure using inexpensive 
aryl bromides, magnesium as a low-cost reducing agent with little toxicity and a 
trialkylborate as cheap boron source was established. In order to overcome the lack of a 
convenient and practical direct synthesis for α-substituted β,γ-unsaturated ketones and 
esters, their preparation via the addition of readily available substituted allylic zinc 
reagents to a broad range of acid chlorides and chloroformates was disclosed. Moreover, 
the LiCl-mediated metal insertion into alkyl bromides, aromatic halides as well as 
benzylic chlorides was extended to highly functionalized alkenyl bromides for the 
effective preparation of alkenyl zinc reagents bearing for the first time sensitive 
functional moieties.  Due to the lack of a general methodology for the selective synthesis 
of adamantyl organometallic reagents, a mild and convenient procedure for the selective 
synthesis of adamantyl organometallics and their subsequent functionalization was 
developed. Furthermore, the adamantyl moiety was introduced as substituent in 
oligothiophenes, dramatically increasing their solubility. Finally, a methodology for the 
selective and predictable functionalization of all positions of the imidazole scaffold 
starting from simple imidazole by directed metalation and sulfoxide/magnesium 
exchange was developed. 
  
7.1 HIGHLY REGIOSELECTIVE PREPARATION OF HETEROARYL-MAGNESIUM 
REAGENTS USING A Br/Mg-EXCHANGE 
A highly regioselective preparation of five- and six-membered heteroarylmagnesium 
derivatives was developed. The efficient Br/Mg-exchange reagents iPrMgCl·LiCl (1a) 
and isitylMgBr·LiCl (1c) proved to undergo highly regioselective Br/Mg-exchange 
reactions with unsymmetrically substituted dibromo-heterocycles 2 derived from 
thiophenes, benzo[b]thiophenes or pyridines. Ring-substituents such as thioether or 
trimethylsilyl groups, as well as pyridyl and thienyl groups or ortho-substituted aryl 
groups directed the Br/Mg-exchange in position 5 with a regioselectivity of up to >99:1 
(Scheme 141). The corresponding magnesium reagents 3 were readily functionalized 
through e.g. Negishi cross-coupling reactions, acylations or addition to aldehydes.  
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Scheme 141: Regioselective Br/Mg-exchange on unsymmetrical dibromoheterocycles using 
iPrMgCl·LiCl (1a). 
 
In order to exemplify the further functionalization of monobromo-thiophenes of type 5 
obtained after the selective Br/Mg-exchange, the previously prepared monobromo-
thiophene 5g was submitted to a second Br/Mg-exchange reaction using iPrMgCl·LiCl 
(1a). The resulting magnesium reagent 6 was readily used in different types of 
functionalization reactions (Scheme 142). 
 
Scheme 142: Further functionalization of cross-couling product 5g via Br/Mg-exchange and 
subsequent reactions with different electrophiles. 
 
In case of alkyl substituted dibromo-thiophene or -furan derivatives the sterically 
hindered Grignard reagent 2,4,6-triisopropylphenylmagnesium bromide 
(isitylMgBr·LiCl, 1c) furnished in combination with the chelating diamine 2,2'-oxy-
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bis(N,N-dimethylethanamine) (L2) the best regioselectivities in the Br/Mg-exchange. The 
selectively magnesiated heterocyclic scaffolds 12 were subsequently funtionalized with a 
broad range of different electrophiles like aldehydes, aryl iodides, acyl chlorides or aryl 
sulfinyl chlorides (Scheme 143). 
 
Scheme 143: Regioselective Br/Mg-exchange on unsymmetrical dibromoheterocycles of using 
isitylMgBr·LiCl (1c) and ligand L2. 
 
The disclosed method is very versatile and might find application e.g. for the synthesis 
of poly(3-hexylthiophene) (P3HT),266 in which the regioregularity determines 
macroscopic physical properties of the polymers.267 
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7.2 ONE-POT PREPARATION OF MAGNESIUM DI(HETERO)ARYL- AND DIALKENYL-
BORONATES FOR SUZUKI-MIYAURA CROSS-COUPLINGS 
Organoboronic derivatives are essential reagents for modern cross coupling chemistry. 
Since there is a continuous need for efficient synthetic routes for their preparation, a 
convenient, general and atom-economical method for preparing boronic derivatives in 
one step was investigated. The treatment of aryl and heteroaryl bromides as well as 
alkenyl halides with Mg turnings, B(OBu)3 and LiCl in THF at ambient temperature 
leads within 1 h to the corresponding magnesium organoboronates tolerating a broad 
variety of functional groups. This atom-economical synthesis gives readily access to 
functionalized diaryl and diheteroaryl as well as to dialkenylboronates 20 from their 
corresponding organic bromides and might find its way into industrial syntheses. A good 
atom economy was achieved without loss of yield by using 0.5 equiv of B(OBu)3 and 
forming therefore magnesium diorganoboronates of type 20 (Scheme 144).  
 
Scheme 144: General equation for the synthesis and cross-coupling of magnesium diorgano-
boronates of type 20. 
 
Remarkably, both organo-groups (R1) were transferred under typical Suzuki-Miyaura 
cross-coupling conditions with various aryl halides or pseudo-halides of type R2-X (22-
24) furnishing the corresponding products in excellent yields (Figure 12). 
 
Figure 12: Cross-coupling products generated from diorganoboronates of type 20. 
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7.3 PREPARATION OF α-SUBSTITUTED β,γ-UNSATURATED KETONES AND ESTERS 
VIA THE DIRECT ADDITION OF SUBSTITUTED ALLYLIC ZINC REAGENTS 
A practical and convenient procedure for the synthesis of α-substituted β,γ-
unsaturated ketones and esters was developed. Substituted allylic zinc reagents, prepared 
via direct metal insertion in substituted allylic halides, react readily with a broad range of 
acid chlorides and chloroformates furnishing the corresponding α-substituted β,γ-
unsaturated ketones and esters in high yield and perfect regioselectivity. 
The recently by Knochel et al. developed method allowed the preparation of poly-
substituted allyl zinc reagents starting from the corresponding allyl halides almost 
without formation of homocoupling products.178 In order to expand this protocol, a broad 
variety of new allylic zinc organometallics was synthesized (Scheme 145).  
 
Scheme 145: LiCl-mediated preparation of substituted allylic zinc organometallics 30 via direct 
insertion of zinc powder.  
 
The addition of these highly reactive allylic zinc reagents (30a-i) to a broad range of 
acid chlorides 31 and chloroformates 35 proceeded under exceedingly mild conditions  
(-78 °C, 1-2 h) and furnished selectively β,γ-unsaturated ketones 32  and esters 36 
without any traces of the α,β-unsaturated isomers (Scheme 146).  
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Scheme 146: Preparation of α-substituted β,γ-unsaturated ketones (32) and esters (36) from 
allylic zinc reagents of type 30. 
 
The diene-precursor 33 for a ring-closing metathesis (RCM) was readily synthesized 
from a α-substituted β,γ-unsaturated ketone 32d in only one step via the 
diastereoselective addition of allyl magnesium chloride to the carbonyl moiety of 32d in 
almost quantitative yield (Scheme 147). The subsequent RCM using the second 
generation of Grubbs’ catalyst furnished diastereoselectively cyclopentene derivative 34 
in 97% yield. 
 
Scheme 147: Diastereoselective addition of allyl magnesium chloride to 32d and subsequent 
ring-closing metathesis forming the cyclopentene derivative 34. 
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7.4 PREPARATION OF FUNCTIONALIZED ALKENYLZINC REAGENTS BEARING 
CARBONYL GROUPS VIA DIRECT METAL INSERTION 
A convenient, mild and atom-economical protocol for the synthesis of highly 
functionalized alkenylzinc reagents bearing sensitive carbonyl groups such as an 
aldehyde, a ketone or an ester was developed. Activated alkenyl bromides 37 underwent 
a direct insertion of zinc in the presence of LiCl furnishing the corresponding organozinc 
compounds 38. Subsequent functionalization reactions like Negishi cross-couplings, 
acylations or allylations were performed readily leading to polyfunctional compounds 40 
in excellent yields (Scheme 148).  
 
Scheme 148: Preparation of alkenylzinc reagents 38 from activated alkenyl bromides 37 via 
direct zinc insertion and subsequent functionalization. 
 
Furthermore, acyclic alkenylzinc reagents 38f-i could be prepared from the 
corresponding acyclic bromides 37f-i without loosing their stereochemistry due to the 
chelating effect of the Zn-center with the vicinal carbonyl group and allowed therefore 
the synthesis of trisubstituted olefins with excellent Z-selectivity (Scheme 149). 
 
Scheme 149: LiCl-mediated zinc insertion into acyclic alkenyl bromides 37f-i leading to zinc 
reagents 38f-i and subsequent cross-coupling. 
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Electronically less activated alkenyl bromides 42 were converted to their 
corresponding zinc reagents 43 by using the stronger reducing metal magnesium in the 
presence of LiCl and ZnCl2. Their subsequent functionalization with a broad variety of 
electrophiles furnished the substituted alkenyl derivatives 44 in high yields  
(Scheme 150). 
 
Scheme 150: Preparation of alkenylzinc reagents 43 from less activated alkenyl bromides 42 via 
magnesium insertion in presence of ZnCl2 and subsequent functionalization. 
 
Due to their highly reactive nature, unsaturated 1,4-dicarbonyl compounds readily 
undergo condensation reactions with hydrazine providing tetrahydrophthalazines. 
Therefore, compound 40v smoothly reacted with hydrazine hydrate (NH2NH2·H2O) in 
methanol to the corresponding 1-substituted tetrahydrophthalazine 41a in 54% yield 
(Scheme 151). Following this protocol, compounds 41b and 41c, bearing a  
3-chlorophenyl- and a 2-thienyl-substituent respectively were prepared in 49-54% yield. 
 
Scheme 151: Synthesis of substituted tetrahydrophthalazines of type 41. 
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7.5 SYNTHESIS OF FUNCTIONALIZED ADAMANTYLZINC REAGENTS USING A Br/Mg-
INSERTION IN THE PRESENCE OF ZnCl2 
A practical and convenient procedure for the synthesis of substituted adamantyl zinc 
reagents was developed. The LiCl-mediated Mg insertion in the presence of ZnCl2 
allowed an efficient synthesis of adamantylzinc reagents starting from the corresponding 
functionalized tertiary bromides (Scheme 152). 
+ Mg + LiCl
THF
0 to 25 °C
2-3 h
+ ZnCl2Br
R
ZnCl MgBrCl LiCl
R
(2 equiv) (1.1 equiv)(1.1 equiv)
ZnX
46a: 85%
ZnX
46b: 63%
ZnX
46c: 57%
CO2Et O
O
45 46: 57-85%
Scheme 152: Preparation of functionalized adamantylzinc reagents 46 via the LiCl-mediated 
Mg-insertion in the presence of ZnCl2 (additional complexed salts are omitted for the sake of 
clarity). 
 
The highly reactive adamantylzinc species 46a-c readily undergo a broad variety of 
functionalization reactions in the presence of an appropriate catalyst. As illustrated in 
Scheme 153, Negishi cross-couplings, Cu(I)-catalyzed acylation and allylation as well as 
1,4-addition reactions and many more could be successfully employed to generate highly 
functionalized adamantyl derivatives in high yields. 
Scheme 153: Highly functionalized adamantyl derivatives synthesized via functionalization of 
the corresponding adamantylzinc species 46a-c. 
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Furthermore, the adamantyl moiety could be introduced as substituent in 
oligothiophenes, dramatically increasing their solubility. Adamantylzinc reagent 46a 
readily underwent a Negishi cross-coulpling reaction with the 5-bromo-terthiophene 49h 
furnishing the corresponding α-substituted oligothiophene 48s. Selective bromination of 
48s followed by a Ni-catalyzed homocoupling reaction of the corresponding Grignard 
reagent of the bromo-oligiothiophene 59 led to the α,α’-diadamantyl-sexithiophene 60 
(Scheme 154). 
Scheme 154: Synthesis of α,α’-diadamantyl-sexithiophene 60. 
 
The presence of the apolar adamantyl-moiety strongly increases the lipophilicity of 
the sexithiophene. Combined with the bulkiness of the adamantine substituents 
preventing the pi-stacking of the oligothiophenes, this explains the excellent solubility of 
compound 60 compared to the unsubstituted sexithiophene (solubility lower than 50 mg/l 
in chloroform234).  
Recently Garnier et al. reported, that β-alkyl substituted oligothiophenes show an 
even higher solubility than the corresponding α-substituted ones.234 Since the adamantyl-
subtituents in α-position already proved to have an excellent impact on the solubility, it 
should be worth to investigate their effect as β-substituents. The increased solubility 
should provide the opportunity to synthesize much longer oligomers which would serve 
as desired models for the better understanding of polymeric systems.233 
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7.6 FULL FUNCTIONALIZATION OF THE IMIDAZOLE SCAFFOLD BY SELECTIVE 
METALATION AND SULFOXIDE/MAGNESIUM EXCHANGE 
A general, selective and flexible approach for the synthesis of complex substituted 
imidazoles was developed. All three C–H bonds of the imidazole core could be 
functionalized in a regioselective and sequential manner by metalation using 
TMPMgCl·LiCl (62) and TMP2Zn·2MgCl·2LiCl (65) as bases as well as by a selective 
sulfoxide/magnesium exchange triggered by iPrMgCl·LiCl (63) (Scheme 155).  
Scheme 155: Selective fully functionalization of the imidazole ring in a regioselective manner. 
 
The N,N-dimethylsulfamoyl group at nitrogen N-1 directed the metalation of 
imidazole 61 with TMPMgCl·LiCl (62) regioselectively in position 5. The subsequent 
sulfinylation employing 4-methoxy-3,5-dimethyl-benzenesulfinyl chloride (68a) led to 
imidazole 67. This substituent was found to be essential for the full functionalization 
procedure, since it allows both the direct metalation in ortho position and its replacement 
by a sulfoxide/magnesium exchange. Hence, the subsequent metalation with 
TMPMgCl·LiCl (62) occured in position 4 enabling the selective functionalization in this 
position. The next functionalization step was performed in position 5 by means of a 
sulfoxide/magnesium exchange. Treatment of imidazole derivatives 70 with 
iPrMgCl·LiCl (63) led to the corresponding magnesium intermediates 71 which could 
readily be functionalized leading to imidazoles of type 72. After selective removal of the 
TBDMS-group in position 2 with TBAF·3H2O (64), metalation either using 
TMPMgCl·LiCl (62) or TMP2Zn·2MgCl·2LiCl (65) furnished the corresponding 
organometallic reagents 74 and 75 that were subsequently functionalized to give the fully 
substituted imidazoles of type 76 (Scheme 156).  
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Scheme 156: Fully functionalized imidazole derivatives of type 76. 
 
N-sulfamoylimidazoles are known to react with alkylating reagents exclusively via 
their nonsubstituted nitrogen atom since alkylation on N-1 is blocked. Moreover, the 
formation of an imidazolium salt by N-3-alkylation increases the lability of the 
dimethylsulfamoyl group allowing its removal via the addition of concentrated HCl. 
Hence, the fully functionalized imidazole derivatives of type 76 were treated with 
Meerwein’s reagent (66, trimethyloxonium tetrafluoroborate) generating the 
corresponding imidazolium salts 77. The N,N-dimethylsulfamoyl group at the N-1 was 
then cleaved by addition of concentrated HCl furnishing the alkylated imidazoles of type 
78 (Scheme 157). 
 
Scheme 157: Selective methylation with Meerwein’s reagent (66) at position N-3 of the 
imidazole ring and subsequent deprotection at position N-1. 
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1. GENERAL CONSIDERATIONS 
All reactions were carried out under argon or nitrogen atmosphere in glassware dried 
with a heat gun. Syringes which were used to transfer anhydrous solvents or reagents 
were purged thrice with argon or nitrogen prior to use. THF was freshly distilled from 
sodium benzophenone ketyl under nitrogen prior to use. Indicated yields are isolated 
yields of compounds estimated to be >95% pure as determined by 1H-NMR (25 °C) and 
capillary GC. Column chromatography was performed using SiO2 (0.040 – 0.063 mm, 
230 – 400 mesh ASTM) from Merck. Unless otherwise indicated, all reagents were 
obtained from commercial sources. Liquid starting materials were distilled prior to use. 
Magnesium turnings (> 99.5%), magnesium powder (> 99%) and zinc dust (> 90%) were 
obtained from Riedel-de Haën. CuCN, ZnCl2 and LiCl were obtained from Fluka.  
 
1.1 SOLVENTS 
Solvents were dried according to standard procedures by distillation over drying agents 
and stored under argon. 
CH2Cl2 was predried over CaCl2 and distilled from CaH2. 
CHCl3 was predried over CaCl2 and distilled from CaH2. 
DMF was heated to reflux for 14 h over CaH2 and distilled from CaH2.  
EtOH was treated with phthalic anhydride (25 g/L) and sodium, heated to reflux for 6 h 
and distilled. 
Et2O was predried over calcium hydride and dried with the solvent purification system 
SPS-400-2 from INNOVATIVE TECHNOLOGIES INC. 
THF was continuously refluxed and freshly distilled from sodium benzophenone ketyl 
under nitrogen. 
Toluene was predried over CaCl2 and distilled from CaH2. 
NEt3 was dried over KOH and distilled. 
Solvents for column chromatography were distilled on a rotary evaporator prior to use.  
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1.2 REAGENTS 
All reagents were obtained from commercial sources and used without further 
purification unless otherwise stated. Liquid reagents were distilled prior to use.  
iPrMgCl·LiCl solution in THF was purchased from Chemetall. 
nBuLi solution in hexane was purchased from Chemetall. 
TMPMgCl·LiCl was prepared according to a literature procedure.28a 
TMP2Zn·2MgCl2·2LiCl was prepared according to a literature procedure.68a 
CuCN·2LiCl solution (1.00 M) was prepared by drying CuCN (80.0 mmol, 7.17 g) and 
LiCl (160 mmol, 6.77 g) in a Schlenk-flask under vacuum at 140 °C for 5 h. After 
cooling, 80 mL dry THF were added and stirring was continued until the salts were 
dissolved. 
ZnCl2 solution (1.00 M) was prepared by drying ZnCl2 (100 mmol, 136 g) in a Schlenk-
flask under vacuum at 140 °C for 5 h. After cooling, 100 mL dry THF were added and 
stirring was continued until the salt was dissolved.  
 
1.3 CONTENT DETERMINATION OF ORGANOMETALLIC REAGENTS 
Organozinc and organomagnesium reagents were titrated with I2 in THF.192  
Organolithium reagents were titrated with dry 2-propanol and 1,10-phenanthroline as 
indicator in THF.268  
TMPMgCl·LiCl and TMP2Zn·2MgCl2·2LiCl were titrated with benzoic acid and  
4-(phenylazo)diphenylamine as indicator in THF.28a, 68 
 
1.4 CHROMATOGRAPHY 
Flash column chromatography was performed using silica gel 60 (0.040-0.063 mm) 
from MERCK. 
Thin layer chromatography was performed using SiO2 pre-coated aluminium plates 
(Merck 60, F-254). The chromatograms were examined under 254 nm UV irradiation, by 
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incubating the plates in an iodine chamber and/or by staining of the TLC plate with one 
of the reagents given below followed by heating with a heat gun: 
- KMnO4 (3.0 g), 5 drops of conc. H2SO4 in water (300 mL). 
- Phosphomolybdic acid (5.0 g), Ce(SO4)2 (2.0 g) and conc. H2SO4 (12 mL) in water 
(230 mL). 
- Ninhydrin (0.3 g) and AcOH (3.0 mL) in butanol (100 mL).  
 
1.5 ANALYTICAL DATA 
1H-NMR and 13C-NMR spectra were recorded on VARIAN Mercury 200, BRUKER 
ARX 300, VARIAN VXR 400 S and BRUKER AMX 600 instruments. Chemical shifts 
are reported as δ-values in ppm relative to tetramethylsilane. The following abbreviations 
were used to characterize signal multiplicities: s (singlet), d (doublet), t (triplet),  
q (quartet), qn (quintet), spt (septet), m (multiplet) as well as br (broadened). 
Mass spectroscopy: High resolution (HRMS) and low resolution (MS) spectra were 
recorded on a FINNIGAN MAT 95Q instrument. Electron impact ionization (EI) was 
conducted with an ionization energy of 70 eV.  
For coupled gas chromatography/mass spectrometry, a HEWLETT-PACKARD HP 
6890/MSD 5973 GC/MS system was used. Molecular fragments are reported starting at a 
relative intensity of 10%. 
Infrared spectra (IR) were recorded from 4500 cm-1 to 650 cm-1 on a PERKIN ELMER 
Spectrum BX-59343 instrument. For detection a SMITHS DETECTION DuraSamplIR II 
Diamond ATR sensor was used. Wavenumbers are reported in cm-1 starting at an 
absorption of 10%. 
Melting points (m.p.) were determined on a BÜCHI B-540 melting point apparatus and 
are uncorrected. Compounds decomposing upon melting are indicated by (decomp.). 
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2. HIGHLY REGIOSELECTIVE PREPARATION OF HETEROARYL-
MAGNESIUM REAGENTS USING A BR/MG-EXCHANGE 
2.1 PREPARATION OF STARTING MATERIALS 
Preparation of 2,4,6-triisopropylphenylmagnesium bromide (1c) 
 
Magnesium turnings (3.64 g, 150 mmol, 1.5 equiv) and anhydrous LiCl (4.20 g,  
100 mmol, 1.0 equiv) were placed in an Ar-flushed flask and dried with a heatgun at  
450 °C for 10 min in vacuo. After cooling to 25 °C and purging with argon, THF  
(50 mL) was added. After addition of THF (60 mL), the magnesium was activated using 
1,2-dibromoethane (2 mol %) and Me3SiCl (5 mol %). Subsequently, a solution of  
1-bromo-2,4,6-triisopropylbenzene (28.3 g, 100 mmol) in THF (40 mL) was slowly 
added at 25 °C. After addition, the reaction mixture was stirred for 12 h at 25 °C. 
Residual Mg was removed by cannulating the grey solution of 2,4,6-triisopropyl-
magnesium bromide (1c) to a dry and argon-flushed flask. The reagent was titrated prior 
to use by the method of Paquette,268 or the method developed in our laboratory.192  
 
Dibromo-heteroaryl compounds 2a,269 2d,270 2i,271 11c272 and 11f273 were prepared 
according to literature procedures; compounds 11a, 11b and 11e were commercially 
available.  
 
2,5-dibromo thiophenes 2b-c and 2e-h and 2j were prepared from 2,5-dibromo 
thiophene following a literature procedure.269  For 2b and 2c, the (2,5-dibromothiophen-
3-yl)lithium was quenched with the corresponding diorgano disulfide at -78 °C followed 
by a standard aqueous workup and column chromatography. For the compounds 2f-h and 
2j (2,5-dibromothiophen-3-yl)lithium was transmetalated with ZnCl2 at -40 °C followed 
by a Negishi cross-coupling reaction with 4% Pd(PPh3)4 and 0.9 equiv of the 
corresponding aryl iodide in THF at 50 °C over night. After a standard workup the crude 
was purified via column chromatography. 
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2,5-dibromothieno[3,2-b]thiophene (2e) was prepared following a literature 
procedure147c replacing NCS by NBS. The NBS was used as purchased without 
recrystallization. 
 
2,5-dibromo pyridines 8a-8d and 15 were prepared from 2,5-dibromo pyridine 
following a literature procedure.28a For 8a-8c, the magnesiated 2,5-dibromo pyridine 
derivative was transmetalated with ZnCl2 at -40 °C followed by a Negishi cross-coupling 
reaction with 4 mol % Pd(PPh3)4 and 0.9 equiv of the corresponding aryl iodide in THF 
at 50 °C over night. After a standard workup the crude was purified via column 
chromatography. For 8d and 15, the magnesiated 2,5-dibromo pyridine derivative was 
quenched either with S-phenyl benzenesulfonothioate or TMSCN at -78 °C followed by a 
standard aqueous workup and column chromatography.  
 
2,5-dibromo-3-(phenylthio)thiophene (2b) 
  
m.p.: 46.6-48.1 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.22-7.32 (m, 5H), 7.07 (s, 1H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 135.6, 133.4, 130.1, 129.3, 128.4, 127.1, 119.6, 
116.2. 
MS (70 eV, EI),, m/z (%) = 350 (M+, 45), 348 (M+, 21), 271 (24), 269 (22), 192 (10),  
191 (14), 190 (100), 146 (13), 77 (9). 
HRMS (EI), m/z calc. for C10H6Br2S2 (349.8257): 349.8245 (M+). 
IR (ATR) υ (cm-1) = 3092, 3043, 3017, 3007, 2360, 2338, 1966, 1947, 1883, 1865, 1805, 
1733, 1646, 1578, 1489, 1476, 1437, 1390, 1302, 1138, 1078, 1009, 965, 824, 737, 686, 
678. 
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2-((2,5-dibromothiophen-3-yl)thio)pyridine (2c) 
 
m.p.: 45.8-47.5 °C.  
1H NMR (400 MHz, d6-DMSO) δ (ppm) = 8.42 (ddd, J=4.8Hz, 1.8Hz, 1.0Hz, 1H), 7.72 
(td, J=7.8Hz, 1.9Hz, 1H), 7.21 (ddd, J=7.4Hz, 4.9Hz, 2.0Hz, 1H) 7.58 (s, 1H), 7.04 (d, 
J=8.2Hz, 1H). 
13C NMR (100 MHz, d6-DMSO) δ (ppm) = 157.5, 150.2, 138.4, 134.4, 126.0, 121.8, 
121.7, 120.7, 118.1. 
MS (70 eV, EI), m/z (%) = 351 (M+, 8), 349 (M+, 4), 274 (10), 273 (13), 272 (100),  
270 (88), 191 (25), 147 (5), 78 (7). 
HRMS (EI), m/z calc. for C9H5Br2S2 (348.8230): 348.8215 (M+). 
IR (ATR) υ (cm-1) = 3085, 3045, 2996, 2971, 1739, 1570, 1557, 1485, 1451, 1444, 1414, 
1391, 1377, 1366, 1299, 1229, 1217, 1117, 1012, 969, 830, 806, 756, 717, 679. 
 
(2,5-dibromothieno[3,2-b]thiophen-3-yl)trimethylsilane (2e) 
 
m.p.: 45.3-47.2 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.28 (s, 1 H), 0.43 (s, 9 H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 143.4, 141.0, 136.1, 122.7, 115.2, 107.7, -0.9. 
MS (70 eV, EI), m/z (%) = 370 (M+, 52), 368 (M+, 24), 358 (10), 357 (62), 356 (16),  
355 (100), 353 (54), 261 (12), 259 (11), 233 (44), 231 (46), 137 (11), 73 (22). 
HRMS (EI), m/z calc. for C9H10Br2S2Si (369.8339) = 369.8331 (M+). 
IR (ATR) υ (cm-1) = 3100, 2955, 2895, 1739, 1478, 1417, 1409, 1313, 1246, 1152, 1012, 
970, 833, 799, 756, 712, 698. 
 
2,5-dibromo-3-(o-tolyl)thiophene (2f) 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.20-7.39 (m, 4H), 7.03 (s, 1H), 2.28 (s, 3H).  
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13C NMR (75 MHz, CDCl3) δ (ppm) = 139.7, 138.1, 132.3, 131.3, 131.2, 130.3, 129.4, 
125.7, 111.9, 109.2, 20.1. 
MS (70 eV, EI), m/z (%) = 332 (M+, 32), 330 (M+, 17), 252 (10), 173 (14), 172 (100), 
171 (37), 128 (14), 86 (16), 80 (9), 42 (12). 
HRMS (EI), m/z calc. for C11H8Br2S (329.8713): 329.8703 (M+). 
IR (ATR) υ (cm-1) = 3094, 3062, 3045, 3020, 2970, 2952, 2921, 1531, 1482, 1451, 1379, 
1301, 1128, 979, 816, 751, 721, 685. 
 
2-(2,5-dibromothiophen-3-yl)-N,N-dimethylaniline (2g) 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.37-7.42 (m, 1H), 7.28-7.35 (m, 1H), 6.99 (s, 
3H), 2.63 (s, 6H).  
13C NMR (75 MHz, CDCl3) δ (ppm) = 152.2, 139.3, 132.4, 132.0, 129.8, 124.6, 121.2, 
118.2, 112.7, 108.0, 43.2. 
MS (70 eV, EI), m/z (%) = 361 (M+, 20), 359 (M+, 10), 283 (12), 280 (14), 279 (80),  
277 (12), 266 (48), 265 (10), 264 (53), 202 (12), 201 (44), 200 (100), 185 (14), 168 (30), 
167 (10), 115 (16), 101 (27), 93 (10). 
HRMS (EI), m/z calc. for C12H11Br2NS (360.8958): 360.8971 (M+). 
IR (ATR) υ (cm-1) = 3093, 3062, 2979, 2938, 2860, 2829, 2782, 1594, 1483, 1451, 1428, 
1323, 1303, 1191, 1159, 1131, 1098, 1049, 979, 955, 942, 935, 811, 758, 741, 684. 
 
2,5-dibromo-3-(2-methoxyphenyl)thiophene (2h) 
 
m.p.: 65.0-67.0 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.33-7.48 (m, 2H), 6.93-7.10 (m, 3H), 3.85  
(s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 156.9, 136.3, 132.4, 132.0, 130.6, 120.7, 120.4, 
112.2, 111.3, 109.0, 55.6. 
MS (70 eV, EI), m/z (%) = 348 (M+, 100), 346 (M+, 53), 254 (83), 253 (12), 252 (88), 
188 (40), 187 (40), 174 (17), 173 (12), 115 (13), 82 (12), 80 (12). 
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HRMS (EI), m/z calc. for C11H8Br2OS (347.8642): 347.8659 (M+). 
IR (ATR) υ (cm-1) = 3094, 3082, 3019, 2967, 2936, 2835, 1595, 1579, 1481, 1476, 1461, 
1455, 1432, 1286, 1250, 1182, 1132, 1111, 1052, 1027, 980, 813, 805, 791, 744, 734. 
 
2',5'-dibromo-2,3'-bithiophene (2j) 
 
m.p.: 43.2-45.1 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.35 (dd, J=5.7Hz, 4.3Hz, 2H), 7.07 (dd, 
J=5.1Hz, 3.7Hz, 1H), 6.99 (s, 1H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 134.0, 133.8, 133.4, 127.3, 127.1, 126.6, 111.1, 
107.0. 
MS (70 eV, EI), m/z (%) = 324 (M+, 100), 322 (M+, 51), 245 (10), 244 (10), 165 (9),  
164 (77), 93 (7), 82 (15). 
HRMS (EI), m/z calc. for C8H4Br2S2 (323.8101): 323.8085 (M+). 
IR (ATR) υ (cm-1) = 3096, 3064, 3027, 2956, 2924, 2851, 2238, 1606, 1536, 1505, 1436, 
1397, 1107, 1015, 971, 909, 858, 841, 832, 823, 774, 704, 662. 
 
3,5-dibromo-2-(4-(trifluoromethyl)phenyl)pyridine (8a) 
 
m.p.: 73.8-75.2 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.69 (d, J=1.9Hz, 1H), 8.18 (d, J=2.2Hz, 1H), 
7.76-7.82 (m, 2H), 7.69-7.75 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 155.2, 149.3, 143.3, 141.8, 131.0 (q, J=32.7Hz), 
129.7, 125.1 (q, J=4.0Hz), 124.0 (q, J=272.4Hz), 119.7, 119.6. 
MS (70 eV, EI), m/z (%) = 381 (M+, 66), 379 (M+, 32), 303 (14), 301 (14), 300 (100), 
221 (61), 220 (15), 194 (13), 171 (10), 50 (11). 
HRMS (EI), m/z calc. for C12H6Br2F3N (380.8799): 380.8778 (M+). 
IR (ATR) υ (cm-1) = 3090, 3053, 2970, 1931, 1739, 1618, 1554, 1428, 1409, 1328, 1193, 
1170, 1100, 1075, 1056, 1023, 1009, 888, 857, 842, 814, 762, 736, 690. 
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3,5-dibromo-2-(4-methoxyphenyl)pyridine (8b) 
 
m.p.: 100.8-108.8 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.64 (d, J=1.9Hz, 1H), 8.12 (d, J=1.9Hz, 1H),  
7.65 (d, J=9.1Hz, 2H), 6.82-7.07 (m, 2H), 3.86 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 160.2, 156.2, 149.0, 143.1, 130.8, 130.7, 119.6, 
118.1, 113.4, 55.3. 
MS (70 eV, EI), m/z (%) = 343 (M+, 100), 341 (M+, 48), 300 (12), 264 (40), 249 (11), 
247 (12), 221 (19), 183 (25), 140 (32), 113 (17). 
HRMS (EI), m/z calc. for C12H6Br2NO (342.9030): 342.9031 (M+). 
IR (ATR) υ (cm-1) = 3085, 3034, 3010, 2971, 2937, 2912, 2836, 1739, 1607, 1578, 1508, 
1434, 1366, 1250, 1218, 1173, 1104, 1060, 1026, 1013, 1000, 905, 844, 836, 770, 756. 
 
3,5-dibromo-2-(thiophen-2-yl)pyridine (8c) 
 
m.p.: 69.6-71.0 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.56 (d, J=2.2Hz, 1H), 8.13 (dd, J=3.9Hz, 1.1Hz, 
1H), 8.09 (d, 1H), 7.49 (dd, J=5.0Hz, 1.11Hz, 1H), 7.13 (dd, J=5.3Hz, 3.9Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 149.3, 148.6, 143.9, 142.0, 129.4, 129.2, 127.7, 
117.4, 117.1. 
MS (70 eV, EI), m/z (%) = 319 (M+, 100), 317 (M+, 43), 278 (18), 277 (43), 240 (16), 
238 (17), 183 (10), 159 (38). 
HRMS (EI), m/z calc. for C9H5Br2NS (318.8489): 318.8527 (M+). 
IR (ATR) υ (cm-1) = 3066, 3055, 3019, 3006, 1739, 1530, 1475, 1434, 1412, 1370, 1353, 
1272, 1108, 1090, 1043, 1025, 966, 896, 852, 833, 775, 754, 740, 708, 692. 
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3,5-dibromo-2-(phenylthio)pyridine (8d) 
 
m.p.: 67.5-69.6 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.29 (d, J=2.2Hz, 1H), 7.89 (d, J=2.2Hz, 1H), 
7.51-7.59 (m, 2H), 7.41-7.48 (m, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 158.0, 148.8, 141.4, 135.5, 129.7, 129.3, 129.2, 
118.2, 115.8. 
MS (70 eV, EI), m/z (%) = 345 (M+, 31), 344 (M+, 100), 342 (M+, 45), 185 (11), 133 (7), 
109 (8), 65 (7). 
HRMS (EI), m/z calc. for C11H7Br2NS (344.8645): 344.8656 (M+). 
IR (ATR) υ (cm-1) = 3076, 3050, 3037, 2985, 1575, 1544, 1476, 1438, 1414, 1396, 1347, 
1228, 1213, 1138, 1097, 1018, 1000, 886, 786, 744, 713, 705, 687. 
 
3,5-dibromo-2-(trimethylsilyl)pyridine (15) 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.72 (d, J=2.2Hz, 1H), 7.93 (d, J=1.9Hz, 1H), 
0.41 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 165.5, 148.9, 140.2, 126.5, 120.4, -1.1. 
MS (70 eV, EI), m/z (%) = 308 (M+, 21), 306 (M+, 12), 296 (42), 295 (12), 294 (100), 
292 (37), 230 (16), 228 (17), 215 (10). 
HRMS (EI), m/z calc. for C8H11Br2NSi (306.9028): 306.9008 (M+). 
IR (ATR) υ (cm-1) = 3356, 2989, 2965, 2910, 2890, 1729, 1710, 1553, 1524, 1473, 1326, 
1277, 1251, 1178, 1158, 1148, 1129, 1101, 1049, 1020, 1012, 905, 855, 788, 760, 725, 
658. 
 
2.2 TYPICAL PROCEDURES  
Typical procedure 1 (TP1): Regioselective preparation of heteroarylmagnesium 
reagents using 1a 
A dry and argon-flushed Schlenk-flask, equipped with a magnetic stirring bar and a 
septum, was charged with iPrMgCl·LiCl (1a; 1.05 equiv, 1.2 M in THF). The substituted 
dibromoheterocycle (1 equiv) was added as a solution in THF (1.0 M) at the given 
temperature and continuously stirred for the indicated time. Complete Br/Mg-exchange 
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was monitored by GC-analysis of iodolyzed reaction aliquots using undecane as internal 
standard.  
 
Typical procedure 2 (TP2): Regioselective preparation of heteroarylmagnesium 
reagents using 1c and L2 
A dry and argon-flushed Schlenk-flask, equipped with a magnetic stirring bar and a 
septum, was charged with 2,4,6-triisopropylmagnesium bromide (1c; 1.05 equiv, 0.7 M in 
THF) and 2,2’-oxy-bis(N,N-diethylethanamine) (L2; 1.05 equiv). After stirring for  
15 min at 25 °C, the substituted dibromoheterocycle (1 equiv) was added as a solution in 
THF (1.0 M) at the given temperature and continuously stirred for the indicated time. 
Complete Br/Mg-exchange was monitored by GC-analysis of iodolyzed reaction aliquots 
using undecane as internal standard.  
 
Typical procedure 3 (TP3): Cross-coupling reactions of heteroarylmagnesium 
reagents 
To the freshly prepared heteroarylmagnesium reagent was added ZnCl2 (1.0 M in THF,  
1 equiv) and the reaction mixture was stirred for 15 min at the indicated temperature. 
Pd(PPh3)4 (4 mol %) and the aryl iodide (0.9 equiv) were added and the reaction mixture 
was warmed to 25 °C. After stirring for the indicated time, the reaction mixture was 
quenched with saturated aqueous NH4Cl solution, extracted three times with EtOAc, 
dried over Na2SO4 and concentrated in vacuo. The crude residue was purified by flash 
column chromatography on silica gel.  
 
Typical procedure 4 (TP4):  Acylation reactions of heteroarylmagnesium reagents 
To the freshly prepared heteroarylmagnesium reagent was added ZnCl2 (1.0 M in THF,  
1 equiv) and the reaction mixture was stirred for 15 min at the indicated temperature. 
CuCN·2LiCl (1.0 M in THF, 20 mol %) and the acyl chloride (0.9 equiv) were added and 
the reaction mixture was warmed to 25 °C. After stirring for the indicated time, the 
reaction mixture was quenched with saturated aqueous NH4Cl/NH3 solution (10:1), 
extracted three times with EtOAc, dried over Na2SO4 and concentrated in vacuo. The 
crude residue was purified by flash column chromatography on silica gel. 
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Typical procedure 5 (TP5): Preparation of sulfoxides using heteroarylmagnesium 
reagents 
A dry and argon-flushed Schlenk-flask, equipped with a magnetic stirring bar and a 
septum, was charged with a solution of 4-methoxybenzenesulfinyl chloride (0.9 equiv) 
and cooled to -20 °C. The freshly prepared heteroarylmagnesium reagent (1 equiv) in 
THF was added dropwise and the reaction mixture was warmed to 25 °C. After stirring 
for the indicated time, the reaction mixture was quenched with saturated aqueous NH4Cl 
solution, extracted three times with EtOAc, dried over Na2SO4 and concentrated in 
vacuo. The crude residue was purified by flash column chromatography on silica gel. 
 
2.3 PREPARATION OF FUNCTIONALIZED THIOPHENES AND THIENOTHIOPHENES 
OF TYPE 5 
Preparation of (5-bromo-4-(methylthio)thiophen-2-yl)(3-chloro-4-methoxyphenyl)-
methanol (5a) 
 
Prepared according to TP1 from 2,5-dibromo-3-(methylthio)thiophene (2a; 576 mg,  
2 mmol) and iPrMgCl·LiCl (1a; 1.75 mL, 2.1 mmol, 1.2 M in THF) at 0 °C in 1 h. 
Subsequently, the reaction mixture was cooled to −20 °C and 3-chloro-4-
methoxybenzaldehyde (4a; 307 mg, 1.8 mmol) in THF was added. The reaction mixture 
was allowed to slowly warm to 25 °C and continuously stirred for 1 h. Subsequently,  
sat. aq. NH4Cl (10 mL) was added. The aqueous layer was extracted with EtOAc  
(3x 10 mL). The combined organic phases were dried over Na2SO4 and concentrated  
in vacuo. Flash column chromatographical purification (pentane/Et2O, 1:1) furnished 5a 
as a yellow oil (504 mg, 74%). 
 
1H NMR (400 MHz, d6-DMSO) δ (ppm) = 7.40 (d, J=2.1Hz, 1H), 7.29 (dd, J=8.5Hz, 
2.1Hz, 1H), 7.08 (d, J=8.5Hz, 1H), 6.84 (s, 1H), 6.42 (d, J=4.4Hz, 1H), 5.81 (d, J=3.5Hz, 
1H), 3.79 (s, 3H), 2.39 (s, 3H). 
13C NMR (100 MHz, d6-DMSO) δ (ppm) = 154.2, 152.8, 137.6, 131.5, 127.8, 127.1, 
126.4, 121.2, 113.4, 113.1, 69.8, 56.5, 20.1. 
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MS (70 eV, EI), m/z (%) = 380 (M+, 100), 378 (M+, 78), 363 (42), 361 (27), 236 (21), 
170 (38), 128 (15), 108 (14). 
HRMS (EI), m/z calc. for C13H12BrClO2S2 (377.9151): 377.9133 (M+). 
IR (ATR) υ (cm-1) = 3083, 3002, 2965, 2921, 2868, 2837, 1602, 1499, 1460, 1438, 1414, 
1283, 1256, 1196, 1183, 1149, 1116, 1061, 1021, 968, 884, 821, 813, 794, 688. 
 
Preparation of 1-(5'-bromo-4'-(methylthio)-[2,2'-bithiophen]-5-yl)ethanone (5b) 
 
Prepared according to TP1 from 2,5-dibromo-3-(methylthio)thiophene (2a; 576 mg,  
2 mmol) and iPrMgCl·LiCl (1a; 1.75 mL, 2.1 mmol, 1.2 M in THF) at 0 °C in 1 h. 
Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2  
(2.0 mL, 2.0 mmol, 1.0 M in THF), Pd(PPh3)4 (92 mg, 0.08 mmol) and 1-(5-iodothio-
phen-2-yl)ethanone (4b; 454 mg, 1.8 mmol) in 2 h. Flash column chromatographical 
purification on silica gel (pentane/Et2O, 8:2) afforded 5b as a red-brown yellow solid 
(491 mg, 82%). 
 
m.p.: 73.8-75.4 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.58 (d, J=3.9Hz, 1H), 7.17 (s, 1H), 7.12 (d, 
J=3.9Hz, 1H), 2.55 (s, 3H), 2.52 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 190.3, 143.7, 143.2, 137.2, 134.4, 133.2, 128.3, 
124.4, 115.5, 26.6, 20.2. 
MS (70 eV, EI), m/z (%) = 334 (M+, 45), 332 (M+, 40), 319 (36), 317 (31), 263 (21),  
262 (100), 183 (70), 108 (26), 44 (36), 43 (33). 
HRMS (EI), m/z calc. for C11H9BrOS3 (333.8999): 333.8992 (M+). 
IR (ATR) υ (cm-1) = 3074, 3055, 2994, 2916, 1643, 1500, 1435, 1408, 1354, 1289, 1272, 
1074, 1039, 1029, 966, 933, 882, 796, 744, 691, 662. 
 
Preparation of 1,4-bis(5-bromo-4-(methylthio)thiophen-2-yl)benzene (5c) 
 
Prepared according to TP1 from 2,5-dibromo-3-(methylthio)thiophene (2a; 576 mg,  
2 mmol) and iPrMgCl·LiCl (1a; 1.75 mL, 2.1 mmol, 1.2 M in THF) at 0 °C in 1 h. 
Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2  
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(2.0 mL, 2.0 mmol, 1.0 M in THF), Pd(PPh3)4 (92 mg, 0.08 mmol) and 1,4-diiodobenzene 
(4c; 314 mg, 0.95 mmol) in 1 h. Recristallisation from EtOAc afforded 5c as a pale 
yellow solid (391 mg, 84%). 
 
m.p.: 182.7-183.3 °C.  
1H NMR (400 MHz, CD2Cl2) δ (ppm) = 7.55 (s, 4H), 7.25 (s, 2H), 2.52 (s, 6H). 
13C NMR (100 MHz, CD2Cl2) δ (ppm) = 144.5, 132.8, 132.7, 126.5, 125.8, 115.8, 20.2. 
MS (70 eV, EI), m/z (%) = 494 (M+, 55), 492 (M+, 100), 490 (M+, 40), 479 (26),  
477 (42), 475 (20), 383 (6), 246 (7), 242 (8), 236 (7). 
HRMS (EI), m/z calc. for C16H12Br2S4 (489.8189): 489.8171 (M+). 
IR (ATR) υ (cm-1) = 3085, 3068, 3034, 2991, 2917, 2846, 2822, 1484, 1434, 1418, 1408, 
1335, 1319, 1289, 1272, 1169, 1120, 1104, 1020, 1008, 967, 951, 808. 
 
Preparation of tert-butyl 5-bromo-4-(methylthio)thiophene-2-carboxylate (5d) 
 
Prepared according to TP1 from 2,5-dibromo-3-(methylthio)thiophene (2a; 576 mg,  
2 mmol) and iPrMgCl·LiCl (1a; 1.75 mL, 2.1 mmol, 1.2 M in THF) at 0 °C in 1 h. 
Subsequently, the reaction mixture was cooled to −40 °C and di-tert-butyl dicarbonate 
(4d; 524 mg, 2.4 mmol) in THF was added. The reaction mixture was allowed to slowly 
warm to 25 °C and continuously stirred for 3 h. Subsequently, sat. aq. NH4Cl (10 mL) 
was added. The aqueous layer was extracted with EtOAc (3x 10 mL). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. Flash column 
chromatographical purification (pentane/EtOAc, 50:1) furnished 5d as a white solid  
(521 mg, 85%). 
 
m.p.: 48.0-49.8 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.54 (s, 1H), 2.57 (s, 3H), 1.56 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 159.8, 142.1, 135.4, 134.3, 111.3, 82.5, 28.2, 
19.0. 
MS (70 eV, EI), m/z (%) = 310 (M+, 32), 308 (M+, 29), 256 (26), 255 (25), 254 (16),  
253 (24), 252 (19), 239 (56), 237 (100), 235 (36), 127 (20). 
HRMS (EI), m/z calc. for C10H13BrO2S2 (307.9540): 307.9532 (M+). 
IR (ATR) υ (cm-1) = 3098, 3008, 2979, 2931, 2920, 1691, 1514, 1391, 1368, 1330, 1266, 
1252, 1166, 1152, 1134, 1076, 1031, 850, 835, 799, 746. 
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Preparation of (5-bromo-4-(phenylthio)thiophen-2-yl)(4-methoxyphenyl)methanol 
(5e) 
 
Prepared according to TP1 from 2,5-dibromo-3-(phenylthio)thiophene (2b; 350 mg,  
1 mmol) and iPrMgCl·LiCl (1a; 0.88 mL, 1.05 mmol, 1.2 M in THF) at 0 °C in 1 h. 
Subsequently, the reaction mixture was cooled to −20 °C and 4-methoxybenzaldehyde 
(4e; 123 mg, 0.9 mmol) in THF was added. The reaction mixture was allowed to slowly 
warm to 25 °C and continuously stirred for 2 h. Subsequently, sat. aq. NH4Cl (10 mL) 
was added. The aqueous layer was extracted with EtOAc (3x 10 mL). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. Flash column 
chromatographical purification (pentane/Et2O, 8.5:1.5) furnished 5e as a white solid  
(334 mg, 91%). 
 
m.p.: 94.0-95.7 °C.  
1H NMR (400 MHz, d6-DMSO) δ (ppm) = 7.27-7.33 (m, 3H), 7.20 (t, J=7.3Hz, 1H), 
7.12 (d, J=7.2Hz, 2H), 6.81-6.98 (m, 3H), 6.39 (d, J=4.5Hz, 1H), 5.83 (d, J=4.5Hz, 1H), 
3.70 (s, 3H). 
13C NMR (100 MHz, d6-DMSO) δ (ppm) = 159.1, 157.5, 136.2, 136.1, 129.9, 127.8, 
127.7, 127.5, 127.2, 125.3, 119.7, 114.2, 70.6, 55.5. 
MS (70 eV, EI), m/z (%) = 408 (M+, 58), 406 (M+, 60), 388 (21), 386 (18), 298 (12),  
218 (19), 217 (30), 190 (13), 137 (11), 125 (100), 109 (15), 77 (31). 
HRMS (EI), m/z calc. for C18H15BrO2S2 (405.9697): 405.9680 (M+). 
IR (ATR) υ (cm-1) = 3436, 3070, 3046, 3006, 2957, 2836, 2362, 2339, 1610, 1581, 1515, 
1476, 1454, 1439, 1313, 1251, 1173, 1144, 1104, 1033, 1022, 996, 844, 820, 816, 741, 
684. 
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Preparation of 2-bromo-5-(4-nitrophenyl)-3-(phenylthio)thiophene (5f) 
 
Prepared according to TP1 from 2,5-dibromo-3-(phenylthio)thiophene (2b; 350 mg,  
1 mmol) and iPrMgCl·LiCl (1a; 0.88 mL, 1.05 mmol, 1.2 M in THF) at 0 °C in 1 h. 
Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2  
(1.0 mL, 1.0 mmol, 1.0 M in THF), Pd(PPh3)4 (46 mg, 0.04 mmol) and 1-iodo-4-
nitrobenzene (4f; 224 mg, 0.9 mmol) in 1 h. Flash column chromatographical purification 
on silica gel (pentane/Et2O, 100:3) afforded 5f as a yellow solid (302 mg, 86%). 
 
m.p.: 129.0-130.9 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.21-8.29 (m, 2H), 7.62-7.69 (m, 2H), 7.42 (s, 
1H), 7.25-7.39 (m, 5H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 147.3, 144.5, 138.7, 135.2, 132.1, 129.4, 129.3, 
128.9, 127.5, 125.9, 124.5, 119.9. 
MS (70 eV, EI), m/z (%) = 395 (M+, 10), 393 (M+, 100), 391 (95), 312 (13), 267 (15), 
266 (72), 265 (24), 234 (14), 221 (36), 189 (13), 121 (11), 113 (15), 77 (14), 43 (14). 
HRMS (EI), m/z calc. for C16H10BrNO2S2 (390.9336): 390.9333 (M+). 
IR (ATR) υ (cm-1) = 3092, 3076, 3061, 2932, 2842, 1591, 1578, 1516, 1506, 1477, 1341, 
1332, 1108, 1022, 851, 819, 740, 726, 687. 
 
Preparation of 2-bromo-5-(4-methoxyphenyl)-3-(phenylthio)thiophene (5g) 
 
Prepared according to TP1 from 2,5-dibromo-3-(phenylthio)thiophene (2b; 5.25 g,  
15 mmol) and iPrMgCl·LiCl (1a; 13.13 mL, 15.75 mmol, 1.2 M in THF) at 0 °C in 1 h. 
Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2  
(15 mL, 15.0 mmol, 1.0 M in THF), Pd(PPh3)4 (867 mg, 0.75 mmol) and 1-iodo-4-
methoxybenzene (4g; 3.16 g, 13.5 mmol) in 1 h. Flash column chromatographical 
purification on silica gel (pentane/Et2O, 50:1) afforded 5g as a pale yellow solid (4.9 g, 
96%). 
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m.p.: 96.0-98.4 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.40-7.51 (m, 2H), 7.13-7.34 (m, 6H), 6.85-6.98 
(m, 2H), 3.78-3.89 (m, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 160.1, 148.8, 136.7, 129.1, 127.7, 127.0, 126.5, 
125.7, 125.6, 125.5, 121.1, 114.5, 55.4  
MS (70 eV, EI), m/z (%) = 378 (M+, 100), 376 (M+, 100), 297 (47), 253 (23), 221 (30), 
177 (19), 151 (19), 108 (19), 77 (45), 43 (24). 
HRMS (EI), m/z calc. for C17H13BrOS2 (377.9571): 377.9569 (M+). 
IR (ATR) υ (cm-1) = 3071, 3052, 2998, 2962, 2936, 2907, 2831, 1604, 1572, 1527, 1492,  
1476, 1436, 1412, 1283, 1247, 1178, 1112, 1023, 813, 800, 738, 688. 
 
Preparation of ethyl 4-(5-bromo-4-(pyridin-2-ylthio)thiophen-2-yl)benzoate (5h) 
 
Prepared according to TP1 from 2-((2,5-dibromothiophen-3-yl)thio)pyridine (2c; 351 
mg, 1 mmol) and iPrMgCl·LiCl (1a; 0.88 mL, 1.05 mmol, 1.2 M in THF) at 0 °C in 1 h. 
Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2  
(1.0 mL, 1.0 mmol, 1.0 M in THF), Pd(PPh3)4 (46 mg, 0.04 mmol) and ethyl 4-
iodobenzoate (4h; 249 mg, 0.9 mmol) in 1 h. Flash column chromatographical 
purification on silica gel (pentane/Et2O, 8.5:1.5 + 1% NEt3) afforded 5h as a pale yellow 
solid (347 mg, 92%). 
 
m.p.: 102.6-104.3 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.46 (dd, J=3.9Hz, 2.0Hz, 1H), 8.04-8.13 (m, 
2H),  7.59-7.68 (m, 2H), 7.55 (td, J=7.7Hz, 2.0Hz, 1H), 7.45 (s, 1 H), 7.06 (ddd, 
J=7.5Hz, 5.0Hz, 1.1Hz, 1H), 6.92-7.02 (m, 1H), 4.40 (q, J=7.2Hz, 2H), 1.42 (t, J=7.1Hz, 
3H).  
13C NMR (75 MHz, CDCl3) δ (ppm) = 165.9, 159.2, 149.7, 148.2, 137.1, 136.6, 130.5, 
130.4, 128.0, 125.8, 125.4, 122.5, 120.5, 120.4, 61.2, 14.3. 
MS (70 eV, EI), m/z (%) = 421 (M+, 5), 419 (M+, 5), 342 (12), 341 (25), 340 (100),  
313 (12), 312 (64), 267 (11), 266 (10). 
HRMS (EI), m/z calc. for C18H14BrNO2S2 (418.9649): 418.9617 (M+). 
IR (ATR) υ (cm-1) = 3087, 3068, 3046, 2982, 2957, 2935, 2896, 1704, 1605, 1569, 1562, 
1444, 1418, 1276, 1180, 1117, 1107, 1088, 1019, 851, 834, 822, 815, 765, 719, 692. 
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Preparation of (5-bromo-4-(trimethylsilyl)thiophen-2-yl)(2,3-dichlorophenyl)-
methanol (5i) 
 
Prepared according to TP1 from (2,5-dibromothiophen-3-yl)trimethylsilane (2d; 628 mg,  
2 mmol) and iPrMgCl·LiCl (1a; 1.75 mL, 2.1 mmol, 1.2 M in THF) at 0 °C in 1 h. 
Subsequently, the reaction mixture was cooled to −20 °C and 2,3-dichlorobenzaldehyde 
(4i; 315 mg, 1.8 mmol) in THF was added. The reaction mixture was allowed to slowly 
warm to 25 °C and continuously stirred for 2 h. Subsequently, sat. aq. NH4Cl (10 mL) 
was added. The aqueous layer was extracted with EtOAc (3x 10 mL). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. Flash column 
chromatographical purification (pentane/Et2O, 8.5:1.5) furnished 5i as a colorless oil 
(635 mg, 86%). 
 
1H NMR (400 MHz, d6-DMSO) δ (ppm) = 7.65-7.69 (m, 1H), 7.59 (dd, J=8.0Hz, 1.8Hz, 
1H), 7.44 (t, J=7.8Hz, 1H), 6.98 (d, J=0.8Hz, 1H), 6.65 (d, J=4.7Hz, 1H), 6.22 (d, 
J=4.3Hz, 1H), 0.32 (s, 9H). 
13C NMR (100 MHz, d6-DMSO) δ (ppm) = 153.6, 144.3, 133.5, 132.1, 130.1, 130.0, 
129.3, 129.0, 126.7, 116.1, 67.5, -0.5. 
MS (70 eV, EI), m/z (%) = 410 (M+, 35), 408 (M+, 40), 399 (11), 398 (12), 397 (56),  
396 (22), 395 (100), 394 (15), 393 (64), 337 (16), 335 (18), 237 (25), 235 (25), 175 (25), 
139 (46), 137 (39), 73 (100). 
HRMS (EI), m/z calc. for C14H15BrCl2OSSi (407.9173): 407.9172 (M+). 
IR (ATR) υ (cm-1) = 3332, 2957, 2897, 2873, 2361, 2349, 1515, 1450, 1419, 1330, 1298, 
1264, 1249, 1179, 1154, 1102, 1052, 1027, 993, 837, 816, 788, 773, 754, 742, 731, 697, 
655. 
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Preparation of (2-bromo-5-(4-methoxyphenyl)thiophen-3-yl)trimethylsilane (5j) 
 
Prepared according to TP1 from (2,5-dibromothiophen-3-yl)trimethylsilane (2d; 3.14 g, 
10 mmol) and iPrMgCl·LiCl (1a; 8.75 mL, 10.5 mmol, 1.2 M in THF) at 0 °C in 1 h. 
Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2  
(10 mL, 10 mmol, 1.0 M in THF), Pd(PPh3)4 (462 mg, 0.4 mmol) and 1-iodo-4-
methoxybenzene (4g; 2.57 g, 11 mmol) in 2 h. Flash column chromatographical 
purification on silica gel (pentane/Et2O, 100:1) afforded 5j as a pale yellow solid (3.0 g, 
87%). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.45-7.55 (m, 2H), 7.19 (s, 1H), 6.88-6.95 (m, 
2H), 3.85 (s, 3H), 0.43 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 159.6, 149.1, 132.7, 127.3, 127.1, 126.1, 117.6, 
114.3, 55.4, -0.7. 
MS (70 eV, EI), m/z (%) = 342 (M+, 70), 340 (M+, 42), 327 (35), 325 (21), 203 (52),  
173 (27), 139 (31), 137 (28), 74 (22), 73 (30), 45 (68), 44 (100), 43 (32). 
HRMS (EI), m/z calc. for C14H17BrOSSi (339.9953): 339.9939 (M+). 
IR (ATR) υ (cm-1) = 3090, 3054, 2997, 2955, 2935, 2899, 2831, 1878, 1606, 1532, 1490, 
1456, 1422, 1308, 1288, 1249, 1179, 1108, 1035, 1001, 948, 835, 818, 808, 753, 698. 
 
Preparation of (5-bromo-4-(trimethylsilyl)thiophen-2-yl)(furan-3-yl)methanone (5k) 
SBr
O
TMS
O
 
(2,5-dibromothiophen-3-yl)trimethylsilane (2d; 628 mg, 2 mmol) and iPrMgCl·LiCl (1a;  
1.75 mL, 2.1 mmol, 1.2 M in THF) at 0 °C in 1 h. Subsequently, the acylation reaction 
was accomplished according to TP4 with ZnCl2 (2 mL, 2 mmol, 1.0 M in THF), 
CuCN·2LiCl (0.2 mL, 0.2 mmol, 1.0M in THF) and furan-2-carbonyl chloride (4j;  
235 mg, 1.8 mmol) in 8 h. Flash column chromatographical purification on silica gel 
(pentane/Et2O, 50:1) afforded 5k as a pale yellow solid (423 mg, 72%). 
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m.p.: 108.6-110.2 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.10 (s, 1H), 7.70 (dd, J=1.8Hz, 0.7Hz, 1H), 7.42 
(dd, J=3.6Hz, 0.8Hz, 1H), 6.62 (dd, J=3.6Hz, 1.7Hz, 1H), 0.45 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 172.0, 152.1, 146.7, 145.5, 145.0, 137.6, 119.3, 
117.6, 112.6, -1.0. 
MS (70 eV, EI), m/z (%) = 330 (M+, 33), 328 (M+, 31), 316 (12), 315 (72), 313 (68),  
163 (28), 139 (17), 99 (16), 95 (100), 73 (16). 
HRMS (EI), m/z calc. for C12H13BrO2SSi (327.9589): 327.9588 (M+). 
IR (ATR) υ (cm-1) = 3137, 3110, 2959, 2362, 2349, 1623, 1566, 1491, 1462, 1396, 1296, 
1247, 1226, 1174, 1143, 1124, 1076, 998, 941, 844, 828, 788, 766, 742, 720. 
 
Preparation of (5-bromo-6-(trimethylsilyl)thieno[3,2-b]thiophen-2-yl)(4-methoxy-
phenyl)methanol (5l) 
 
Prepared according to TP1 from (2,5-dibromothieno[3,2-b]thiophen-3-yl)trimethylsilane 
(2e; 370 mg, 1 mmol) and iPrMgCl·LiCl (1a; 0.88 mL, 1.05 mmol, 1.2 M in THF) at 0 °C 
in 1 h. Subsequently, the reaction mixture was cooled to −20 °C and 4-methoxy-
benzaldehyde (4e; 123 mg, 0.9 mmol) in THF was added. The reaction mixture was 
allowed to slowly warm to 25 °C and continuously stirred for 2 h. Subsequently,  
sat. aq. NH4Cl (10 mL) was added. The aqueous layer was extracted with EtOAc  
(3x 10 mL). The combined organic phases were dried over Na2SO4 and concentrated  
in vacuo. Flash column chromatographical purification (pentane/Et2O, 8:2) furnished 5l 
as a colorless oil (311 mg, 81%). 
 
1H NMR (400 MHz, d6-DMSO) δ (ppm) = 7.30-7.36 (m, 2H), 7.24 (d, J=1.0Hz, 1H), 
6.87-6.90 (m, 2H), 6.38 (d, J=4.3 Hz, 1H), 5.92 (d, J=4.3 Hz, 1H), 3.71 (s, 3H),  
0.36 (s, 9H). 
13C NMR (100 MHz, d6-DMSO) δ (ppm) = 159.0, 155.9, 141.9, 141.7, 136.8, 135.5, 
127.9, 117.5, 114.0, 108.8, 71.0, 55.5, -0.5. 
MS (70 eV, EI), m/z (%) = 426 (M+, 44), 424 (M+, 22), 412 (60), 411 (74), 409 (51),  
397 (19), 395 (22), 332 (11), 331 (14), 139 (12), 137 (13), 136 (12), 135 (100), 121 (14), 
77 (21), 75 (24), 73 (39). 
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HRMS (EI), m/z calc. for C17H17BrO2S2Si (423.9623): 423.9619 (M+). 
IR (ATR) υ (cm-1) = 3393, 3075, 3034, 2999, 2954, 2896, 2865, 2835, 2060, 1610, 1586, 
1510, 1328, 1304, 1246, 1171, 1110, 1032, 1002, 829, 757, 699, 664. 
 
Preparation of (2-bromo-5-(4-methoxyphenyl)thieno[3,2-b]thiophen-3-yl)trimethyl-
silane (5m) 
 
Prepared according to TP1 from (2,5-dibromothieno[3,2-b]thiophen-3-yl)trimethylsilane 
(2e; 370 mg, 1 mmol) and iPrMgCl·LiCl (1a; 0.88 mL, 1.05 mmol, 1.2 M in THF) at 0 °C 
in 1 h. Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2 
(1.0 mL, 1.0 mmol, 1.0 M in THF), Pd(PPh3)4 (46 mg, 0.04 mmol) and 1-iodo- 
4-methoxybenzene (4g; 258 mg, 1.1 mmol) in 1 h. Flash column chromatographical 
purification on silica gel (pentane/Et2O, 100:1) afforded 5m as white solid (381 mg, 
96%). 
 
m.p.: 133.7-135.5 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.53-7.60 (m, 2H), 7.37 (s, 1H), 6.92-6.98 (m, 
2H), 3.86 (s, 3H), 0.41-0.53 (m, 9H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 159.7, 147.6, 143.0, 141.8, 135.7, 127.3, 127.2, 
114.7, 114.4, 108.8, 55.4, -0.8. 
MS (70 eV, EI), m/z (%) = 398 (M+, 100), 396 (M+, 86), 383 (40), 381 (36), 326 (33), 
324 (32), 311 (16), 309 (17), 260 (12), 259 (66), 216 (12), 75 (16), 73 (19), 43 (19). 
HRMS (EI), m/z calc. for C16H17BrOS2Si (395.9673): 395.9662 (M+). 
IR (ATR) υ (cm-1) = 3080, 3000, 2955, 2940, 2895, 2834, 1603, 1523, 1488, 1438, 1425, 
1291, 1247, 1185, 1030, 1007, 965, 874, 837, 828, 813, 802, 789, 756, 698, 681. 
 
Preparation of 2-bromo-5-(4-methoxyphenyl)-3-(o-tolyl)thiophene (5n) 
 
Prepared according to TP1 from 2,5-dibromo-3-(o-tolyl)thiophene (2f; 332 mg, 1 mmol) 
and iPrMgCl·LiCl (1a; 0.88 mL, 1.05 mmol, 1.2 M in THF) at 0 °C in 1 h. Subsequently, 
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the cross-coupling was accomplished according to TP3 with ZnCl2 (1.0 mL, 1.0 mmol, 
1.0 M in THF), Pd(PPh3)4 (46 mg, 0.04 mmol) and 1-iodo-4-methoxybenzene (4g;  
211 mg, 0.9 mmol) in 1 h. Flash column chromatographical purification on silica gel 
(pentane/Et2O, 100:1) afforded 5n as a pale yellow oil (310 mg, 96%). 
 
m.p.: 56.9-58.7 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.48-7.54 (m, 2H), 7.24-7.38 (m, 4H), 6.88-6.98 
(m, 2H) 7.15 (s, 1H), 3.85 (s, 3H), 2.33 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 159.7, 143.8, 138.1, 136.1, 132.3, 131.2, 130.2, 
129.0, 126.8, 126.1, 125.6, 124.8, 114.4, 110.2, 55.4, 20.2. 
MS (70 eV, EI), m/z (%) = 360 (M+, 100), 358 (M+, 95), 345 (12), 338 (11), 279 (15), 
277 (10), 263 (9), 235 (12), 203 (15), 171 (8), 115 (9). 
HRMS (EI), m/z calc. for C18H15BrOS (358.0027): 358.0024 (M+). 
IR (ATR) υ (cm-1) = 3092, 3058, 3012, 2955, 2933, 2904, 2834, 1605, 1515, 1486, 1460, 
1450, 1439, 1289, 1250, 1178, 1111, 1024, 972, 819, 808, 798, 756, 750, 720, 694, 663. 
 
Preparation of 4-(5-bromo-4-(2-(dimethylamino)phenyl)thiophen-2-yl)benzonitrile 
(5o) 
 
Prepared according to TP1 from 2-(2,5-dibromothiophen-3-yl)-N,N-dimethylaniline (2g;  
361 mg, 1 mmol) and iPrMgCl·LiCl (1a; 0.88 mL, 1.05 mmol, 1.2 M in THF) at 0 °C in  
1 h. Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2 
(1.0 mL, 1.0 mmol, 1.0 M in THF), Pd(PPh3)4 (46 mg, 0.04 mmol) and 4-iodobenzonitrile 
(4k; 206 mg, 0.9 mmol) in 1 h. Flash column chromatographical purification on silica gel 
(pentane/Et2O, 50:1 + 1% NEt3) afforded 5o as a pale yellow solid (312 mg, 91%). 
 
m.p.: 111.8-113.1 °C.  
1H NMR (600 MHz, CDCl3) δ (ppm) = 7.68 (s, 4H), 7.43 (dd, J=7.7Hz, 1.7Hz, 1H), 
7.31-7.40 (m, 2H), 7.08 (dd, J=8.2Hz, 1.1Hz, 1H), 7.03 (td, J=7.4Hz, 1.1Hz, 1H), 2.67 
(s, 6H). 
13C NMR (150 MHz, CDCl3) δ (ppm) = 152.3, 141.1, 139.5, 137.7, 132.8, 132.5, 129.9, 
127.9, 125.6, 124.4, 121.1, 118.7, 118.1, 111.0, 110.2, 43.2. 
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MS (70 eV, EI), m/z (%) = 384 (M+, 20), 382 (M+, 19), 304 (23), 303 (100), 301 (29), 
289 (13), 288 (60), 287 (11), 269 (10), 146 (13), 43 (26). 
HRMS (EI), m/z calc. for C19H15BrN2S (382.0139): 382.0132 (M+). 
IR (ATR) υ (cm-1) = 3063, 3044, 2969, 2934, 2858, 2830, 2784, 2223, 1602, 1594, 1484, 
1451, 1440, 1330, 1316, 1176, 1159, 1049, 974, 946, 935, 837, 827, 817, 763, 742, 696. 
 
Preparation of 4-(5-bromo-4-(2-methoxyphenyl)thiophen-2-yl)benzonitrile (5p) 
 
Prepared according to TP1 from 2,5-dibromo-3-(2-methoxyphenyl)thiophene (2h;  
348 mg, 1 mmol) and iPrMgCl·LiCl (1a; 0.88 mL, 1.05 mmol, 1.2 M in THF) at 0 °C in  
1 h. Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2 
(1.0 mL, 1.0 mmol, 1.0 M in THF), Pd(PPh3)4 (46 mg, 0.04 mmol) and 4-iodobenzonitrile 
(4k; 206 mg, 0.9 mmol) in 1 h. Flash column chromatographical purification on silica gel 
(pentane/Et2O, 9:1) afforded 5p as a pale yellow solid (300 mg, 90%). 
 
m.p.: 128.6-130.5 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.67 (s, 4H), 7.40-7.50 (m, 2H), 7.38 (s, 1H), 
7.01-7.09 (m, 2H), 3.88 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 157.0, 141.2, 137.6, 136.3, 132.8, 132.0, 130.7, 
128.2, 125.7, 120.9, 120.5, 118.6, 111.4, 111.1, 111.1, 55.7. 
MS (70 eV, EI), m/z (%) = 371 (M+, 100), 369 (M+, 95), 276 (19), 275 (99), 246 (16), 
146 (9). 
HRMS (EI), m/z calc. for C18H12BrNOS (368.9823): 368.9790 (M+). 
IR (ATR) υ (cm-1) = 3086, 3059, 3016, 2979, 2949, 2845, 2224, 1597, 1485, 1464, 1438, 
1330, 1251, 1178, 1166, 1112, 1011, 971, 844, 828, 817, 790, 757, 738, 721, 701, 660. 
 
 
 
 
 
 
 
C. EXPERIMENTAL SECTION 
170 
Preparation of ethyl 4-(5-bromo-4-(pyridin-2-yl)thiophen-2-yl)benzoate (5q) 
 
Prepared according to TP1 from 2-(2,5-dibromothiophen-3-yl)pyridine (2i; 319 mg,  
1 mmol) and iPrMgCl·LiCl (1a; 0.88 mL, 1.05 mmol, 1.2 M in THF) at 0 °C in 1 h. 
Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2  
(1.0 mL, 1.0 mmol, 1.0 M in THF), Pd(PPh3)4 (46 mg, 0.04 mmol) and ethyl 4-iodo-
benzoate (4h; 249 mg, 0.9 mmol) in 1 h. Flash column chromatographical purification on 
silica gel (pentane/Et2O, 8.5:1.5 + 1% NEt3) afforded 5q as a white solid (310 mg, 89%). 
 
m.p.: 104.6-106.2 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.63 (dd, J=5.8Hz, 2.0Hz, 1H), 8.36 (dt, 
J=8.2Hz, 0.9Hz, 1H), 8.36 (dt, J=8.2Hz, 0.9Hz, 1H), 7.99-8.13 (m, 2H), 7.77 (td, 
J=7.8Hz, 1.8Hz, 1H), 7.63-7.72 (m, 2H), 7.37 (s, 1H), 7.24 (ddd, J=7.6Hz, 4.8Hz, 1.1Hz, 
1H), 4.40 (q, J=7.2Hz, 2H), 1.41 (t, J=7.2 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.0, 151.0, 149.6, 143.6, 139.3, 137.0, 136.5, 
130.3, 130.0, 129.5, 125.2, 122.7, 120.6, 108.2, 61.1, 14.3. 
MS (70 eV, EI), m/z (%) = 389 (M+, 100), 387 (M+, 96), 359 (21), 342 (24), 235 (25), 
234 (12), 190 (5). 
HRMS (EI), m/z calc. for C18H14BrNO2S (386.9929): 386.9951 (M+). 
IR (ATR) υ (cm-1) = 3069, 2990, 2979, 2931, 2902, 2871, 1706, 1603, 1579, 1505, 1469, 
1434, 1409, 1365, 1266, 1180, 1109, 1100, 1015, 855, 832, 781, 767, 742, 714, 694. 
 
Preparation of 2'-bromo-5'-(3-methoxyphenyl)-2,3'-bithiophene (5r) 
 
Prepared according to TP1 from 2',5'-dibromo-2,3'-bithiophene (2j; 324 mg, 1 mmol) 
and iPrMgCl·LiCl (1a; 0.88 mL, 1.05 mmol, 1.2 M in THF) at -20 °C in 1 h. 
Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2  
(1.0 mL, 1.0 mmol, 1.0 M in THF), Pd(PPh3)4 (46 mg, 0.04 mmol) and 1-iodo-3-
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methoxybenzene (4l; 211 mg, 0.9 mmol) in 1 h. Flash column chromatographical 
purification on silica gel (pentane/Et2O, 40:1) afforded 5r as a yellow oil (261 mg, 83%). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.43-7.49 (m, 1H), 7.34-7.38 (m, 1H), 7.31 (t, 
J=7.9 Hz, 1H), 7.22 (bs, 1H), 7.13-7.18 (m, 1H), 7.06-7.12 (m, 2H), 6.88 (dd, J=8.0Hz, 
2.5Hz, 1H), 3.86 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 160.1, 142.2, 134.4, 134.1, 131.5, 130.1, 127.6, 
127.3, 126.6, 126.1, 118.0, 113.9, 111.1, 108.1, 55.4. 
MS (70 eV, EI), m/z (%) = 352 (M+, 100), 350 (M+, 93), 309 (16), 307 (15), 240 (3),  
228 (4), 176 (4), 175 (3), 108 (3). 
HRMS (EI), m/z calc. for C15H11BrOS2 (275.9820): 275.9817 (M+). 
IR (ATR) υ (cm-1) = 3101, 3068, 2999, 2955, 2934, 2832, 1597, 1578, 1480, 1462, 1429, 
1288, 1272, 1260, 1201, 1166, 1045, 837, 824, 809, 770, 682. 
 
Preparation of (5-bromo-4-(2-methoxyphenyl)thiophen-2-yl)(5-iodofuran-2-yl)-
methanol (5s) 
 
Prepared according to TP1 from 2,5-dibromo-3-(2-methoxyphenyl)thiophene (2h;  
348 mg, 1 mmol) and iPrMgCl·LiCl (1a; 0.88 mL, 1.05 mmol, 1.2 M in THF) at 0 °C in  
1 h. Subsequently, the reaction mixture was cooled to 0 °C and ZnCl2 (0.5 mL, 0.5 mmol, 
1.0 M in THF) was added. The reaction mixture was allowed to warm to 25 °C in 30 min. 
Then, 5-iodofuran-2-carbaldehyde (4m; 200 mg, 0.9 mmol) in THF was added and the 
reaction mixture was continuously stirred for 2 h. Subsequently, sat. aq. NH4Cl (10 mL) 
was added. The aqueous layer was extracted with EtOAc (3x 10 mL). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. Flash column 
chromatographical purification (pentane/Et2O, 8:2) furnished 5s as a brown oil (266 mg, 
60%). 
 
1H NMR (400 MHz, d6-DMSO) δ (ppm) = 7.40 (ddd, J=15.6Hz, 7.4Hz, 1.8Hz, 1H), 
7.31 (dd, J=7.6Hz, 1.8 Hz, 1H), 7.11 (dd, J=8.4Hz, 1.0Hz, 1H), 7.00 (dt, J=7.5Hz, 1.2Hz, 
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1H), 6.93 (d, J=1.0Hz, 1H), 6.64 (d, J=3.1Hz, 1H), 6.56 (d, J=5.3Hz, 1H), 6.30 (dd, 
J=3.2Hz, 0.7Hz, 1H), 5.94 (d, J=5.3Hz, 1H), 3.76 (s, 3H).  
13C NMR (100 MHz, d6-DMSO) δ (ppm) = 161.1, 157.1, 146.9, 133.9, 132.1, 131.0, 
127.4, 121.0, 121.0, 120.8, 112.2, 110.4, 108.6, 91.8, 64.6, 56.0. 
MS (70 eV, EI), m/z (%) = 492 (M+, 88), 490 (M+, 100), 488 (17), 475 (40), 473 (37), 
411 (17), 364 (14), 362 (12), 224 (16), 221 (25), 190 (27), 128 (15), 127 (12), 115 (10). 
HRMS (EI), m/z calc. for C16H12BrIO3S (489.8735): 489.8737 (M+). 
IR (ATR) υ (cm-1) = 3070, 3051, 2960, 2930, 2894, 2362, 2337, 1775, 1699, 1641, 1596, 
1458, 1430, 1394, 1328, 1248, 1174, 1148, 1119, 1045, 1019, 956, 927, 748. 
 
Preparation of 5-(5-bromo-4-(2-methoxyphenyl)thiophen-2-yl)furan-2-carb-
aldehyde (5t) 
 
Prepared according to TP1 from 2,5-dibromo-3-(2-methoxyphenyl)thiophene (2h;  
348 mg, 1 mmol) and iPrMgCl·LiCl (1a; 0.88 mL, 1.05 mmol, 1.2 M in THF) at 0 °C in  
1 h. Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2 
(1.0 mL, 1.0 mmol, 1.0 M in THF), Pd(PPh3)4 (46 mg, 0.04 mmol) and 5-iodofuran-2-
carbaldehyde (4m; 200 mg, 0.9 mmol) in 1 h. Flash column chromatographical 
purification on silica gel (pentane/Et2O, 100:1) afforded 5t as a light brown solid  
(249 mg, 76%). 
 
m.p.: 114.8-116.4 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 9.63 (s, 1H), 7.38-7.52 (m, 3H), 7.30 (d, 
J=3.6Hz, 1H), 6.99-7.08 (m, 2H), 6.69 (d, J=3.9Hz, 1H), 3.87 (s, 3H).  
13C NMR (75 MHz, CDCl3) δ (ppm) = 176.9, 156.9, 153.5, 151.7, 136.6, 132.0, 131.1, 
130.7, 128.9, 120.6, 120.5, 111.4, 110.9, 107.9, 55.6. 
MS (70 eV, EI), m/z (%) = 364 (M+, 100), 362 (M+, 99), 269 (12), 268 (74), 211 (33), 
139 (11). 
HRMS (EI), m/z calc. for C16H11BrO3S (361.9612): 361.9604 (M+). 
IR (ATR) υ (cm-1) = 3125, 3107, 3096, 2998, 2982, 2950, 2925, 2843, 1664, 1484, 1470, 
1461, 1393, 1280, 1251, 1238, 1034, 1016, 961, 893, 794, 762. 
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2.3.1 FURTHER FUNCTIONALIZATION OF MONOBROMOTHIOPHENE 5g 
Preparation of (3,4-dichlorophenyl)(5-(4-methoxyphenyl)-3-(phenylthio)thiophen-2-
yl)methanol (7a) 
 
A dry and argon-flushed Schlenk-flask, equipped with a magnetic stirring bar and a 
septum, was charged with iPrMgCl·LiCl (1a; 0.92 ml, 1.1 mmol, 1.2 M in THF).  
2-bromo-5-(4-methoxy-phenyl)-3-(phenylthio)thiophene (5g; 377 mg, 1.0 mmol) was 
added as a solution in THF (1.0 M) at 25 °C and continuously stirred for 1 h. Complete 
Br/Mg-exchange was monitored by GC-analysis of iodolyzed reaction aliquots using 
undecane as internal standard. Subsequently, the reaction mixture was cooled to −20 °C 
and 3,4-dichlorobenzaldehyde (4n; 158 mg, 0.9 mmol) in THF was added. The reaction 
mixture was allowed to slowly warm to 25 °C and continuously stirred for 1 h. 
Subsequently, sat. aq. NH4Cl (10 mL) was added. The aqueous layer was extracted with 
EtOAc (3x 10 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. Flash column chromatographical purification (pentane/Et2O, 6:4) 
furnished 7a as a white solid (328 mg, 77%). 
 
m.p.: 108.6-110.1 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.44-7.51 (m, 2H), 7.42 (dd, J=1.4 Hz,  
0.8 Hz,1H), 7.22-7.31 (m, 3H), 7.10-7.21 (m, 5H), 6.85-6.92 (m, 2H), 6.10 (d, J=3.0 Hz, 
1H), 3.82 (s, 3H), 2.45 (d, J=3.6 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 159.9, 150.5, 149.3, 142.8, 137.8, 132.5, 131.3, 
130.3, 129.2, 128.1, 127.1, 126.8, 126.3, 126.2, 125.4, 124.4, 121.4, 114.4, 69.4, 55.4. 
MS (70 eV, EI), m/z (%) = 472 (M+, 100), 456 (11), 217 (13), 190 (15), 175 (36),  
173 (42), 151 (15), 145 (20), 121 (11), 111 (19), 77 (30). 
HRMS (EI), m/z calc. for C24H18Cl2O2S2 (472.0125): 472.0114 (M+). 
IR (ATR) υ (cm-1) = 3533, 3466, 3070, 3049, 3003, 2955, 2928, 2897, 2836, 1603, 1581, 
1571, 1505, 1478, 1463, 1417, 1291, 1251, 1177, 1031, 1024, 828, 822, 772, 739, 733, 
687. 
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Preparation of ethyl 4-(5-(4-methoxyphenyl)-3-(phenylthio)thiophen-2-yl)benzoate 
(7b) 
 
A dry and argon-flushed Schlenk-flask, equipped with a magnetic stirring bar and a 
septum, was charged with iPrMgCl·LiCl (1a; 0.92 ml, 1.1 mmol, 1.2 M in THF).  
2-bromo-5-(4-methoxy-phenyl)-3-(phenylthio)thiophene (5g; 377 mg, 1.0 mmol) was 
added as a solution in THF (1.0 M) at 25 °C and continuously stirred for 1 h. Complete 
Br/Mg-exchange was monitored by GC-analysis of iodolyzed reaction aliquots using 
undecane as internal standard. Subsequently, the cross-coupling was accomplished 
according to TP3 with ZnCl2 (1.0 mL, 1.0 mmol, 1.0 M in THF), Pd(PPh3)4 (58 mg,  
0.05 mmol) and ethyl 4-iodobenzoate (4h; 249 mg, 0.9 mmol) in 1 h. Flash column 
chromatographical purification on silica gel (pentane/Et2O, 9:1) afforded 7b as a pale 
yellow solid (293 mg, 73%). 
 
m.p.: 129.4-132.0 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.06 (d, J=8.6Hz, 2H), 7.50-7.69 (m, 4H), 7.36 
(s, 1H), 7.12-7.28 (m, 5H), 6.94 (d, J=8.9 Hz, 2H), 4.39 (q, J=7.1 Hz, 2H), 3.84 (s, 3H), 
1.40 (t, J=7.2 Hz, 3H)  
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.4, 159.9, 148.2, 147.6, 139.8, 138.6, 129.5, 
129.1, 128.7, 127.1, 126.9, 126.2, 126.1, 126.1, 124.5, 124.2, 114.5, 61.0, 55.4, 14.3. 
MS (70 eV, EI), m/z (%) = 446 (M+, 100), 403 (7), 296 (6), 281 (9), 221 (12), 200 (8),  
77 (12). 
HRMS (EI), m/z calc. for C26H22O3S2 (446.1010): 446.1004 (M+). 
IR (ATR) υ (cm-1) = 3071, 3050, 3000, 2983, 2928, 2904, 2852, 2830, 1709, 1607, 1581, 
1517, 1499, 1428, 1269, 1250, 1183, 1176, 1101, 1024, 851, 824, 798, 773, 738, 702, 
690. 
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Preparation of (4-chlorophenyl)(5-(4-methoxyphenyl)-3-(phenylthio)thiophen-2-
yl)methanone (7c) 
 
A dry and argon-flushed Schlenk-flask, equipped with a magnetic stirring bar and a 
septum, was charged with iPrMgCl·LiCl (1a; 0.92 ml, 1.1 mmol, 1.2 M in THF).  
2-bromo-5-(4-methoxy-phenyl)-3-(phenylthio)thiophene (5g; 377 mg, 1.0 mmol) was 
added as a solution in THF (1.0 M) at 25 °C and continuously stirred for 1 h. Complete 
Br/Mg-exchange was monitored by GC-analysis of iodolyzed reaction aliquots using 
undecane as internal standard. Subsequently, the acylation reaction was accomplished 
according to TP4 with ZnCl2 (1 mL, 1 mmol, 1.0 M in THF), CuCN·2LiCl (0.1 mL,  
0.1 mmol, 1.0 M in THF) and 4-chlorobenzoyl chloride (4o; 158 mg, 0.9 mmol) in 8 h. 
Flash column chromatographical purification on silica gel (pentane/Et2O, 9:1) afforded 
7c as a pale yellow oil (274 mg, 70%). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.74-7.85 (m, 2H), 7.50-7.65 (m, 2H), 7.28-7.50 
(m, 7H), 7.23-7.27 (m, 1H), 6.78-6.91 (m, 2H),3.80 (s, 3 H).  
13C NMR (75 MHz, CDCl3) δ (ppm) = 189.1, 159.7, 147.6, 142.9, 138.7, 137.4, 137.0, 
134.2, 133.1, 130.7, 129.6, 129.2, 128.7, 126.9, 125.8, 123.6, 114.4, 55.4. 
MS (70 eV, EI), m/z (%) = 436 (M+, 100), 421 (12), 325 (5), 281 (5), 253 (5), 221 (8), 
141 (14), 139 (42). 
HRMS (EI), m/z calc. for C24H17ClO2S2 (436.0358): 436.0359 (M+). 
IR (ATR) υ (cm-1) = 3054, 2998, 2953, 2926, 2869, 2845, 2834, 1630, 1607, 1585, 1536, 
1500, 1421, 1407, 1292, 1248, 1172, 1087, 1031, 1007, 998, 823, 806, 788, 760, 746, 
688. 
 
 
 
 
C. EXPERIMENTAL SECTION 
176 
2.4 PREPARATION OF FUNCTIONALIZED PYRIDINES OF TYPE 10 
Preparation of ethyl 4-(5-bromo-2-(4-(trifluoromethyl)phenyl)pyridin-3-yl)benzoate 
(10a) 
 
Prepared according to TP1 from 3,5-dibromo-2-(4-(trifluoromethyl)phenyl)pyridine (8a; 
381 mg, 1 mmol) and iPrMgCl·LiCl (1a; 0.88 mL, 1.05 mmol, 1.2 M in THF) at -55 °C 
in 2 h. Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2 
(1.0 mL, 1.0 mmol, 1.0 M in THF), Pd(PPh3)4 (46 mg, 0.04 mmol) and ethyl 4-
iodobenzoate (4h; 249 mg, 0.9 mmol) in 1 h. Flash column chromatographical 
purification on silica gel (pentane/Et2O, 9:1 + 1% NEt3) afforded 10a as a white solid 
(354 mg, 88%). 
 
m.p.: 97.5-99.1 °C.  
1H NMR (600 MHz, CDCl3) δ (ppm) = 8.80 (d, J=2.2Hz, 1H), 7.99-8.02 (m, 2H), 7.92 
(d, J=2.2Hz, 1H), 7.51 (d, J=8.2Hz, 2H), 7.44 (d, J=8.2Hz, 2H), 7.23-7.26 (m, 2H), 4.39 
(q, J=7.4Hz, 2H), 1.41 (t, J=7.4Hz, 3H). 
13C NMR (150 MHz, CDCl3) δ (ppm) = 166.0, 154.0, 150.0, 142.4, 142.2 (q, J=1.1Hz),  
140.7, 136.8, 130.3 (q, J=32.8Hz), 130.2, 130.0, 129.9, 129.4, 125.1 (q, J=3.7Hz), 123.9 
(q, J=272.4Hz),  119.9, 61.2, 14.3. 
MS (70 eV, EI), m/z (%) = 451 (M+, 97), 450 (M+, 100), 449 (M+, 95), 448 (M+, 85),  
421 (32), 419 (35), 406 (21), 404 (21), 378 (15), 376 (17), 297 (31), 296 (15), 228 (11),  
227 (11). 
HRMS (EI), m/z calc. for C21H15BrF3NO2 (449.0238): 449.0231 (M+). 
IR (ATR) υ (cm-1) = 3055, 2982, 2940, 2904, 1705, 1608, 1426, 1368, 1323, 1310, 1288, 
1273, 1166, 1120, 1111, 1101, 1068, 1024, 1009, 854, 783, 769, 715, 706 
 
 
 
 
. 
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Preparation of ethyl 4-(5-bromo-2-(4-methoxyphenyl)pyridin-3-yl)benzoate (10b) 
 
Prepared according to TP1 from 3,5-dibromo-2-(4-methoxyphenyl)pyridine (8b; 343 mg,  
1 mmol) and iPrMgCl·LiCl (1a; 0.88 mL, 1.05 mmol, 1.2 M in THF) at -78 °C in 2 h. 
Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2  
(1.0 mL, 1.0 mmol, 1.0 M in THF), Pd(PPh3)4 (46 mg, 0.04 mmol) and ethyl 4-
iodobenzoate (4h; 249 mg, 0.9 mmol) in 1 h. Flash column chromatographical 
purification on silica gel (pentane/Et2O, 8.5:1.5 + 1% NEt3) afforded 10b as a white solid 
(236 mg, 64%). 
 
m.p.: 157.5-160.1 °C.  
1H NMR (600 MHz, CDCl3) δ (ppm) = 8.71 (d, J=2.2Hz, 1H), 7.91-8.02 (m, 2H), 7.82 
(d, J=2.2Hz, 1H), 7.14-7.32 (m, 4H), 6.68-6.79 (m, 2H), 4.36 (q, J=7.1Hz, 2H), 3.76 (s, 
3H), 1.38 (t, J=7.1Hz, 3H). 
13C NMR (150 MHz, CDCl3) δ (ppm) = 166.2, 159.7, 155.3, 149.6, 143.4, 140.4, 136.1, 
131.1, 131.0, 129.7, 129.7, 129.3, 118.4, 113.6, 61.1, 55.2, 14.3. 
MS (70 eV, EI), m/z (%) = 413 (M+, 91), 411 (M+, 100), 410 (M+, 61), 384 (27),  
382 (26), 340 (11), 339 (11), 338 (10). 
HRMS (EI), m/z calc. for C21H18BrNO3 (411.0470): 411.0473 (M+). 
IR (ATR) υ (cm-1) = 3062, 3003, 2979, 2961, 2936, 2843, 1708, 1604, 1511, 1424, 1402, 
1368, 1308, 1283, 1271, 1252, 1175, 1115, 1098, 1043, 1026, 1022, 1010, 1004, 909, 
860, 841, 793, 782, 772, 706. 
 
Preparation of 4-(5-bromo-2-(thiophen-2-yl)pyridin-3-yl)benzonitrile (10c) 
 
Prepared according to TP1 from 3,5-dibromo-2-(thiophen-2-yl)pyridine (8c; 343 mg,  
1 mmol) and iPrMgCl·LiCl (1a; 0.88 mL, 1.05 mmol, 1.2 M in THF) at 0 °C in 1 h. 
Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2  
(1.0 mL, 1.0 mmol, 1.0 M in THF), Pd(PPh3)4 (46 mg, 0.04 mmol) and 4-iodobenzonitrile 
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(4k; 206 mg, 0.9 mmol) in 1 h. Flash column chromatographical purification on silica gel 
(pentane/Et2O, 8.5:1.5 + 1% NEt3) afforded 10c as a white solid (228 mg, 74%). 
 
m.p.: 192.0-193.9 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.68 (d, J=2.2Hz, 1H), 7.66-7.81 (m, 3H), 7.39-
7.51 (m, 2H), 7.34 (dd, J=5.3Hz, 1.1Hz, 1H), 6.84 (dd, J=5.1Hz, 3.7Hz, 1H), 6.54 (dd, 
J=3.9Hz, 1.1Hz, 1H) . 
13C NMR (75 MHz, CDCl3) δ (ppm) = 150.0, 148.7, 143.3, 142.3, 140.4, 134.0, 132.7, 
130.0, 128.5, 128.5, 127.7, 118.3, 118.1, 112.5. 
MS (70 eV, EI), m/z (%) = 342 (M+, 100), 341 (M+, 79), 340 (M+, 100), 339 (M+, 60), 
261 (13), 260 (36). 
HRMS (EI), m/z calc. for C16H9BrN2S (339.9670): 339.9667 (M+). 
IR (ATR) υ (cm-1) = 3096, 3092, 3064, 3027, 2956, 2924, 2851, 2238, 1606, 1536, 1505, 
1436, 1397, 1268, 1188, 1180, 1107, 1015, 971, 909, 858, 841, 832, 823, 774, 704, 662. 
 
Preparation of 5-bromo-3-(4-methoxyphenyl)-2-(phenylthio)pyridine (10d) 
 
Prepared according to TP1 from 3,5-dibromo-2-(phenylthio)pyridine (8d; 343 mg,  
1 mmol) and iPr2Mg·LiCl (1a; 0.5 mL, 0.55 mmol, 1.1 M in THF) at -65 °C in 1 h. 
Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2  
(1.0 mL, 1.0 mmol, 1.0 M in THF), Pd(PPh3)4 (46 mg, 0.04 mmol) and 1-iodo-4-
methoxybenzene (4g; 211 mg, 0.9 mmol) in 12 h. Flash column chromatographical 
purification on silica gel (pentane/Et2O, 100:3 + 1% NEt3) afforded 10d as a white solid 
(199 mg, 60%). 
 
m.p.: 107.8-109.8 °C. 
1H NMR (400 MHz, d6-DMSO) δ (ppm) = 8.36 (d, J=2.4Hz, 1H), 7.78 (d, J=2.4Hz, 
1H), 7.35-7.44 (m, 7H), 7.01-7.05 (m, 2H), 3.79 (s, 3H). 
13C NMR (100 MHz, d6-DMSO) δ (ppm) = 160.0, 156.0, 148.8, 139.6, 137.3, 135.2, 
130.9, 130.7, 129.6, 129.1, 128.8, 117.2, 114.5, 55.7. 
MS (70 eV, EI), m/z (%) = 374 (M+, 23), 373 (M+, 100), 371 (M+, 88), 328 (12),  
140 (29), 88 (10), 61 (12), 44 (29), 43 (58). 
HRMS (EI), m/z calc. for C18H14BrNOS (370.9979): 370.9971 (M+). 
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IR (ATR) υ (cm-1) = 3039, 3009, 2963, 2940, 2837, 2361, 2339, 1610, 1513, 1440, 1395, 
1383, 1290, 1283, 1245, 1176, 1126, 1084, 1032, 1020, 1003, 903, 833, 815, 747, 683, 
664. 
 
2.5 PREPARATION OF FUNCTIONALIZED HETEROCYCLES OF TYPE 14 AND 17 
Preparation of tert-butyl 5-bromo-4-methylthiophene-2-carboxylate (14a) 
SBr
Me
CO2tBu
 
Prepared according to TP2 from 2,5-dibromo-3-(methylthio)thiophene (11a; 512 mg,  
2 mmol), 2,4,6-triisopropylmagnesium bromide (1c; 3.0 mL, 2.1 mmol, 0.7 M in THF) 
and 2,2’-oxy-bis(N,N-diethylethanamine) (L2; 336 mg, 2.1 mmol) at -10 °C in 16 h. 
Subsequently, the reaction mixture was cooled to −40 °C and di-tert-butyl dicarbonate 
(4d; 524 mg, 2.4 mmol) in THF was added. The reaction mixture was allowed to slowly 
warm to 25 °C and continuously stirred for 4 h. Subsequently, sat. aq. NH4Cl (10 mL) 
was added. The aqueous layer was extracted with EtOAc (3x 10 mL). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. Flash column 
chromatographical purification (pentane/EtOAc, 100:1) furnished 14a as a yellow oil 
(460 mg, 83%). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.39 (s, 1H), 2.19 (s, 3H), 1.56 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 160.6, 138.2, 134.5, 134.1, 116.7, 82.1, 28.2, 
15.2. 
MS (70 eV, EI), m/z (%) = 278 (M+, 14), 276 (M+, 15), 223 (10), 222 (100), 221 (12), 
220 (100), 205 (43), 203 (44), 186 (26), 141 (60), 96 (24), 69 (10), 57 (60), 55 (21). 
HRMS (EI), m/z calc. for C10H13BrO2S (275.9820): 275.9817 (M+). 
IR (ATR) υ (cm-1) = 2978, 2932, 1702, 1426, 1368, 1296, 1254, 1156, 1074, 848, 818, 
798, 748, 718. 
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Preparation of ethyl 4-(5-bromo-4-methylthiophen-2-yl)benzoate (14b) 
SBr
Me
CO2Et
 
Prepared according to TP2 from 2,5-dibromo-3-(methylthio)thiophene (11a; 512 mg,  
2 mmol), 2,4,6-triisopropylmagnesium bromide (1c; 3.0 mL, 2.1 mmol, 0.7 M in THF) 
and 2,2’-oxy-bis(N,N-diethylethanamine) (L2; 336 mg, 2.1 mmol) at -10 °C in 16 h. 
Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2  
(2.0 mL, 2.0 mmol, 1.0 M in THF), Pd(PPh3)4 (92 mg, 0.04 mmol) and ethyl 4-
iodobenzoate (4h; 498 mg, 1.8 mmol) in 1 h. Flash column chromatographical 
purification on silica gel (pentane/Et2O, 95:5) afforded 14b as a pale yellow solid  
(556 mg, 83%). 
 
m.p.: 89.2-90.7 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.03 (d, J=8.8Hz, 2H), 7.54 (d, J=8.6Hz, 2H), 
7.09 (s, 1H), 4.39 (q, J=7.1Hz, 2H), 2.22 (s, 3H), 1.4 (t, J=7.1Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.1, 142.1, 138.6, 137.8, 130.3, 129.4, 126.2, 
124.9, 110.4, 61.0, 15.3, 14.4. 
MS (70 eV, EI), m/z (%) =327 (14), 326 (M+, 100), 325 (14), 324 (M+, 93), 298 (33),  
296 (30), 281 (57), 279 (56), 217 (11), 172 (32), 171 (31). 
HRMS (EI), m/z calc. for C14H13BrO2S (323.9820): 323.9807 (M+). 
IR (ATR) υ (cm-1) = 3076, 2984, 2906, 1704, 1604, 1510, 1472, 1438, 1364, 1272, 1232, 
1186, 1128, 1110, 1020, 850, 764, 690. 
 
Preparation of (5-bromo-4-methylthiophen-2-yl)(thiophen-2-yl)methanone (14c) 
SBr
Me
O
S
 
Prepared according to TP2 from 2,5-dibromo-3-methylthiophene (11a; 512 mg,  
2 mmol), 2,4,6-triisopropylmagnesium bromide (1c; 3.0 mL, 2.1 mmol, 0.7 M in THF) 
and 2,2’-oxy-bis(N,N-diethylethanamine) (L2; 336 mg, 2.1 mmol) at -10 °C in 16 h. 
Subsequently, the acylation reaction was accomplished according to TP4 with ZnCl2  
(2 mL, 2 mmol, 1.0 M in THF), CuCN·2LiCl (0.2 mL, 0.2 mmol, 1.0 M in THF) and 
thiophene-2-carbonyl chloride (4p; 352 mg, 2.4 mmol) in 4 h. Flash column 
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chromatographical purification on silica gel (pentane/Et2O, 95:5) afforded 14c an off-
white solid (488 mg, 85%). 
 
m.p.: 100.2-101.4 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.85 (dd, J=3.8Hz, 1.1Hz, 1H), 7.69 (dd, 
J=4.9Hz, 1.1Hz, 1H), 7.57 (s, 1H), 7.17 (dd, J=5.0Hz, 3.8Hz, 1H), 2.25 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 177.6, 142.2, 141.8, 138.7, 134.6, 133.6, 133.0, 
128.0, 120.0, 15.4. 
MS (70 eV, EI), m/z (%) =289 (11), 288 (M+, 100), 287 (11), 286 (M+, 93), 207 (13),  
205 (37), 203 (36), 111 (77), 96 (11). 
HRMS (EI), m/z calc. for C10H7BrOS2 (285.9122): 285.9117 (M+). 
IR (ATR) υ (cm-1) = 3004, 2362, 2340, 1740, 1658, 1582, 1522, 1432, 1366, 1228, 1222, 
1204, 1098, 1056, 780, 706. 
 
Preparation of 5,5'-dibromo-4,4'-dimethyl-2,2'-bithiophene (14d) 
 
Prepared according to TP2 from 2,5-dibromo-3-methylthiophene (11a; 1.02 g, 4 mmol), 
2,4,6-triisopropylmagnesium bromide (1c; 6.0 mL, 4.2 mmol, 0.7 M in THF) and 2,2’-
oxy-bis(N,N-diethylethanamine) (L2; 672 mg, 2.1 mmol) at -10 °C in 16 h. Subsequently, 
at -40 °C, ZnCl2 (2 mL, 2 mmol, 1 M in THF) and CuCN·2LiCl (2 mL, 2 mmol, 1 M in 
THF) were successively added and continuously stirred for 10 min. The reaction mixture 
was added dropwise to a solution of chloranil (1.47 g, 6 mmol) in THF (15 mL) at 0 °C. 
Then, the solution was allowed to slowly warm to 25 °C and continuously stirred for 1 h. 
Subsequently, sat. aq. NH4Cl (10 mL) was added. The aqueous layer was extracted with 
CH2Cl2 (5x 10 mL). The combined organic phases were washed with aq. NH3 (2 M,  
2x 30 mL), dried over Na2SO4 and concentrated in vacuo. Flash column 
chromatographical purification (pentane/EtOAc, 95:5) furnished 14d as a pale yellow 
solid (612 mg, 87%). 
 
m.p.: 106.2-107.8 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 6.77 (s, 2H), 2.17 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 138.1, 135.9, 125.5, 108.4, 15.2. 
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MS (70 eV, EI), m/z (%) = 354 (M+, 51), 353 (10), 352 (M+, 100), 350 (M+, 43),  
229 (10), 192 (19), 191 (11). 
HRMS (EI), m/z calc. for C10H879Br2S2 (349.8434): 349.8422 (M+). 
IR (ATR) υ (cm-1) = 3054, 2916, 1740, 1634, 1544, 1410, 1374, 1318, 1186, 1022, 994, 
942, 834, 812, 734. 
 
Preparation of (5-bromo-4-hexylthiophen-2-yl)(4-methoxyphenyl)methanol (14e) 
 
Prepared according to TP2 from 2,5-dibromo-3-hexylthiophene (11b; 652 mg, 2 mmol), 
2,4,6-triisopropylmagnesium bromide (1c; 3.0 mL, 2.1 mmol, 0.7 M in THF) and 2,2’-
oxy-bis(N,N-diethylethanamine) (L2; 336 mg, 2.1 mmol) at -10 °C in 16 h. Subsequently, 
the reaction mixture was cooled to −20 °C and 4-methoxybenzaldehyde (4e; 245 mg,  
1.8 mmol) in THF was added. The reaction mixture was allowed to slowly warm to  
25 °C and continuously stirred for 2 h. Subsequently, sat. aq. NH4Cl (10 mL) was added. 
The aqueous layer was extracted with EtOAc (3x 10 mL). The combined organic phases 
were dried over Na2SO4 and concentrated in vacuo. Flash column chromatographical 
purification (pentane/Et2O, 8.5:1.5) furnished 14e as a pale yellow oil (487 mg, 71%). 
 
1H NMR (400 MHz, d6-DMSO) δ (ppm) = 7.27 (d, J=8.8Hz, 2H), 6.81-6.93 (m, 2H), 
6.59 (d, J=0.8Hz, 1H), 6.19 (d, J=4.4Hz, 1H), 5.75 (d, J=4.4Hz, 1H), 3.71 (s, 3H), 2.33-
2.43 (m, 2H), 1.35-1.49 (m, 2H), 1.13-1.28 (m, 6H), 0.72-0.90 (m, 3H). 
13C NMR (100 MHz, d6-DMSO) δ (ppm) = 158.9, 151.2, 141.4, 136.8, 127.8, 125.0, 
114.0, 107.0, 70.7, 55.5, 31.4, 29.6, 29.3, 28.6, 22.5, 14.4. 
MS (70 eV, EI), m/z (%) = 384 (M+, 25), 382 (M+, 26), 367 (28), 365 (27), 304 (19),  
303 (100), 287 (17), 233 (20), 137 (20), 135 (94), 109 (25), 77 (11). 
HRMS (EI), m/z calc. for C18H23BrO2S (382.0602): 382.0593 (M+). 
IR (ATR) υ (cm-1) = 3063, 3035, 3000, 2954, 2926, 2855, 1610, 1510, 1457, 1441, 1303, 
1245, 1170, 1135, 1109, 1032, 1008, 996, 833. 
 
 
 
C. EXPERIMENTAL SECTION 
183 
Preparation of 2-bromo-3-hexyl-5-((4-methoxyphenyl)sulfinyl)thiophene (14f) 
 
Prepared according to TP2 from 2,5-dibromo-3-hexylthiophene (11b, 652 mg, 2 mmol), 
2,4,6-triisopropylmagnesium bromide (1c; 3.0 mL, 2.1 mmol, 0.7 M in THF) and 2,2’-
oxy-bis(N,N-diethylethanamine) (L2; 336 mg, 2.1 mmol) at -10 °C in 16 h. Subsequently, 
the sulfoxide was prepared according to TP5 with 4-methoxybenzenesulfinyl chloride 
(4q; 343 mg, 1.8 mmol) in 4 h. Flash column chromatographical purification on silica gel 
(pentane/EtOAc, 8:2) afforded 14f as colorless oil (503 mg, 70%). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.56-7.69 (m, 2H), 7.25 (s, 1H), 6.97-7.09 (m, 
2H), 3.86 (s, 3H), 2.47-2.58 (m, 2H), 1.47-1.64 (m, 2H), 1.20-1.38 (m, 6H), 0.72-0.98 
(m, 3H).  
13C NMR (75 MHz, CDCl3) δ (ppm) = 162.3, 147.4, 142.8, 135.5, 131.6, 126.4, 116.6, 
114.8, 55.5, 31.5, 29.5, 29.4, 28.8, 22.5, 14.0. 
MS (70 eV, EI), m/z (%) = 400 (M+, 2), 354 (46), 352 (43), 204 (23), 203 (100),  
139 (31), 123 (10), 77 (7), 41 (8). 
HRMS (EI), m/z calc. for C17H21BrO2S2 (400.0166): 400.0166 (M+). 
IR (ATR) υ (cm-1) = 3069, 3043, 3005, 2954, 2926, 2856, 1592, 1577, 1494, 1460, 
1441, 1406, 1304, 1249, 1180, 1170, 1085, 1049, 1026, 989, 827, 796. 
 
Preparation of (5-bromo-4-methylfuran-2-yl)(thiophen-2-yl)methanone (14g) 
OBr
Me
O
S
 
Prepared according to TP2 from 2,5-dibromo-3-methylfuran (11c; 480 mg, 2 mmol), 
2,4,6-triisopropylmagnesium bromide (1c; 3.0 mL, 2.1 mmol, 0.7 M in THF) and 2,2’-
oxy-bis(N,N-diethylethanamine) (L2; 336 mg, 2.1 mmol) at -10 °C in 16 h. Subsequently, 
the acylation reaction was accomplished according to TP4 with ZnCl2 (2 mL, 2 mmol, 
1.0 M in THF), CuCN·2LiCl (0.2 mL, 0.2 mmol, 1.0 M in THF) and thiophene-2-carbonyl 
chloride (4p; 352 mg, 2.4 mmol) in 4 h. Flash column chromatographical purification on 
silica gel (pentane/Et2O, 95:5) afforded 14g as a pale yellow solid (428 mg, 79%). 
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m.p.: 80.6-81.9 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.14 (dd, J=3.8Hz, 1.1Hz, 1H), 7.70 (dd, 
J=5.0Hz, 1.2Hz, 1H), 7.24 (s, 1H), 7.19 (t, J=4.4Hz, 1H), 2.07 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 172.1, 152.9, 141.9, 134.1, 133.8, 128.3, 126.6, 
123.0, 122.0, 10.5. 
MS (70 eV, EI), m/z (%) =272 (M+, 31), 270 (M+, 31), 190 (11), 135 (26), 111 (100). 
HRMS (EI), m/z calc. for C10H7BrO2S (269.9350): 269.9347 (M+). 
IR (ATR) υ (cm-1) = 3118, 3112, 2962, 2926, 2360, 2342, 1714, 1608, 1596, 1490, 1410, 
1356, 1306, 1294, 1240, 1208, 1168, 1074, 1060, 964, 812, 744, 734, 616. 
 
Preparation of 4-(5-bromo-4-methylfuran-2-yl)benzonitrile (14h) 
OBr
Me
CN
 
Prepared according to TP2 from 2,5-dibromo-3-methylfuran (11c; 480 mg, 2 mmol), 
2,4,6-triisopropylmagnesium bromide (1c; 3.0 mL, 2.1 mmol, 0.7 M in THF) and 2,2’-
oxy-bis(N,N-diethylethanamine) (L2; 336 mg, 2.1 mmol) at -10 °C in 16 h. Subsequently, 
the cross-coupling was accomplished according to TP3 with ZnCl2 (2.0 mL, 2.0 mmol, 
1.0 M in THF), Pd(PPh3)4 (92 mg, 0.08 mmol) and 4-iodobenzonitrile (4k; 550 mg,  
2.4 mmol) in 1 h. Flash column chromatographical purification on silica gel 
(pentane/Et2O, 95:5) afforded 14h as a yellow solid (409 mg, 78%). 
 
m.p.: 99.5-101.6 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.6-7.7 (m, 4H), 6.68 (s, 1H), 2.03 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 152.7, 133.7, 132.6, 124.9, 123.5, 122.3, 118.8, 
112.0, 110.5, 10.6. 
MS (70 eV, EI), m/z (%) = 264 (9), 263 (M+, 72), 262 (10), 261 (M+, 73), 182 (22),  
155 (13), 154 (100), 153 (24), 130 (19), 127 (45), 126 (11), 102 (13), 77 (11), 63 (13). 
HRMS (EI), m/z calc. for C12H8BrNO (260.9789): 260.9780 (M+). 
IR (ATR) υ (cm-1) = 3108, 2962, 2926, 2870, 2222, 1918, 1766, 1606, 1532, 1516, 1484, 
1446, 1386, 1348, 1266, 1178, 1078, 924, 834, 814, 684, 660. 
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Preparation of 1-(5-bromo-4-methylfuran-2-yl)-2,2-dimethylpropan-1-ol (14i) 
OBr
Me
OH
tBu
 
Prepared according to TP2 from 2,5-dibromo-3-methylfuran (11c; 480 mg, 2 mmol), 
2,4,6-triisopropylmagnesium bromide (1c; 3.0 mL, 2.1 mmol, 0.7 M in THF) and 2,2’-
oxy-bis(N,N-diethylethanamine) (L2; 336 mg, 2.1 mmol) at -10 °C in 16 h. Subsequently, 
the reaction mixture was cooled to −20 °C and pivaldehyde (4r; 206 mg, 2.4 mmol) in 
THF was added. The reaction mixture was allowed to slowly warm to 25 °C and 
continuously stirred for 1 h. Subsequently, sat. aq. NH4Cl (10 mL) was added. The 
aqueous layer was extracted with EtOAc (3x 10 mL). The combined organic phases were 
dried over Na2SO4 and concentrated in vacuo. Flash column chromatographical 
purification (pentane/EtOAc, 95:5) furnished 14i as a yellow oil (361 mg, 73%). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 6.11 (s, 1H), 4.21 (s, 1H), 1.94-2.01 (m, 4H), 
0.96 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 156.7, 119.6, 118.6, 111.5, 76.4, 35.6, 25.7, 10.5. 
MS (70 eV, EI), m/z (%) = 248 (M+, 6), 246 (M+, 8), 231 (19), 229 (19), 192 (8),  
191 (94), 190 (11), 189 (100), 57 (32), 55 (17), 53 (18).  
HRMS (EI), m/z calc. for C10H15BrO2 (246.0255): 246.0242 (M+). 
IR (ATR) υ (cm-1) = 3426, 2956, 2870, 1542, 1396, 1366, 1206, 1158, 1074, 1048, 1008, 
934, 902, 814, 794, 734, 612. 
 
Preparation of 4-(3,5-dibromo-4-methylthiophen-2-yl)benzonitrile (14j) 
 
Prepared according to TP2 from 2,3,5-tribromo-4-methylthiophene (11e; 670 mg,  
2 mmol), 2,4,6-triisopropylmagnesium bromide (1c; 3.0 mL, 2.1 mmol, 0.7 M in THF) 
and 2,2’-oxy-bis(N,N-diethylethanamine) (L2; 336 mg, 2.1 mmol) at 0 °C in 1 h. 
Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2  
(2.0 mL, 2.0 mmol, 1.0 M in THF), Pd(PPh3)4 (92 mg, 0.08 mmol) and 4-iodobenzonitrile 
(4k; 550 mg, 2.4 mmol) in 1 h. Flash column chromatographical purification on silica gel 
(pentane/Et2O, 50:1) afforded 14j as a white solid (545 mg, 77%). 
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m.p.: 160.8-162.3 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.72 (s, 4H), 2.29 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 138.3, 137.2, 135.8, 132.4, 129.4, 118.4, 112.0, 
111.2, 110.0, 16.4. 
MS (70 eV, EI), m/z (%) = 357 (M+, 87), 355 (M+, 49), 278 (21), 276 (21), 197 (22),  
196 (17), 152 (11), 70 (18), 61 (13), 45 (18), 44 (57), 43 (100). 
HRMS (EI), m/z calc. for C12H7Br2NS (354.8666): 354.8657 (M+). 
IR (ATR) υ (cm-1) = 3085, 3070, 3056, 3035, 2957, 2919, 2852, 2359, 2228, 1920, 1605, 
1504, 1454, 1407, 1393, 1386, 1380, 1334, 1328, 1308, 1180, 1110, 1044, 1019, 924, 
842, 832, 807, 800, 755. 
 
Preparation of (3,5-dibromo-4-methylthiophen-2-yl)(2,4-dichlorophenyl)methanone 
(14k) 
 
Prepared according to TP2 from 2,3,5-tribromo-4-methylthiophene (11e; 670 mg,  
2 mmol), 2,4,6-triisopropylmagnesium bromide (1c; 3.0 mL, 2.1 mmol, 0.7 M in THF) 
and 2,2’-oxy-bis(N,N-diethylethanamine) (L2; 336 mg, 2.1 mmol) at 0 °C in 1 h. 
Subsequently, the acylation reaction was accomplished according to TP4 with ZnCl2  
(2 mL, 2 mmol, 1.0 M in THF), CuCN·2LiCl (0.2 mL, 0.2 mmol, 1.0 M in THF) and 2,4-
dichlorobenzoyl chloride (4s; 377 mg, 1.8 mmol) in 8 h. Flash column chromatographical 
purification on silica gel (pentane/Et2O, 50:1) afforded 14k as a pale yellow solid (662 
mg, 86%). 
 
m.p.: 133.6-134.8 °C. 
1H NMR (400 MHz, d6-DMSO) δ (ppm) = 7.74-7.83 (m, 1H), 7.55-7.61 (m, 2H),  
2.16 (s, 3H). 
13C NMR (100 MHz, d6-DMSO) δ (ppm) = 184.6, 140.8, 137.3, 137.2, 136.6, 131.4, 
130.7, 130.0, 128.5, 121.1, 119.7, 16.3. 
MS (70 eV, EI), m/z (%) = 429 (M+, 79), 427 (M+, 31), 177 (11), 175 (61), 173 (100), 
147 (19), 145 (32), 44 (22). 
HRMS (EI), m/z calc. for C12H6Br2Cl2OS (427.7863): 427.7931 (M+). 
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IR (ATR) υ (cm-1) = 3066, 2915, 2362, 2339, 1614, 1587, 1418, 1379, 1323, 1289, 1241, 
1138, 1102, 1053, 1020, 865, 844, 818, 776, 753, 706, 670. 
 
Preparation of (3,5-dibromo-4-methylthiophen-2-yl)(4-methoxyphenyl)methanol 
(14l) 
 
Prepared according to TP2 from 2,3,5-tribromo-4-methylthiophene (11e; 670 mg,  
2 mmol), 2,4,6-triisopropylmagnesium bromide (1c; 3.0 mL, 2.1 mmol, 0.7 M in THF) 
and 2,2’-oxy-bis(N,N-diethylethanamine) (L2; 336 mg, 2.1 mmol) at 0 °C in 1 h. 
Subsequently, the reaction mixture was cooled to −20 °C and 4-methoxybenzaldehyde 
(4e; 245 mg, 1.8 mmol) in THF was added. The reaction mixture was allowed to slowly 
warm to 25 °C and continuously stirred for 2 h. Subsequently, sat. aq. NH4Cl (10 mL) 
was added. The aqueous layer was extracted with EtOAc (3x 10 mL). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. Flash column 
chromatographical purification (pentane/Et2O, 8:2) furnished 14l as a colorless oil  
(618 mg, 88%). 
 
1H NMR (400 MHz, d6-DMSO) δ (ppm) = 7.21-7.29 (m, 2H), 6.82-6.89 (m, 2H), 6.41 
(d, J=4.1Hz, 1H), 5.79 (d, J=4.1Hz, 1H), 3.69 (s, 3H), 2.05 (s, 3H).  
13C NMR (100 MHz, d6-DMSO) δ (ppm) = 159.1, 146.0, 136.1, 135.1, 128.1, 114.1, 
108.3, 107.4, 70.8, 55.5, 15.8. 
MS (70 eV, EI), m/z (%) = 392 (M+, 57), 390 (M+, 27), 377 (16), 375 (33), 311 (15),  
283 (18), 136 (16), 135 (42), 109 (100), 108 (20), 92 (11), 77 (25). 
HRMS (EI), m/z calc. for C13H12Br2O2S (389.8925): 389.8917 (M+). 
IR (ATR) υ (cm-1) = 3334, 2999, 2953, 2922, 2834, 1609, 1586, 1510, 1462, 1440, 1379, 
1328, 1304, 1246, 1173, 1148, 1110, 1030, 952, 831, 797, 760, 740, 685. 
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Preparation of 2,4-dibromo-5-((4-methoxyphenyl)sulfinyl)-3-methylthiophene (14m) 
 
Prepared according to TP2 from 2,3,5-tribromo-4-methylthiophene (11e; 670 mg,  
2 mmol), 2,4,6-triisopropylmagnesium bromide (1c; 3.0 mL, 2.1 mmol, 0.7 M in THF) 
and 2,2’-oxy-bis(N,N-diethylethanamine) (L2; 336 mg, 2.1 mmol) at 0 °C in 1 h. 
Subsequently, the sulfoxide was prepared according to TP5 with 4-methoxybenzene-
sulfinyl chloride (4q; 496 mg, 2.6 mmol) in 4 h. Flash column chromatographical 
purification on silica gel (pentane/EtOAc, 6:4) afforded 14m as white solid (770 mg, 
94%). 
 
m.p.: 110.8-112.7 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.64-7.77 (m, 2H), 6.98-7.04 (m, 2H), 3.85 (s, 
3H), 2.17 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 162.5, 144.1, 138.2, 134.6, 126.8, 115.6, 115.2, 
114.8, 55.6, 15.5. 
MS (70 eV, EI), m/z (%) = 412 (M+, 14), 410 (M+, 15), 364 (49), 361 (100), 360 (47), 
347 (23), 345 (11), 155 (32), 139 (38), 123 (14), 92 (12), 77 (12). 
HRMS (EI), m/z calc. for C12H10Br2O2S2 (409.8468): 409.8503 (M+). 
IR (ATR) υ (cm-1) = 3088, 3067, 3002, 2963, 2933, 2904, 2842, 2361, 2339, 1590, 1574, 
1494, 1452, 1446, 1388, 1324, 1301, 1255, 1184, 1176, 1081, 1062, 1045, 1024, 993, 
932, 834, 822, 794, 780. 
 
Preparation of (5-bromo-3-methoxythiophen-2-yl)(3-chloro-4-methoxyphenyl)-
methanol (14n) 
 
Prepared according to TP2 from 2,5-dibromo-3-methoxythiophene (11f; 544 mg,  
2 mmol), 2,4,6-triisopropylmagnesium bromide (1c; 3.0 mL, 2.1 mmol, 0.7 M in THF) 
C. EXPERIMENTAL SECTION 
189 
and 2,2’-oxy-bis(N,N-diethylethanamine) (L2; 336 mg, 2.1 mmol) at -10 °C in 16 h. 
Subsequently, the reaction mixture was cooled to −20 °C and 3-chloro-4-
methoxybenzaldehyde (4a; 307 mg, 1.8 mmol) in THF was added. The reaction mixture 
was allowed to slowly warm to 25 °C and continuously stirred for 2 h. Subsequently,  
sat. aq. NH4Cl (10 mL) was added. The aqueous layer was extracted with EtOAc  
(3x 10 mL). The combined organic phases were dried over Na2SO4 and concentrated  
in vacuo. Flash column chromatographical purification (pentane/Et2O, 6:4) furnished 14n 
as a yellow oil (478 mg, 73%). 
 
1H NMR (400 MHz, d6-DMSO) δ (ppm) = 7.29 (d, J=2.2Hz, 1H), 7.20 (dd, J=8.8Hz,  
2.1Hz, 1H), 7.11 (s, 1H), 7.04 (d, J=8.6Hz, 1H), 6.17 (bs, 1H), 5.82 (s, 1H), 3.78 (s, 3H),  
3.71 (s, 3H). 
13C NMR (100 MHz, d6-DMSO) δ (ppm) = 153.9, 151.8, 138.0, 127.9, 127.5, 126.1, 
121.2, 121.0, 112.9, 109.2, 66.4, 59.4, 56.5. 
MS (70 eV, EI), m/z (%) = 364 (M+, 49), 362 (M+, 32), 347 (58), 345 (38), 285 (37), 283 
(100), 223 (28), 219 (33), 171 (32), 155 (26), 111 (30), 108 (36), 85 (46), 77 (52),  
63 (48), 42 (54). 
HRMS (EI), m/z calc. for C13H12BrClO3S (361.9379): 361.9371 (M+). 
IR (ATR) υ (cm-1) = 3094, 3004, 2962, 2935, 2905, 2840, 1697, 1595, 1580, 1558, 1498, 
1459, 1438, 1366, 1309, 1282, 1255, 1207, 1196, 1183, 1150, 1090, 1061, 1020, 981, 
914, 884, 809, 726, 692, 685. 
 
Preparation of 4-(5-bromo-3-methoxythiophen-2-yl)benzonitrile (14o) 
 
Prepared according to TP2 from 2,5-dibromo-3-methoxythiophene (11f; 544 mg,  
2 mmol), 2,4,6-triisopropylmagnesium bromide (1c; 3.0 mL, 2.1 mmol, 0.7 M in THF) 
and 2,2’-oxy-bis(N,N-diethylethanamine) (L2; 336 mg, 2.1 mmol) at -10 °C in 16 h. 
Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2  
(2.0 mL, 2.0 mmol, 1.0 M in THF), Pd(PPh3)4 (92 mg, 0.08 mmol) and 4-iodobenzonitrile 
(4k 412 mg, 1.8 mmol) in 1 h. Flash column chromatographical purification on silica gel 
(pentane/Et2O, 9:1) afforded 14o as a yellow solid (361 mg, 69%). 
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m.p.: 162.1-164.0 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.67-7.80 (m, 2H), 7.54-7.64 (m, 2H), 6.95 (s, 
1H), 3.93 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 154.5, 137.2, 132.4, 126.4, 120.6, 119.3, 119.1, 
112.5, 109.2, 59.0. 
MS (70 eV, EI), m/z (%) = 295 (M+, 84), 293 (M+, 80), 201 (16), 200 (39), 147 (10),  
146 (100), 139 (12), 127 (32), 125 (10), 114 (14), 102 (38), 75 (15), 63 (16), 62 (14),  
45 (16), 43 (17). 
HRMS (EI), m/z calc. for C12H8BrNOS (292.9510): 292.9511 (M+). 
IR (ATR) υ (cm-1) = 3099, 3082, 2980, 2940, 2852, 2223, 1601, 1556, 1543, 1508, 1433, 
1369, 1313, 1204, 1181, 1165, 1079, 988, 911, 826, 800, 705, 660, 653. 
 
Preparation of 2(5-bromo-3-methoxythiophen-2-yl)(4-chlorophenyl)methanone 
(14p) 
 
Prepared according to TP2 from 2,5-dibromo-3-methoxythiophene (11f; 544 mg,  
2 mmol), 2,4,6-triisopropylmagnesium bromide (1c; 3.0 mL, 2.1 mmol, 0.7 M in THF) 
and 2,2’-oxy-bis(N,N-diethylethanamine) (L2; 336 mg, 2.1 mmol) at -10 °C in 16 h. 
Subsequently, the acylation reaction was accomplished according to TP4 with ZnCl2  
(2 mL, 2 mmol, 1.0 M in THF), CuCN·2LiCl (0.2 mL, 0.2 mmol, 1.0 M in THF) and 4-
chlorobenzoyl chloride (4o; 315 mg, 1.8 mmol) in 2 h. Flash column chromatographical 
purification on silica gel (pentane/Et2O, 8.5:1.5) afforded 14p as a pale yellow solid  
(389 mg, 66%). 
 
m.p.: 137.0-138.7 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.65-7.75 (m, 2H), 7.36-7.46 (m, 2H), 6.91 (s, 
1H), 3.81 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 185.5, 159.0, 138.2, 137.1, 130.3, 128.1, 122.9, 
122.4, 119.8, 59.0. 
MS (70 eV, EI), m/z (%) = 332 (M+, 63), 330 (M+, 44), 315 (20), 297 (23), 295 (24),  
221 (59), 219 (58), 216 (20), 139 (100), 111 (97), 75 (37). 
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HRMS (EI), m/z calc. for C12H8BrClO2S (329.9117): 329.9115 (M+). 
IR (ATR) υ (cm-1) = 3108, 3098, 2980, 2945, 2862, 1604, 1532, 1422, 1380, 1290, 1277, 
1211, 1088, 1014, 986, 871, 827, 805, 748, 701, 693. 
 
Preparation of 4-(5-bromo-6-(trimethylsilyl)pyridin-3-yl)benzonitrile (17a) 
N
Br
TMS
CN
 
Prepared according to TP2 from 3,5-dibromo-2-(trimethylsilyl)pyridine (15; 309 mg,  
1 mmol), 2,4,6-triisopropylmagnesium bromide (1c; 1.5 mL, 1.05 mmol, 0.7 M in THF) 
and 2,2’-oxy-bis(N,N-diethylethanamine) (L2; 168 mg, 2.1 mmol) at 25 °C in 2 h. 
Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2 (1.0 
mL, 1.0 mmol, 1.0 M in THF), Pd(PPh3)4 (46 mg, 0.04 mmol) and 4-iodobenzonitrile (4k; 
206 mg, 0.9 mmol) in 2 h. Flash column chromatographical purification on silica gel 
(pentane/Et2O, 9:1 + 1% NEt3) afforded 17a as a pale yellow solid (179 mg, 60%). 
 
m.p.: 126.5-128.4 °C. 
1H NMR (400 MHz, d6-DMSO) δ (ppm) = 9.04 (d, J=2.0Hz, 1H), 8.29 (d, J=2.1Hz, 
1H), 7.90-7.97 (m, 4H), 0.37 (s, 9H). 
13C NMR (100 MHz, d6-DMSO) δ (ppm) = 166.2, 146.7, 140.5, 136.7, 135.2, 133.4, 
129.3, 128.5, 119.0, 111.8, -0.5. 
MS (70 eV, EI), m/z (%) = 332 (M+, 15), 330 (M+, 16), 318 (18), 317 (100), 316 (20), 
315 (92), 271 (10), 251 (38), 194 (12), 139 (11), 137 (11), 73 (10), 72 (14). 
HRMS (EI), m/z calc. for C15H15BrN2Si (330.0188): 330.0136 (M+). 
IR (ATR) υ (cm-1) = 3095, 3049, 2966, 2949, 2896, 2227, 1609, 1577, 1505, 1430, 1358, 
1348, 1247, 1147, 1047, 1024, 1012, 856, 836, 769, 757, 722. 
 
Preparation of ethyl 4-(5-bromo-6-(trimethylsilyl)pyridin-3-yl)benzoate (17b) 
 
Prepared according to TP2 from 3,5-dibromo-2-(trimethylsilyl)pyridine (15; 309 mg,  
1 mmol), 2,4,6-triisopropylmagnesium bromide (1d; 1.5 mL, 1.05 mmol, 0.7 M in THF) 
and 2,2’-oxy-bis(N,N-diethylethanamine) (L2; 168 mg, 2.1 mmol) at 25 °C in 2 h. 
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Subsequently, the cross-coupling was accomplished according to TP3 with ZnCl2 (1.0 
mL, 1.0 mmol, 1.0 M in THF), Pd(PPh3)4 (46 mg, 0.04 mmol) and ethyl 4-iodobenzoate 
(4h; 249 mg, 0.9 mmol) in 2 h. Flash column chromatographical purification on silica gel 
(pentane/Et2O, 95:5) afforded 17b as a pale yellow solid (208 mg, 61%). 
 
m.p.: 88.2-89.8 °C. 
1H NMR (400 MHz, d6-DMSO) δ (ppm) = 9.02 (d, J=2.0Hz, 1H), 8.25 (d, J=2.0Hz, 
1H), 7.95-8.03 (m, 2H), 7.84-7.90 (m, 2H), 4.29 (q, J=7.1Hz, 2H), 1.29 (t, J=7.2Hz, 3H), 
0.37 (s, 9H). 
13C NMR (100 MHz, d6-DMSO) δ (ppm) = 165.8, 165.7, 146.7, 140.4, 136.5, 135.8, 
130.3, 130.2, 129.3, 127.9, 61.3, 14.6, -0.5. 
MS (70 eV, EI), m/z (%) = 379 (M+, 44), 377 (M+, 44), 365 (22), 364 (100), 363 (20), 
362 (94), 334 (31), 332 (17), 299 (47), 298 (79), 284 (30), 270 (12), 139 (11), 137 (11), 
44 (32), 43 (30). 
HRMS (EI), m/z calc. for C17H20BrNO2Si (379.0426): 379.0417 (M+). 
IR (ATR) υ (cm-1) = 3045, 3041, 2976, 2953, 2899, 1701, 1608, 1573, 1479, 1410, 1365, 
1355, 1288, 1274, 1244, 1226, 1184, 1115, 1103, 1046, 1022, 1012, 855, 838, 807, 724, 
699. 
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3. ONE-POT PREPARATION OF MAGNESIUM DI(HETERO)ARYL- AND 
DIALKENYLBORONATES FOR SUZUKI-MIYAURA CROSS-COUPLINGS 
3.1 TYPICAL PROCEDURES 
Typical procedure 1 (TP1): Preparation of magnesium diorganoboronates 
R2B(OBu)2MgX via direct Mg insertion in the presence of B(OBu)3 
A dry, argon-flushed Schlenk flask equipped with a magnetic stirring bar and a septum 
was charged with Mg turnings (78 mg, 3.2 mmol) and LiCl (93 mg, 2.2 mmol). LiCl was 
dried in vacuo using a heatgun (450 °C, 5 min). After addition of THF (2 mL), the Mg 
was activated with 1,2-dibromoethane (2 mol%) and Me3SiCl (5 mol%). Then B(OBu)3 
(230 mg, 1 mmol) was added at 25 °C followed by a solution of the organic halide  
(2 mmol) in THF (2 mL) and stirred for the given time leading to a THF-solution of the 
magnesium diorganoboronate. 
 
Typical procedure 2 (TP2): Preparation of magnesium organoboronates 
RB(OBu)3MgX via direct Mg insertion in the presence of B(OBu)3 
A dry, argon-flushed Schlenk flask equipped with a magnetic stirring bar and a septum 
was charged with Mg turnings (78 mg, 3.2 mmol) and LiCl (93 mg, 2.2 mmol). LiCl was 
dried in vacuo using a heatgun (450 °C, 5 min). After addition of THF (2 mL), the Mg 
was activated with 1,2-dibromoethane (2 mol%) and Me3SiCl (5 mol%). Then B(OBu)3 
(460 mg, 2 mmol) was added at 25 °C followed by a solution of the organic halide  
(2 mmol) in THF (2 mL) and stirred for the given time leading to a THF-solution of the 
magnesium organoboronate. 
 
Typical procedure 3 (TP3): Suzuki-Miyaura cross-coupling reactions 
A dry, argon-flushed Schlenk flask was charged with the electrophile E–X (1.6 mmol), 
PdCl2 (44 mg, 4 mol%), dppf (14 mg, 4 mol%) and Cs2CO3 (1.3 g, 4 mmol) and 
suspended in EtOH (4 mL) and DMF (1 mL). Afterwards the magnesium (di-)organo-
boronate solution (2 mmol) was transferred to this mixture via cannula. The resulting 
suspension was stirred at 65 °C for the given time. Subsequently, the reaction mixture 
was diluted with EtOAc (5 mL) and quenched with brine (10 mL). The aqueous layer 
was extracted with CH2Cl2 (3x 15 mL). The combined organic phases were dried over 
Na2SO4 and the solvent was removed in vacuo. The crude product was purified by flash 
column chromatography to give the analytically pure product. 
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Typical procedure 4 (TP4): Suzuki-Miyaura cross-coupling reactions 
A dry, argon-flushed Schlenk flask was charged with the electrophile E–X (1.6 mmol), 
Pd(PPh3)4 (93 mg, 4 mol%) and Cs2CO3 (1.3 g, 4 mmol) and suspended in EtOH (4 mL). 
Afterwards the magnesium (di-)organoboronate solution (2 mmol) was transferred to this 
mixture via cannula. The resulting suspension was stirred at 65 °C for the given time. 
Subsequently, the reaction mixture was diluted with EtOAc (5 mL) and quenched with 
brine (10 mL). The aqueous layer was extracted with CH2Cl2 (3x 15 mL). The combined 
organic phases were dried over Na2SO4 and the solvent was removed in vacuo. The crude 
product was purified by flash column chromatography to give the analytically pure 
product. 
 
Typical procedure 5 (TP5): Suzuki-Miyaura cross-coupling reactions 
A dry, argon-flushed Schlenk flask was charged with the electrophile E–X (1.4 mmol), 
Pd(PPh3)4 (93 mg, 4 mol%) and Na2CO3·10H2O (0.76 g, 2.66 mmol) and suspended in 
1,4-dioxane (4 mL) and H2O (1.5 mL). Afterwards the magnesium (di-)organo-boronate 
solution (2 mmol) was transferred to this mixture via cannula. The resulting suspension 
was stirred at 110 °C for the given time. Subsequently, the reaction mixture was diluted 
with EtOAc (5 mL) and quenched with brine (10 mL). The aqueous layer was extracted 
with CH2Cl2 (3x 15 mL). The combined organic phases were dried over Na2SO4 and the 
solvent was removed in vacuo. The crude product was purified by flash column 
chromatography to give the analytically pure product. 
 
3.2 PREPARATION OF FUNCTIONALIZED MAGNESIUM (DI)ARYLBORONATES AND 
SUBSEQUENT SUZUKI-MIYAURA CROSS-COUPLINGS 
Preparation of methyl 4'-cyanobiphenyl-2-carboxylate (21a) 
 
The magnesium organoboronate 19a was prepared according to TP2 from methyl  
2-bromobenzoate (18a, 430 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling reaction was 
performed according to TP3 with 4-bromobenzonitrile (22a, 291 mg, 1.6 mmol) in 12 h. 
Flash column chromatographical purifitacion (pentane/Et2O = 7:3) furnished 21a as a 
brown oil (243 mg, 65%). 
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1H NMR (300 MHz, CDCl3) δ (ppm) = 7.95 (dd, J=7.7Hz, 1.1Hz, 1H), 7.70 (d,  
J=8.3Hz, 2H), 7.55-7.63 (m, 1H), 7.46-7.53 (m, 1H), 7.41 (d, J=8.3Hz, 2H), 7.32 (dd, 
J=7.5Hz, 0.8Hz, 1H), 3.68 (s, 3H).  
13C NMR (75 MHz, CDCl3) δ (ppm) = 167.9, 146.3, 141.0, 131.7, 131.7, 130.5, 130.4, 
130.0, 129.1, 128.2, 118.8, 111.0, 52.0. 
MS (70 eV, EI), m/z (%) = 237 (M+, 43), 207 (15), 206 (100), 178 (22), 177 (18),  
151 (17). 
HRMS (EI), m/z calc. for C15H11NO2 (237.0790): 237.0780 (M+). 
IR (ATR) υ (cm-1) = 3062, 3000, 2951, 2855, 2227, 1720, 1608, 1598, 1482, 1446, 1432, 
1288, 1276, 1254, 1190, 1126, 1089, 1028, 1006, 959, 842, 762, 734, 704. 
 
Preparation of tert-butyl (4'-(tert-butylcarbamoyl)-biphenyl-4-yl) carbonate (21b) 
 
The magnesium diorganoboronate 20a was prepared according to TP1 from 4-
bromophenyl tert-butyl carbonate (18b, 546 mg, 2 mmol) in 1 h at 25 °C. A cross-
coupling reaction was performed according to TP3 with 4-bromo-N-(tert-
butyl)benzamide (22b, 410 mg, 1.6 mmol) in 12 h. Flash column chromatographical 
purification (pentane/Et2O = 5.5:4.5) furnished 21b as a white solid (539 mg, 91%). 
 
m.p.: 166.0-168.8 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.79 (d, J=8.0Hz, 2H), 7.59 (d, J=8.8Hz, 4H), 
7.26 (d, J=8.6Hz, 2H), 6.02 (br s, 1H), 1.58 (s, 9H), 1.50 (s, 9H).    
13C NMR (75 MHz, CDCl3) δ (ppm) = 151.7, 150.9, 142.9, 137.7, 134.7, 128.1, 127.2, 
127.0, 121.7, 83.7, 51.6, 28.9, 27.7. 
MS (70 eV, EI), m/z (%) = 369 (M+, 1), 269 (37), 213 (56), 198 (11), 197 (100), 57 (20), 
42 (27), 41 (10). 
HRMS (EI), m/z calc. for C22H27NO4 (369.1940): 369.1943 (M+). 
IR (ATR) υ (cm-1) = 3253, 2973, 2925, 1750, 1630, 1609, 1544, 1487, 1455, 1368, 1273, 
1256, 1218, 1143, 1006, 895, 881, 838, 824, 794, 777, 683. 
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Preparation of 6-hydroxy-5-methoxy-3',5'-bis(trifluoromethyl)-biphenyl-3-carb-
aldehyde (21c)  
F3C
CF3
CHO
OH
OMe
 
The magnesium diorganoboronate 20b was prepared according to TP1 from  
3,5-di(trifluoromethyl)bromobenzene (18c, 586 mg, 2 mmol) in 15 min at 25 °C. A 
cross-coupling reaction was performed according to TP3 with 5-bromovanillin (22c,  
368 mg, 1.6 mmol) in 12 h. Flash column chromatographical purification 
(pentane/EtOAc = 8:2) furnished 21c as a pale yellow solid (483 mg, 87%). 
 
m.p.: >275 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 9.9 (s, 1H), 8.1 (s, 2H), 7.9 (s, 1H), 7.6 (s, 1H), 
7.5 (s, 1H), 4.1 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 190.5, 157.5, 148.7, 147.6, 138.3, 131.7 (q, 
J=33.4Hz), 129.7, 129.1, 128.4, 127.5 (m), 121.5 (m), 108.8, 56.6. 
MS (70 eV, EI), m/z (%) = 364 (M+, 5), 228 (8), 88 (4), 61 (12), 45 (13), 43 (100). 
HRMS (EI), m/z calc. for C16H10F6O3 (364.0534): 364.0522 (M+). 
IR (ATR) υ (cm-1) = 3294, 2970, 2360, 1740, 1672, 1500, 1468, 1382, 1362, 1294, 1272, 
1180, 1152, 1118, 898, 864, 844, 750, 710, 682. 
 
Preparation of 4'-acetyl-biphenyl-4-carbonitrile (21d)  
NC
Me
O
 
The magnesium diorganoboronate 20c was prepared according to TP1 from 4-bromo-
benzonitrile (18d, 364 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling reaction was 
performed according to TP3 with 4-bromoacetophenone (22d, 318 mg, 1.6 mmol) in  
12 h. Flash column chromatographical purification (pentane/EtOAc = 9:1) furnished 21d 
as a white solid (290 mg, 82%). 
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m.p.: 106.2-107.8 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.08 (d, J=8.7Hz, 2H), 7.67-7.81 (m, 6H), 2.66 
(s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 197.4, 144.3, 143.5, 136.9, 132.9, 129.1, 127.9,  
27.4, 118.6, 111.9, 26.7. 
MS (70 eV, EI), m/z (%) = 222 (5), 221 (M+, 19), 207 (14), 206 (100), 178 (30),  
177 (18), 151(24). 
HRMS (EI), m/z calc. for C15H11NO (221.0841): 221.0826 (M+). 
IR (ATR) υ (cm-1) = 3050, 2226, 1682, 1602, 1396, 1358, 1266, 1178, 1116, 1004, 956, 
862, 814, 742, 714, 622. 
 
Preparation of 6-hydroxy-5-methoxy-4'-(methylthio)-biphenyl-3-carbaldehyde (21e)  
CHO
OH
OMe
MeS
 
The magnesium diorganoboronate 20d was prepared according to TP1 from  
4-bromothioanisole (18e, 406 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling reaction 
was performed according to TP3 with 5-bromovanillin (22c, 370 mg, 1.6 mmol) in 6 h. 
Flash column chromatographical purification (pentane/EtOAc = 3:1) furnished 21e as a 
white solid (382 mg, 87%). 
 
m.p.: 124.9-125.6 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 9.88 (s, 1H), 7.57 (d, J=8.2Hz, 2H), 7.52 (d, 
J=1.9Hz, 1H), 7.42 (d, J=1.9Hz, 1H), 7.35 (d, J=8.5Hz, 2H), 6.46 (br s, 1H), 4.03 (s, 
3H), 2.54 (s, 3H).  
13C NMR (75 MHz, CDCl3) δ (ppm) = 190.9, 148.6, 147.5, 138.3, 132.9, 129.4, 128.3, 
127.1, 126.4, 108.7, 107.4, 56.5, 15.7. 
MS (70 eV, EI), m/z (%) = 276 (5), 275 (14), 274 (M+, 100), 212 (5), 184 (6). 
HRMS (EI), m/z calc. for C15H14O3S (274.0664): 274.0655 (M+). 
IR (ATR) υ (cm-1) = 3198, 2978, 2922, 2848, 2362, 1732, 1666, 1588, 1498, 1454, 1428, 
1388, 1366, 1304, 1246, 1150, 1124, 1090, 1044, 1014, 854, 822, 732, 706, 680. 
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Preparatin of 5-(4-(methylthio)phenyl)-1H-indole (21f)  
N
H
MeS
 
The magnesium diorganoboronate 20d was prepared according to TP1 from 4-
bromothio-anisole (18e, 406 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling reaction was 
performed according to TP3 with 5-bromo-1H-indole (22e, 314 mg, 1.6 mmol) in 6 h. 
Flash column chromatographical purification (pentane/EtOAc = 8.5:1.5) furnished 21f as 
a pale yellow solid (352 mg, 92%). 
 
m.p.: 82.6-83.9 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.16 (br s, 1H), 7.87 (s, 1H), 7.61 (d, J=8.6Hz, 
2H), 7.43-7.48 (m, 2H), 7.37 (d, J=8.4Hz, 2H), 7.24 (t, J=2.4Hz, 1H), 6.59-6.65 (m, 1H), 
2.55 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 139.6, 136.1, 135.2, 132.7, 128.4, 127.7, 127.2, 
124.9, 121.6, 118.9, 111.2, 103.0, 16.2. 
MS (70 eV, EI), m/z (%) = 240 (15), 239 (M+, 100), 224 (54), 57 (12). 
HRMS (EI), m/z calc. for C15H13NS (239.0769): 239.0764 (M+). 
IR (ATR) υ (cm-1) = 3402, 3022, 2920, 1738, 1594, 1578, 1464, 1412, 1342, 1230, 1210, 
1096, 1066, 1008, 970, 954, 886, 800, 722. 
 
Preparation of 4'-(tert-butylcarbamoyl)-biphenyl-3-yl diethylcarbamate (21g)  
O
NEt2
O
O
NHtBu
 
The magnesium diorganoboronate 20e was prepared according to TP1 from 3-bromo-
phenyl diethylcarbamate (18f, 544 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling 
reaction was performed according to TP3 with 4-bromo-N-(tert-butyl)benzamide (22b, 
410 mg, 1.6 mmol) in 7 h. Flash column chromatographical purification (pentane/Et2O = 
4:6) furnished 21g as a pale yellow solid (525 mg, 90%). 
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m.p.: 140.1-143.6 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.78 (d, J=8.0Hz, 2H), 7.62 (d, J=8.0Hz, 2H), 
7.39-7.44 (m, 2H), 7.35-7.38 (m, 1H), 7.12-7.17 (m, 1H), 6.02 (br s, 1H), 3.44 (q, 
J=6.9Hz, 4H), 1.49 (s, 9H), 1.25 (t, J=8.0Hz, 6H).   
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.5, 154.1, 151.9, 143.0, 141.4, 134.7, 129.6, 
127.2, 127.1, 123.8, 121.2, 120.5, 51.6, 42.1 (d, J=24.8Hz), 28.9, 13.8 (d, J=66.0Hz). 
MS (70 eV, EI), m/z (%) = 368 (M+, 6), 100 (100), 72 (30). 
HRMS (EI), m/z calc. for C22H28N2O3 (368.2100): 368.2092 (M+). 
IR (ATR) υ (cm-1) = 3486, 3393, 3035, 2972, 2946, 2894, 2876, 1707, 1621, 1595, 1516, 
1485, 1442, 1333, 1247, 1164, 1116, 1096, 1073, 1040, 877, 820, 796, 735, 692. 
 
Preparation of ethyl 5-(2-fluorophenyl)nicotinate (21h)  
N
CO2Et
F
 
The magnesium diorganoboronate 20f was prepared according to TP1 from 1-bromo-2-
fluorobenzene (18g, 350 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling reaction was 
performed according to TP3 with ethyl 5-bromonicotinate (22f, 368 mg, 1.6 mmol) in  
3 h. Flash column chromatographical purification (pentane/EtOAc = 8:2) furnished 21h 
as a brown powder (307 mg, 79%). 
 
m.p.: 80.2-81.0 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 9.18 (br s, 1H), 8.91 (br s, 1H), 8.42 (s, 1H), 
7.32-7.45 (m, 2H), 7.12-7.24 (m, 2H), 4.39 (q, J=7.1Hz, 2H), 1.38 (t, J=7.1Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 165.2, 159.8 (d, J=249.0Hz), 153.1, 149.8, 137.1 
(d, J=3.1Hz), 131.6, 130.6 (d, J=1.7Hz), 130.5 (d, J=3.9 Hz), 126.3, 124.9 (d, J=3.9Hz), 
124.7, 116.5 (d, J=22.1Hz), 61.6, 14.4. 
MS (70 eV, EI), m/z (%) = 246 (14), 245 (M+, 100), 217 (71), 200 (94), 172 (93),  
145 (26), 125 (23), 100 (7), 75 (7). 
HRMS (EI), m/z calc. for C14H12FNO2 (245.0852): 245.0848 (M+). 
IR (ATR) υ (cm-1) = 3059, 2986, 1724, 1496, 1438, 1367, 1314, 1275, 1250, 1232, 1211, 
1109, 1053, 1026, 916, 865, 819, 755, 728, 704, 662. 
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Preparation of ethyl 5-(4-(dimethylamino)phenyl)nicotinate (21i)  
N
CO2Et
Me2N
 
The magnesium diorganoboronate 20g was prepared according to TP1 from 4-bromo-
N,N-dimethylaniline (18h, 400 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling reaction 
was performed according to TP3 with ethyl 5-bromonicotinate (22f, 368 mg, 1.6 mmol) 
in 2 h. Flash column chromatographical purification (pentane/EtOAc = 7:3) furnished 21i 
as a brown solid (390 mg, 90%). 
 
m.p.: 100.8-102.2 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 9.05 (d, J=1.9Hz, 1H), 8.94 (d, J=2.3Hz, 1H), 
8.41 (t, J=2.1Hz, 1H), 7.50-7.53 (m, 2H), 6.78-6.81 (m, 2H), 4.41 (q, J=7.1Hz, 2H), 2.99 
(s, 6H), 1.41 (t, J=6.9Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 165.8, 151.0, 150.8, 148.0, 136.5, 134.1, 127.9, 
126.3, 124.2, 112.9, 61.5, 40.5, 14.5. 
MS (70 eV, EI), m/z (%) = 271 (16), 270 (M+, 100), 242 (46), 225 (7), 154 (7), 98 (10). 
HRMS (EI), m/z calc. for C16H18N2O2 (270.1368): 270.1363 (M+). 
IR (ATR) υ (cm-1) = 3788, 2980, 2900, 2814, 2361, 2341, 1716, 1607, 1529, 1434, 1362, 
1306, 1290, 1255, 1230, 1119, 1006, 815, 768. 
 
Preparation of diethyl 2'-chloro-5'-methoxy-biphenyl-2,4-dicarboxylate (21j)  
EtO2C
Cl
CO2Et
MeO
 
The magnesium diorganoboronate 20h was prepared according to TP1 from 2-bromo-1-
chloro-4-methoxybenzene (18i, 443 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling 
reaction was performed according to TP3 with diethyl 4-bromoisophthalate (22g,  
482 mg, 1.6 mmol) in 6 h. Flash column chromatographical purification (pentane/Et2O = 
8:2) furnished 21j as yellow oil (467 mg, 81%). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.67 (dd, J=1.9Hz, 0.4Hz, 1H), 8.23 (dd, 
J=7.9Hz, 1.8Hz, 1H), 7.37 (dd, J=7.9Hz, 0.5Hz, 1H), 7.32 (dd, J=8.8Hz, 0.4Hz, 1H), 
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6.87 (dd, J=8.8Hz, 3.0Hz, 1H), 6.79 (d, J=3.0Hz, 1H), 4.44 (q, J=7.1Hz, 2H), 4.17 (q, 
J=7.1Hz, 2H), 3.81 (s, 3H), 1.43 (t, J=7.2Hz, 3H), 1.10 (t, J=7.2Hz, 3H).   
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.3, 165.5, 158.0, 144.3, 140.7, 132.4, 131.3, 
131.2, 131.2, 130.3, 129.7, 124.0, 115.4, 114.4, 61.4, 61.2, 55.6, 14.3, 13.7. 
MS (70 eV, EI), m/z (%) = 362 (M+, 2), 328 (21), 327 (100), 317 (13), 300 (18),  
299 (99), 271 (40), 253 (10). 
HRMS (EI), m/z calc. for C19H19ClO5 (362.0921): 362.0916 (M+). 
IR (ATR) υ (cm-1) = 3487, 3392, 3018, 2964, 2953, 2924, 2885, 2861, 1699, 1621, 1485, 
1442, 1333, 1260, 1191, 1161, 1118, 1040, 990, 879, 796, 692. 
 
Preparation of 3-fluoro-4'-((triisopropylsilyl)oxy)-biphenyl-4-carbonitrile (21k)  
CN
TIPSO
F
 
The magnesium diorganoboronate 20i was prepared according to TP1 from (4-bromo-
phenoxy)-triisopropylsilane (18j, 659 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling 
reaction was performed according to TP3 with 4-bromo-2-fluorobenzonitrile (22h,  
320 mg, 1.6 mmol) in 4 h. Flash column chromatographical purification  
(pentane/Et2O = 9.5:0.5) furnished 21k as a pale brown solid (411 mg, 70%). 
 
m.p.: 56.2-57.9 °C.  
1H NMR (600 MHz, CDCl3) δ (ppm) = 7.64 (dd, J=8.1Hz, 6.8Hz, 1H), 7.46-7.49 (m, 
2H), 7.44 (dd, J=8.1Hz, 1.7Hz, 1H), 7.39 (dd, J=10.5Hz, 1.7Hz, 1H), 6.96-7.01 (m, 2H), 
1.31 (spt, J=7.5Hz, 3H), 1.13 (d, J=7.5Hz, 18H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 163.5 (d, J=256.5Hz), 157.5, 148.2 (d, J=8.3Hz), 
133.5, 130.5 (d, J=2.3Hz), 128.3, 122.7 (d, J=3.0Hz), 120.6, 114.2, 114.0 (d, J=19.5Hz), 
98.9 (d, J=15.8Hz), 17.9, 12.7. 
MS (70 eV, EI), m/z (%) = 269 (M+, 20), 327 (19), 326 (66), 298 (36), 271 (20),  
270 (100), 257 (11), 256 (54), 240 (13), 196 (11), 135 (31), 43(16). 
HRMS (EI), m/z calc. for C22H28FNOSi (369.1924): 369.1921 (M+). 
IR (ATR) υ (cm-1) = 3488, 3392, 3048, 3036, 2958, 2935, 2878, 2857, 2243, 2222, 1623, 
1514, 1484, 1442, 1333, 1310, 1253, 1160, 1115, 1096, 1073, 1041, 868, 796, 692. 
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Preparation of ethyl 2-(4-(methylthio)phenyl)-3-propylhex-2-enoate (21l)  
MeS
COOEt
Pr
Pr
 
The magnesium diorganoboronate 20d was prepared according to TP1 from  
4-bromothioanisole (18e, 406 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling reaction 
was performed according to TP3 with ethyl 2-bromo-3-propylhex-2-enoate (22i, 421 mg, 
1.6 mmol) in 12 h. Flash column chromatographical purification (pentane/Et2O = 9.5:0.5) 
furnished 21l as a colorless oil (365 mg, 75%). 
 
1H NMR (600 MHz, CDCl3) δ (ppm) = 7.22 (dt, J=8.5Hz, 1.9Hz, 2H), 7.11 (dt, J=8.5Hz, 
2.2Hz, 2H), 4.15 (q, J=7.0Hz, 2H), 2.50 (s, 3H), 2.35-2.40 (m, 2H), 1.93-1.97 (m, 2H), 
1.54-1.58 (m, 2H), 1.36-1.41 (m, 2H), 1.22 (t, J=7.1Hz, 3H), 0.98 (t, J=7.4Hz, 3H), 0.78 
(t, J=7.4Hz, 3H). 
13C NMR (150 MHz, CDCl3) δ (ppm) = 168.9, 150.6, 136.9, 134.8, 130.3, 129.9, 126.1, 
60.4, 34.9, 34.9, 22.1, 21.4, 15.7, 14.3, 14.2. 
MS (70 eV, EI), m/z (%) = 307 (26), 306 (M+, 100), 260 (62), 245 (50), 231 (55),  
203 (37), 189 (48), 143 (62), 129 (58), 128 (40), 115 (43). 
HRMS (EI), m/z calc. for C18H26O2S (306.1654): 306.1645 (M+). 
IR (ATR) υ (cm-1) = 3487, 3392, 3072, 2981, 2946, 2887, 2845, 1735, 1695, 1621, 1515, 
1485, 1444, 1333, 1260, 1215, 1161, 1120, 1097, 1073, 1046, 878, 796, 692. 
 
Preparation of 2-(4-methoxyphenyl)nicotinonitrile (21m)  
N
MeO
NC
 
The magnesium diorganoboronate 20j was prepared according to TP1 from 4-bromo-
anisole (18k, 374 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling reaction was performed 
according to TP3 with 2-chloronicotinonitrile (23a, 222 mg, 1.6 mmol) in 12 h. Flash 
column chromatographical purification (pentane/EtOAc = 7:3) furnished 21m as a 
yellow powder (260 mg, 78%). 
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m.p.: 138.0-139.7 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.79-8.81 (m, 1H), 7.99-8.01 (m, 1H), 7.89-7.93 
(m, 2H), 7.26-7.29 (m, 1H), 6.99-7.03 (m, 2H), 3.85 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 159.7, 158.9, 150.9, 140.3, 128.8, 128.0, 119.3, 
116.4, 112.5, 105.1, 53.8. 
MS (70 eV, EI), m/z (%) = 211 (17), 210 (M+, 100), 195 (26), 167 (39), 140 (19). 
HRMS (EI), m/z calc. for C13H10N2O (210.0793): 210.0776 (M+). 
IR (ATR) υ (cm-1) = 3070, 3010, 2967, 2838, 2224, 1882, 1607, 1582, 1574, 1553, 1516, 
1458, 1431, 1416, 1308, 1247, 1183, 1108, 1040, 1021, 830, 804, 787, 772. 
 
Preparation of dimethyl 3-(4-(trimethylsilyl)phenyl)pyridine-2,4-dicarboxylate 
(21n)  
 
The magnesium diorganoboronate 20k was prepared according to TP1 from (4-bromo-
phenyl)trimethylsilane (18l, 458 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling reaction 
was performed according to TP3 with dimethyl 3-chloropyridine-2,4-dicarboxylate (23b, 
368 mg, 1.6 mmol) in 12 h. Flash column chromatographical purification  
(pentane/Et2O = 4:6) furnished 21n as a pale yellow oil (429 mg, 78%). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 9.21 (d, J=1.7Hz, 1H), 8.38 (d, J=1.7Hz, 1H), 
7.61 (d, J=8.0Hz, 2H), 7.36 (d, J=8.3Hz, 2H), 3.99 (s, 3H), 3.82 (s, 3H), 0.31 (s, 9H).  
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.6, 164.8, 151.6, 148.7, 141.0, 139.6, 137.2, 
137.0, 133.6, 127.4, 127.2, 52.8, 52.7, -1.2. 
MS (70 eV, EI), m/z (%) = 343 (M+, 26), 329 (26), 328 (100), 208 (10), 180 (27),  
106 (19), 89 (90), 59 (11). 
HRMS (EI), m/z calc. for C18H21NO4Si (343.1240): 343.1232 (M+). 
IR (ATR) υ (cm-1) = 3488, 3392, 3062, 3040, 3012, 2981, 2925, 2868, 1713, 1621, 1515, 
1485, 1441, 1333, 1274, 1162, 1113, 1095, 1073, 902, 877, 796, 692. 
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Preparation of tert-butyl (4-(2-methylquinolin-8-yl)phenyl) carbonate (21o)  
N Me
OBoc
 
The magnesium diorganoboronate 20a was prepared according to TP1 from 4-bromo-
phenyl tert-butyl carbonate (18b, 546 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling 
reaction was performed according to TP3 with 2-methyl-8-(perfluorobutoxy)quinoline 
(24a, 706 mg, 1.6 mmol) in 3 h. Flash column chromatographical purification 
(pentane/EtOAc = 8.5:1.5) furnished 21o as a white solid (415 mg, 78%). 
 
m.p.: 98.2-100.4 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.07 (d, J=8.4Hz, 1H), 7.63-7.91 (m, 4H), 7.53 
(t, J=7.6Hz, 1H), 7.29 (dd, J=8.2Hz, 2.1Hz, 3H), 2.70 (s, 3H), 1.62 (s, 9H).  
13C NMR (75 MHz, CDCl3) δ (ppm) = 158.7, 152.0, 150.3, 145.3, 138.9, 137.1, 136.2, 
131.9, 130.2, 127.3, 126.9, 125.3, 121.8, 120.4, 83.4, 27.7, 25.6. 
MS (70 eV, EI), m/z (%) = 335 (M+, 73), 235 (59), 234 (100), 218 (10), 57 (12), 43 (11). 
HRMS (EI), m/z calc. for C21H21NO3 (335.1521): 335.1524 (M+). 
IR (ATR) υ (cm-1) = 3005, 2982, 2933, 2359, 2333, 1749, 1601, 1500, 1370, 1274, 1258, 
1218, 1145, 892, 831, 813, 783, 756. 
 
Preparation of 2-methyl-4-(4-(trifluoromethyl)phenyl)quinoline (21p)  
N Me
CF3
 
The magnesium diorganoboronate 20l was prepared according to TP1 from 1-bromo-4-
(trifluoromethyl)benzene (18m, 450 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling 
reaction was performed according to TP3 with 2-methylquinolin-4-yl 4-methylbenzene-
sulfonate (24b, 502 mg, 1.6 mmol) in 12 h. Flash column chromatographical purification 
(pentane/Et2O = 6:4) furnished 21p as a pale yellow solid (314 mg, 70%). 
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m.p.: 111.2-112.9 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.13 (d, J=8.3Hz, 1H), 7.67-7.85 (m, 4H), 7.62 
(d, J=8.0Hz, 2H), 7.41-7.50 (m, 1H), 7.23 (s, 1H), 2.80 (s, 3H).  
13C NMR (75 MHz, CDCl3) δ (ppm) = 158.5, 148.3, 147.0, 141.8, 130.5 (q, J=32.3Hz), 
129.8, 129.6, 129.1, 126.1, 125.5 (q, J=3.8Hz), 125.1, 124.6, 124.1 (q, J=270.8Hz), 
122.1, 25.3. 
MS (70 eV, EI), m/z (%) = 288 (12), 287 (M+, 73), 286 (15), 218 (11), 70 (11), 61 (14), 
45 (12), 43 (100). 
HRMS (EI), m/z calc. for C17H12F3N (287.0922): 287.0921 (M+). 
IR (ATR) υ (cm-1) = 3069, 2970, 2923, 1737, 1619, 1597, 1557, 1504, 1414, 1403, 1377, 
1322, 1154, 1113, 1065, 1018, 852, 837, 766, 757. 
 
Preparation of (2'-methoxy-biphenyl-4-yl)(methyl)sulfane (21q)  
MeS
MeO
 
The magnesium diorganoboronate 20d was prepared according to TP1 from  
4-bromothioanisole (18e, 406 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling reaction 
was performed according to TP3 with 2-methoxyphenyl trifluoromethanesulfonate (24c, 
410 mg, 1.6 mmol) in 12 h. Flash column chromatographical purification (pentane/Et2O 
= 9.5:0.5) furnished 21q as a pale yellow solid (298 mg, 81%). 
 
m.p.: 78.0-81.1 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.50 (d, J=8.3Hz, 2H), 7.29-7.40 (m, 4H), 7.04 
(dd, J=15.5Hz, 7.2Hz, 2H), 3.84 (s, 3H), 2.54 (s, 3H).  
13C NMR (75 MHz, CDCl3) δ (ppm) = 156.4, 137.0, 135.3, 130.6, 129.9, 128.6, 127.0, 
126.3, 120.8, 111.2, 55.5, 15.9. 
MS (70 eV, EI), m/z (%) = 230 (M+, 100), 168 (100). 
HRMS (EI), m/z calc. for C14H14OS (230.0765): 230.0749 (M+). 
IR (ATR) υ (cm-1) = 3052, 3024, 3000, 2964, 2937, 2919, 2836, 2361, 2337, 1739, 1593, 
1576, 1478, 1465, 1434, 1256, 1228, 1182, 1089, 1050, 1025, 1002, 815, 803, 753, 719. 
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Preparation of 4'-amino-3'-chloro-biphenyl-2-ol (21r)  
NH2
Cl
OH
 
The magnesium organoboronate 19b was prepared according to TP2 from  
2-bromophenyl tert-butyl carbonate (18n, 546 mg, 2 mmol) in 1 h at 25 °C. A cross-
coupling reaction was performed according to TP3 with 4-bromo-2-chloroaniline (22j, 
330 mg, 1.6 mmol) in 6 h. Flash column chromatographical purification (pentane/Et2O = 
4:6) furnished 21r as a brown solid (301 mg, 86%) (Note: under the reaction conditions, 
the protecting group is cleaved and the free phenol is obtained). 
 
m.p.: 119.9-122.0 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.41 (d, J=1.9Hz, 1H), 7.14-7.31 (m, 3H), 6.91-
7.10 (m, 2H), 6.88 (d, J=8.3Hz, 1H), 4.28 (bs, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 152.5, 142.5, 130.1, 130.0, 128.8, 128.4, 127.7, 
127.1, 120.8, 119.8, 116.2, 115.7. 
MS (70 eV, EI), m/z (%) = 221 (29), 220 (12), 219 (M+, 100), 184 (45), 183 (27),  
156 (35), 109 (10), 78 (16), 77 (17). 
HRMS (EI), m/z calc. for C12H10ClNO (219.0451): 219.0447 (M+). 
IR (ATR) υ (cm-1) = 3365, 3275, 2957, 2923, 2853, 1745, 1605, 1589, 1495, 1486, 1448, 
1369, 1293, 1272, 1203, 1158, 1112, 1050, 880, 857, 833, 803, 754, 717, 679. 
 
Preparation of ethyl 4'-cyano-3'-fluoro-biphenyl-4-carboxylate (21s)  
CO2Et
NC
F
 
The magnesium organoboronate 19c was prepared according to TP2 from 4-bromo-2-
fluorobenzonitrile (18o, 400 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling reaction was 
performed according to TP3 with ethyl 4-bromobenzoate (22k, 367 mg, 1.6 mmol) in  
12 h. Flash column chromatographical purification (pentane/Et2O = 8:2) furnished 21s as 
a white solid (270 mg, 72%). 
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m.p.: 131.5-133.4 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.16 (dt, J=8.4Hz, J=2.1Hz, 2H), 7.72 (dd, 
J=8.1Hz, 6.6Hz. 1H), 7.65 (dt, J=8.6Hz, 1.9Hz, 2H), 7.49 (ddd, J=15.0Hz, 8.0Hz, 1.7Hz, 
2H), 4.42 (q, J=7.1Hz, 2H), 1.43 (t, J=7.2Hz, 3H).  
13C NMR (75 MHz, CDCl3) δ (ppm) = 165.9, 163.4 (d, J=258.0Hz), 147.3 (d, J=7.5Hz), 
142.0 (d, J=1.5Hz), 133.9, 131.1, 130.4, 127.1, 123.6 (d, J=3.8Hz), 115.1 (d, J=20.3Hz), 
113.8, 100.7 (d, J=15.8Hz), 61.3, 14.3. 
MS (70 eV, EI), m/z (%) =269 (M+, 23), 241 (36), 225 (20), 224 (100), 196 (35),  
195 (30), 176 (18), 169 (34), 168 (13), 112 (17), 98 (27), 85 (11), 84 (24), 45 (12). 
HRMS (EI), m/z calc. for C16H12FNO2 (269.0852): 269.0845 (M+). 
IR (ATR) υ (cm-1) = 3392, 3208, 3065, 3034, 2924, 2234, 1703, 1622, 1515, 1485, 1443, 
1333, 1161, 1117, 1096, 1073, 876. 
 
Preparation of tert-butyl 4'-methoxy-biphenyl-4-carboxylate (21t)  
 
The magnesium organoboronate 19d was prepared according to TP2 from tert-butyl 4-
bromo-benzoate (18p, 514 mg, 1 mmol) in 1 h at 25 °C. A cross-coupling reaction was 
performed according to TP3 with 4-bromoanisole (22l, 300 mg, 1.6 mmol) in 12 h. Flash 
column chromatographical purification (pentane/Et2O = 9.5:0.5) furnished 21t as a white 
solid (402 mg, 89%). 
 
m.p.: 101.3-103.9 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.05 (d, J=8.3Hz, 2H), 7.59 (t, J=8.8Hz, 4H), 
7.01 (d, J=8.6Hz, 2H), 3.87 (s, 3H), 1.63 (s, 9H).  
13C NMR (75 MHz, CDCl3) δ (ppm) = 165.7, 159.7, 144.7, 132.6, 129.9, 128.3, 127.0, 
126.3, 114.3, 80.9, 55.3, 28.2. 
MS (70 eV, EI), m/z (%) = 284 (M+, 20), 241 (14), 228 (13), 227 (100), 212 (22),  
210 (12), 184 (11), 43 (44). 
HRMS (EI), m/z calc. for C18H20O3 (284.1412): 284.1408 (M+). 
IR (ATR) υ (cm-1) = 2990, 2976, 2932, 2852, 2835, 1706, 1598, 1529, 1488, 1456, 1366, 
1292, 1250, 1181, 1162, 1106, 1035, 1007, 848, 829, 772, 760, 698. 
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Preparation of 4'-tert-butyl 3-ethyl biphenyl-3,4'-dicarboxylate (21u)  
 
The magnesium organoboronate 19d was prepared according to TP2 from tert-butyl 4-
bromo-benzoate (18p, 514 mg, 1 mmol) in 1 h at 25 °C. A cross-coupling reaction was 
performed according to TP3 with ethyl 4-bromobenzoate (22m, 386 mg, 1.6 mmol) in  
12 h. Flash column chromatographical purification (pentane/Et2O = 9:1) furnished 21u as 
a colorless oil (402 mg, 78%). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.31 (s, 1H), 7.99- 8.15 (m, 3H), 7.80 (d, 
J=7.7Hz, 1H), 7.67 (d, J=8.3Hz, 2H), 7.53 (t, J=7.7Hz, 1H), 4.43 (q, J=7.2Hz, 2H), 1.63 
(s, 9H), 1.43 (t, J=7.2Hz, 3H).  
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.3, 165.5, 144.0, 140.4, 131.4, 131.2, 131.2, 
130.0, 129.0, 128.9, 128.3, 126.9, 81.1, 61.1, 28.2, 14.3. 
MS (70 eV, EI), m/z (%) = 326 (M+, 2), 270 (10), 225 (12), 70 (13), 61 (15). 
HRMS (EI), m/z calc. for C18H22O4 (326.1518): 326.1519 (M+). 
IR (ATR) υ (cm-1) = 2977, 2932, 2906, 1708, 1608, 1477, 1439, 1392, 1366, 1291, 1237, 
1162, 1103, 1083, 1042, 1015, 858, 848, 746, 691. 
 
3.3 PREPARATION OF FUNCTIONALIZED MAGNESIUM DIALKENYLBORONATES AND 
SUBSEQUENT SUZUKI-MIYAURA CROSS-COUPLINGS 
Preparation of 2',3',4',5'-tetrahydro-biphenyl-4-carbonitrile (26a)  
CN
 
The magnesium organoboronate 19e was prepared according to TP2 from 1-iodo-
cyclohex-1-ene (25a, 416 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling reaction was 
performed according to TP3 with 4-bromo-benzonitrile (22a, 291 mg, 1.6 mmol) in 12 h. 
Flash column chromatographical purification (pentane/Et2O = 9.5:0.5) furnished 26a as a 
pale yellow oil (206 mg, 71%). 
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1H NMR (300 MHz, CDCl3) δ (ppm) = 7.58 (d, J=8.3Hz, 2H), 7.45 (d,  J=8.3Hz, 2H), 
6.21-6.32 (m, 1H), 2.34-2.47 (m, 2H), 2.19-2.33 (m, 2H), 1.74-1.86 (m, 2H), 1.61-1.74 
(m, 2H).  
13C NMR (75 MHz, CDCl3) δ (ppm) = 147.0, 135.3, 132.0, 128.3, 125.3, 119.2, 109.8, 
27.0, 25.9, 22.7, 21.8. 
MS (70 eV, EI), m/z (%) = 184 (16), 183 (M+, 100), 182 (28), 169 (13), 168 (74),  
167 (11), 155 (55), 154 (56), 153 (16), 142 (17), 141 (10), 140 (35), 129 (23), 128 (14), 
127 (19), 116 (18), 115 (35). 
HRMS (EI), m/z calc. for C13H13N (183.1048): 183.1038 (M+). 
IR (ATR) υ (cm-1) = 3057, 2928, 2863, 2833, 2226, 1727, 1692, 1602, 1503, 1432, 1413, 
1350, 1181, 1137, 1080, 918, 862, 821, 799, 712. 
 
Preparation of (E)-4-styrylbenzonitrile (26b)  
CN
 
The magnesium organoboronate 19f was prepared according to TP2 from (E)-(2-
iodovinyl)benzene (25b, 460 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling reaction was 
performed according to TP3 with 4-bromo-benzonitrile (22a, 291 mg, 1.6 mmol) in 12 h. 
Flash column chromatographical purification (pentane/Et2O = 8:2) furnished 26b as a 
pale yellow solid (310 mg, 95%). 
 
m.p.: 118.0-119.2 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.48-7.73 (m, 6H), 7.30-7.44 (m, 3H), 7.23 (d, 
J=16.3Hz, 1H), 7.10 (d, J=16.3Hz, 1H).  
13C NMR (75 MHz, CDCl3) δ (ppm) = 141.8, 136.3, 132.4, 132.4, 128.8, 128.6, 126.9, 
126.8, 126.7, 119.0, 110.5. 
MS (70 eV, EI), m/z (%) = 206 (15), 205 (M+, 100), 204 (98), 203 (34), 190 (44),  
178 (12), 177 (24), 176 (19), 165 (21), 102 (22), 89 (43), 88 (47). 
HRMS (EI), m/z calc. for C15H11N (205.0891): 205.0883 (M+). 
IR (ATR) υ (cm-1) = 3082, 3023, 3001, 2954, 2921, 2224, 1739, 1600, 1575, 1502, 1449, 
1412, 1174, 972, 956, 872, 823, 757, 718, 690. 
 
 
 
C. EXPERIMENTAL SECTION 
210 
Preparation of ethyl 4-(1-phenylvinyl)benzoate (26c)  
 
The magnesium diorganoboronate 20m was prepared according to TP1 from  
(1-bromovinyl)-benzene (25c, 366 mg, 2 mmol) in 30 min at 0 °C. A cross-coupling 
reaction was performed according to TP3 with ethyl 4-bromobenzoate (22k, 367 mg, 
1.6 mmol) in 6 h. Flash column chromatographical purification (pentane/Et2O = 9.5:0.5) 
furnished 26c as a colorless oil (383 mg, 95%). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.01 (d, J=8.7Hz, 2H), 7.40 (d, J=8.7Hz, 2H), 
7.28-7.37 (m, 5H), 5.55 (d, J=1.0Hz, 1H), 5.53 (d, J=1.0Hz, 1H), 4.39 (q, J=7.1Hz, 2H), 
1.40 (t, J=7.1Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.4, 149.3, 145.9, 140.8, 129.7, 129.5, 128.3, 
128.2, 128.0, 127.8, 115.8, 60.9, 14.3. 
MS (70 eV, EI), m/z (%) = 252 (M+, 34), 207 (39), 179 (24), 178 (30), 155 (11),  
141 (12), 127 (16), 113 (20), 111 (14), 99 (25), 96 (25), 85 (60), 84 (11), 83 (24),  
71 (79), 70 (16), 69 (23), 57 (100), 56 (17), 55 (27), 43 (100), 41 (21). 
HRMS (EI), m/z calc. for C17H16O2 (252.1150): 252.1150 (M+). 
IR (ATR) υ (cm-1) = 2982, 1714, 1608, 1494, 1446, 1404, 1366, 1268, 1176, 1102, 1018, 
904, 864, 774, 700. 
 
3.4 PREPARATION OF FUNCTIONALIZED MAGNESIUM DIHETEROARYLBORONATES 
AND SUBSEQUENT SUZUKI-MIYAURA CROSS-COUPLINGS 
Preparation of methyl 2-amino-5-(benzofuran-3-yl)benzoate (28a)  
O
NH2
CO2Me
 
The magnesium diorganoboronate 20n was prepared according to TP1 from 3-bromo-1-
benzofuran (27a, 394 mg, 2 mmol) in 30 min at 25 °C. A cross-coupling reaction was 
performed according to TP3 with methyl 2-amino-5-bromobenzoate (22n, 368 mg, 
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1.6 mmol) in 6 h. Flash column chromatographical purification (pentane/EtOAc = 8:2 
with 0.5% NEt3) furnished 28a as a white solid (359 mg, 84%). 
 
m.p.: 86.3-87.4 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.17 (d, J=2.2Hz, 1H), 7.81 (dd, J=4.7Hz, 2.2Hz, 
1H), 7.74 (s, 1H), 7.51-7.59 (m, 2H), 7.28-7.40 (m, 2H), 6.81 (d, J=8.4Hz, 1H),  
3.93 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 168.4, 155.7, 149.5, 140.5, 133.4, 130.0, 126.6, 
124.4, 122.8, 121.5, 120.2, 120.2, 117.4, 111.7, 111.2, 51.7. 
HRMS (ESI) = m/z calc. for C16H14NO3 (268.0974): 268.0967 ([M+H]+). 
IR (ATR) υ (cm-1) = 3492, 3378, 2954, 1684, 1628, 1578, 1556, 1450, 1438, 1360, 1306, 
1292, 1230, 1102, 1084, 826, 790, 746, 710. 
 
Preparation of 4-(benzofuran-3-yl)phenyl diethylcarbamate (28b)  
O
O NEt2
O
 
The magnesium diorganoboronate 20n was prepared according to TP1 from 3-bromo-1-
benzofuran (27a, 394 mg, 2 mmol) in 30 min at 25 °C. A cross-coupling reaction was 
performed according to TP3 with 3-bromophenyl diethylcarbamate (22o, 436 mg, 
1.6 mmol) in 3 h. Flash column chromatographical purification (pentane/Et2O = 7.5:2.5) 
furnished 28b as a orange oil (428 mg, 86%). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.84-7.91 (m, 1H), 7.82 (s, 1H), 7.45-7.61 (m, 
3H), 7.41-7.45 (m, 1H), 7.28-7.41 (m, 2H), 7.16 (dt, J=6.7Hz, 2.5Hz, 1H), 3.20-3.64 (m, 
4H), 1.10-1.37 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 155.7, 154.1, 152.0, 141.5, 133.2, 129.6, 126.3, 
124.5, 124.1, 123.0, 121.7, 120.8, 120.8, 120.3, 111.7, 42.1 (d, J=25.5Hz),  
13.8 (d, J=65.3Hz). 
MS (70 eV, EI), m/z (%) = 310 (12), 309 (M+, 65), 181 (14), 152 (19), 100 (47),  
72 (100), 44 (15). 
HRMS (EI), m/z calc. for C19H19NO3 (309.1365): 309.1368 (M+). 
IR (ATR) υ (cm-1) = 3487, 3392, 3009, 2955, 2915, 2859, 1740, 1691, 1622, 1485, 1440, 
1398, 1332, 1246, 1167, 1119, 1073, 975, 872, 796, 734. 
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Preparation of diethyl 4-(thiophen-3-yl)isophthalate (28c)  
S
EtO2C CO2Et
 
The magnesium diorganoboronate 20o was prepared according to TP1 from 3-bromo-
thiophene (27b, 406 mg, 2 mmol) in 30 min at 0 °C. A cross-coupling reaction was 
performed according to TP3 with diethyl 4-bromoisophthalate (22g, 482 mg, 1.6 mmol) 
in 4 h. Flash column chromatographical purification (pentane/Et2O = 8.5:1.5) furnished 
28c as a pale brown solid (346 mg, 72%). 
 
m.p.: 48.8-50.5 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.42 (d, J=1.9Hz, 1H), 8.15 (dd, J=8.2Hz, 1.8Hz, 
1H), 7.50 (d, J=8.0Hz, 1H), 7.34-7.40 (m, 1H), 7.32 (dd, J=3.0Hz, 1.4Hz, 1H), 7.12 (dd, 
J=5.0Hz, 1.4Hz, 1H), 4.42 (q, J=7.1Hz, 2H), 4.21 (q, J=7.2Hz, 2H), 1.42 (t, J=7.0Hz, 
3H), 1.16 (t, J=7.2Hz, 3H).  
13C NMR (75 MHz, CDCl3) δ (ppm) = 168.1, 165.6, 140.7, 140.5, 131.8, 131.7, 130.7, 
130.5, 129.4, 128.2, 125.4, 123.1, 61.4, 61.3, 14.3, 13.8. 
MS (70 eV, EI), m/z (%) = 305 (16), 304 (M+, 90), 259 (100), 232 (17). 
HRMS (EI), m/z calc. for C16H16O4S (304.0769): 304.0739 (M+). 
IR (ATR) υ (cm-1) = 3487, 3392, 3117, 3075, 3034, 2951, 2918, 2884, 1737, 1694, 1621, 
1485, 1442, 1333, 1261, 1216, 1160, 1117, 1073, 981, 873, 795, 774, 751, 692. 
 
Preparation of 2-(methylthio)-3-(thiophen-3-yl)pyrazine (28d)  
N
N
S
MeS
 
The magnesium diorganoboronate 20o was prepared according to TP1 from 3-bromo-
thiophene (27b, 406 mg, 2 mmol) in 30 min at 0 °C. A cross-coupling reaction was 
performed according to TP3 with 2-bromo-3-(methylthio)pyrazine (22p, 328 mg, 
1.6 mmol) in 12 h. Flash column chromatographical purification (pentane/Et2O = 9:1) 
furnished 28d as a brown oil (262 mg, 79%). 
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1H NMR (300 MHz, CDCl3) δ (ppm) = 8.31 (d, J=2.4Hz, 1H), 8.26 (d, J=2.6Hz, 1H), 
8.03 (dd, J=2.8Hz, 1.3Hz, 1H) 7.68 (dd, J=5.0Hz, 1.3Hz, 1H), 7.41 (dd, J=5.0Hz, 2.8Hz, 
1H), 2.57 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 155.0, 147.9, 141.2, 138.3, 138.0, 128.4, 126.8, 
125.4, 13.6. 
MS (70 eV, EI), m/z (%) = 209 (11), 208 (M+, 100), 207 (17), 193 (32), 175 (72), 
134(10), 110 (16). 
HRMS (EI), m/z calc. for C9H8N2S2 (208.0129): 208.0128 (M+). 
IR (ATR) υ (cm-1) = 3486, 3392, 3142, 3059, 2940, 2895, 1621, 1485, 1333, 1260, 1162, 
1124, 1096, 1072, 1041, 880, 794, 736, 692. 
 
Preparation of 4-(benzothiophen-3-yl)-N-(tert-butyl)benzamide (28e)  
S
O
NHtBu
 
The magnesium diorganoboronate 20p was prepared according to TP1 from 3-bromo-
benzothiophene (27c, 426 mg, 2 mmol) in 1 h at 0 °C. A cross-coupling reaction was 
performed according to TP3 with 4-bromo-N-(tert-butyl)benzamide (22b, 410 mg, 
1.6 mmol) in 12 h. Flash column chromatographical purification (pentane/Et2O = 7:3) 
furnished 28e as a white solid (380 mg, 77%). 
 
m.p.: 114.9-116.7 °C.  
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.91-7.96 (m, 1H), 7.82-7.91 (m, 3H), 7.64 (d, 
J=8.0Hz, 2H), 7.45 (s, 1H), 7.38-7.41 (m, 2H), 6.07 (br s, 1H), 1.52 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 166.5, 140.7, 138.7, 137.5, 137.0, 134.8, 128.6, 
127.2, 124.5, 124.5, 124.2, 122.9, 122.6, 51.7, 28.9. 
MS (70 eV, EI), m/z (%) = 309 (M+, 38), 253 (60), 238 (15), 237 (100), 209 (17),  
208 (30), 165 (19), 104 (10). 
HRMS (EI), m/z calc. for C19H19NOS (309.1187): 309.1192 (M+). 
IR (ATR) υ (cm-1) = 3485, 3392, 3209, 3074, 3037, 1621, 1485, 1333, 1260, 1161, 1116, 
1096, 1073, 1045, 879, 796, 692. 
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Preparation of ethyl 4-(3-methylisoxazol-4-yl)benzoate (28f)  
N
O
CO2EtMe
 
The magnesium organoboronate 19g was prepared according to TP2 from 4-bromo-3,5-
dimethylisoxazole (27d, 352 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling reaction was 
performed according to TP3 with ethyl 4-bromobenzoate (22k, 367 mg, 1.6 mmol) in 12 
h. Flash column chromatographical purification (pentane/Et2O = 7.5:2.5) furnished 28f as 
a pale brown solid (232 mg, 60%). 
 
m.p.: 71.1-72.2 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.12 (dt, J=8.6Hz, 1.7Hz, 2H), 7.34 (dt, J=8.6Hz, 
1.7Hz, 2H), 4.41 (q, J=7.1Hz, 2H), 2.43 (s, 3H), 2.29 (s, 3H), 1.41 (t, J=7.2Hz, 3H).   
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.1, 165.7, 158.3, 135.1, 130.0, 129.5, 128.8, 
116.0, 61.1, 14.3, 11.6, 10.8. 
MS (70 eV, EI), m/z (%) = 246 (10), 245 (M+, 75), 217 (15), 202 (10), 201 (13),  
200 (100), 172 (12), 131 (39), 103 (13), 77 (10). 
HRMS (EI), m/z calc. for C14H15NO3 (245.1052): 245.1046 (M+). 
IR (ATR) υ (cm-1) = 3486, 3392, 3062, 3035, 2986, 2942, 1710, 1621, 1515, 1485, 1443, 
1333, 1259, 1161, 1116, 1096, 1073, 1041, 878, 796, 692. 
 
Preparation of dimethyl 3-(thiophen-2-yl)pyridine-2,5-dicarboxylate (28g)  
N
CO2Me
MeO2C
S
 
The magnesium diorganoboronate 20q was prepared according to TP1 from 2-chloro-
thiophene (27e, 237 mg, 2 mmol) in 30 min at 25 °C. A cross-coupling reaction was 
performed according to TP3 with dimethyl 3-chloropyridine-2,5-dicarboxylate (23c,  
367 mg, 1.6 mmol) in 6 h. Flash column chromatographical purification  
(pentane/EtOAc = 9:1) furnished 28g as a pale yellow solid (381 mg, 86%). 
 
m.p.: 110.9-111.7 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 9.17 (d, J=1.9Hz, 1H), 8.46 (d, J= 1.9Hz, 1H), 
7.48 (dd, J=5.1Hz, 1.2Hz, 1H), 7.21 (dd, J=3.6Hz, 1.2Hz, 1H), 7.13 (dd, J=5.0Hz, 3.6Hz, 
1H), 4.01 (s, 3H), 3.90 (s, 3H). 
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13C NMR (75 MHz, CDCl3) δ (ppm) = 166.7, 164.7, 152.0, 148.8, 139.3, 137.3, 129.3, 
128.0, 127.8, 127.7, 127.1, 53.0, 52.8. 
MS (70 eV, EI), m/z (%) = 277 (M+, 57), 246 (11), 219 (56), 218 (25), 171 (21),  
161 (65), 70 (15), 61 (21), 45 (15), 43 (100). 
HRMS (EI), m/z calc. for C13H11NO4S (277.0409): 277.0405 (M+). 
IR (ATR) υ (cm-1) = 3074, 2956, 1736, 1724, 1594, 1556, 1450, 1424, 1300, 1256, 1198, 
1130, 1106, 1012, 766, 734. 
 
Preparation of ethyl 5-(pyridin-3-yl)furan-2-carboxylate (28h)  
N
O
CO2Et
 
The magnesium diorganoboronate 20r was prepared according to TP1 from 3-bromo-
pyridine (27f, 316 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling reaction was performed 
according to TP5 with ethyl 5-bromofuran-2-carboxylate (22q, 307 mg, 1.4 mmol) in  
24 h. Flash column chromatographical purification (pentane/EtOAc = 7:3 with 0.5% 
NEt3) furnished 28h as a white solid (248 mg, 82%). 
 
m.p.: 44.5-45.7 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.95 (d, J=1.5Hz, 1H), 8.51 (dd, J=4.8Hz, 1.6Hz, 
1H), 7.99-8.02 (m, 1H), 7.29 (dd, J=8.0Hz, 4.8Hz, 1H), 7.19 (d, J=3.6Hz, 1H), 6.77 (d, 
J=3.6Hz, 1H), 4.33 (q, J=7.1Hz, 2H), 1.34 (t, J=7.1Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 158.6, 154.4, 149.6, 146.3, 144.9, 131.9, 125.8, 
123.7, 119.6, 108.1, 61.2, 14.4. 
MS (70 eV, EI), m/z (%) = 218 (11), 217 (M+, 100), 189 (72), 172 (54), 145 (35),  
116 (43), 89 (14), 44 (10). 
HRMS (EI), m/z calc. for C12H11NO3 (217.0739): 217.0728 (M+). 
IR (ATR) υ (cm-1) = 3120, 3085, 3049, 2982, 2928, 2904, 1716, 1566, 1524, 1516, 1470, 
1415, 1371, 1334, 1301, 1279, 1226, 1149, 1113, 1017, 964, 920, 867, 821, 806, 758, 
712, 675. 
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Preparation of 2-methoxy-5-(4-nitrophenyl)pyridine (28i)  
NMeO
NO2
 
The magnesium diorganoboronate 9h was prepared according to TP1 from 5-bromo-2-
methoxypyridine (27g, 376 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling reaction was 
performed according to TP3 with 1-bromo-4-nitrobenzene (22r, 323 mg, 1.6 mmol) in  
12 h. Flash column chromatographical purification (pentane/EtOAc = 8.5:1.5) furnished 
28i as a pale yellow solid (311 mg, 85%). 
 
m.p.: 162.9-164.4 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.42 (d, J=2.6Hz, 1H), 8.26-8.30 (m, 2H), 7.81 
(dd, J=8.6Hz, 2.6Hz, 1H), 7.64-7.68 (m, 2H), 6.85 (dd, J=8.6Hz, 0.6Hz, 1H), 3.98 (s, 
3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 164.8, 147.2, 145.8, 144.6, 137.5, 127.9, 127.3, 
124.6, 111.5, 53.9. 
MS (70 eV, EI), m/z (%) = 231 (16), 230 (M+, 100), 201 (56), 183 (29), 154 (52),  
141 (34), 127 (31), 114 (24), 42 (17). 
HRMS (EI), m/z calc. for C12H10N203 (230.0691): 230.0669 (M+). 
IR (ATR) υ (cm-1) = 3075, 2949, 2440, 1596, 1564, 1505, 1477, 1442, 1415, 1395, 1375, 
1341, 1309, 1297, 1257, 1179, 1139, 1106, 1042, 1019, 999, 923, 855, 834, 733. 695. 
 
Preparation of ethyl 5-(6-chloropyridin-3-yl)thiophene-2-carboxylate (28j)  
N
S
CO2Et
Cl
 
The magnesium diorganoboronate 20t was prepared according to TP1 from 5-bromo-2-
chloropyridine (27h, 385 mg, 2 mmol) in 1 h at 25 °C. A cross-coupling reaction was 
performed according to TP4 with 5-bromothiophene-2-carboxylate (22s, 329 mg, 
1.4 mmol) in 12 h. Flash column chromatographical purification (pentane/EtOAc = 9:1) 
furnished 28j as a white solid (270 mg, 72%). 
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m.p.: 81.8-83.3 °C.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.64 (dd, J=2.6Hz, 0.7Hz, 1H), 7.83 (dd, 
J=8.3Hz, 2.6Hz, 1H), 7.75-7.77 (m, 1H), 7.30 (d, J=3.9Hz, 1H), 4.36 (q, J=7.1Hz, 1H), 
1.38 (t, J=7.1Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 162.0, 151.5, 145.4, 136.1, 134.6, 134.4, 128.8, 
125.2, 124.7, 61.7, 14.5. 
MS (70 eV, EI), m/z (%) = 268 (10), 267 (M+, 64), 240 (20), 221 (100), 152 (17),  
102 (6), 61 (10). 
HRMS (EI), m/z calc. for C12H10ClNO2S (267.0121): 267.0119 (M+). 
IR (ATR) υ (cm-1) = 3394, 2993, 2340, 1710, 1532, 1443, 1363, 1288, 1275, 1098, 1008, 
834, 814, 745. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
C. EXPERIMENTAL SECTION 
218 
4. PREPARATION OF α-SUBSTITUTED β,γ-UNSATURATED KETONES 
AND ESTERS VIA THE DIRECT ADDITION OF SUBSTITUTED ALLYLIC 
ZINC REAGENTS 
4.1 PREPARATION OF STARTING MATERIALS 
All reagents were obtained from commercial sources. Compounds 29f176a, 29g178b as well 
as 29h274 and 29i274 were prepared according to literature known procedures. 
 
4.2 TYPICAL PROCEDURES 
Typical procedure 1 (TP1): Preparation of allylic zinc reagents RZnX·LiCl via 
direct zinc insertion in the presence of lithium chloride 
A dry, argon-flushed Schlenk flask equipped with a magnetic stirring bar and a septum 
was charged with Zn powder (1.31 g, 20 mmol) and LiCl (466 mg, 11 mmol). LiCl was 
dried in vacuo using a heatgun (450 °C, 5 min). After addition of THF (10 mL), the  
Zn powder was activated with 1,2-dibromoethane (2 mol%) and Me3SiCl (5 mol%). 
Then a solution of the allyl halide (10 mmol) in THF (10 mL) was added at 25 °C and 
stirred for 1 h until GC-analysis of hydrolyzed reaction aliquot showed full consumption 
of the starting material. Then, the remaining Zn powder was allowed to settle down or 
centrifuged (10 min, 2000 rpm). The yield of the insertion reaction was determined by 
iodometric titration.192  
 
Typical procedure 2 (TP2): Preparation of α-substituted β,γ-unsaturated ketones 
and esters via direct addition of allylic zinc reagents to acid chlorides and 
chloroformates 
A dry, argon-flushed Schlenk flask equipped with a magnetic stirring bar and a septum 
was charged with a solution of the corresponding acid chloride or chloroformate  
(0.8 equiv) in THF (1.0 M) and cooled down to the indicated temperature. Subsequently, 
the freshly prepared allylic zinc reagent in THF (1 equiv) was added dropwise and the 
reaction mixture was stirred at the indicated temperature for the given time. The reaction 
mixture was quenched at room temperature with sat. NH4Cl solution (10 mL) and 
extracted with EtOAc (3x20 mL). The combined organic phases were dried over Na2SO4 
and concentrated in vacuo. The crude residue obtained was purified by flash column 
chromatography to give the analytically pure product. 
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4.3 PREPARATION OF SUBSTITUTED ALLYLIC ZINC REAGENTS 
Preparation of but-2-en-1-ylzinc bromide (30a) 
ZnBr⋅LiClMe
 
According to TP1, the allyic zinc reagent 30a was prepared from 1-bromobut-2-ene 
(29a, 1.35 g, 10.0 mmol) using Zn powder (1.31 g, 20 mmol) and LiCl (466 mg,  
11 mmol) at 25 °C in 1 h. Titration with iodine indicates a concentration of 0.42 M 
(83%). 
 
Preparation of cinnamylzinc chloride (30b) 
ZnCl⋅LiClPh
 
According to TP1, the allyic zinc reagent 30b was prepared from cinnamyl chloride 
(29b, 1.53 g, 10.0 mmol) using Zn powder (1.31 g, 20 mmol) and LiCl (466 mg,  
11 mmol) at 25 °C in 1 h. Titration with iodine indicates a concentration of 0.43 M 
(86%). 
 
Preparation of (3-methylbut-2-en-1-yl)zinc bromide (30c) 
ZnBr⋅LiClMe
Me
 
According to TP1, the allyic zinc reagent 30c was prepared from 1-bromo-3-methylbut-
2-ene (29c, 1.49 g, 10.0 mmol) using Zn powder (1.31 g, 20 mmol) and LiCl (466 mg,  
11 mmol) at 25 °C in 1 h. Titration with iodine indicates a concentration of  
0.46 M (92%). 
 
Preparation of (2-(trimethylsilyl)but-2-en-1-yl)zinc chloride (30d) 
ZnCl⋅LiCl
Me
TMS
 
According to TP1, the allyic zinc reagent 30d was prepared according a literature-known 
procedure2 from (1-chlorobut-2-en-2-yl)trimethylsilane (29d, 1.63 g, 10.0 mmol) using  
Zn powder (6.54 g, 100 mmol) and LiCl (1.27 g, 30 mmol) at 25 °C in 18 h. Titration 
with iodine indicates a concentration of 0.41 M (81%). 
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Preparation of (3,7-dimethylocta-2,6-dien-1-yl)zinc bromide (30e) 
Me
ZnBr⋅LiCl
MeMe
 
According to TP1, the allyic zinc reagent 30e was prepared from 1-bromo-3,7-
dimethylocta-2,6-diene (29e, 2.17 g, 10.0 mmol) using Zn powder (1.31 g, 20 mmol) and 
LiCl (466 mg, 11 mmol) at 25 °C in 1 h. Titration with iodine indicates a concentration 
of 0.42 M (83%). 
 
Preparation of cyclohex-2-en-1-ylzinc bromide (30f) 
ZnBr⋅LiCl
 
According to TP1, the allyic zinc reagent 30f was prepared from 3-bromocyclohex-1-ene 
(29f, 1.61 g, 10.0 mmol) using Zn powder (1.31 g, 20 mmol) and LiCl (466 mg, 11 
mmol) at 25 °C in 1 h. Titration with iodine indicates a concentration of 0.45 M (89%). 
 
Preparation of 2-methyl-6,6-dimethyl-bicyclo[3.1.1]hept-2-enylzinc chloride (30g) 
 
Zinc powder (1.60 g, 25.0 mmol) and dry LiCl (500 mg, 12.0 mmol) were covered with 
dry THF (10 mL) and activated by the addition of 1,2-dibromoethane (2 mol%) and 
Me3SiCl (5 mol%). Subsequently, a solution of 2-chloromethyl-6,6-dimethyl-
bicyclo[3.1.1]hept-2-ene (29g, 1.71 g, 10.0 mmol) in THF (10 mL) was added in with a 
syringe pump at 25 °C within 2 h. The resulting mixture was stirred under nitrogen at  
25 °C for 30 h. The remaining zinc powder was allowed to settle down. Titration with 
iodine indicates a concentration of 0.37 M (73%). 
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Preparation of 2-enecarboxylic acid ethyl ester-6-cyclohexenylzinc chloride (30h) 
ZnCl⋅LiCl
CO2Et
 
According to TP1, the allyic zinc reagent 30h was prepared from 6-chloro cyclohex-1-
enecarboxylic acid ethyl ester (29h, 1.89 g, 10.0 mmol) using Zn powder (1.31 g,  
20 mmol) and LiCl (466 mg, 11 mmol) at 25 °C in 1 h. Titration with iodine indicates a 
concentration of 0.45 M (90%). 
 
Preparation of 2-cyano-5-cyclopentenylzinc chloride (30i) 
ZnCl⋅LiCl
CN
 
According to TP1, the allyic zinc reagent 30i was prepared from 5-chloro-cyclopent-1-
enecarbonitrile (29i, 1.28 g, 10.0 mmol) using Zn powder (1.31 g, 20 mmol) and LiCl 
(466 mg, 11 mmol) at 25 °C in 1 h. Titration with iodine indicates a concentration of  
0.35 M (69%). 
 
4.4 PREPARATION OF α-SUBSTITUTED β,γ-UNSATURATED KETONES  
Preparation of 1-(4-(tert-butyl)phenyl)-2-methylbut-3-en-1-one (32a) 
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32a was prepared from 30a 
(4.75 mL, 2.00 mmol, 0.42 M in THF) and 4-(tert-butyl)benzoyl chloride (31a, 315 mg, 
1.6 mmol) at -78 °C in 1 h. Flash column chromatography (silica, pentane:Et2O 50:1) 
furnished 4a as a colorless oil (294 mg, 85 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.96 (d, J=8.6Hz, 2H), 7.50 (d, J=8.9Hz, 2H), 
5.95-6.11 (m, 1H), 5.08-5.27 (m, 2H), 4.10-4.25 (m, 1H), 1.28-1.48 (m, 12H).  
13C-NMR (75 MHz, CDCl3) δ (ppm) = 200.8, 156.7, 138.4, 133.7, 128.5, 125.5, 116.3, 
45.4, 35.1, 31.1, 17.1. 
MS (70 eV, EI), m/z (%) = 216 (M+, 1), 162 (27), 161 (100), 160 (6), 146 (23), 118 (24), 
115 (8), 91 (14). 
HRMS (EI), m/z calc. for C15H20O (216.1514): 216.1501 (M+). 
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IR (ATR) υ (cm-1) = 3080, 3055, 3039, 2964, 2933, 2905, 2870, 1678, 1634, 1604, 1455, 
1408, 1364, 1268, 1220, 1191, 1109, 993, 974, 963, 916, 847, 790, 719. 
 
Preparation of 2-methyl-1-(thiophen-2-yl)but-3-en-1-one (32b) 
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32b was prepared from 30a 
(4.75 mL, 2.00 mmol, 0.42 M in THF) and thiophene-2-carbonyl chloride (31b, 235 mg, 
1.6 mmol) at -78 °C in 1 h. Flash column chromatography (silica, pentane:Et2O 30:1) 
furnished 32b as a colorless oil (226 mg, 85 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.79 (dd, J=3.9Hz, 1.1Hz, 1H), 7.66 (dd, 
J=5.0Hz, 1.1Hz, 1H), 7.15 (dd, J=5.0Hz, 3.9Hz, 1 H), 6.01 (ddd, J=17.5Hz, 10.0Hz, 
7.9Hz, 1H), 5.11-5.30 (m, 2H), 3.93-4.07 (m, 1H), 1.37 (d, J=6.9Hz, 3H).   
13C-NMR (75 MHz, CDCl3) δ (ppm) = 194.0, 143.6, 138.0, 133.8, 132.1, 128.1, 116.6, 
47.4, 17.2.  
MS (70 eV, EI), m/z (%) = 166 (M+, 21), 112 (39), 111 (100), 83 (37), 55 (13), 45 (7). 
HRMS (EI), m/z calc. C9H10OS (166.0452): 166.0447 (M+). 
IR (ATR) υ (cm-1) = 3081, 2976, 2932, 2873, 1655, 1632, 1517, 1412, 1354, 1234, 1212, 
1056, 991, 918, 862, 830, 772, 719.  
 
Preparation of 2-methyl-1-(3,4,5-trimethoxyphenyl)but-3-en-1-one (32c) 
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32c was prepared from 30a 
(4.75 mL, 2.00 mmol, 0.42 M in THF) and 3,4,5-trimethoxybenzoyl chloride (31c,  
369 mg, 1.6 mmol) at -78 °C in 1 h. Flash column chromatography (silica, pentane:Et2O 
7:3) furnished 32c as a white solid (260 mg, 65 %). 
 
m.p.: 60.4-61.3 °C. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.27 (s, 2H), 5.92-6.09 (m, 1H), 5.15-5.23 (m, 
2H), 4.07-4.21 (m, 1H), 3.78-4.03 (m, 9H), 1.35 (d, J=6.9Hz, 3 H). 
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13C-NMR (75 MHz, CDCl3) δ (ppm) = 199.9, 153.0, 142.6, 138.4, 131.5, 116.4, 106.2, 
60.9, 56.3, 45.5, 17.2. 
MS (70 eV, EI), m/z (%) = 250 (M+, 55), 235 (13), 219 (28), 196 (62), 195 (100),  
167 (19), 139 (16), 124 (15), 122 (27), 92 (12), 77 (26), 66 (17), 55 (20), 53 (16). 
HRMS (EI), m/z calc. for C14H18O4 (250.1205): 250.1198 (M+). 
IR (ATR) υ (cm-1) = 3080, 3009, 2971, 2953, 2933, 2873, 2839, 1670, 1580, 1507, 1464, 
1453, 1411, 1339, 1310, 1230, 1166, 1154, 1149, 1125, 990, 918, 867, 781, 771, 742.  
 
Preparation of 1-(4-(tert-butyl)phenyl)-2-phenylbut-3-en-1-one (32d) 
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32d was prepared from 30b 
(4.65 mL, 2.00 mmol, 0.43 M in THF) and 4-(tert-butyl)benzoyl chloride (31a, 315 mg, 
1.6 mmol) at -78 °C in 1 h. Flash column chromatography (silica, pentane:Et2O 30:1) 
furnished 32d as a yellow oil (401 mg, 90 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.96 (d, J=8.9Hz, 2H), 7.45 (d, J=8.9Hz, 2H), 
7.24-7.40 (m, 5 H), 6.32-6.47 (m, 1H), 5.20-5.34 (m, 2H), 5.07-5.17 (m, 1H),  
1.32 (s, 9H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 198.1, 156.8, 138.6, 137.4, 133.8, 129.0, 128.9, 
128.4, 127.1, 125.5, 117.0, 57.9, 35.1, 31.0. 
MS (70 eV, EI), m/z (%) = 278 (M+, 6), 222 (21), 221 (24), 162 (11), 161 (100),  
146 (10), 118 (17), 117 (15), 115 (15), 91 (17). 
HRMS (EI), m/z calc. for C20H22O (278.1671): 278.1669 (M+). 
IR (ATR) υ (cm-1) = 3060, 3028, 2962, 2904, 2867, 1720, 1676, 1602, 1452, 1408, 1363, 
1268, 1223, 1187, 1108, 844, 760, 698.  
 
Preparation of 2-phenyl-1-(thiophen-2-yl)but-3-en-1-one (32e) 
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32e was prepared from 30b 
(4.65 mL, 2.00 mmol, 0.43 M in THF) and thiophene-2-carbonyl chloride (31b, 235 mg, 
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1.6 mmol) at -78 °C in 1 h. Flash column chromatography (silica, pentane:Et2O 30:1) 
furnished 32e as a yellow oil (281 mg, 77 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.75 (dd, J=3.9Hz, 1.1Hz, 1H), 7.62 (dd, 
J=5.0Hz, 1.1Hz, 1H), 7.17-7.49 (m, 5H), 7.10 (dd, J=5.0Hz, 3.9Hz, 1H), 6.39 (ddd, 
J=17.0Hz, 10.1Hz, 8.0Hz, 1H), 5.02-5.43 (m, 3H).  
13C-NMR (75 MHz, CDCl3) δ (ppm) = 191.3, 143.5, 138.4, 136.6, 134.0, 132.7, 129.0, 
128.3, 128.1, 127.4, 117.5, 59.4. 
MS (70 eV, EI), m/z (%) = 228 (M+, 37), 195 (14), 117 (21), 115 (32), 111 (100),  
91 (14), 44 (16). 
HRMS (EI), m/z calc. for C14H12OS (228.0609): 228.0601 (M+). 
IR (ATR) υ (cm-1) = 3104, 3087, 3060, 3025, 2977, 1643, 1634, 1515, 1454, 1410, 1357, 
1316, 1249, 1204, 1069, 991, 921, 801, 752, 720, 696, 669, 652.  
 
Preparation of 1-(furan-2-yl)-2-phenylbut-3-en-1-one (32f) 
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32f was prepared from 30b 
(4.65 mL, 2.00 mmol, 0.43 M in THF) and furan-2-carbonyl chloride (31d, 209 mg,  
1.6 mmol) at -78 °C in 1 h. Flash column chromatography (silica, pentane:Et2O 30:1) 
furnished 32f as an off-white solid (285 mg, 84 %). 
 
m.p.: 42.0-43.1 °C. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.57 (dd, J=1.7Hz, 0.8Hz, 1H), 7.14-7.46 (m, 
6H), 6.50 (dd, J=3.6Hz, 1.7Hz, 1H), 6.38 (ddd, J=17.1Hz, 10.1Hz, 8.0Hz, 1H), 5.08-
5.31 (m, 3 H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 187.3, 152.0, 146.6, 138.1, 136.2, 128.8, 128.4, 
127.3, 118.2, 117.7, 112.4, 58.0. 
MS (70 eV, EI), m/z (%) = 212 (M+, 24), 170 (17), 118 (12), 117 (100), 116 (16),  
115 (60), 91 (29). 
HRMS (EI), m/z calc. for C14H12O2 (212.0837): 212.0836 (M+). 
IR (ATR) υ (cm-1) = 3144, 3119, 3096, 3083, 3060, 3029, 3021, 1665, 1650, 1463, 1453, 
1390, 1327, 1256, 1165, 1041, 1001, 993, 943, 928, 917, 905, 824, 770, 762, 751, 728, 
695, 668.  
C. EXPERIMENTAL SECTION 
225 
Preparation of 7-chloro-3-phenylhept-1-en-4-one (32g) 
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32g was prepared from 30b 
(4.65 mL, 2.00 mmol, 0.43 M in THF) and 4-chlorobutanoyl chloride (31e, 226 mg,  
1.6 mmol) at -20 °C → 25 °C in 2 h. Flash column chromatography (silica,  
pentane:Et2O 9.5:0.5) furnished 32g as a yellow oil (257 mg, 72 %). 
 
1H-NMR (600 MHz, CDCl3) δ (ppm) = 7.18-7.36 (m, 5H), 6.13-6.35 (m, 1H), 5.03-5.26 
(m, 2H), 4.39 (d, J=8.2Hz, 1H), 3.24-3.69 (m, 2H), 2.51-2.75 (m, 2H), 1.59- 
2.26 (m, 2H). 
13C-NMR (150 MHz, CDCl3) δ (ppm) = 207.7, 137.7, 135.6, 129.0, 128.2, 127.5, 117.8, 
63.2, 44.2, 38.1, 26.4. 
MS (70 eV, EI), m/z (%) = 222 (M+, 5), 186 (10), 129 (5), 116 (18), 115 (63), 107 (28),  
105 (100), 91 (22), 77 (16), 41 (28). 
HRMS (EI), m/z calc. for C13H15ClO (222.0811): 222.0804 (M+). 
IR (ATR) υ (cm-1) = 3080, 3056, 3025, 2961, 2925, 1711, 1687, 1671, 1620, 1598, 1494, 
1441, 1311, 1296, 1241, 1216, 1124, 1072, 1030, 974, 942, 917, 762, 700.  
 
Preparation of 1-(4-(tert-butyl)phenyl)-2,2-dimethylbut-3-en-1-one (32h) 
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32h was prepared from 30c 
(4.35 mL, 2.00 mmol, 0.46 M in THF) and 4-(tert-butyl)benzoyl chloride (31a, 315 mg, 
1.6 mmol) at -78 °C in 1 h. Flash column chromatography (silica, pentane:Et2O 30:1) 
furnished 32h as a colorless oil (343 mg, 93 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.89 (d, J=8.3Hz, 2H), 7.41 (d, J=8.6Hz, 2H), 
6.16-6.29 (m, 1H), 5.17-5.31 (m, 2H), 1.42 (s, 6H), 1.34 (s, 9H).  
13C-NMR (75 MHz, CDCl3) δ (ppm) = 203.8, 155.3, 144.2, 134.0, 129.5, 124.9, 113.8, 
50.0, 34.9, 31.1, 26.2. 
MS (70 eV, EI), m/z (%) = 230 (M+, 5), 162 (100), 161 (52), 146 (61), 145 (11),  
118 (60), 117 (23), 115 (21), 105 (14), 91 (33), 77 (15), 41 (30). 
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HRMS (EI), m/z calc. for C16H12O (230.1671): 230.1663 (M+). 
IR (ATR) υ (cm-1) = 3084, 2964, 2905, 2868, 1674, 1632, 1604, 1463, 1411, 1363, 1260, 
1173, 1109, 973, 917, 846, 773, 668.  
 
Preparation of 1-(4-(tert-butyl)phenyl)-2-methyl-3-(trimethyl-silyl)but-3-en-1-one 
(32i) 
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32i was prepared from 30d 
(4.90 mL, 2.00 mmol, 0.41 M in THF) and 4-(tert-butyl)benzoyl chloride (31a, 315 mg, 
1.6 mmol) at 25 °C over night. Flash column chromatography (silica,  
pentane:Et2O 9.5:0.5) furnished 32i as a colorless oil (415 mg, 98 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.87 (d, J=8.6Hz, 2H), 7.45 (d, J=8.6Hz, 2H), 
5.57-5.74 (m, 1H), 5.50 (d, J=1.9Hz, 1H), 4.16-4.32 (m, 1H), 1.35 (s, 9H), 1.31 (d, 
J=6.6Hz, 3H), 0.18 (s, 9H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 201.0, 156.2, 151.9, 134.2, 128.5, 126.9, 125.3, 
46.5, 35.0, 31.1, 18.1, -0.7. 
MS (70 eV, EI), m/z (%) = 288 (M+, 1), 274 (25), 162 (100), 161 (69), 146 (31),  
118 (26), 115 (12), 91 (17), 73 (57), 57 (20). 
HRMS (EI), m/z calc. for C18H28OSi (288.1909): 288.1906 (M+). 
IR (ATR) υ (cm-1) = 3081, 3074, 2965, 2940, 2871, 1667, 1517, 1419, 1369, 1358, 1254, 
1232, 1059, 939, 856, 837, 729, 671.  
 
Preparation of 2-methyl-1-(thiophen-2-yl)-3-(trimethylsilyl)-but-3-en-1-one (32j) 
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32j was prepared from 30d 
(4.90 mL, 2.00 mmol, 0.41 M in THF) and thiophene-2-carbonyl chloride (31b, 235 mg, 
1.6 mmol) at -78 °C in 1 h. Flash column chromatography (silica, pentane:Et2O 25:1) 
furnished 32j as a colorless oil (378 mg, 99 %). 
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1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.65-7.73 (m, 1H), 7.55-7.63 (m, 1H), 7.03-7.17 
(m, 1H), 5.70-5.79 (m, 1H), 5.53 (d, J=1.7Hz, 1H), 4.03-4.19 (m, 1H), 1.33 (d, J=6.4Hz,  
3H), 0.16 (s, 9H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 194.2, 151.6, 144.2, 133.1, 131.8, 127.9, 127.1, 
48.5, 18.1, -0.7. 
MS (70 eV, EI), m/z (%) = 238 (M+, 5), 224 (18), 223 (80), 149 (9), 111 (100), 75 (17), 
73 (40), 45 (9). 
HRMS (EI), m/z calc. for C12H18OSSi (238.0848): 238.0853 (M+). 
IR (ATR) υ (cm-1) = 3104, 3084, 3054, 2954, 2933, 2896, 2874, 1656, 1512, 1452, 1414, 
1369, 1354, 1247, 1233, 1222, 1053, 931, 872, 832, 756, 716, 690.  
 
Preparation of 1-(4-(tert-butyl)phenyl)-6-methyl-2-vinylhept-5-en-1-one (32k) 
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32k was prepared from 30e 
(4.75 mL, 2.00 mmol, 0.42 M in THF) and 4-(tert-butyl)benzoyl chloride (31a, 315 mg, 
1.6 mmol) at -78 °C in 1 h. Flash column chromatography (silica, pentane:Et2O 50:1) 
furnished 32k as a colorless oil (319 mg,70 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.86 (d, J=8.9Hz, 2H), 7.41 (d, J=8.9Hz, 2H), 
6.13-6.28 (m, 1H), 5.16-5.31 (m, 2H), 5.00-5.10 (m, 1H), 1.91-2.04 (m, 2H), 1.74-1.85 
(m, 2H), 1.65 (s, 3H), 1.26-1.53 (m, 15H).  
13C-NMR (75 MHz, CDCl3) δ (ppm) = 203.9, 155.1, 143.5, 134.7, 131.9, 129.2, 124.8, 
124.1, 114.5, 53.5, 39.1, 34.9, 31.1, 25.6, 23.1, 23.0, 17.4. 
MS (70 eV, EI), m/z (%) = 298 (M+, 17), 230 (44), 217 (16), 216 (100), 147 (11),  
146 (88), 145 (18), 122 (16), 117 (34), 115 (19), 103 (12), 91 (44), 90 (11), 77 (16),  
41 (31). 
HRMS (EI), m/z calc. for C21H30O (298.2297): 298.2283 (M+). 
IR (ATR) υ (cm-1) = 3081, 3043, 2964, 2906, 2868, 1715, 1674, 1605, 1461, 1364, 1268, 
1188, 1110, 1070, 1016, 972, 914, 843, 835, 775, 707.  
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Preparation of 1-(furan-2-yl)-6-methyl-2-vinylhept-5-en-1-one (32l) 
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32l was prepared from 30e 
(4.75 mL, 2.00 mmol, 0.42 M in THF) and furan-2-carbonyl chloride (31d, 209 mg,  
1.6 mmol) at -78 °C in 1 h. Flash column chromatography (silica, pentane:Et2O 50:1) 
furnished 32l as a yellow oil (276 mg, 79 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.55 (dd, J=1.7Hz, 0.8Hz, 1H), 7.23 (dd, 
J=3.6Hz, 0.8Hz, 1H), 6.49 (dd, J=3.6Hz, 1.7Hz, 1H), 6.23 (dd, J=17.4Hz, 10.8Hz, 1H), 
5.13-5.26 (m, 2H), 5.00-5.13 (m, 1H), 1.78-2.08 (m, 4H), 1.65 (s, 3H), 1.52 (s, 3H),  
1.41 (s, 3H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 191.5, 152.1, 145.3, 142.1, 132.0, 124.0, 118.6, 
114.7, 111.6, 52.7, 38.2, 25.6, 23.0, 21.2, 17.5. 
MS (70 eV, EI), m/z (%) = 232 (M+, 1), 150 (100), 122 (22), 121 (37), 81 (14), 73 (11), 
70 (20), 69 (57), 67 (12), 61 (34), 55 (10), 43 (10), 42 (13), 41 (45). 
HRMS (EI), m/z calc. for C15H20O2 (232.1483): 232.1472 (M+). 
IR (ATR) υ (cm-1) = 3130, 3084, 2971, 2935, 2875, 1720, 1663, 1560, 1461, 1384, 1278, 
1225, 1161, 1078, 1068, 1012, 979, 910, 884, 824, 762.  
 
Preparation of 1-chloro-9-methyl-5-vinyldec-8-en-4-one (32m) 
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32m was prepared from 30e 
(4.75 mL, 2.00 mmol, 0.42 M in THF) and 4-chlorobutanoyl chloride (31e, 226 mg,  
1.6 mmol) at -78 °C in 1 h. Flash column chromatography (silica, pentane:Et2O 50:1) 
furnished 32m as a colorless oil (271 mg, 74 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 5.94 (dd, J=17.6Hz, 10.6Hz, 1H), 4.97-5.36 (m, 
3H), 3.57 (t, J=6.2Hz, 2H), 2.66 (dt, J=7.0Hz, 3.5Hz, 2H), 1.40-2.33 (m, 12H), 1.14-
1.36 (m, 3H). 
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13C-NMR (75 MHz, CDCl3) δ (ppm) = 211.7, 141.4, 132.0, 123.9, 115.2, 54.2, 44.6, 
37.6, 34.6, 26.7, 25.7, 23.0, 19.6, 17.6. 
MS (70 eV, EI), m/z (%) = 242 (M+, 1), 162 (13), 160 (41), 107 (18), 105 (57), 88 (29), 
83 (34), 81 (24), 77 (14), 73 (35), 70 (70), 69 (96), 67 (17), 61 (100), 45 (94), 43 (67),  
42 (41), 41 (68). 
HRMS (EI), m/z calc. for C14H23ClO (242.1437): 242.1432 (M+). 
IR (ATR) υ (cm-1) = 3085, 3050, 2967, 2925, 2856, 1705, 1632, 1447, 1410, 1374, 1358, 
1296, 1101, 1076, 1002, 919, 731.  
 
Preparation of 1-(cyclohex-2-en-1-yl)-2-phenoxyethanone (32n) 
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32n was prepared from 30f 
(4.45 mL, 2.00 mmol, 0.45 M in THF) and 2-phenoxyacetyl chloride (31f, 273 mg,  
1.6 mmol) at -78 °C in 1 h. Flash column chromatography (silica, pentane:Et2O 9.5:0.5) 
furnished 32n as a yellow oil (260 mg, 75 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.24-7.41 (m, 2H), 6.82-7.07 (m, 3H), 5.89-6.01 
(m, 1H), 5.81 (ddd, J=10.2Hz, 5.3Hz, 2.2Hz, 1H), 4.61-4.81 (m, 2H), 3.50 (ddd, 
J=9.1Hz, 6.1Hz, 3.3Hz, 1H), 2.00-2.13 (m, 1H), 1.51-1.98 (m, 5H).  
13C-NMR (75 MHz, CDCl3) δ (ppm) = 207.9, 157.9, 131.0, 129.7, 122.9, 121.7, 114.6, 
71.7, 45.5, 24.7, 24.3, 20.6. 
MS (70 eV, EI), m/z (%) = 216 (M+, 29), 188 (11), 123 (25), 122 (11), 109 (46),  
108 (16), 107 (58), 95 (28), 81 (100), 80 (14), 79 (50), 77 (64), 66 (10), 65 (13), 53 (11), 
41 (10). 
HRMS (EI), m/z calc. for C14H16O2 (216.1150): 216.1149 (M+). 
IR (ATR) υ (cm-1) = 3097, 3060, 3041, 2936, 2867, 1707, 1681, 1598, 1588, 1494, 1432, 
1198, 1173, 1085, 1072, 1049, 963, 885, 833, 751, 690. 
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Preparation of (4-(tert-butyl)phenyl)(cyclohex-2-en-1-yl)-methanone (32o) 
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32o was prepared from 30f 
(4.45 mL, 2.00 mmol, 0.45 M in THF) and 4-(tert-butyl)benzoyl chloride (31a, 315 mg, 
1.6 mmol) at -78 °C in 1 h. Flash column chromatography (silica, pentane:Et2O 30:1) 
furnished 32o as a yellow oil (322 mg, 83 %). 
 
1H-NMR (600 MHz, CDCl3) δ (ppm) =  7.91 (d, J=8.8Hz, 2H), 7.47 (d, J=8.8Hz, 2H), 
5.85-6.01 (m, 1H), 5.65-5.79 (m, 1H), 4.01-4.11 (m, 1H), 1.81-2.12 (m, 5H), 1.62-1.73 
(m, 1H), 1.25-1.39 (m, 9H). 
13C-NMR (150 MHz, CDCl3) δ (ppm) = 201.5, 156.5, 133.6, 129.9, 128.5, 125.5, 124.9, 
43.8, 35.1, 31.1, 25.9, 24.8, 20.9. 
MS (70 eV, EI), m/z (%) = 242 (M+, 1), 238 (3), 227 (2), 223 (6), 185 (6), 162 (13),  
161 (100), 146 (7), 117 (3), 115 (2), 91 (3), 77 (2). 
HRMS (EI), m/z calc. for C17H22O (242.1671): 242.1662 (M+). 
IR (ATR) υ (cm-1) = 3087, 3062, 3032, 2958, 2905, 2867, 1675, 1650, 1603, 1461, 1407, 
1363, 1267, 1233, 1187, 1116, 1110, 1102, 1015, 963, 845, 718, 700.  
 
Preparation of (4-(tert-butyl)phenyl)((1S,5S)-6,6-dimethyl-2-methylenebicyclo-
[3.1.1]heptan-3-yl)methanone (32p) 
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32p was prepared from 30g 
(5.41 mL, 2.00 mmol, 0.37 M in THF) and 4-(tert-butyl)benzoyl chloride (31a, 315 mg, 
1.6 mmol) at -78 °C in 1 h. Flash column chromatography (silica, pentane:Et2O 50:1) 
furnished 32p as a white solid (318 mg, 67 %). 
 
m.p.: 122.8-124.8 °C. 
1H-NMR (400 MHz, CDCl3) δ (ppm) = 7.92 (d, J=8.6Hz, 2H), 7.48 (d, J=8.6Hz, 2H), 
4.76-4.87 (m, 1H), 4.59 (s, 1H), 4.43-4.55 (m, 1H), 2.46-2.59 (m, 1H), 2.30-2.42 (m, 
1H), 2.19-2.30 (m, 1H), 1.98-2.10 (m, 2H), 1.66 (d, J=10.2Hz, 1H), 1.34 (s, 9H), 1.28 (s, 
3H), 0.85 (s, 3H). 
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13C-NMR (100 MHz, CDCl3) δ (ppm) = 202.2, 156.4, 149.3, 134.7, 128.9, 125.5, 111.0, 
51.7, 42.1, 40.3, 40.2, 35.0, 31.1, 28.6, 27.3, 25.8, 21.6. 
MS (70 eV, EI), m/z (%) = 296 (M+, 3), 255 (11), 162 (26), 161 (100), 146 (12),  
134 (16), 119 (12), 118 (17), 93 (11), 91 (15), 57 (11), 41 (10). 
HRMS (EI), m/z calc. for C21H28O (296.2140): 296.2144 (M+). 
IR (ATR) υ (cm-1) = 3076, 3063, 2960, 2944, 2915, 2864, 1669, 1629, 1602, 1464, 1363, 
1333, 1268, 1237, 1220, 1195, 1106, 1050, 1006, 938, 886, 861, 846, 838, 824, 800, 752, 
711, 683.  
 
Preparation of ((1S,5S)-6,6-dimethyl-2-methylenebicyclo-[3.1.1]heptan-3-yl)-
(thiophen-2-yl)methanone (32q) 
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32q was prepared from 30g 
(5.41 mL, 2.00 mmol, 0.37 M in THF) and thiophene-2-carbonyl chloride (31b, 235 mg, 
1.6 mmol) at -78 °C → 25 °C in 2 h. Flash column chromatography (silica,  
pentane:Et2O 30:1) furnished 32q as a yellow oil (351 mg, 89 %). 
 
1H-NMR (400 MHz, CDCl3) δ (ppm) = 7.75 (dd, J=3.8Hz, 1.1Hz, 1H), 7.66 (dd, 
J=4.9Hz, 1.2Hz, 1H), 7.16 (dd, J=5.0Hz, 3.8Hz, 1H), 4.83 (s, 1H), 4.64-4.74 (m, 1H), 
4.28-4.40 (m, 1H), 2.52 (t, J=5. Hz, 1H), 2.32-2.44 (m, 1H), 2.20-2.30 (m, 1H), 1.99-
2.15 (m, 2H), 1.75 (d, J=9.9Hz, 1H), 1.28 (s, 3H), 0.84 (s, 3H). 
13C-NMR (100 MHz, CDCl3) δ (ppm) = 195.5, 149.0, 145.3, 134.0, 132.3, 128.1, 111.2, 
51.5, 43.6, 40.3, 39.9, 28.8, 27.3, 25.8, 21.6. 
MS (70 eV, EI), m/z (%) = 246 (M+, 1), 177 (7), 135 (19), 134 (11), 119 (10), 111 (100), 
93 (37), 91 (12), 69 (7), 43 (26), 41 (28). 
HRMS (EI), m/z calc. for C15H18OS (246.1078): 246.1073 (M+). 
IR (ATR) υ (cm-1) = 3098, 3083, 2974, 2918, 2866, 1660, 1632, 1517, 1412, 1353, 1235, 
1212, 1196, 1064, 1050, 938, 885, 833, 761, 718.  
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Preparation of ethyl 6-(furan-2-carbonyl)cyclohex-1-ene-carboxylate (32r) 
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32r was prepared from 30h 
(4.45 mL, 2.00 mmol, 0.45 M in THF) and furan-2-carbonyl chloride (31d, 209 mg,  
1.6 mmol) at -78 °C → 25 °C over night. Flash column chromatography (silica, 
pentane:Et2O 1:1) furnished 32r as a white solid (223 mg, 90 %). 
 
m.p.: 56.6-57.2 °C. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.56-7.61 (m, 1H), 7.29 (dt, J=4.0Hz, 1.4Hz, 
1H), 7.24 (dt, J=3.6Hz, 0. Hz, 1H), 6.53 (dd, J=3.6Hz, 1.7Hz, 1H), 4.23-4.33 (m, 1H), 
4.02-4.16 (m, 2H), 2.18-2.40 (m, 2H), 1.81-2.01 (m, 2H), 1.56-1.71 (m, 2H), 1.14  
(t, J=7.3Hz, 3H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 190.2, 166.4, 152.1, 146.2, 142.9, 128.6, 117.2, 
112.2, 60.4, 42.7, 26.3, 25.4, 18.6, 14.0. 
MS (70 eV, EI), m/z (%) = 248 (M+, 10), 203 (23), 202 (100), 174 (17), 95 (45), 79 (16). 
HRMS (EI), m/z calc. for C14H16O4 (248.1049): 248.1046 (M+). 
IR (ATR) υ (cm-1) = 3139, 3123, 3096, 2984, 2968, 2957, 2907, 2869, 2827, 1696, 1657, 
1646, 1470, 1395, 1374, 1285, 1267, 1253, 1233, 1201, 1171, 1142, 1094, 1080, 1071, 
1055, 1034, 1020, 1007, 957, 943, 923, 789, 753, 730, 707. 
 
Preparation of ethyl 6-(4-chlorobenzoyl)cyclohex-1-ene-carboxylate (32s) 
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32s was prepared from 30h 
(4.45 mL, 2.00 mmol, 0.45 M in THF) and 4-chlorobenzoyl chloride (31g, 280 mg,  
1.6 mmol) at -78 °C → 25 °C over night. Flash column chromatography (silica, 
pentane:Et2O 8:2) furnished 32s as a white solid (234 mg, 80 %). 
 
m.p.: 59.4-60.3 °C. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.89-8.01 (m, 2H), 7.37-7.50 (m, 2H), 7.26-7.37 
(m, 1H), 4.39-4.51 (m, 1H), 4.09 (dq, J=7.1Hz, 1.7Hz, 2H), 2.15-2.40 (m, 2H), 1.89-2.02 
(m, 1H), 1.74-1.87 (m, 1H), 1.50-1.71 (m, 2H), 1.15 (t, J=7.1Hz, 3H). 
C. EXPERIMENTAL SECTION 
233 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 200.2, 166.5, 142.6, 139.2, 134.6, 129.9, 129.2, 
128.9, 60.5, 42.0, 26.1, 25.4, 18.5, 14.1. 
MS (70 eV, EI), m/z (%) = 292 (M+, 2), 247 (4), 246 (8), 140 (7), 139 (100), 111 (11),  
79 (4). 
HRMS (EI), m/z calc. for C16H17ClO3 (292.0866): 292.0860 (M+). 
IR (ATR) υ (cm-1) = 3097, 3069, 2990, 2938, 2863, 2824, 1699, 1677, 1586, 1481, 1446, 
1397, 1281, 1245, 1214, 1101, 1091, 1082, 1065, 1043, 1005, 947, 916, 834, 751, 737, 
674.  
 
Preparation of 5-(4-chlorobenzoyl)cyclopent-1-enecarbonitrile (32t) 
O
Cl
CN
 
According to TP2, the α-substituted β,γ-unsaturated ketone 32t was prepared from 30i 
(5.70 mL, 2.00 mmol, 0.35 M in THF) and 4-chlorobenzoyl chloride (31g, 280 mg,  
1.6 mmol) at -78 °C → 25 °C over night. Flash column chromatography (silica, 
pentane:Et2O 1:1) furnished 32t as a white solid (162 mg, 70 %). 
 
m.p.: 77.3-79.5 °C. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.86-7.97 (m, 2H), 7.42-7.53 (m, 2H), 6.88 (q, 
J=2.5Hz, 1H), 4.59-4.73 (m, 1H), 2.58-2.74 (m, 2H), 2.38-2.55 (m, 1H), 2.09- 
2.23 (m, 1H).  
13C-NMR (75 MHz, CDCl3) δ (ppm) = 196.7, 152.0, 140.4, 133.6, 130.1, 129.2, 115.7, 
113.7, 53.9, 33.1, 28.2. 
MS (70 eV, EI), m/z (%) = 231 (M+, 1), 142 (2), 140 (6), 139 (100), 111 (21), 92 (2),  
76 (3), 75 (7), 65 (2). 
HRMS (EI), m/z calc. for C13H10ClNO (231.0451): 231.0443 (M+). 
IR (ATR) υ (cm-1) = 3091, 3066, 2976, 2921, 2848, 2220, 1675, 1587, 1573, 1486, 1434, 
1399, 1345, 1319, 1282, 1222, 1209, 1086, 1006, 859, 844, 832, 818, 732, 720, 670. 
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4.4.1 FURTHER FUNCTIONALIZATION OF β,γ-UNSATURATED KETONE 32d  
Preparation of (3S,4S)-4-(4-(tert-butyl)phenyl)-3-phenylhepta-1,6-dien-4-ol (rac)(33) 
 
A dry and argon-flushed Schlenk-flask, equipped with a magnetic stirring bar and a 
septum, was charged with 1-(4-(tert-butyl)phenyl)-2-phenylbut-3-en-1-one (32d,  
557 mg, 2.0 mmol) and cooled to 0 °C. Then, allyl Grignard reagent (1.80 mL, 2.2 mmol, 
1.22 M in THF) was added dropwise and the reaction mixture was warmed to 25 °C. 
After stirring for 1.5 h, the reaction mixture was quenched with saturated aqueous NH4Cl 
solution (10 mL), extracted with EtOAc (3x10 mL), dried over Na2SO4 and concentrated 
in vacuo. The compound was used directly for the metathesis reaction without further 
purification since GC-analysis indicated >98 % purity. 
 
Preparation of (1S,2S)-1-(4-(tert-butyl)phenyl)-2-phenylcyclo-pent-3-enol (rac)(34) 
tBu
HO
Ph
 
The synthesis of 34 is following a literature-known procedure.275 A dry and argon-
flushed Schlenk-flask, equipped with a magnetic stirring bar and a septum, was charged 
with Grubbs II catalyst (85 mg, 0.10 mmol) and dissolved in dichloromethane (15 mL).  
The crude of 7 (641 mg, 2.0 mmol) was dissolved in dichloromethane (5 mL) and added 
dropwise to the reaction mixture. After heating to 40 °C for 4 h, the solvent was removed 
in vacuo and the crude residue obtained was purified by flash column chromatography 
(silica, pentane:Et2O 9:1) to give the analytically pure product 34 as an off-white solid 
(567 mg, 97 %). 
 
m.p.: 67.9-69.3 °C. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.37-7.48 (m, 4H), 7.26-7.36 (m, 3H), 7.02-7.15 
(m, 2H), 6.04-6.16 (m, 1H), 5.82-5.98 (m, 1H), 4.37-4.50 (m, 1H), 3.01-3.13 (m, 1H), 
2.82-2.96 (m, 1H), 1.53-1.65 (m, 1H), 1.40 (s, 9H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 149.4, 144.0, 137.2, 131.4, 130.3, 129.0, 128.5, 
127.5, 124.9, 124.9, 83.0, 63.7, 50.6, 34.4, 31.4. 
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MS (70 eV, EI) m/z (%) = 292 (M+, 52), 275 (21), 274 (94), 260 (24), 259 (100), 215 
(15), 146 (10), 129 (14), 128 (10), 118 (16), 117 (25), 116 (11), 115 (25), 91 (33), 57 
(16), 41 (14). 
HRMS (EI), m/z calc. for C21H24O (292.1827): 292.1821 (M+). 
IR (ATR) υ (cm-1) = 3530, 3502, 3076, 3053, 3023, 2957, 2925, 2911, 2866, 1491, 1452, 
1363, 1273, 1109, 1067, 1031, 1026, 1021, 959, 904, 897, 827, 822, 770, 752, 740, 709, 
694, 687. 
 
4.5 PREPARATION OF α-SUBSTITUTED β,γ-UNSATURATED ESTERS  
Preparation of ethyl 2-phenylbut-3-enoate (36a) 
 
According to TP2, the α-substituted β,γ-unsaturated ester 36a was prepared from 30b  
(4.65 mL, 2.00 mmol, 0.43 M in THF) and ethyl carbonochloridate (35a, 174 mg,  
1.6 mmol) at -78 °C in 1 h. Flash column chromatography (silica, pentane:Et2O 30:1) 
furnished 36a as a colorless oil (195 mg, 64 %). 
 
1H-NMR (600 MHz, CDCl3) δ (ppm) = 7.22-7.41 (m, 5H), 6.16-6.28 (m, 1H), 5.09-5.25 
(m, 2H), 4.31 (d, J=8.1Hz, 1H), 4.09-4.26 (m, 2H), 1.24 (t, J=7.2Hz, 3H). 
13C-NMR (150 MHz, CDCl3) δ (ppm) = 172.3, 138.1, 135.9, 128.7, 128.0, 127.3, 117.4, 
61.0, 55.8, 14.1. 
MS (70 eV, EI), m/z (%) = 190 (M+, 7), 117 (100), 116 (8), 115 (31), 91 (10). 
HRMS (EI), m/z calc. for C12H14O2 (190.0994): 190.0985 (M+). 
IR (ATR) υ (cm-1) = 3084, 3063, 3029, 2981, 2936, 2905, 2872, 1729, 1495, 1454, 1367, 
1306, 1225, 1191, 1151, 1027, 990, 922, 728, 697.  
 
Preparation of phenyl 2-phenylbut-3-enoate (36b) 
 
According to TP2, the α-substituted β,γ-unsaturated ester 36b was prepared from 30b  
(4.65 mL, 2.00 mmol, 0.43 M in THF) and phenyl carbonochloridate (35b, 251 mg,  
1.6 mmol) at -78 °C → 25 °C in 2 h. Flash column chromatography (silica,  
pentane:Et2O 30:1) furnished 36b as a colorless oil (297 mg, 78 %). 
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1H-NMR (400 MHz, CDCl3) δ (ppm) = 7.12-7.55 (m, 8H), 6.94-7.11 (m, 2H), 6.33 (ddd, 
J=17.1Hz, 10.2Hz, 7.9Hz, 1H), 5.21-5.36 (m, 2H), 4.56 (d, J=7.8Hz, 1H). 
13C-NMR (100 MHz, CDCl3) δ (ppm) = 170.7, 150.7, 137.6, 135.2, 129.4, 128.9, 128.0, 
127.6, 125.9, 121.3, 118.1, 55.7. 
MS (70 eV, EI), m/z (%) = 238 (M+, 1), 145 (22), 144 (100), 116 (26), 115 (65), 91 (20), 
65 (10). 
HRMS (EI), m/z calc. for C16H14O2 (238.0994): 238.0993 (M+). 
IR (ATR) υ (cm-1) = 3081, 3067, 3025, 2983, 2925, 1743, 1590, 1490, 1453, 1304, 1290, 
1186, 1161, 1144, 1119, 1069, 984, 979, 941, 821, 756, 729, 696, 687.  
 
Preparation of allyl 2-phenylbut-3-enoate (36c) 
 
According to TP2, the α-substituted β,γ-unsaturated ester 36c was prepared from 30b  
(4.65 mL, 2.00 mmol, 0.43 M in THF) and allyl carbonochloridate (35c, 193 mg,  
1.6 mmol) at -78 °C → 25 °C in 2 h. Flash column chromatography (silica,  
pentane:Et2O 30:1) furnished 36c as a colorless oil (265 mg, 82 %). 
 
1H-NMR (600 MHz, CDCl3) δ (ppm) = 7.21-7.41 (m, 5H), 6.19-6.28 (m, 1H), 5.82-5.93 
(m, 1H), 5.10-5.32 (m, 4H), 4.55-4.67 (m, 2H), 4.35 (d, J=8.2Hz, 1H). 
13C-NMR (150 MHz, CDCl3) δ (ppm) = 172.0, 138.0, 135.7, 131.9, 128.7, 128.0, 127.4, 
118.3, 117.6, 65.5, 55.8. 
MS (70 eV, EI), m/z (%) = 202 (M+, 1), 118 (13), 117 (100), 116 (11), 115 (42), 91 (13), 
41 (11). 
HRMS (EI), m/z calc. for C13H14O2 (202.0994): 202.0985 (M+). 
IR (ATR) υ (cm-1) = 3084, 3063, 3029, 2983, 2941, 2882, 1732, 1495, 1453, 1306, 1220, 
1190, 1149, 989, 921, 729, 697.  
 
Preparation of phenyl 2,2-dimethylbut-3-enoate (36d) 
 
According to TP2, the α-substituted β,γ-unsaturated ester 36d was prepared from 30c  
(4.35 mL, 2.00 mmol, 0.46 M in THF) and phenyl carbonochloridate (35b, 251 mg,  
C. EXPERIMENTAL SECTION 
237 
1.6 mmol) at -20 °C → 25 °C in 2 h. Flash column chromatography (silica,  
pentane:Et2O 30:1) furnished 36d as a colorless oil (213 mg, 70 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.31-7.47 (m, 2H), 7.18-7.29 (m, 1H), 7.00-7.15 
(m, 2H), 6.20 (dd, J=17.4Hz, 10.8Hz, 1H), 5.14-5.34 (m, 2H), 1.49 (s, 6H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 174.8, 151.0, 142.0, 129.4, 125.7, 121.4, 113.6, 
45.1, 24.6. 
MS (70 eV, EI), m/z (%) = 190 (M+, 7), 97 (10), 95 (11), 94 (100), 69 (89), 41 (36). 
HRMS (EI), m/z calc. for C12H14O2 (190.0994): 190.0996 (M+). 
IR (ATR) υ (cm-1) = 3088, 3067, 3043, 2979, 2935, 2873, 1747, 1638, 1593, 1493, 1470, 
1192, 1161, 1106, 1070, 1001, 915, 832, 738, 688, 670. 
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5. PREPARATION OF FUNCTIONALIZED ALKENYLZINC REAGENTS 
BEARING CARBONYL GROUPS VIA DIRECT METAL INSERTION 
5.1 PREPARATION OF STARTING MATERIALS 
All reagents were obtained from commercial sources. Compounds 37a,276 37b,277 37c,278 
37d,279 37e and 42d280, 37f,281 37g and 37h,282 37i,283 42a and 42b,284 42c285 as well as 
42e286 were prepared according to literature-known procedures. Compound 42f was 
synthesized analogous a literature-known procedure280 employing PhSSO2Ph as 
electrophile. 
 
5.2 TYPICAL PROCEDURES 
Typical procedure 1 (TP1): LiCl-mediated zinc insertion into activated alkenyl 
bromides 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with LiCl (1.5-2 equiv) and heated with a heat gun under high vacuum  
(5 min). After cooling to room temperature, zinc powder (1.5-2 equiv) was added, 
followed by THF (1 mL/mmol). The zinc powder then was activated using  
1,2-dibromoethane (5 mol%) and TMSCl (5 mol%). Then, the substrate (1 equiv) was 
added neat at 25 °C. In the case of very exothermic reactions, the reaction mixture was 
kept at 25 °C using a water bath and stirred for the given time until GC-analysis of 
hydrolyzed reaction aliquot showed full consumption of the starting material. Then, the 
remaining zinc powder was allowed to settle down or centrifuged (10 min, 2000 rpm). 
The yield of the insertion rection was determined by iodometric titration192 and the 
supernatant solution was then used in the reaction with electrophiles. 
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Typical procedure 2 (TP2): LiCl-mediated magnesium insertion in the presence of 
zinc chloride into less activated alkenyl bromides 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with LiCl (1.5 equiv) and heated with a heat gun under high vacuum  
(5 min). After cooling to room temperature, magnesium turnings (2.5 equiv) were added, 
followed by THF (1 mL/mmol). The magnesium was activated using 1,2-dibromoethane 
(5 mol%) and TMSCl (5 mol%). Then, ZnCl2-solution (1.1 equiv, 1 M in THF) was 
added followed by the substrate (1 equiv). The reaction mixture was stirred at 25 °C until 
GC-analysis of hydrolyzed reaction aliquot showed full consumption of the starting 
material. Then, solids were allowed to settle or the reation mixture was centrifuged 
(10 min, 2000 rpm). The yield of the insertion rection was determined by iodometric 
titration192 of the supernatant solution. 
 
Typical procedure 3 (TP3): Allylation or Acylation of alkenyl zinc reagents 
The freshly prepared zinc reagent was cooled to -40 °C and the corresponding allyl 
bromide (0.8–0.9 equiv) was added, followed by CuCN·2LiCl (1 M in THF). The 
reaction mixture was allowed to warm to 0 °C. After stirring for the given time, the 
reaction mixture was quenched with sat. NH4Cl/NH3 (9:1) solution (10 mL), washed with 
sat. NH4Cl/NH3 solution (9:1, 2x10 mL) and extracted with EtOAc (3x10 mL). The 
combined organic phases were washed with sat. NaCl solution (10 mL), dried over 
Na2SO4 and concentrated in vacuo. The crude residue obtained was purified by flash 
column chromatography to give the analytically pure product. 
  
Typical procedure 4 (TP4): Cross-coupling reactions of alkenyl zinc reagents 
The desired aryl bromide or iodide (0.8 equiv) was added to the freshly prepared zinc 
reagent followed by Pd(PPh3)4 (2 mol%) and the mixture was stirred for the given time at 
50 °C. The reaction mixture was quenched with sat. NH4Cl solution (10 mL) and 
extracted with Et2O (3x20 mL). The combined organic phases were washed with sat. 
NaCl solution (10 mL), dried over Na2SO4 and concentrated in vacuo. The crude residue 
obtained was purified by flash column chromatography to give the analytically pure 
product. 
 
Typical procedure 5 (TP5): Preparation of tetrahydrophthalazines of type 5 
The freshly prepared zinc reagent was cooled to -40 °C and CuCN·2LiCl (ca. 0.03 mL, 
0.03 mmol, 1 M in THF) was added followed by the corresponding acid chloride (0.6- 
C. EXPERIMENTAL SECTION 
240 
0.8 equiv). After stirring for the given time at -40 °C, the reaction mixture was quenched 
with sat. NH4Cl/NH3 (9:1) solution (10 mL), washed with sat. NH4Cl/NH3 solution (9:1, 
2x10 mL) and extracted with Et2O (3x10 mL). The combined organic phases were 
washed with sat. NaCl solution (10 mL), dried over Na2SO4 and concentrated in vacuo. 
The crude residue obtained was dissolved in MeOH (20 mL) and hydrazine hydrate  
(3 equiv) was added at room temperature. After stirring for 14 h, the reaction mixture 
was concentrated in vacuo. The crude residue obtained was purified by flash column 
chromatography to give the analytically pure product. 
 
5.3 PREPARATION OF ALKENYL ZINC REAGENTS FROM ACTIVATED ALKENYL 
BROMIDES 
Preparation of (2-formylcyclohex-1-en-1-yl)zinc bromide (38a) 
 
According to TP1, the zinc reagent 38a was prepared from 2-bromocyclohex-1-ene-1-
carbaldehyde (37a, 1.89 g, 10.0 mmol) using Zn powder (1.31 g, 20.0 mmol) and LiCl  
(848 mg, 20.0 mmol) in 1 h at 25 °C. Titration with iodine indicates a concentration of  
0.77 M (86%). 
 
Preparation of (5-formyl-3,6-dihydro-2H-pyran-4-yl)zinc bromide (38b) 
 
According to TP1, the zinc reagent 38b was prepared from 4-bromo-5,6-dihydro-2H-
pyran-3-carbaldehyde (37b, 955 mg, 5.00 mmol) using Zn powder (490 mg, 7.50 mmol) 
and LiCl (318 mg, 7.5 mmol) in 1 h at 25 °C. Titration with iodine indicates a 
concentration of 0.72 M (77%). 
 
Preparation of (3-oxocyclohex-1-en-1-yl)zinc bromide (38c) 
 
According to TP1, the zinc reagent 38c was prepared from 3-bromocyclohex-2-enone 
(37c, 1.75 g, 10.0 mmol) using Zn powder (981 mg, 15.0 mmol) and LiCl (636 mg, 15.0 
mmol) in 1 h at 25 °C. Titration with iodine indicates a concentration of 0.77 M (86%). 
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Preparation of (3-oxocyclohex-1-en-1-yl)zinc bromide (38d) 
 
According to TP1, the zinc reagent 38d was prepared from 3-bromocyclopent-2-enone 
(37d, 1.50 g, 10.0 mmol) using Zn powder (981 mg, 15.0 mmol) and LiCl (636 mg,  
15.0 mmol) in 1 h at 25 °C. Titration with iodine indicates a concentration of  
0.99 M (94%). 
 
Preparation of (2-benzoylcyclopent-1-en-1-yl)zinc bromide (38e) 
 
According to TP1, the zinc reagent 38e was prepared from (2-bromocyclopent-1-en-1-
yl)(phenyl)methanone (37e, 2.51 g, 10.0 mmol) using Zn powder (981 mg, 15.0 mmol) 
and LiCl (636 mg, 15.0 mmol) in 1 h at 25 °C. Titration with iodine indicates a 
concentration of 0.56 M (62%). 
 
Preparation of (Z)-(4,4-dimethyl-1-oxopent-2-en-3-yl)zinc bromide (38f) 
 
According to TP1, the zinc reagent 38f was prepared from (Z)-3-bromo-4,4-
dimethylpent-2-enal (37f, 1.91 g, 10.0 mmol) using Zn powder (981 mg, 15.0 mmol) and 
LiCl (636 mg, 15.0 mmol) in 1 h at 25 °C. Titration with iodine indicates a concentration 
of 0.61 M (67%). 
 
Preparation of (Z)-(1-(4-fluorophenyl)-3-oxoprop-1-en-1-yl)zinc bromide (38g) 
 
According to TP1, the zinc reagent 38g was prepared from (Z)-3-bromo-3-(4-
fluorophenyl)acrylaldehyde (37g, 2.29 g, 10.0 mmol) using Zn powder (981 mg,  
15.0 mmol) and LiCl (636 mg, 15.0 mmol) in 1 h at 25 °C. Titration with iodine indicates 
a concentration of 0.32 M (35%). 
C. EXPERIMENTAL SECTION 
242 
Preparation of (Z)-(1-(4-methoxyphenyl)-3-oxoprop-1-en-1-yl)zinc bromide (38h) 
 
According to TP1, the zinc reagent 38h was prepared from (Z)-3-bromo-3-(4-
methoxyphenyl)acrylaldehyde (37h, 2.41 g, 10.0 mmol) using Zn powder (981 mg,  
15.0 mmol) and LiCl (636 mg, 15.0 mmol) in 1 h at 25 °C. Titration with iodine indicates 
a concentration of 0.37 M (41%). 
 
Preparation of (Z)-(3-ethoxy-3-oxo-1-phenylprop-1-en-1-yl)zinc bromide (38i) 
 
According to TP1, the zinc reagent 38i was prepared from (Z)-ethyl 3-bromo-3-
phenylacrylate (37i, 2.55 g, 10.0 mmol) using Zn powder (981 mg, 15.0 mmol) and LiCl 
(636 mg, 15.0 mmol) in 1 h at 25 °C. Titration with iodine indicates a concentration of 
0.56 M (62%). 
 
5.4 REACTIONS OF ALKENYL ZINC REAGENTS OF TYPE 38 WITH ELECTROPHILES 
Preparation of 4-(2-formylcyclohex-1-en-1-yl)benzonitrile (40a) 
 
The cross-coupling reaction of 38a (2.60 mL, 2.00 mmol, 0.77 M in THF) with  
4-bromobenzonitrile (39a, 291 mg, 1.60 mmol) was performed according to TP4 in  
1.5 h. Flash column chromatography (silica, pentane:Et2O 8.5:1.5) furnished 40a as a 
yellow solid (276 mg, 82 %). 
 
m.p.: 78.0-79.8 °C. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 9.42 (s, 1 H), 7.68 (d, J=8.6Hz, 2H), 7.35 (d, 
J=8.6Hz, 2H), 2.57-2.47 (m, 2H), 2.43-2.11 (m, 2H), 1.89-1.65 (m, 4H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 192.2, 156.7, 144.3, 136.9, 132.0, 129.3, 118.3, 
112.1, 33.6, 22.2, 22.2, 21.2. 
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MS (70 eV, EI), m/z (%) = 211 (M+, 100), 210 (84), 182 (28), 154 (29), 140 (24),  
116 (32). 
HRMS m/z calc. for C14H13NO (211.0997): 211.0992. 
IR (ATR) (cm-1) υ = 2928, 2856, 2227, 1709, 1663, 1621, 1604, 1500, 1408, 1361, 1275, 
1211, 1193, 1171, 984, 856, 826, 711.  
 
Preparation of ethyl 2-[(2-formylcyclohex-1-en-1-yl)methyl]prop-2-enoate (40b) 
 
The allylation reaction of 38a (2.60 mL, 2.00 mmol, 0.77 M in THF) with CuCN·2LiCl  
(ca. 0.03 mL, 0.03 mmol,  1 M in THF) and ethyl (2-bromomethyl)acrylate (39b, 347 mg,  
1.80 mmol) was performed according to TP3 in 1 h. Flash column chromatography 
(silica, pentane:Et2O 9:1) furnished 40b as a colorless oil (377 mg, 94 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 10.07 (s, 1H), 6.27 (d, J=1.1Hz, 1H), 5.51 (d, 
J=1.1Hz, 1H), 4.21 (d, J=7.1Hz, 2H), 3.54 (s, 2H), 2.28-2.14 (m, 4H), 1.16 (dt, J=6.4Hz,  
3.2Hz, 4H), 1.37 (t, J=7.1Hz, 3H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 191.2, 166.5, 154.8, 138.0, 135.5, 126.2, 61.0, 
33.7, 31.6, 22.4, 22.0, 21.6, 14.1. 
MS (70 eV, EI), m/z (%) = 222 (M+, 3), 149 (100), 148 (49), 147 (28), 119 (25), 91 (37),  
79 (25). 
HRMS m/z calc. for C13H18O3 (222.1256): 222.1258. 
IR (ATR)
 
υ (cm-1) = 2956, 2257, 1781, 1678, 1629, 1588, 1505, 1377, 1255, 1169, 1144, 
1112, 1035, 934, 814, 762.  
 
Preparation of ethyl 3-(2-formylcyclohex-1-en-1-yl)prop-2-ynoate (40c) 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with the alkenyl zinc reagent 38a (2.80 mL, 2.40 mmol, 0.85 M in THF) and 
cooled to -78 °C. CuCN·2LiCl (0.24 mL, 0.24 mmol, 1.0 M in THF) was added, followed 
by ethyl 3-bromoprop-2-ynoate (39c, 354 mg, 2.00 mmol) and the reaction mixture was 
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stirred for 3 h at -78 °C. The reaction was quenched with sat. NH4Cl solution (10 mL) 
and extracted with Et2O (3x20 mL). The combined organic phases were washed with sat. 
NaCl solution (10 mL), dried over Na2SO4 and concentrated in vacuo. The crude residue 
obtained was purified by flash column chromatography (silica, hexanes:Et2O 4:1) to give 
40c as a colorless oil (331 mg, 80 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 10.15 (s, 1H), 4.28 (q, J=6.0Hz, 2H), 2.50-2.40 
(m, 2H), 2.35-2.25 (m, 2H), 1.75-1.60 (m, 4H), 1.33 (t, J=6.0Hz, 3H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 191.5, 153.3, 147.6, 135.8, 88.3, 81.8, 62.4, 31.2, 
22.3, 21.5, 20.6, 14.0. 
MS (70 eV, EI), m/z (%) = 296 (M+, 9), 162 (75), 105 (36), 91 (40), 77 (49), 43 (100). 
HRMS m/z calc. for C12H14O3 (206.0943): 206.0946. 
IR (ATR)
 
υ (cm-1) = 2939, 2210, 1708, 1678, 1366, 1255, 1217, 1140, 1017, 747. 
 
Preparation of 2-[(2-bromophenyl)carbonyl]cyclohex-1-ene-1-carbaldehyde (40d) 
 
The acylation reaction of 38a (2.80 mL, 2.40 mmol, 0.85 M in THF) with CuCN·2LiCl  
(2.40 mL, 2.40 mmol, 1 M in THF) and 2-bromobenzoyl chloride (39d, 439 mg,  
2.00 mmol) was performed according to TP3 in 4 h. Flash column chromatography 
(silica, pentane:Et2O 10:1 then 4:1) furnished 40d as a colorless oil (297 mg, 51 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 9.74 (s, 1H). 7.70-7.55 (m, 2H), 7.45-7.35 (m, 
2H), 2.50-2.35 (m, 4H), 1.80-1.70 (m, 4H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 197.3, 191.2, 154.6, 141.7, 139.0, 134.3, 133.2, 
131.2, 127.9, 120.7, 28.7, 22.5, 21.8, 20.8. 
MS (70 eV, EI), m/z (%) =213 (M+, 100), 185 (77), 183 (77), 109 (72), 43 (80). 
HRMS m/z calc. for C14H13BrO2 (292.0099): 292.0092. 
IR (ATR)
 
υ (cm-1) = 2937, 1751, 1434, 1172, 1065, 1026, 1008, 911, 755, 734. 
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Preparation of 5-(2-formylcyclohex-1-en-1-yl)pyridine-3-carbonitrile (40e) 
 
The cross-coupling reaction of 38a (2.80 mL, 2.40 mmol, 0.85 M in THF) with  
5-bromopyridine-3-carbonitrile (39e, 366 mg, 2.00 mmol) was performed according to 
TP4 in 3 h. Flash column chromatography (silica, hexanes:Et2O 1:1) furnished 40e as a 
yellow oil (276 mg, 65 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 9.42 (s, 1H), 8.88-8.87 (m, 1H), 8.69-8.68 (m, 
1H), 7.88-7.87(m, 1H), 2.55-2.45 (m, 2H), 2.43-2.35 (m, 2H), 1.85-1.70 (m, 4H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 191.0, 152.2, 151.9, 151.7, 138.8, 138.6, 135.5, 
115.9, 109.9, 33.8, 22.3, 22.1, 21.0. 
MS (70 eV, EI), m/z (%) = 212 (M+, 73), 211 (73), 183 (100), 169 (29), 155 (63). 
HRMS m/z calc. for C13H12N2O (212.0950): 212.0939. 
IR (ATR)
 
υ (cm-1) = 2934, 2860, 2234, 1667, 1625, 1418, 1223, 1024, 905, 707, 652. 
 
Preparation of 2-[4-(trifluoromethyl)phenyl]cyclohex-1-ene-1-carbaldehyde (40f) 
 
The cross-coupling reaction of 38a (2.80 mL, 2.40 mmol, 0.85 M in THF) with  
4-bromobenzotrifluoride (39f, 450 mg, 2.00 mmol) was performed according to TP4 in  
4 h. Flash column chromatography (silica, hexanes:Et2O 10:1 then 4:1) furnished 40f as a 
yellow oil (369 mg, 73 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 9.45 (s, 1H). 7.66 (q, J=9.0Hz, 2H), 7.37 (q,  
J=9.0Hz, 2H), 2.60-2.50 (m, 2H), 2.40-2.30 (m, 2H), 1.85-1.60 (m, 4H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 192.1, 157.4, 143.2, 136.7, 130.4 (q, J=33Hz), 
128.9, 125.3 (q, J=4Hz), 123.9 (q, J=272Hz), 33.9, 22.3, 22.2, 21.3. 
MS (70 eV, EI), m/z (%) = 254 (M+, 25), 253 (22), 185 (50), 159 (19), 43 (100). 
HRMS m/z calc. for C14H13F3O (254.0918): 254.0907. 
IR (ATR)
 
ν~
 (cm-1) = 2937, 1671, 1614, 1322, 1211, 1163, 1121, 1109, 1067, 1017, 840. 
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Preparation of 2-[(dimethylamino)methyl]cyclohex-1-ene-1-carbaldehyde (40g) 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with CH2Cl2 (2 mL) and N,N,N’,N’-tetramethyldiaminomethane (204 mg,  
2.00 mmol) and was cooled to 0 °C. Then, trifluoroacetic anhydride (420 mg, 2 mmol) 
was added dropwise at 0 °C and the resulting clear solution was stirred for 15 min. Then, 
the alkenyl zinc reagent 38a (2.82 mL, 2.00 mmol, 0.71 M in THF) was added and the 
reaction mixture was stirred for 30 min. The reaction was quenched with sat. NaCl 
solution (10 mL) and extracted with EtOAc (3x20 mL). The combined organic phases 
were dried over Na2SO4 and concentrated in vacuo. The crude residue obtained was 
dissolved in EtOAc (30 mL) and washed with HCl (2x20 mL, 2 M). The aqueous solution 
was neutralized with NaHCO3, NaOH (2 M, 10 mL) was added and subsequently 
extracted with EtOAc (3x10 mL). After drying over Na2SO4 and evaporation of solvents 
40g was isolated as a yellow liquid (226 mg, 68 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 10.13 (s, 1H), 3.27 (s, 2H), 2.36-2.27 (m, 2H), 
2.24 (s, 6H), 2.24-2.19 (m, 2H), 1.68-1.54 (m, 4H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 188.4, 155.1, 136.5, 59.7, 45.4, 30.8, 22.4, 22.0, 
21.6. 
MS (70 eV, EI), m/z (%) = 167 (M+, 20), 138 (100), 122 (22), 110 (22), 79 (23), 58 (34),  
42 (57). 
HRMS m/z calc. for C10H17NO (167.1310): 167.1307. 
IR (ATR)
 
ν~
 (cm-1) = 2945, 1675, 1604, 1454, 1319, 1277, 1256, 1169, 1104, 1033, 
1012, 951, 843, 832, 762, 675.  
 
Preparation of 4-[(dimethylamino)methyl]-5,6-dihydro-2H-pyran-3-carbaldehyde 
(40h) 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with CH2Cl2 (2 mL) and N,N,N`,N’-tetramethyldiaminomethane (163 mg, 
1.6 mmol) and was cooled to 0 °C. Then, trifluoroacetic anhydride (336 mg, 1.6 mmol) 
was added dropwise at 0 °C and the resulting clear solution was stirred for 15 min. Then, 
the alkenylzinc reagent 38b (3.1 mL, 2.00 mmol, 0.65 M in THF) was added and the 
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reaction mixture was stirred for 30 min. The reaction was quenched with sat. NaCl 
solution (10 mL) and extracted with EtOAc (3x20 mL). The combined organic phases 
were dried over Na2SO4 and concentrated in vacuo. The crude residue obtained was 
dissolved in EtOAc (30 mL) and washed with HCl (2x 20 mL, 2 M). The aqueous 
solution was neutralized with NaHCO3, NaOH (2 M, 10 mL) was added and subsequently 
extracted with EtOAc (3x10 mL). After drying over Na2SO4 and evaporation of solvents 
40h was isolated as a yellow liquid (237 mg, 88 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 10.08 (s, 1H), 4.49-4.45 (m, 2H), 3.39  
(t, J=5.5Hz, 2H), 2.67 (s, 2H), 2.01-1.95 (m, 2H), 1.83 (s, 6H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 188.1, 152.7, 136.1, 64.3, 64.0, 58.9, 45.4, 29.7. 
MS (70 eV, EI), m/z (%) = 169 (M+, 19), 124 (100), 123 (16), 94 (25), 58 (87), 44 (15),  
42 (16). 
HRMS m/z calc. for C9H15NO2 (169.1103): 161.1108. 
IR (ATR)
 
υ (cm-1) = 2944, 2822, 2768, 1663, 1461, 1387, 1290, 1252, 1165, 1115, 1041, 
1016, 1002, 950, 855, 839, 758, 694, 675.  
 
Preparation of 3-(4-Cyanophenyl)-2-cyclohexen-1-one (40i) 
 
The cross-coupling reaction of 38c (4.80 mL, 2.40 mmol, 0.50 M in THF) with  
4-iodobenzonitrile (39a, 458 mg, 2.00 mmol) was performed according to TP4 in 3 h. 
Flash column chromatography (silica, hexanes:Et2O 1:1 then 1:2) furnished 40i as a 
colorless solid (349 mg, 88 %). 
 
m.p.: 95.8-97.4 °C. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.70 (d, J=8.3Hz, 2 H), 7.61 (d, J=8.5Hz, 2 H), 
6.41 (s, 1H), 2.75 (dt, J=6.0Hz, 1.2Hz, 2H), 2.50 (d, J=7.1Hz, 2H), 2.18 (quint, 
J=6.4Hz, 2H),  
13C-NMR (75 MHz, CDCl3) δ (ppm) = 199.1, 157.2, 143.3, 132.5, 127.3, 126.6, 118.2, 
113.2, 37.1, 27.9, 22.6,  
MS (70 eV, EI), m/z (%) = 197 (M+, 44), 169 (100), 141 (69), 140 (90), 113 (24). 
HRMS m/z calc. for C13H11NO (197.0841): 197.0838. 
IR (ATR)
 
υ (cm-1) = 2951, 2223, 1662, 1603, 1343, 1259, 1183, 1130, 889, 830, 816. 
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Preparation of 3-[4-(ethoxycarbonyl)phenyl]-2-cyclohexen-1-one (40j) 
 
The cross-coupling reaction of 38c (4.80 mL, 2.40 mmol, 0.50 M in THF) with ethyl  
4-iodobenzoate (39h, 552 mg, 2.00 mmol) was performed according to TP4 in 3 h. Flash 
column chromatography (silica, hexanes:Et2O 2:1 then 1:1) furnished 40j as a colorless 
solid (373 mg, 76 %). 
 
m.p.: 62.2-64.3 °C. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 8.07 (d, J = 8.8 Hz, 2 H), 7.58 (d, J = 8.8 Hz,  
2 H), 6.44 (t, J = 1.5 Hz, 1 H), 4.39 (q, J = 7.1 Hz, 2 H), 2.78 (dt, J = 6.1, 1.5 Hz, 2 H), 
2.53-2.47 (m, 2 H), 2.17 (quint, J = 6.4 Hz, 2 H), 1.40 (t, J = 7.1 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 199.5, 165.9, 158.4, 143.0, 131.5, 129.8, 126.7, 
125.9, 61.2, 37.2, 28.0, 22.7, 14.3. 
MS (70 eV, EI), m/z (%) = 244 (M+, 100), 216 (41), 199 (48), 171 (99), 144 (94). 
HRMS m/z : calc. for C15H16O3 244.1099, found 244.1099. 
IR (ATR)
 
ν~
 (cm-1) = 2944, 1704, 1665, 1602, 1287, 1269, 1184, 1110, 1021, 766, 698. 
 
Preparation of ethyl 1,1'-bi(cyclohexane)-1,2'-dien-3-one (40k) 
 
The allylation reaction of 38c (4.80 mL, 2.40 mmol, 0.50 M in THF) with CuCN·2LiCl  
(ca. 0.03 mL, 0.03 mmol, 1 M in THF) and 3-bromocyclohexene (39i, 322 mg,  
2.00 mmol) was performed according to TP3 in 1 h. Flash column chromatography 
(silica, pentane:Et2O 4:5) furnished 40k as a colorless oil (269 mg, 76 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 5.90-5.80 (m, 2H), 5.55-5.48 (m, 1H), 2.95-2.85 
(m, 1H), 2.40-2.20 (m, 4H), 2.15-1.80 (m, 5H), 1.75-1.40 (m, 3H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 200.1, 169.4, 129.7, 126.9, 125.8, 43.22, 37.5, 
28.3, 27.6, 24.9, 23.0, 20.6. 
MS (70 eV, EI), m/z (%) = 176 (M+, 45), 120 (100), 105 (72), 92 (74), 91 (92). 
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HRMS m/z calc. for C12H16O (176.1201): 176.1201. 
IR (ATR)
 
υ (cm-1) = 2930, 1662, 1619, 1257, 1241, 1187, 1133, 965, 884, 725. 
 
Preparation of 3-[2-(Ethoxycarbonyl)ethynyl]-2-cyclohexen-1-one (40l) 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with the alkenyl zinc reagent 38c (4.80 mL, 2.40 mmol, 0.50 M in THF) and 
cooled to -78 °C. CuCN·2LiCl (0.24 mL, 0.24 mmol, 1.0 M in THF) was added, followed 
by ethyl 3-bromoprop-2-ynoate (39c, 354 mg, 2.00 mmol) and the reaction mixture was 
stirred for 3 h at -78 °C. The reaction was quenched with sat. NH4Cl solution (10 mL) 
and extracted with Et2O (3x20 mL). The combined organic phases were washed with sat. 
NaCl solution (10 mL), dried over Na2SO4 and concentrated in vacuo. The crude residue 
obtained was purified by flash column chromatography (silica, hexanes:Et2O 2:1) to give 
40l as a colorless oil (273 mg, 71 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 6.35 (t, J=1.9Hz, 1H), 4.27 (q, J=7.1Hz, 2H), 
2.50-2.40 (m, 4H), 2.11-2.01 (m, 2H), 1.33 (t, J=7.2Hz, 3H),  
13C-NMR (75 MHz, CDCl3) δ (ppm) = 197.6, 153.1, 139.4, 135.7, 88.2, 83.1, 62.5, 37.2, 
29.3, 22.3, 13.9. 
MS (70 eV, EI), m/z (%) = 192 (M+, 41), 164 (85), 147 (85), 120 (99), 92 (100). 
HRMS m/z calc. for C11H12O3 (192.0786): 192.0780. 
IR (ATR)
 
υ (cm-1) = 2942, 2218, 1707, 1676, 1261, 1245, 1187, 1145, 1135, 1015, 747. 
 
Preparation of 3-[4-(trifluoromethyl)phenyl]-2-cyclopenten-1-one (40m) 
 
The cross-coupling reaction of 38d (3.43 mL, 2.40 mmol, 0.70 M in THF) with  
4-iodobenzotrifluoride (39f, 544 mg, 2.00 mmol) was performed according to TP4 in 3 h. 
Flash column chromatography (silica, hexanes:Et2O 1:1 then 1:2) furnished 40m as a 
colorless solid (333 mg, 74 %). 
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m.p.: 106.5-108.2 °C. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.78-7.70 (m, 4H), 6.64 (t, J=1.5Hz, 1H), 3.09-
3.06 (m, 2H), 2.65-2.62 (m, 2H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 208.7, 171.7, 137.4, 132.6 (q, J=32Hz), 129.4, 
127.0, 125.9 (q, J=4Hz), 123.7 (q, J=272Hz), 35.3, 28.7. 
MS (70 eV, EI), m/z (%) = 226 (M+, 95), 225 (33), 170 (28), 157 (100), 129 (38). 
HRMS m/z calc. for C12H9F3O (226.0605): 226.0597. 
IR (ATR)
 
υ (cm-1) = 2925, 1689, 1677, 1601, 1319, 1163, 1132, 1110, 1064, 1014, 829. 
 
Preparation of ethyl 4-(2-benzoylcyclopent-1-en-1-yl)benzoate (40n) 
 
The cross-coupling reaction of 38e (3.60 mL, 2.00 mmol, 0.56 M in THF) with ethyl  
4-bromobenzoate (39j, 367 mg, 1.60 mmol) was performed according to TP4 over night. 
Flash column chromatography (silica, hexanes:Et2O 9:1) furnished 40n as a white solid  
(359 mg, 70 %). 
 
m.p.: 70.5-71.9 °C. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.62-7.87 (m, 4H), 7.33-7.48 (m, 1H), 7.16- 
7.33 (m, 4H), 4.29 (q, J=7.2Hz, 2H), 2.84-3.14 (m, 4H), 2.15 (quin, J=7.6Hz, 2H), 1.32 
(t, J=7.1Hz, 3H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 198.1, 166.1, 144.2, 140.4, 139.7, 136.2, 133.1, 
129.3, 129.3, 129.2, 128.4, 127.6, 60.9, 38.0, 37.7, 22.7, 14.2.  
MS (70 eV, EI), m/z (%) = 320 (M+, 42), 319 (29), 292 (27), 291 (100), 275 (12),  
247 (42), 141 (13), 105 (54), 77 (23). 
HRMS m/z calc. for C21H20O3 (320.1412): 320.1407. 
IR (ATR)
 
υ (cm-1) = 3061, 2981, 2961, 2930, 2901, 2868, 2836, 1709, 1645, 1606, 1592, 
1578, 1447, 1406, 1365, 1342, 1309, 1266, 1176, 1172, 1104, 1022, 862, 844, 772, 715, 
703, 692, 674. 
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Preparation of ethyl 2-((2-benzoylcyclopent-1-en-1-yl)methyl)acrylate (4o) 
 
The allylation reaction of 38e (3.60 mL, 2.00 mmol, 0.56 M in THF) with CuCN·2LiCl  
(2.00 mL, 2.00 mmol, 1 M in THF) and ethyl (2-bromomethyl)acrylate (39b, 347 mg,  
1.80 mmol) was performed according to TP3 over night. Flash column chromatography 
(silica, pentane:Et2O 9:1) furnished 40o as a colorless oil (404 mg, 79 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.70-7.85 (m, 2H), 7.47-7.56 (m, 1H), 7.35- 
7.47 (m, 2H), 6.16 (d, J=1.1Hz, 1H), 5.48 (q, J=1.4Hz, 1H), 4.11 (q, J=7.0Hz, 2H), 3.14 
(s, 2H), 2.63-2.84 (m, 2H), 2.49 (t, J=7.6Hz, 2H), 1.77-2.05 (m, 2H), 1.21  
(t, J=7.1Hz, 3 H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 197.0, 166.7, 148.5, 138.5, 138.2, 137.6, 132.5, 
128.8, 128.4, 126.2, 60.7, 37.2, 36.2, 32.2, 22.4, 14.1. 
MS (70 eV, EI), m/z (%) = 284 (M+, 18), 211 (10), 184 (15), 105 (100), 77 (20). 
HRMS m/z calc. for C8H20O3 (284.1412): 284.1402. 
IR (ATR)
 
υ (cm-1) = 3075, 3061, 3027, 2977, 2954, 2937, 2905, 2852, 1712, 1643, 1596, 
1578, 1447, 1298, 1267, 1235, 1174, 1141, 1124, 1023, 947, 865, 817, 795, 712, 695. 
 
Preparation of 2-[1-tert-butyl-3-oxoprop-1-en-1-yl]benzaldehyde (40p) 
 
The cross-coupling reaction of 38f (3.80 mL, 2.00 mmol, 0.53 M in THF) with  
2-bromobenzaldehyde (39k, 296 mg, 1.60 mmol) was performed according to TP4 in 2 
h. Flash column chromatography (silica, hexanes:Et2O 1:1) furnished 40p as a yellow 
wax (319 mg, 92 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 10.04 (s, 1H). 9.10 (d, J=8.0Hz, 1H), 8.02 (dd,  
J =8.0Hz, 1.4Hz, 1H), 7.65 (td, J =7.5Hz, 1.7Hz, 1H), 7.56 (dt, J=7.5Hz, 1.4Hz, 1H),  
7.22 (dd, J=7.6Hz, 1.0Hz, 1H), 6.39 (d, J=8.0Hz, 1H), 1.18 (s, 9H). 
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13C-NMR (75 MHz, CDCl3) δ (ppm) = 193.0, 190.9, 171.3, 139.3, 134.6, 133.3, 130.2, 
129.3, 128.7, 128.7, 38.0, 29.3. 
MS (70 eV, EI), m/z (%) = 216 (M+, >1), 187 (100), 160 (17), 131 (23), 103 (11),  
77 (13), 57 (17), 41 (11). 
HRMS m/z calc. for C14H16O2 (216.1150): 216.1158. 
IR (ATR)
 
υ (cm-1) = 2970, 2850, 2758 (vw), 1684, 1671, 1591, 1480, 1396, 1366, 1264, 
1198, 1176, 1132, 878, 826, 803, 781, 754, 713, 702.  
 
Preparation of ethyl 2-[(2-formylcyclohex-1-en-1-yl)methyl]prop-2-enoate (40q) 
 
The allylation reaction of 38f (3.85 mL, 2.00 mmol, 0.52 M in THF) with 3-bromocyclo-
hexene (39i, 258 mg, 1.60 mmol) was performed according to TP3 in 30 min. Flash 
column chromatography (silica, pentane:Et2O 95:5) furnished 40q as a colorless oil  
(294 mg, 96 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 10.36 (d, J=8.3Hz, 1H), 5.84 (dd, J=8.2Hz, 
1.2Hz, 1H), 5.77-5.58 (m, 2H), 3.35-3.14 (m, 1H), 2.23-2.09 (m, 3H ), 2.00-1.81 (m, 
1H), 1.79-1.51 (m, 2H), 1.14 (s, 9H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 191.2, 188.1, 152.7, 145.9, 136.1, 64.3, 64.0, 
58.9, 45.4, 29.7, 26.5. 
MS (70 eV, EI), m/z (%) = 192 (M+, 23), 163 (85), 135 (100), 108 (75), 79 (86), 57 (81),  
41 (89). 
HRMS m/z calc. for C13H20O (192.1514): 192.1508. 
IR (ATR)
 
υ (cm-1) = 2938, 2868, 1668, 1614, 1449, 1394, 1366, 1208, 1152, 1134, 1030, 
890, 855, 722, 664.  
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Preparation of (E)-ethyl 4-(4-fluorophenyl)-2-methylene-6-oxohex-4-enoate (40r) 
 
The allylation reaction of 38g (6.30 mL, 2.00 mmol, 0.32 M in THF) with CuCN·2LiCl  
(2.00 mL, 2.00 mmol, 1 M in THF) and ethyl (2-bromomethyl)acrylate (39b, 347 mg,  
1.80 mmol) was performed according to TP3 in 1 h. Flash column chromatography 
(silica, pentane:Et2O 7.5:2.5) furnished 40r as a yellow oil (466 mg, 95 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 10.05 (d, J=7.7Hz, 1H), 7.39-7.54 (m, 2H), 6.96-
7.15 (m, 2H), 6.43 (d, J=7.7Hz, 1H), 6.27 (s, 1H), 5.49 (t, J=1.8Hz, 1H), 4.23 (q, 
J=7.0Hz, 2H), 4.02 (s, 2H) 1.30 (t, J=7.0Hz, 3H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 191.0, 166.1, 163.8 (d, J=251.3Hz), 156.2, 137.3, 
135.0 (d, J=3.4Hz), 128.8, 128.7 (d, J=8.4Hz), 127.0, 116.0 (d, J=21.6Hz), 61.3, 31.6, 
14.1. 
MS (70 eV, EI), m/z (%) = 262 (M+, 9), 233 (22), 205 (20), 190 (12), 189 (100),  
159 (13), 146 (22), 133 (9). 
HRMS m/z calc. for C15H15FO3 (262.1005): 262.1003. 
IR (ATR)
 
υ (cm-1) = 3116, 3062, 2982, 2937, 2910, 2857, 2762, 2724, 1712, 1662, 1600, 
1506, 1225, 1197, 1178, 1159, 1110, 1096, 1027, 1017, 855, 834, 769, 717, 654. 
 
Preparation of (E)-ethyl 4-(4-methoxyphenyl)-2-methylene-6-oxohex-4-enoate (40s) 
 
The allylation reaction of 38h (5.40 mL, 2.00 mmol, 0.37 M in THF) with CuCN·2LiCl  
(2.00 mL, 2.00 mmol, 1 M in THF) and ethyl (2-bromomethyl)acrylate (39b, 347 mg,  
1.80 mmol) was performed according to TP3 in 1 h. Flash column chromatography 
(silica, pentane:Et2O 6:4) furnished 40s as a yellow oil (439 mg, 89 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) =  10.02 (d, J=7.7 Hz, 1H), 7.35-7.59 (m, 2H), 
6.80-7.00 (m, 2H), 6.47 (d, J=7.7Hz, 1H), 6.26 (s, 1H), 5.49 (s, 1H), 4.24 (q, J=7.2Hz, 
2H), 4.01 (s, 2H), 3.82 (s, 3H), 1.30 (t, J=7.2Hz,  3H). 
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13C-NMR (75 MHz, CDCl3) δ (ppm) = 191.2, 166.3, 161.4, 156.9, 137.7, 130.8, 128.3, 
127.2, 126.8, 114.2, 61.2, 55.3, 31.2, 14.1. 
MS (70 eV, EI), m/z (%) = 274 (M+, 9), 246 (11), 245 (19), 228 (20), 217 (15), 202 (14),  
201 (100), 199 (18), 173 (19), 171 (13), 161 (27), 158 (15), 133 (11), 128 (11). 
HRMS m/z calc. for C16H18O4 (274.1205): 274.1198. 
IR (ATR)
 
υ (cm-1) = 3093, 3037, 2978, 2961, 2936, 2905, 2839, 1710, 1661, 1600, 1567, 
1510, 1462, 1442, 1291, 1246, 1177, 1140, 1115, 1027, 961, 828, 752. 
 
Preparation of (Z)-ethyl 4-(4-chlorophenyl)-4-oxo-3-phenylbut-2-enoate (40t) 
 
The acylation reaction of 38i (3.60 mL, 2.00 mmol, 0.56 M in THF) with CuCN·2LiCl  
(2.00 mL, 2.00 mmol, 1 M in THF) and 4-chlorobenzoyl chloride (39l, 280 mg,  
1.60 mmol) was performed according to TP3 in 3 h. Flash column chromatography 
(silica, pentane:Et2O 8.5:1.5) furnished 40t as a white solid (427 mg, 85 %). 
 
m.p.: 126.6-129.3 °C. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.82-7.95 (m, 2H), 7.29-7.54 (m, 7H), 6.50  
(s, 1H), 4.09 (q, J=7.2Hz, 2H), 1.15 (t, J=7.1Hz, 3H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 195.2, 165.0, 155.0, 139.9, 134.5, 133.9, 130.6, 
130.2, 129.2, 129.1, 126.9, 118.0, 61.0, 13.9. 
MS (70 eV, EI), m/z (%) = 314 (M+, 36), 286 (14), 269 (10), 141 (25), 139 (100),  
111 (12). 
HRMS m/z calc. for C18H15ClO3 (314.0710): 314.0702. 
IR (ATR)
 
υ (cm-1) = 3089, 3066, 3030, 2991, 2980, 2903, 1703, 1671, 1615, 1585, 1571, 
1367, 1349, 1340, 1288, 1280, 1219, 1194, 1185, 1175, 1156, 1093, 1021, 1009, 971, 
966, 914, 869, 845, 838, 776, 762, 736, 688. 
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Preparation of (E)-diethyl 5-methylene-3-phenylhex-2-enedioate (40u) 
 
The allylation reaction of 38i (3.60 mL, 2.00 mmol, 0.56 M in THF) with CuCN·2LiCl  
(2.00 mL, 2.00 mmol, 1 M in THF) and ethyl (2-bromomethyl)acrylate (39b, 307 mg,  
1.60 mmol) was performed according to TP3 over night. Flash column chromatography 
(silica, pentane:Et2O 9:1) furnished 40u as a yellow oil (364 mg, 79 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.28-7.52 (m, 5H), 6.31 (s, 1H), 6.17  
(t, J=1.4Hz, 1H), 5.43 (t, J=1.5Hz, 1H), 4.07-4.31 (m, 6H), 1.18-1.40 (m, 6H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 166.8, 166.0, 155.3, 140.3, 137.7, 129.1, 128.5, 
126.7, 125.2, 119.5, 60.8, 60.1, 32.4, 14.2, 14.1. 
MS (70 eV, EI), m/z (%) = 288 (M+, 6), 243 (34), 242 (100), 214 (19), 213 (12),  
185 (17), 170 (29), 169 (68), 142 (22), 141 (91), 115 (21). 
HRMS m/z calc. for C17H20O4 (288.1362): 288.1358. 
IR (ATR)
 
υ (cm-1) = 3104, 3083, 3058, 2980, 2937, 2904, 2872, 1708, 1624, 1446, 1367, 
1268, 1251, 1197, 1164, 1157, 1131, 1095, 1050, 1022, 941, 877, 816, 767, 696. 
 
5.4.1 PREPARATION OF 1-SUBSTITUTED TETRAHYDOPHTHALAZINES  
Preparation of 1-phenyl-5,6,7,8-tetrahydrophthalazine (41a) 
 
The acylation reaction of 38a (3.10 mL, 2.00 mmol, 0.65 M in THF) with benzoyl 
chloride (225 mg, 1.60 mmol) was performed in 14 h followed by the reaction hydrazine 
hydrate (300 mg, 6.00 mmol) according to TP5. Flash column chromatography (silica, 
CH2Cl2:EtOAc 9:1) furnished 41a as a colorless solid (166 mg, 54 %). 
 
m.p.: 80.0-84.2 °C. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 8.86 (s, 1H), 7.30-7.64 (m, 5H), 2.83  
(t, J=6.3Hz, 2H), 2.65 (t, J=6.2Hz, 2 H), 1.73-1.94 (m, 4H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 160.2, 151.5, 138.7, 137.7, 135.8, 134.3, 129.6, 
127.3, 26.4, 26.1, 22.0, 21.3.  
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MS (70 eV, EI), m/z (%) = 210 (M+, 67), 209 (100), 195 (11), 165 (11), 152 (11),  
77 (14). 
HRMS (EI) m/z calc. for C14H14N2 (209.1073): 209.1079. 
IR (ATR)
 
υ (cm-1) = 2922, 2859, 1663, 1565, 1444, 1427, 1407, 1339, 1234, 1070, 1027, 
1017, 1001, 951, 928, 777, 756, 708. 
 
Preparation of 1-(3-chlorophenyl)-5,6,7,8-tetrahydrophthalazine (41b) 
 
The acylation reaction of 38a (3.77 mL, 2.00 mmol, 0.53 M in THF) with  
3-chlorobenzoyl chloride (210 mg, 1.20 mmol) was performed in 14 h followed by the 
reaction hydrazine hydrate (300 mg, 6.00 mmol) according to TP5. Flash column 
chromatography (silica, CH2Cl2:EtOAc 1:1) furnished 41b as a brown solid (160 mg,  
54 %). 
 
m.p.: 110.3-112.0 °C. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 8.85 (s, 1H), 7.56-7.51 (m, 1H), 7.46-7.36  
(m, 3H), 2.81 (t, J=6.3Hz, 2H), 2.64 (t, J=6.2Hz, 2H), 1.93-1.72 (m, 4H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 160.1, 151.5, 138.7, 137.6, 135.7, 134.3, 129.6, 
129.2, 128.9, 127.2, 26.4, 26.0, 22.0, 21.3.  
MS (70 eV, EI), m/z (%): 244 (M+, 61), 243 (100), 229 (14), 109 (7), 165 (8), 153 (8),  
152 (16). 
HRMS (EI) m/z calc. for C14H13ClN2 (245.0846 [M++H]): 245.0839. 
IR (ATR)
 
υ (cm-1) = 2944, 2855, 1562, 1425, 1398, 1331, 1231, 1076, 1022, 1006, 956, 
885, 860, 828, 800, 768, 728, 700.  
 
Preparation of 1-thiophen-2-yl-5,6,7,8-tetrahydrophthalazine (41c) 
 
The acylation reaction of 38a (4.00 mL, 3.00 mmol, 0.75 M in THF) with  
2-thiophenecarbonyl chloride (264 mg, 1.80 mmol) was performed in 14 h followed by 
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the reaction hydrazine hydrate (450 mg, 9.00 mmol) according to TP5. Flash column 
chromatography (silica, CH2Cl2:EtOAc 9:1) furnished 41c as a yellow solid  
(164 mg, 49 %). 
 
m.p.: 120.6-123.4 °C. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 8.72 (s, 1H), 7.52 (dd, J=3.7Hz, 1.1Hz, 1H), 
7.49 (dd, J=5.0Hz, 1.1Hz, 1H), 7.15 (dd, J=5.2Hz, 3.7Hz, 1H), 2.99-2.86 (m, 2H), 2.84-
2.71 (m, 2H), 1.96-1.76 (m, 4H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 154.8, 150.6, 140.5, 137.2, 134.1, 128.6, 128.5, 
127.4, 26.9, 26.3, 22.2, 21.1.  
MS (70 eV, EI), m/z (%): 216 (M+, 100), 215 (68), 160 (50), 91 (49), 77 (54), 44 (67),  
41 (66). 
HRMS (EI) m/z calc. for C12H12N2S (216.0721): 216.0719. 
IR (ATR):
 
υ (cm-1) = 2940, 2860, 1559, 1542, 1437, 1414, 1365, 1300, 1114, 1053, 940, 
928, 858, 836, 798, 708. 
 
5.5 PREPARATION OF ALKENYL ZINC REAGENTS OF FROM LESS ACTIVATED 
ALKENYL BROMIDES  
Preparation of (2-(ethoxycarbonyl)cyclohex-1-en-1-yl)zinc chloride (43a) 
 
According to TP2, the zinc reagent 43a was prepared from ethyl 2-bromocyclohex-1-
ene-1-carboxylate (42a, 2.33 g, 10.0 mmol) using Mg turnings (608 mg, 25.0 mmol), 
LiCl (636 mg, 15.0 mmol) and ZnCl2 (11.0 mL, 1 M in THF) in 14 h at 25 °C. Titration 
with iodine indicates a concentration of 0.33 M (70 %). 
 
Preparation of (2-(ethoxycarbonyl)cyclopent-1-en-1-yl)zinc chloride (43b) 
 
According to TP2, the zinc reagent 7c was prepared from ethyl 2-bromocyclopent-1-ene-
1-carboxylate (42b, 438 mg, 2.00 mmol) using Mg turnings (122 mg, 5.00 mmol), LiCl 
(127 mg, 3.00 mmol) and ZnCl2 (2.2 mL, 1 M in THF) in 14 h at 25 °C. Titration with 
iodine indicates a concentration of 0.42 M (84 %). 
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Preparation of (Z)-(1-methoxy-1-oxohex-2-en-3-yl)zinc chloride (43c) 
 
According to TP2, the zinc reagent 43c was prepared from (Z)-methyl 3-bromohex-2-
enoate (42c, 2.07 g, 10.0 mmol) using Mg turnings (608 mg, 25.0 mmol), LiCl (636 mg, 
15.0 mmol) and ZnCl2 (11.0 mL, 1 M in THF) in 1 h at 25 °C. Titration with iodine 
indicates a concentration of 0.26 M (50 %). 
 
Preparation of 2-bromocyclopentenzinc chloride (43d) 
 
According to TP2, the zinc reagent 43d was prepared from 1,2-dibromocyclopentene 
(42d, 2.26 g, 10.0 mmol) using Mg turnings (608 mg, 25.0 mmol), LiCl (636 mg,  
15.0 mmol) and ZnCl2 (11.0 mL, 1 M in THF) in 8 h at 25 °C. Titration with iodine 
indicates a concentration of 0.51 M (98 %). 
 
Preparation of ((1S,4R)-3-bromobicyclo[2.2.1]hepta-2,5-dien-2-yl)zinc chloride (43e) 
 
According to TP2, the zinc reagent 43e was prepared from 2,3-dibromobicyclo-
[2.2.1]hepta-2,5-diene (43e, 2.50 g, 10.0 mmol) using Mg turnings (608 mg, 25.0 mmol), 
LiCl (636 mg, 15.0 mmol) and ZnCl2 (11.0 mL, 1 M in THF) in 1 h at 25 °C. Titration 
with iodine indicates a concentration of 0.39 M (70 %). 
 
Preparation of (2-(phenylthio)cyclopent-1-en-1-yl)zinc chloride (43f) 
 
According to TP2, the zinc reagent 43f was prepared from (2-bromocyclopent-1-en-1-
yl)(phenyl)sulfane (42f, 2.55 g, 10.0 mmol) using Mg turnings (608 mg, 25.0 mmol), 
LiCl (636 mg, 15.0 mmol) and ZnCl2 (11.0 mL, 1 M in THF) in 1 h at 25 °C. Titration 
with iodine indicates a concentration of 0.35 M (68 %). 
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5.6 REACTIONS OF ALKENYL ZINC REAGENTS OF TYPE 43 WITH ELECTROPHILES 
Preparation of ethyl 2-(5-(trimethylsilyl)thiophen-2-yl)cyclohex-1-enecarboxylate 
(44a) 
 
The cross-coupling reaction of 43a (4.00 mL, 2.00 mmol, 0.50 M in THF) with 2-bromo-
5-trimethylsilylthiophene (39m, 470 mg, 2.00 mmol) was performed according to TP4 in  
3 h. Flash column chromatography (silica, hexanes:Et2O 1:1 then 9:1) furnished 44a as a 
colorless solid (436 mg, 71 %). 
 
m.p.: 106.5-108.2 °C. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.07 (d, J=3.5Hz, 1H), 6.98 (d, J=3.3Hz, 1H), 
4.03 (q, J=7.2Hz, 2H), 2.46-2.38 (m, 4H), 1.75-1.68 (m, 4H), 1.01 (t, J=7.2Hz, 3H),  
0.28 (s, 9H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 170.8, 149.3, 139.7, 134.9, 133.6, 129.7, 126.0, 
60.5, 32.4, 27.2, 22.4, 21.6, 13.6, -0.1. 
MS (70 eV, EI), m/z (%) = 308 (M+, 100), 293 (41), 262 (18), 235 (43), 234 (30),  
103 (20). 
HRMS m/z calc. for C16H24O2SSi (308.1266): 308.1246.  
IR (ATR)
 
υ (cm-1) = 2936, 1709, 1277, 1247, 1218, 1046, 990, 836, 804, 755. 
 
Preparation of ethyl 5-[2-(ethoxycarbonyl)cyclopent-1-en-1-yl]thiophene-2-
carboxylate (44b) 
 
The cross-coupling reaction of 43b (6.25 mL, 2.00 mmol, 0.32 M in THF) with ethyl  
5-bromothiophene-2-carboxylate (39n, 376 mg, 1.60 mmol) was performed according to 
TP4 in 1.5 h. Flash column chromatography (silica, hexanes:Et2O 9:1) furnished 44b as a 
colorless solid (373 mg, 79 %). 
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m.p.: 64.2-65.5 °C. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.70 (d, J=3.9Hz, 1H), 7.46 (d, J=3.9Hz, 1H), 
4.35 (q, J=7.1 Hz, 2H), 4.27 (q, J=7.1Hz, 2H), 3.00 (tt, J=7.7Hz, 2.3Hz, 2H), 2.91-2.83 
(m, 2H), 1.98 (quint, J=7.7Hz, 2H), 1.38 (t, J=7.2Hz, 3H), 1.32 (t, J=7.2Hz, 3H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 165.9, 162.4, 143.8, 143.0, 134.7, 132.6, 129.9, 
129.7, 61.1, 60.5, 39.7, 35.9, 21.5, 14.3, 14.2.  
MS (70 eV, EI), m/z (%) = 294 (M+, 100), 265 (30), 251 (45), 223 (16), 222 (58),  
221 (36), 193 (11), 147 (12). 
HRMS m/z calc. for C15H18O4S (294.0926): 294.0920. 
IR (ATR)
 
υ (cm-1) = 2982, 2961, 1695, 1599, 1519, 1474, 1440, 1366, 1328, 1216, 1098, 
1040, 1022, 824, 752. 
 
Preparation of ethyl 2-[2-(ethoxycarbonyl)prop-2-en-1-yl]cyclopent-1-ene-1-
carboxylate (44c) 
 
The allylation reaction of 43b (6.25 mL, 2.00 mmol, 0.32 M in THF) with CuCN·2LiCl  
(ca. 0.03 mL, 0.03 mmol, 1 M in THF) and ethyl (2-bromomethyl)acrylate (39b, 309 mg, 
1.60 mmol) was performed according to TP3 in 1.5 h. Flash column chromatography 
(silica, pentane:Et2O 9:1) furnished 44c as a colorless oil (348 mg, 86 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 6.23-6.18 (m, 1H), 5.54-5.49 (m, 1H), 4.26-4.12 
(m, 4H), 3.66-3.61 (m, 2H), 2.69-2.60 (m, 2H), 2.49-2.39 (m, 2H), 1.81 (quint, J=7.7 Hz, 
2H), 1.33-1.21 (m, 6H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 167.0, 165.9, 155.1, 137.8, 129.4, 125.5, 60.7, 
59.7, 37.9, 33.6, 31.9, 21.5, 14.3, 14.1. 
MS (70 eV, EI), m/z (%) = 252 (M+, 2), 206 (100), 149 (56), 134 (35), 133 (75),  
105 (68), 79 (31). 
HRMS m/z calc. for C14H20O4 (252.1362): 252.1353. 
IR (ATR)
 
υ (cm-1) = 2980, 1706, 1631, 1446, 1368, 1255, 1174, 1144, 1107, 1026, 946, 
771.  
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Preparation of (Z)-methyl 3-(4-chlorobenzoyl)hex-2-enoate (44d) 
 
The acylation reaction of 43c (7.70 mL, 2.00 mmol, 0.26 M in THF) with CuCN·2LiCl  
(2.00 mL, 2.00 mmol, 1 M in THF) and 4-chlorobenzoyl chloride (39l, 315 mg,  
1.80 mmol) was performed according to TP3 in 1 h. Flash column chromatography 
(silica, pentane:Et2O 9:1) furnished 44d as a yellow oil (412 mg, 86 %). 
 
1H-NMR (400 MHz, CDCl3) δ (ppm) = 7.75-7.90 (m, 2H), 7.35-7.51 (m, 2H), 5.99  
(t, J=1.6Hz, 1H), 3.55 (s, 3H), 2.36 (dt, J=7.8Hz, 1.6Hz, 2H), 1.46-1.61 (m, 2H), 0.96  
(t, J=7.4Hz, 3H). 
13C-NMR (100 MHz, CDCl3) δ (ppm) = 196.9, 165.4, 159.0, 139.9, 133.5, 129.9, 129.1, 
118.3, 51.7, 37.1, 20.3, 13.6. 
MS (70 eV, EI), m/z (%) = 266 (M+, 3), 236 (10), 235 (16), 234 (23), 199 (23), 172 (10),  
171 (30), 139 (100), 111 (36), 75 (14). 
HRMS m/z calc. for C14H15ClO3 (266.0710): 266.0712. 
IR (ATR)
 
υ (cm-1) = 3095, 3071, 3033, 2991, 2962, 2950, 2927, 2904, 2875, 1718, 1671, 
1635, 1586, 1571, 1436, 1398, 1338, 1286, 1251, 1232, 1195, 1167, 1122, 1107, 1085, 
1023, 1012, 960, 930, 894, 840, 829, 755, 742, 729, 680, 653.  
 
Preparation of (Z)-6-ethyl 1-methyl 5-methylene-3-propylhex-2-enedioate (44e) 
 
The allylation reaction of 43c (7.70 mL, 2.00 mmol, 0.26 M in THF) with CuCN·2LiCl  
(2.00 mL, 2.00 mmol, 1 M in THF) and ethyl (2-bromomethyl)acrylate (39b, 348 mg,  
1.80 mmol) was performed according to TP3 in 2 h. Flash column chromatography 
(silica, pentane:Et2O 9.5:0.5) furnished 44e as a colorless oil (368 mg, 77 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 6.21 (q, J=1.1Hz, 1H), 5.81 (s, 1H), 5.48  
(q, J=1.7Hz, 1H), 4.20 (q, J=7.0Hz, 2H), 3.52-3.83 (m, 5H), 1.97-2.18 (m, 2H), 1.39-
1.55 (m, 2H), 1.28 (t, J=7.1Hz, 3H), 0.89 (t, J=7.5 Hz, 3H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 166.9, 166.6, 159.9, 137.5, 125.3, 117.2, 60.8, 
50.9, 39.9, 33.2, 20.8, 14.1, 13.7. 
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MS (70 eV, EI), m/z (%) = 240 (M+, 3), 208 (53), 195 (32), 194 (52), 180 (30), 167 (28),  
162 (63), 151 (28), 135 (90), 134 (85), 107 (100), 106 (43), 105 (22), 93 (23), 91 (58),  
79 (54), 77 (30). 
HRMS m/z calc. for C13H20O4 (240.1362): 240.1344. 
IR (ATR)
 
υ (cm-1) = 2959, 2934, 2907, 2874, 1713, 1645, 1629, 1433, 1368, 1325, 1272, 
1245, 1191, 1176, 1131, 1093, 1022, 940, 928, 876, 817. 
 
Preparation of 1-bromo-2-(3-cyclohexen-1-yl)cyclopentene (44f) 
 
The allylation reaction of 43d (4.30 mL, 2.40 mmol, 0.56 M in THF) with CuCN·2LiCl  
(ca. 0.03 mL, 0.03 mmol, 1 M in THF) and 3-bromocyclohexene (39i, 322 mg,  
2.00 mmol) was performed according to TP3 in 1 h. Flash column chromatography 
(silica, hexanes) furnished 44f as a colorless oil (392 mg, 86 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 5.85-5.70 (m, 1H), 5.45-5.35 (m, 1H), 3.40-3.30 
(m, 1H), 2.70-2.55 (m, 2H), 2.35-2.20 (m, 2H), 2.20-1.40 (m, 8H).  
13C-NMR (75 MHz, CDCl3) δ (ppm) = 143.9, 128.8, 128.2, 115.2, 39.8, 36.7, 31.1, 26.7, 
24.7, 21.8, 21.7. 
MS (70 eV, EI), m/z (%) = 226 (M+, 7), 147 (100), 119 (37), 91 (57), 91 (57). 
HRMS m/z calc. for C11H15Br (226.0357): 226.0335. 
IR (ATR)
 
υ (cm-1) = 2930, 2855, 1708, 1652, 1445, 1316, 1044, 917, 881, 722. 
 
Preparation of (2-bromocyclopent-1-en-1-yl)(2-bromophenyl)methanone (44g) 
 
The acylation reaction of 44d (3.51 mL, 2.00 mmol, 0.57 M in THF) with CuCN·2LiCl  
(2.00 mL, 2.00 mmol, 1.0 M in THF) and 2-bromobenzoyl chloride (39d, 527 mg,  
2.40 mmol) was performed according to TP3 in 4 h. Flash column chromatography 
(silica, hexanes:CH2Cl2 4:1) furnished 44g as a colorless oil (421 mg, 64 %). 
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1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.67-7.52 (m, 1H), 7.49-7.19 (m, 3H), 2.90  
(tt, J=7.8Hz, 2.3Hz, 2H), 2.84-2.74 (m, 2H), 2.04 (quint, J=7.7Hz, 2H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 193.4, 141.2, 139.5, 133.1, 133.0, 131.3, 128.9, 
127.5, 119.5, 43.9, 33.4, 21.5. 
MS (70 eV, EI), m/z (%) = 330 (M+, 14), 250 (96), 249 (100), 185 (51), 183 (51),  
170 (50). 
HRMS m/z calc. for C12H10Br2O (329.9255): 329.9074. 
IR (ATR)
 
υ (cm-1) = 2925, 1647, 1588, 1431, 1330, 1298, 1250, 1025, 744, 683. 
 
Preparation of 3-(2-bromocyclopent-1-en-1-yl)cyclohexanone (44h) 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with the alkenyl zinc reagent 43d (4.3 mL, 2.40 mmol, 0.56 M in THF) and 
cooled to -40 °C. CuCN·2LiCl (2.40 mL, 2.40 mmol, 1.0 M in THF) was added, followed 
by a solution of cyclohexenone (39o, 192 mg, 2.00 mmol) and chlorotrimethylsilane  
(0.8 mL, 5 mmol) in THF (1 mL) and the reaction mixture was stirred for 0.5 h at -40 °C 
and then 2 h at room temperature. The reaction was quenched with sat. NH4Cl/NH3 (9:1) 
solution (10 mL) and extracted with Et2O (3x20 mL). The combined organic phases were 
washed with sat. NaCl solution (10 mL), dried over Na2SO4 and concentrated in vacuo. 
The crude residue obtained was purified by flash column chromatography (silica, 
hexanes:Et2O 9:1) to give 44h as a colorless oil (338 mg, 70 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 3.04-2.91 (m, 1H), 2.68-2.58 (m, 2H), 2.47-2.20 
(m, 5H), 2.19-2.05 (m, 1H), 2.01-1.88 (m, 2H), 1.85-1.53 (m, 4H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 210.5, 141.6, 116.0, 45.1, 41.1, 39.8, 39.5, 30.3, 
29.0, 25.4, 21.5. 
MS (70 eV, EI), m/z (%) = 242 (M+, >1), 163 (35), 91 (16), 70 (16), 61 (16), 43 (100). 
HRMS m/z calc. for C11H15BrO (242.0306): 242.0288. 
IR (ATR)
 
υ (cm-1) = 2935, 1699, 1652, 1446, 1319, 1261, 1221, 1061, 926, 755. 
 
 
 
 
C. EXPERIMENTAL SECTION 
264 
Preparation of 3-(2-bromocyclopent-1-en-1-yl)cyclohex-3-enone (44i) 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with the alkenylzinc reagent 43d (4.3 mL, 2.40 mmol, 0.56 M in THF) and 
cooled to -40 °C. CuCN·2LiCl (2.40 mL, 2.40 mmol, 1.0 M in THF) was added, followed 
by 3-iodocyclohexenone (39p, 444 mg, 2.00 mmol) and the reaction mixture was stirred 
for 0.5 h at -40 °C and then 2 h at 0 °C. The reaction was quenched with sat. NH4Cl/NH3 
(9:1) solution (10 mL) and extracted with Et2O (3x20 mL). The combined organic phases 
were washed with sat. NaCl solution (10 mL), dried over Na2SO4 and concentrated  
in vacuo. The crude residue obtained was purified by flash column chromatography 
(silica, hexanes:Et2O 9:1) to give 44i as a colorless oil (314 mg, 65 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 6.10 (s, 1H). 2.85-2.70 (m, 4H), 2.65-2.50 (m, 
2H), 2.45-2.35 (m, 2H), 2.20-1.90 (m, 4H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 200.1, 155.9, 137.9, 127.2, 123.7, 43.7, 37.4, 
34.9, 28.3, 22.9, 21.7.  
MS (70 eV, EI), m/z (%) = 242 (31), 240 (M+, 32), 161 (38), 133 (100), 105 (44). 
HRMS m/z calc. for C11H13BrO (240.0150): 240.0146. 
IR (ATR)
 
υ (cm-1) = 2945, 1658, 1589, 1325, 1254, 1188, 1133, 956, 884, 732. 
 
Preparation of 1-bromo-2-(2-ethoxycarbonylethynyl)cyclopentene (44j) 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with the alkenylzinc reagent 43d (3.80 mL, 2.00 mmol, 0.53 M in THF) and 
cooled to -78 °C. CuCN·2LiCl (0.20 mL, 0.20 mmol, 1.0 M in THF) was added, followed 
by a solution of ethyl 3-bromoprop-2-ynoate (39c, 425 mg, 2.40 mmol) in THF (2 mL) 
and the reaction mixture was stirred for 3 h at -78 °C. The reaction was quenched with 
sat. NH4Cl solution (10 mL) and extracted with Et2O (3x20 mL). The combined organic 
phases were washed with sat. NaCl solution (10 mL), dried over Na2SO4 and 
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concentrated in vacuo. The crude residue obtained was purified by flash column 
chromatography (silica, hexanes:Et2O 10:1) to give 44j as a colorless oil (377 mg, 78 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 4.27 (q, J=7.1Hz, 2H), 2.78 (tt, J=7.7Hz, 2.6Hz, 
2H), 2.61-2.51 (m, 2H), 2.11-1.97 (m, 2H), 1.33 (t, J=7.1Hz, 3H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 153.9, 134.8, 121.9, 85.9, 81.4, 62.1, 40.9, 35.5, 
22.6, 14.1. 
MS (70 eV, EI), m/z (%) = 242 (M+, 4), 91 (100), 90 (53), 89 (57), 63 (62), 62 (53). 
HRMS m/z calc. for C10H11BrO2 (241.9942): 241.9936. 
IR (ATR)
 
υ (cm-1) = 2981, 2204, 1704, 1366, 1268, 1207, 1162, 1092, 1020, 746. 
 
Preparation of 5-(2-bromocyclopent-1-en-1-yl)pyridine-3-carbonitrile (44k) 
 
The cross-coupling reaction of 43d (3.92 mL, 2.00 mmol, 0.51 M in THF) with 5-bromo-
3-cyanopyridine (39e, 403 mg, 2.20 mmol) was performed according to TP4 in 3 h. 
Flash column chromatography (silica, hexanes:Et2O 3:1) furnished 44k as a brown solid  
(271 mg, 54 %). 
 
m.p.: 74.8-76.7 °C. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 9.01 (d, J=2.2Hz, 1H), 8.77 (d, J=1.9 Hz, 1H), 
8.25 (t, J=2.1Hz, 1H), 2.97-2.86 (m, 2H), 2.86-2.75 (m, 2H),  2.18-2.04 (m, 2H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 151.5, 150.4, 137.5, 133.3, 132.2, 122.2, 116.4, 
109.5, 42.5, 35.4, 21.8.  
MS (70 eV, EI), m/z (%) = 248 (M+, 34), 169 (100), 168 (23), 142 (12), 115 (12),  
63 (11). 
HRMS m/z calc. for C11H9BrN2 (247.9949): 247.9930. 
IR (ATR)
 
υ (cm-1) = 2943, 2844, 2231, 1620, 1559, 1431, 1423, 1308, 1289, 1186, 1158, 
1092, 1026, 932, 904, 787, 701, 666. 
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Preparation of ethyl 4-((1S,4R)-3-bromobicyclo[2.2.1]hepta-2,5-dien-2-yl)benzoate 
(44l) 
 
The cross-coupling reaction of 43e (5.15 mL, 2.00 mmol, 0.39 M in THF) with ethyl  
4-iodobenzoate (39h, 442 mg, 1.60 mmol) was performed according to TP4 in 5 h. Flash 
column chromatography (silica, pentane:Et2O 50:1) furnished 44l as a yellow oil  
(306 mg, 60 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.96-8.08 (m, 2H), 7.51-7.76 (m, 2H), 6.77-7.09 
(m, 2H), 4.37 (q, J=7.0Hz, 2H), 3.86-4.02 (m, 1H), 3.60-3.78 (m, 1H), 2.36 (dt, J=6.4Hz,  
1.7Hz, 1H), 2.16 (dt, J=6.4Hz, 1.8Hz, 1H), 1.39 (t, J=7.1Hz, 3H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 166.3, 147.6, 141.7, 141.4, 139.3, 132.7, 129.4, 
128.9, 125.7, 70.3, 60.9, 60.8, 54.8, 14.3. 
MS (70 eV, EI), m/z (%) = 320 (M+, 70), 318 (M+, 70), 240 (14), 239 (63), 213 (13),  
211 (19), 168 (10), 167 (63), 166 (86), 165 (100), 152 (14), 66 (35). 
HRMS m/z calc. for C16H15BrO2 (318.0255): 318.0253. 
IR (ATR)
 
υ (cm-1) = 3119, 3066, 2979, 2938, 2904, 2869, 1756, 1710, 1605, 1407, 1366, 
1269, 1251, 1181, 1101, 1018, 854, 771, 761, 718, 701.  
 
Preparation of ethyl 2-(((1S,4R)-3-bromobicyclo[2.2.1]hepta-2,5-dien-2-yl)methyl)-
acrylate (44m) 
 
The allylation reaction of 43e (5.15 mL, 2.00 mmol, 0.39 M in THF) with CuCN·2LiCl  
(2.00 mL, 2.00 mmol, 1 M in THF) and ethyl (2-bromomethyl)acrylate (39b, 348 mg,  
1.80 mmol) was performed according to TP3 overnight. Flash column chromatography 
(silica, pentane:Et2O 50:1) furnished 44m as a yellow oil (310 mg, 61 %). 
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1H-NMR (300 MHz, CDCl3) δ (ppm) = 6.60-6.96 (m, 2H), 6.19 (d, J=1.1Hz, 1H), 4.20 
(q, J=6.8Hz, 2H), 3.51 (bs, 1H), 3.40 (bs, 1H), 3.04-3.29 (m, 2H), 2.21 (dt, J=6.1Hz, 
1.5Hz, 1H), 2.03 (dt, J=6.1Hz, 1.8Hz, 1H), 1.30 (t, J=7.2Hz, 3H), 0.03-0.22 (m, 1H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 166.9, 147.9, 142.0, 141.5, 136.5, 131.6, 126.0, 
71.7, 60.8, 58.2, 53.7, 31.8, 14.2. 
MS (70 eV, EI), m/z (%) = 284 (M+, 16), 282 (M+, 16), 218 (17), 216 (18), 203 (59), 175 
(29), 157 (34), 131 (19), 130 (28), 129 (100), 128 (41), 127 (15), 115 (20), 103 (19),  
91 (20), 66 (23), 43 (13). 
HRMS m/z calc. for C13H15BrO2 (282.0255): 282.0250. 
IR (ATR)
 
υ (cm-1) = 3067, 2977, 2938, 2905, 2869, 1713, 1629, 1368, 1295, 1250, 1219, 
1175, 1140, 1114, 1026, 945, 842, 812, 705.  
 
Preparation of ethyl 4-(2-(phenylthio)cyclopent-1-en-1-yl)benzoate (44n) 
 
The cross-coupling reaction of 43f (5.70 mL, 2.00 mmol, 0.35 M in THF) with ethyl  
4-iodobenzoate (39h, 442 mg, 1.60 mmol) was performed according to TP4 in 3 h. Flash 
column chromatography (silica, pentane:Et2O 9,5:0,5) furnished 44n as a colorless oil 
(420 mg, 81 %). 
 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.94-8.12 (m, 2H), 7.55-7.71 (m, 2H), 7.15-7.47 
(m, 5H), 4.38 (q, J=7.2Hz, 2H), 2.84-2.99 (m, 2H), 2.46-2.62 (m, 2H), 1.96 (quin, 
J=7.3Hz, 2H), 1.39 (t, J=7.1Hz, 3H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 166.4, 141.3, 139.8, 133.7, 132.9, 131.7, 129.3, 
128.9, 128.7, 127.5, 127.3, 60.8, 38.8, 37.4, 22.0, 14.3. 
MS (70 eV, EI), m/z (%) = 324 (M+, 100), 279 (6), 218 (5), 173 (4), 141 (9), 128 (5),  
115 (8). 
HRMS m/z calc. for C20H20O2S (324.1184): 324.1166. 
IR (ATR)
 
υ (cm-1) = 3070, 3056, 2976, 2952, 2934, 2903, 2843, 1709, 1605, 1575, 1474, 
1439, 1405, 1365, 1269, 1181, 1105, 1097, 1022, 850, 771, 741, 700, 690.  
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Preparation of (4-chlorophenyl)(2-(phenylthio)cyclopent-1-en-1-yl)methanone (44o) 
 
The acylation reaction of 43f (5.70 mL, 2.00 mmol, 0.35 M in THF) with CuCN·2LiCl  
(2.00 mL, 2.00 mmol, 1 M in THF) and 4-chlorobenzoyl chloride (39l, 280 mg,  
1.60 mmol) was performed according to TP3 overnight. Flash column chromatography 
(silica, pentane:Et2O 9.5:0.5) furnished 44o as a white solid (432 mg, 86 %). 
 
m.p.: 74.7-76.3 °C. 
1H-NMR (300 MHz, CDCl3) δ (ppm) = 7.63-7.75 (m, 2H), 7.46-7.57 (m, 2H), 7.28-7.46 
(m, 5H), 2.80-2.93 (m, 2H), 2.33-2.46 (m, 2H), 1.80-1.97 (m, 2H). 
13C-NMR (75 MHz, CDCl3) δ (ppm) = 191.2, 159.0, 137.9, 137.7, 134.5, 132.3, 129.6, 
129.0, 129.0, 128.5, 128.5, 38.7, 35.7, 23.6. 
MS (70 eV, EI), m/z (%) = 314 (M+, 61), 236 (18), 203 (22), 175 (15), 147 (13),  
142 (12), 141 (14), 139 (100), 111 (54), 110 (35), 109 (10), 77 (16), 75 (12), 65 (15). 
HRMS m/z calc. for C18H15ClOS (314.0532): 314.0527. 
IR (ATR)
 
υ (cm-1) = 3083, 3063, 3045, 2993, 2984, 2913, 1706, 1675, 1615, 1585, 1574, 
1366, 1349, 1340, 1288, 1280, 1219, 1194, 1185, 1175, 1156, 1093, 1021, 1009, 971, 
966, 914, 869, 846, 773, 764, 736, 688. 
  
C. EXPERIMENTAL SECTION 
269 
6. SYNTHESIS OF FUNCTIONALIZED ADAMANTYLZINC REAGENTS 
USING A Br/Mg-INSERTION IN THE PRESENCE OF ZnCl2 
6.1 PREPARATION OF STARTING MATERIALS 
All reagents were obtained from commercial sources. Compound 45c287 was prepared 
according to a literature-known procedure. 
 
Preparation of ethyl 3-bromoadamantane-1-carboxylate (45b) 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with 3-bromoadamantane-1-carboxylic acid288 (5.2 g, 20 mmol) and 
dissolved in 100 mL EtOH. After cooling to 0 °C, SOCl2 (3,57 g, 30 mmol) was added 
dropwise and the reaction mixture was stirred over night while slowly warming up to 
room temperature. The reaction was quenched with water (100 mL) and extracted with 
EtOAc (3x100 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. The pure product was obtained without further purification as a 
colorless oil (5.69 g, 99 %). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 4.11 (q, J=7.2Hz, 2H), 2.47 (s, 2H), 2.23-2.39 
(m, 4H), 2.14-2.24 (m, 2H), 1.88 (d, J=3.0Hz, 4H), 1.69 (d, J=1.4Hz, 2H), 1.24 (t, 
J=7.0Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 175.4, 63.9, 60.5, 49.7, 48.1, 44.9, 37.1, 34.5, 
31.7, 14.1.  
MS (70 eV, EI), m/z (%) = 285 ([M-H]+, 2), 208 (13), 207 (100), 161 (16), 133 (45),  
91 (14), 79 (13), 43 (18). 
HRMS (EI), m/z calc. for C13H18BrO2 (285.0490 ([M-H])): 285.0490 ([M-H]). 
IR (ATR) υ (cm-1) = 2979, 2935, 2911, 2859, 1724, 1476, 1453, 1365, 1332, 1310, 1244, 
1219, 1171, 1149, 1103, 1075, 1020, 1004, 968, 945, 909, 863, 825, 744, 697, 672. 
 
 
                                                 
287
 M. Xie, W. J. le Noble, J. Org. Chem. 1989, 54, 3836. 
288
 K. H. Min, E. K. Kim, E. S. Kim, D. K. Kim, Y. Xia, Y.  Jin, N. Kaur, K. Lee, K. Lee, H. Y. Jung, Y. 
Choi, M.-K. Park, Y. K. Min, Bioorg. Med. Chem. Lett. 2009, 19, 5376. 
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6.2 TYPICAL PROCEDURES 
Typical procedure 1 (TP1): LiCl-mediated magnesium insertion in the presence of 
zinc chloride in adamantyl bromides 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with LiCl (1.1 equiv) and heated with a heat gun under high vacuum  
(5 min). After cooling to room temperature, magnesium turnings (2 equiv) were added, 
followed by THF (1 mL/mmol). The magnesium was activated using 1,2-dibromoethane 
(5 mol%) and TMSCl (5 mol%). Then, ZnCl2-solution (1.1 equiv, 1 M in THF) was 
added followed by the substrate (1 equiv). The reaction mixture was stirred at 25 °C until 
GC-analysis of hydrolyzed reaction aliquot showed full consumption of the starting 
material. Then, solids were allowed to settle or the reation mixture was centrifuged 
(10 min, 2000 rpm). The yield of the insertion rection was determined by iodometric 
titration192 of the supernatant solution. 
 
Typical procedure 2 (TP2): Cross-coupling reactions of adamantyl zinc reagents  
The desired aryl halide (0.9 equiv) was added to the freshly prepared zinc reagent 
followed by Pd(OAc)2 (1 mol%) and SPhos (2 mol%) and the mixture was stirred for the 
given time at 50 °C. The reaction mixture was quenched with sat. NH4Cl solution  
(10 mL) and extracted with EtOAc (3x20 mL). The combined organic phases were dried 
over Na2SO4 and concentrated in vacuo. The crude residue obtained was purified by flash 
column chromatography to give the analytically pure product. 
 
Typical procedure 3 (TP3):  Acylation of adamantly zinc reagents 
The freshly prepared zinc reagent was cooled to -40 °C and the corresponding acyl 
chloride (0.9 equiv) was added, followed by CuCN·2LiCl (1 M in THF). The reaction 
mixture was allowed to warm to room temperature. After stirring for the given time, the 
reaction mixture was quenched with sat. NH4Cl/NH3 (9:1) solution (10 mL), washed with 
sat. NH4Cl/NH3 solution (9:1, 2x10 mL) and extracted with EtOAc (3x10 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. The crude 
residue obtained was purified by flash column chromatography to give the analytically 
pure product. 
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Typical procedure 4 (TP4):  Addition of adamantly zinc reagents to nitroso 
derivatives 
To the freshly prepared adamantyl zinc reagent was added the nitroso derivative  
(0.9 equiv, 1.0M in THF and the reaction mixture was stirred for the indicated time at 
room temperature. EtOH (1 ml/mmol), FeCl2 (2 equiv) and NaBH4 (1.1 equiv) were 
added and the reaction mixture was stirred at room temperature over night. After stirring 
for the given time, the reaction mixture was quenched with sat. NH4Cl solution (10 mL) 
and extracted with EtOAc (3x10 mL). The combined organic phases were dried over 
Na2SO4 and concentrated in vacuo. The crude residue obtained was purified by flash 
column chromatography to give the analytically pure product. 
 
6.3 PREPARATION OF FUNCTIONALIZED ADAMANTYLZINC REAGENTS 
Preparation of adamantan-1-ylzinc chloride (46a) 
 
According to TP1, the zinc reagent 46a was prepared from 1-bromoadamantane (45a,  
1.08 g, 5.0 mmol) using Mg turnings (241 mg, 10.0 mmol), LiCl (233 mg, 5.5 mmol) and 
ZnCl2 (5.5 mL, 1 M in THF) in 2 h at 25 °C. Titration against iodine indicates a 
concentration of 0.32 M (85 %). 
 
Preparation of 3-(ethoxycarbonyl)adamantan-1-yl)zinc chloride (46b) 
 
According to TP1, the zinc reagent 46b was prepared from ethyl 3-bromoadamantane-1-
carboxylate (45b, 1.44 g, 5.0 mmol) using Mg turnings (241 mg, 10.0 mmol), LiCl  
(233 mg, 5.5 mmol) and ZnCl2 (5.5 mL, 1 M in THF) in 2 h at 25 °C. Titration against 
iodine indicates a concentration of 0.24 M (63 %). 
 
Preparation of spiro[adamantane-2,2'-[1,3]dioxolan]-5-ylzinc chloride (46c) 
 
According to TP1, the zinc reagent 46c was prepared from 5-bromospiro[adamantane-
2,2'-[1,3]dioxolane] (45c, 1.37 g, 5.0 mmol) using Mg turnings (241 mg, 10.0 mmol), 
C. EXPERIMENTAL SECTION 
272 
LiCl (233 mg, 5.5 mmol) and ZnCl2 (5.5 mL, 1 M in THF) in 3 h at 25 °C. Titration 
against iodine indicates a concentration of 0.22 M (57 %). 
6.4 FUNCTIONALIZATION OF ADAMANTYLZINC REAGENTS 
Preparation of ethyl 4-(adamantan-1-yl)benzoate (48a) 
 
The cross-coupling reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with Pd(OAc)2 
 (2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and ethyl 4-chlorobenzoate (47c, 166 mg, 
0.9 mmol) was performed according to TP2 in 2 h. Flash column chromatography (silica, 
pentane:Et2O 50:1) furnished 48a as a white solid (222 mg, 87 %). 
 
m.p.: 119.8-120.8 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.90-8.05 (m, 2H), 7.35-7.49 (m, 2H), 4.36 (q, 
J=7.2Hz, 2H), 2.11 (bs, 3H), 1.92 (d, J=2.8Hz, 6H), 1.70-1.86 (m, 6H), 1.38 (t, J=7.2Hz, 
3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.7, 156.5, 129.4, 127.7, 124.9, 60.7, 42.9, 
36.7, 36.6, 28.8, 14.4.  
MS (70 eV, EI), m/z (%) = 284 (M+, 2), 88 (5), 73 (6), 70 (11), 61 (16), 45 (15), 44 (6),  
43 (100), 42 (6). 
HRMS (EI), m/z calc. for C19H24O2 (284.1776): 284.1771. 
IR (ATR) υ (cm-1) = 2908, 2849, 1712, 1609, 1447, 1408, 1368, 1309, 1275, 1188, 1179, 
1102, 1042, 1015, 977, 960, 874, 860, 851, 814, 768, 714, 704. 
 
Preparation of 4-(adamantan-1-yl)benzonitrile (48b) 
 
The cross-coupling reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and 4-bromobenzonitrile (47d, 164 mg,  
0.9 mmol) was performed according to TP2 in 2 h. Flash column chromatography (silica, 
pentane:Et2O 20:1) furnished 48b as a white solid (187 mg, 88 %). 
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m.p.: 125.3-127.1 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.53-7.66 (m, 2H), 7.37-7.51 (m, 2H), 2.12 (bs, 
3H), 1.89 (d, J=2.8Hz, 6H), 1.67-1.85 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 156.7, 132.0, 125.8, 119.2, 109.3, 42.7, 36.8, 
36.5, 28.7.  
MS (70 eV, EI), m/z (%) = 237 (M+, 56), 181 (27), 180 (75), 135 (20), 94 (25), 61 (17),  
45 (15), 43 (100). 
HRMS (EI), m/z calc. for C17H19N (237.1517): 237.1503. 
IR (ATR) υ (cm-1) = 3069, 3045, 3041, 2915, 2897, 2847, 2233, 1607, 1505, 1448, 1408, 
1398, 1343, 1318, 1289, 1260, 1175, 1100, 1067, 1040, 1031, 1019, 974, 850, 834, 805. 
 
Preparation of 1-(adamantan-1-yl)phenyl)ethanone (48c) 
 
The cross-coupling reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and 1-(4-bromophenyl)ethanone (47e,  
179 mg, 0.9 mmol) was performed according to TP2 in 2 h. Flash column 
chromatography (silica, pentane:Et2O 20:1) furnished 48e as a white solid (192 mg,  
84 %). 
 
m.p.: 115.6-116.8 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.91 (d, J=8.6Hz, 2H), 7.45 (d, J=8.8Hz, 2H), 
2.58 (s, 3H), 2.11 (bs, 3H), 1.93 (d, J=2.8Hz, 6H), 1.67-1.88 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 197.9, 156.9, 134.6, 128.3, 125.1, 42.9, 36.7, 
36.7, 28.8, 26.5.  
MS (70 eV, EI), m/z (%) = 254 (M+, 2), 239 (8), 88 (5), 70 (10), 61 (16), 45 (14),  
43 (100), 42 (6). 
HRMS (EI), m/z calc. for C18H22O (254.1671): 254.1665. 
IR (ATR) υ (cm-1) = 2908, 2848, 1714, 1679, 1602, 1562, 1406, 1359, 1345, 1269, 1244, 
1191, 1177, 1104, 1077, 1058, 1041, 1032, 1012, 976, 963, 951, 847, 832, 804, 768, 678. 
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Preparation of (4-(adamantan-1-yl)phenyl)(methyl)sulfane (48d) 
 
The cross-coupling reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and (4-bromophenyl)-(methyl)sulfane (47f, 
183 mg, 0.9 mmol) was performed according to TP2 in 2 h. Flash column 
chromatography (silica, pentane:Et2O 9:1) furnished 48d as a white solid (218 mg,  
94 %). 
 
 
m.p.: 78.2-80.8 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.19-7.41 (m, 4H), 2.49 (s, 3H), 2.12 (bs, 3H), 
1.91 (d, J=2.8Hz, 6H), 1.69-1.86 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 148.6, 134.8, 126.9, 125.5, 43.2, 36.8, 35.9, 28.9, 
16.3.  
MS (70 eV, EI), m/z (%) = 258 (M+, 100), 201 (47), 164 (13), 154 (28), 57 (14),  43 (11),  
41 (10). 
HRMS (EI), m/z calc. for C17H22S (258.1442): 258.1448. 
IR (ATR) υ (cm-1) = 3074, 3055, 3024, 2906, 2897, 2846, 1495, 1446, 1433, 1398, 1342, 
1246, 1175, 1101, 1092, 1033, 1010, 963, 824, 804, 796, 737, 718. 
 
Preparation of 4-(adamantan-1-yl)-N,N-dimethylaniline (48e) 
 
The cross-coupling reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and 4-bromo-N,N-dimethylaniline (47g,  
180 mg, 0.9 mmol) was performed according to TP2 in 2 h. Flash column 
chromatography (silica, pentane:Et2O 9:1) furnished 48e as a white solid (142 mg, 62 %). 
 
m.p.: 118.2-119.8 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.23-7.35 (m, 2H), 6.72-6.86 (m, 2H), 2.86-3.07 
(m, 6H), 2.12 (bs, 3H), 1.89-2.00 (m, 6H), 1.72-1.87 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 148.6, 140.0, 125.4, 112.8, 43.4, 40.9, 36.9, 35.3, 
29.1.  
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MS (70 eV, EI), m/z (%) = 255 (M+, 100), 199 (16), 198 (87), 184 (8), 161 (10), 135 (8),  
134 (21), 43 (16). 
HRMS (EI), m/z calc. for C18H25N (255.1987): 255.1977. 
IR (ATR) υ (cm-1) = 3090, 3032, 2983, 2896, 2844, 1615, 1518, 1491, 1446, 1442, 1356, 
1350, 1341, 1232, 1205, 1165, 1099, 1063, 975, 949, 822, 797. 
 
Preparation of (4-(adamantan-1-yl)phenyl)trimethylsilane (48f) 
 
The cross-coupling reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and (4-bromophenyl)trimethylsilane (47h, 
206 mg, 0.9 mmol) was performed according to TP2 in 2 h. Flash column 
chromatography (silica, pentane pur) furnished 48f as a white solid (205 mg, 80 %). 
 
m.p.: 126.2-127.9 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.46-7.57 (m, 2H), 7.35-7.44 (m, 2H), 2.13 (bs, 
3H), 1.96 (d, J=2.8Hz, 6H), 1.69-1.89 (m, 6H), 0.29 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 151.9, 137.0, 133.3, 124.3, 43.1, 36.8, 36.2, 29.0, 
-1.0.  
MS (70 eV, EI), m/z (%) = 284 (M+, 9), 271 (8), 270 (23), 269 (100), 135 (4), 73 (8),  
43 (11). 
HRMS (EI), m/z calc. for C19H28Si (284.1960): 284.1958. 
IR (ATR) υ (cm-1) = 3070, 3015, 2954, 2905, 2847, 1596, 1448, 1396, 1342, 1250, 1244, 
1115, 1102, 1031, 1017, 859, 835, 826, 798, 757, 722, 691, 668. 
 
Preparation of 4-(adamantan-1-yl)benzaldehyde (48g) 
 
The cross-coupling reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and 4-bromobenzaldehyde (47i, 167 mg, 
0.9 mmol) was performed according to TP2 in 1 h. Flash column chromatography (silica,  
pentane:Et2O 50:1) furnished 48g as a white solid (190 mg, 88 %). 
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m.p.: 97.0-98.9 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) =  9.98 (s, 1H), 7.75-7.89 (m, 2H), 7.45-7.62 (m, 
2H), 2.13 (bs, 3H), 1.94 (d, J=2.8Hz, 6H), 1.66-1.88 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 192.1, 158.5, 134.1, 129.7, 125.6, 42.9, 36.9, 
36.6, 28.8.  
MS (70 eV, EI), m/z (%) = 240 (M+, 100), 184 (18), 183 (39), 155 (54), 94 (16), 91 (12),  
79 (9). 
HRMS (EI), m/z calc. for C17H20O (240.1514): 240.1500. 
IR (ATR) υ (cm-1) = 3090, 3055, 2901, 2846, 1695, 1685, 1602, 1569, 1446, 1412, 1368, 
1344, 1304, 1222, 1205, 1165, 1112, 1102, 1079, 1030, 1012, 977, 860, 825, 801, 654. 
 
Preparation of 3-(adamantan-1-yl)phenyl diethylcarbamate (48h) 
 
The cross-coupling reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and 3-bromophenyl diethylcarbamate (47j, 
245 mg, 0.9 mmol) was performed according to TP2 in 1 h. Flash column 
chromatography (silica, pentane:Et2O 9:1) furnished 48h as a white solid (206 mg,  
70 %). 
 
m.p.: 66.1-67.2 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.30 (t, J=7.9Hz, 3H), 7.16-7.22 (m, 2H), 7.10 (t, 
J=2.1Hz, 1H), 6.95 (ddd, J=7.9Hz, 2.3Hz, 1.1Hz, 1H), 3.23-3.57 (m, 4H), 2.10 (bs, 3H), 
1.93 (d, J=3.0Hz, 6H), 1.68-1.86 (m, 6H), 1.09-1.36 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 154.4, 152.9, 151.5, 128.6, 121.6, 118.8, 118.4, 
43.1, 42.2, 41.9, 36.8, 36.2, 28.9, 14.3, 13.4.  
MS (70 eV, EI), m/z (%) = 327 (M+, 7), 228 (2), 171 (3), 101 (5), 100 (100), 91 (2),  
79 (2), 72 (18), 43 (2). 
HRMS (EI), m/z calc. for C21H29NO2 (327.2198): 327.2186. 
IR (ATR) υ (cm-1) = 3035, 2977, 2900, 2846, 1709, 1603, 1585, 1489, 1470, 1453, 1412, 
1378, 1345, 1316, 1271, 1237, 1222, 1183, 1165, 1151, 1097, 1088, 1049, 980, 966, 876, 
786, 774, 754, 695. 
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Preparation of 1-(6-methoxynaphthalen-2-yl)adamantane (48i) 
 
The cross-coupling reaction of 48a (3.2 mL, 1.0 mmol, 0.32 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and 2-bromo-6-methoxynaphthalene (47k, 
213 mg, 0.9 mmol) was performed according to TP2 in 3 h. Flash column 
chromatography (silica, pentane:Et2O 7:3) furnished 48i as a white solid (250 mg, 95 %). 
 
m.p.: 150.5-152.7 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.64-7.80 (m, 3H), 7.50-7.61 (m, 1H), 7.07-7.19 
(m, 2H), 3.93 (s, 3H), 2.16 (bs, 3H), 2.04 (s, 6H), 1.73-1.96 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 157.3, 146.6, 132.7, 129.4, 129.0, 126.4, 124.6, 
122.7, 118.4, 105.4, 55.3, 43.2, 36.9, 36.2, 29.0.  
MS (70 eV, EI), m/z (%) = 292 (M+, 100), 236 (13), 235 (52), 220 (12), 203 (6),  
198 (14), 171 (14), 165 (6). 
HRMS (EI), m/z calc. for C21H24O (292.1827): 292.1829. 
IR (ATR) υ (cm-1) = 3049, 3014, 2946, 2899, 2843, 1632, 1605, 1503, 1484, 1460, 1451, 
1391, 1337, 1265, 1223, 1196, 1186, 1179, 1163, 1154, 1122, 1036, 1031, 923, 885, 849, 
822, 814, 797, 726, 672. 
 
Preparation of 2,7-di(adamantan-1-yl)-fluorene (48j) 
 
The cross-coupling reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and 2,7-dibromo-fluorene (47l, 146 mg, 
0.45 mmol) was performed according to TP2 in 3 h. Flash column chromatography 
(silica, pentane:Et2O 9:1) furnished 48j as a white solid (206 mg, 70 %). 
 
m.p.: 308.9-311.8 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.70 (d, J=8.0Hz, 2H), 7.57 (s, 2H), 7.39 (dd, 
J=8.0Hz, 1.7Hz, 2H), 3.88 (s, 2H), 2.16 (bs, 6H), 2.02 (d, J=3.0Hz, 12H), 1.74-1.95 (m, 
12H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 149.8, 143.3, 139.3, 123.3, 121.4, 119.1, 43.5, 
37.2, 36.9, 36.4, 29.1.  
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MS (70 eV, EI), m/z (%) = 434 (M+, 100), 313 (3), 135 (33), 107 (3), 93 (7), 79 (6),  
67 (3). 
HRMS (EI), m/z calc. for C33H38 (434.2974): 434.2961. 
IR (ATR) υ (cm-1) = 2898, 2846, 1649, 1604, 1474, 1446, 1414, 1344, 1314, 1262, 1247, 
1176, 1100, 1079, 1068, 1060, 1038, 976, 875, 861, 827, 800, 742, 714, 694, 673. 
 
Preparation of 4,4'-di(adamantan-1-yl)-1,1'-biphenyl (48k) 
 
The cross-coupling reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with Pd(OAc)2  
(4 mg, 0.02 mmol), SPhos (16 mg, 0.04 mmol) and 4,4'-dibromo-1,1'-biphenyl (47m,  
125 mg, 0.4 mmol) was performed according to TP2 in 2 h. Flash column 
chromatography (silica, pentane:Et2O 98:2) furnished 48k as a white solid (206 mg,  
70 %). 
 
m.p.: >250 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.51-7.68 (m, 4H), 7.36-7.50 (m, 4H), 2.15 (bs, 
6H), 1.99 (d, J=2.8Hz, 12H), 1.66-1.93 (m, 12H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 150.1, 138.3, 126.7, 125.2, 43.2, 36.9, 36.1, 29.0.  
MS (70 eV, EI), m/z (%) = 422 (M+, 100), 365 (4), 328 (5), 301 (9), 136 (4), 135 (31),  
93 (8), 79 (9). 
HRMS (EI), m/z calc. for C32H38 (422.2974): 422.2967. 
IR (ATR) υ (cm-1) = 3083, 3056, 3023, 2898, 2846, 1499, 1448, 1366, 1355, 1342, 1315, 
1243, 1214, 1178, 1101, 1020, 1003, 977, 828, 810, 799, 761, 727, 703. 
 
Preparation of 3-(adamantan-1-yl)benzothiophene (48l) 
 
The cross-coupling reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and 3-bromobenzothiophene (49a, 192 mg, 
0.9 mmol) was performed according to TP2 in 2 h. Flash column chromatography (silica, 
pentane pur) furnished 48l as a white solid (188 mg, 84 %). 
 
 
C. EXPERIMENTAL SECTION 
279 
m.p.: 150.3-151.9 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.11-8.31 (m, 1H), 7.78-7.97 (m, 1H), 7.19-7.44 
(m, 2H), 7.08 (s, 1H), 1.99-2.45 (m, 9H), 1.62-1.99 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 146.1, 141.7, 137.5, 124.7, 123.4, 123.0, 119.8, 
42.0, 37.1, 37.0, 28.8.  
MS (70 eV, EI), m/z (%) = 268 (M+, 100), 225 (6), 212 (14), 211 (84), 185 (5), 184 (6),  
174 (14), 147 (10), 115 (6). 
HRMS (EI), m/z calc. for C18H20S (268.1286): 268.1279. 
IR (ATR) υ (cm-1) = 3104, 3072, 2935, 2910, 2900, 2884, 2848, 1452, 1446, 1423, 1344, 
1308, 1258, 1175, 1163, 1100, 1062, 1028, 994, 974, 932, 871, 846, 790, 757, 705, 652. 
 
Preparation of 3-(adamantan-1-yl)benzofuran (48m) 
 
The cross-coupling reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and 3-bromobenzofuran (49b, 177 mg,  
0.9 mmol) was performed according to TP2 in 3 h. Flash column chromatography (silica, 
pentane:Et2O 100:1) furnished 48m as a white solid (129 mg, 57 %). 
 
m.p.: 69.7-71.5 °C. 
1H NMR (600 MHz, CDCl3) δ (ppm) = 7.83 (d, J=8.0Hz, 1H), 7.49 (d, J=8.2Hz, 1H), 
7.32 (s, 1H), 7.27 (d, J=8.2Hz, 1H), 7.22 (t, J=7.4Hz, 1H), 2.05-2.20 (m, 9H), 1.78-1.92 
(m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 156.0, 139.4, 130.5, 126.5, 123.6, 121.9, 121.7, 
111.7, 42.2, 37.0, 33.3, 28.5.  
MS (70 eV, EI), m/z (%) = 252 (M+, 100), 196 (9), 195 (46), 167 (22), 158 (12), 131 (6). 
HRMS (EI), m/z calc. for C18H20O (252.1514): 252.1511. 
IR (ATR) υ (cm-1) = 3085, 3063, 3032, 2901, 2847, 1582, 1451, 1344, 1284, 1255, 1203, 
1183, 1157, 1104, 1083, 1030, 1004, 976, 929, 867, 793, 766, 744, 684. 
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Preparation of 5-(adamantan-1-yl)-2-methylbenzothiazole (48n) 
 
The cross-coupling reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and 5-bromo-2-methylbenzothiazole (49c, 
205 mg, 0.9 mmol) was performed according to TP2 in 2 h. Flash column 
chromatography (silica, EtOAc pur) furnished 48n as a brown solid (232 mg, 91 %). 
 
m.p.: 147.4-149.6 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.89-8.00 (m,  H), 7.73 (d, J=8.6Hz, 1H), 7.40 
(dd, J=8.6Hz, 1.9Hz, 1H), 2.82 (s, 3H), 2.12 (bs, 3H), 1.93-2.03 (m, 6H), 1.68-1.87 (m, 
6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.8, 153.7, 149.9, 132.5, 122.3, 120.7, 118.6, 
43.4, 36.8, 36.3, 29.0, 20.1.  
MS (70 eV, EI), m/z (%) = 283 (M+, 83), 240 (10), 227 (19), 226 (100), 189 (18),  
184 (5), 162 (10). 
HRMS (EI), m/z calc. for C18H21NS (283.1395): 283.1351. 
IR (ATR) υ (cm-1) = 3054, 3028, 2954, 2925, 2916, 2901, 2843, 1739, 1526, 1458, 1448, 
1415, 1342, 1308, 1260, 1241, 1168, 1160, 1101, 1067, 980, 974, 923, 795, 728, 656. 
 
Preparation of 5-(adamantan-1-yl)-1-methyl-indole (48o) 
 
The cross-coupling reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and 5-bromo-1-methyl-indole (49d, 189 
mg, 0.9 mmol) was performed according to TP2 in 2 h. Flash column chromatography 
(silica, pentane:Et2O 8:2) furnished 48o as a white solid (170 mg, 71 %). 
 
m.p.: 171.7-173.5 °C. 
1H NMR (600 MHz, CDCl3) δ (ppm) = 7.64 (d, J=1.9Hz, 1H), 7.34-7.38 (m, 1H), 7.29-
7.33 (m, 1H), 7.04 (d, J=3.0Hz, 1H), 6.49 (d, J=3.0Hz, 1H), 3.79 (s, 3H), 2.16 (bs, 3H), 
2.05 (d, J=3.0Hz, 6H), 1.75-1.91 (m, 6H). 
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13C NMR (100 MHz, CDCl3) δ (ppm) = 142.6, 135.0, 128.7, 128.4, 119.2, 116.5, 108.7, 
100.9, 43.9, 37.0, 36.0, 32.8, 29.2.  
MS (70 eV, EI), m/z (%) = 265 (M+, 100), 222 (6), 209 (17), 208 (90), 194 (5), 193 (11),  
171 (16), 144 (15), 131 (5), 43 (24). 
HRMS (EI), m/z calc. for C19H23N (265.1830): 265.1823. 
IR (ATR) υ (cm-1) = 3112, 3061, 3037, 2925, 2901, 2843, 2818, 1514, 1489, 1448, 1421, 
1368, 1342, 1333, 1287, 1244, 1167, 1104, 1081, 1030, 1008, 981, 974, 924, 875, 847, 
791, 760, 724, 676. 
 
Preparation of 2-(adamantan-1-yl)thiophene (48p) 
 
The cross-coupling reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and 2-bromothiophene (49e, 147 mg,  
0.9 mmol) was performed according to TP2 in 2 h. Flash column chromatography (silica,  
pentane:Et2O 100:1) furnished 48p as a white solid (120 mg, 61 %). 
 
m.p.: 66.1-67.2 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.14 (dd, J=5.0Hz, 1.1Hz, 1H), 6.89-7.01 (m, 
1H), 6.83 (dd, J=3.5Hz, 1.2Hz, 1H), 2.10 (bs, 3H), 2.00 (d, J=2.8Hz, 6H), 1.71-1.88 (m, 
6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 158.3, 126.3, 121.9, 120.1, 45.0, 36.7, 36.2, 28.9.  
MS (70 eV, EI), m/z (%) = 218 (M+, 71), 175 (7), 163 (5), 162 (13), 161 (100), 128 (6),  
124 (15), 97 (6). 
HRMS (EI), m/z calc. for C14H18S (218.1129): 218.1144. 
IR (ATR) υ (cm-1) = 3098, 3070, 2898, 2846, 1526, 1446, 1342, 1314, 1261, 1228, 1100, 
1077, 1052, 1004, 966, 850, 823, 808, 703, 694, 686. 
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Preparation of ethyl 5-(adamantan-1-yl)thiophene-2-carboxylate (48q) 
 
The cross-coupling reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and ethyl 5-bromothiophene-2-carboxylate 
(49f, 212 mg, 0.9 mmol) was performed according to TP2 in 3 h. Flash column 
chromatography (silica, pentane:Et2O 9.5:0.5) furnished 48q as a white solid (139 mg,  
53 %). 
 
m.p.: 85.9-88.2 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.65 (d, J=3.9Hz, 1H), 6.83 (d, J=3.9Hz, 1H), 
4.33 (q, J=7.2Hz, 2H), 2.09 (bs, 3H), 1.97 (d, J=2.8Hz, 6H), 1.65-1.86 (m, 6H), 1.36 (t, 
J=7.2Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 165.9, 162.6, 133.2, 130.0, 121.4, 60.8, 44.6, 
36.8, 36.4, 28.7, 14.4.  
MS (70 eV, EI), m/z (%) = 290 (M+, 100), 257 (23), 245 (26), 234 (12), 233 (51),  
196 (15), 161 (31), 135 (45), 94 (10), 93 (13), 91 (10), 79 (16). 
HRMS (EI), m/z calc. for C175H22O2S (290.1341): 290.1336. 
IR (ATR) υ (cm-1) = 3077, 2983, 2960, 2918, 2851, 2842, 1707, 1536, 1455, 1366, 1335, 
1317, 1254, 1212, 1192, 1086, 1048, 1036, 1010, 999, 976, 867, 820, 814, 805, 762, 747. 
 
Preparation of 5-(adamantan-1-yl)-2,2'-bithiophene (48r) 
 
The cross-coupling reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and 5-bromo-2,2'-bithiophene (49g,  
221 mg, 0.9 mmol) was performed according to TP2 in 2 h. Flash column 
chromatography (silica, pentane pur) furnished 48r as a white solid (157 mg, 58 %). 
 
m.p.: 69.9-70.7 °C. 
1H NMR (600 MHz, CDCl3) δ (ppm) = 7.17 (dd, J=5.1Hz, 1.2Hz, 1H), 7.11 (dd, 
J=3.6Hz, 1.1Hz, 1H), 6.96-7.05 (m, 2H), 6.72 (d, J=3.6Hz, 1H), 2.10 (bs, 3H), 1.93-2.06 
(m, 6H), 1.71-1.87 (m, 6H). 
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13C NMR (150 MHz, CDCl3) δ (ppm) = 157.6, 138.1, 133.9, 127.6, 123.7, 123.1, 122.9, 
121.0, 44.8, 36.6, 36.6, 36.4, 28.9, 28.9.  
MS (70 eV, EI), m/z (%) = 300 (M+, 100), 257 (4), 245 (6), 244 (13), 243 (63), 210 (11),  
209 (4), 206 (12), 121 (5), 61 (4), 45 (4), 43 (26). 
HRMS (EI), m/z calc. for C18H20S2 (300.1006): 300.0996. 
IR (ATR) υ (cm-1) = 3119, 3069, 2910, 2898, 2846, 1512, 1460, 1445, 1428, 1342, 1318, 
1204, 1184, 1100, 1060, 1003, 976, 887, 876, 840, 823, 810, 797, 688, 684. 
 
Preparation of adamantan-1-yl(4-fluorophenyl)methanone (51a) 
 
The acylation reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with CuCN·2LiCl  
(0.2 mL, 0.2 mmol, 1 M in THF) and 4-fluorobenzoyl chloride (50a, 143 mg, 0.9 mmol) 
was performed according to TP3 over night. Flash column chromatography (silica, 
pentane:Et2O 50:1) furnished 51a as a white solid (207 mg, 89 %). 
 
m.p.: 78.8-80.8 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.53-7.73 (m, 2H), 6.96-7.14 (m, 2H), 2.09 (bs, 
3H), 2.01 (d, J=2.8Hz, 6H), 1.67-1.85 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 208.1, 163.9 (d, J=251.1Hz), 135.3 (d, J=3.4Hz), 
129.9 (d, J=8.5Hz), 115.0 (d, J=21.4Hz), 46.9, 39.2, 36.5, 28.1.  
MS (70 eV, EI), m/z (%) = 258 (M+, 3), 136 (8), 135 (100), 123 (6), 107 (5), 93 (9),  
81 (3), 79 (10), 77 (3), 67 (4). 
HRMS (EI), m/z calc. for C17H19FO (258.1420): 258.1416. 
IR (ATR) υ (cm-1) = 3085, 2957, 2922, 2905, 2890, 2884, 2854, 1665, 1591, 1501, 1452, 
1404, 1346, 1266, 1231, 1208, 1178, 1156, 1112, 1102, 1096, 1039, 1010, 986, 973, 956, 
952, 929, 846, 815, 794, 746, 687, 678. 
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Preparation of adamantan-1-yl(4-chlorophenyl)methanone (51b) 
 
The acylation reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with CuCN·2LiCl  
(0.2 mL, 0.2 mmol, 1 M in THF) and 4-chlorobenzoyl chloride (50b, 158 mg, 0.9 mmol) 
was performed according to TP3 over night. Flash column chromatography (silica, 
pentane:Et2O 92:8) furnished 51b as a pale yellow solid (173 mg, 70 %). 
 
m.p.: 92.4-95.7 °C. 
1H NMR (100 MHz, CDCl3) δ (ppm) = 7.43-7.61 (m, 2H), 7.26-7.40 (m, 2H), 2.07 (bs, 
3H), 1.98 (d, J=2.8Hz, 6H), 1.63-1.81 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 208.6, 137.6, 136.4, 128.8, 128.2, 47.0, 39.1, 
36.5, 28.1.  
MS (70 eV, EI), m/z (%) = 274 (M+, 4), 139 (6), 136 (12), 135 (100), 111 (5), 107 (5),  
93 (11), 79 (13), 67 (5), 42 (17). 
HRMS (EI), m/z calc. for C17H19ClO (274.1124): 274.1111. 
IR (ATR) υ (cm-1) = 2911, 2849, 1724, 1659, 1586, 1484, 1450, 1394, 1343, 1268, 1232, 
1184, 1172, 1115, 1089, 1046, 1010, 989, 972, 957, 950, 927, 840, 816, 808, 768, 760, 
742, 728, 686, 668. 
 
Preparation of adamantan-1-yl(4-methoxyphenyl)methanone (51c) 
 
The acylation reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with CuCN·2LiCl  
(0.2 mL, 0.2 mmol, 1 M in THF) and 4-methoxybenzoyl chloride (50c, 154 mg,  
0.9 mmol) was performed according to TP3 over night. Flash column chromatography 
(silica, pentane:Et2O 9:1) furnished 51c as a white solid (195 mg, 80 %). 
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m.p.: 61.5-63.9 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.61-7.85 (m, 2H), 6.56-7.03 (m, 2H), 3.84 (s, 
3H), 1.88-2.21 (m, 9H), 1.57-1.91 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 207.1, 161.6, 131.1, 130.3, 113.1, 55.3, 46.8, 
39.5, 36.7, 28.3.  
MS (70 eV, EI), m/z (%) = 270 (M+, 20), 136 (9), 135 (100), 107 (6), 93 (13). 
HRMS (EI), m/z calc. for C18H22O2 (270.1620): 270.1617. 
IR (ATR) υ (cm-1) = 3079, 3054, 3020, 3002, 2944, 2902, 2890, 2848, 1656, 1596, 1510, 
1453, 1439, 1319, 1303, 1264, 1233, 1186, 1170, 1113, 1104, 1029, 1010, 986, 974, 952, 
930, 835, 820, 809, 788, 766, 750, 697, 680. 
 
Preparation of adamantan-1-yl(6-chloropyridin-3-yl)methanone (51d) 
 
The acylation reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with CuCN·2LiCl  
(0.2 mL, 0.2 mmol, 1 M in THF) and 6-chloronicotinoyl chloride (50d, 159 mg,  
0.9 mmol) was performed according to TP3 over night. Flash column chromatography 
(silica, pentane:Et2O 9:1) furnished 51d as a yellow oil (109 mg, 44 %). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.66 (d, J=2.5Hz, 1H), 7.86 (dd, J=8.3Hz, 2.5Hz, 
1H), 7.36 (d, J=8.3Hz, 1H), 2.09 (bs, 3H), 1.97 (d, J=2.8Hz, 6H), 1.64-1.84 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 206.4, 153.0, 148.4, 138.0, 133.4, 123.9, 47.2, 
38.8, 36.3, 27.9.  
MS (70 eV, EI), m/z (%) = 275 (M+, 1), 136 (14), 135 (100), 107 (8), 93 (16), 81 (5),  
79 (13). 
HRMS (EI), m/z calc. for C16H18ClNO (275.1077): 275.1071. 
IR (ATR) υ (cm-1) = 2953, 2917, 2849, 1727, 1633, 1570, 1459, 1377, 1261, 1211, 1194, 
1173, 1119, 1093, 1036, 1007, 972, 961, 950, 926, 832, 815, 809, 762, 751, 723, 687. 
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Preparation of ethyl 2-(adamantan-1-ylmethyl)acrylate (53a) 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with the adamantyl zinc reagent 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) 
and cooled to -40 °C. Ethyl 2-(bromomethyl)acrylate (52a, 174 mg, 0.9 mmol) was 
added, followed by CuCN·2LiCl (0.2 mL, 0.2 mmol, 1 M in THF). The reaction mixture 
was allowed to warm to room temperature. After stirring over night, the reaction mixture 
was quenched with sat. NH4Cl/NH3 (9:1) solution (10 mL), washed with sat. NH4Cl/NH3 
solution (9:1, 2x10 mL) and extracted with EtOAc (3x10 mL). The combined organic 
phases were dried over Na2SO4 and concentrated in vacuo. The crude residue obtained 
was purified by flash column chromatography (silica, pentane:Et2O 100:1) to give the 
analytically pure product 53a as a colorless oil (203 mg, 91 %). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 6.18 (d, J=1.9Hz, 1H), 5.40 (d, J=1.9Hz, 1H), 
4.20 (q, J=7.2Hz, 2H), 2.16 (s, 2H), 1.93 (bs, 3H), 1.57-1.67 (m, 6H), 1.39-1.51 (m, 6H), 
1.30 (t, J=7.0Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 168.2, 137.6, 126.8, 60.6, 45.5, 42.1, 36.9, 33.2, 
28.7, 14.2.  
MS (70 eV, EI), m/z (%) = 248 (M+, 2), 177 (3), 149 (3), 136 (11), 135 (100), 107 (4),  
93 (8), 81 (3), 79 (8), 67 (3). 
HRMS (EI), m/z calc. for C16H24O2 (248.1776): 248.1755. 
IR (ATR) υ (cm-1) = 2980, 2899, 2847, 1717, 1625, 1448, 1406, 1366, 1312, 1297, 1291, 
1278, 1208, 1176, 1131, 1101, 1027, 982, 941, 875, 856, 819, 735, 690. 
 
Preparation of ethyl 3-(adamantan-1-yl)propiolate (53b) 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with the adamantyl zinc reagent 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) 
and cooled to -40 °C. CuCN·2LiCl (0.2 mL, 0.2 mmol, 1.0 M in THF) was added, 
followed by ethyl 3-bromoprop-2-ynoate (52b, 159 mg, 0.9 mmol) and the reaction 
mixture was stirred over night slowling warming up to room temperature. The reaction 
was quenched with sat. NH4Cl solution (10 mL) and extracted with EtOAcdried over 
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Na2SO4 and concentrated in vacuo. The crude residue obtained was purified by flash 
column chromatography (silica, pentane:Et2O 100:1) to give 53b as a a white solid  
(138 mg, 66 %). 
 
m.p.: 55.2-56.2 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 4.20 (q, J=7.2Hz, 2H), 1.97 (bs, 3H), 1.92 (d, 
J=2.8Hz, 6H), 1.58-1.78 (m, 6H), 1.29 (t, J=7.2Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 154.2, 95.9, 72.1, 61.7, 41.5, 36.1, 29.6, 27.5, 
14.1.  
MS (70 eV, EI), m/z (%) = 232 (M+, 5), 205 (82), 204 (77), 187 (84), 148 (48), 135 (31),  
119 (100), 93 (30), 91 (52), 79 (48), 77 (36), 43 (47). 
HRMS (EI), m/z calc. for C15H20O2 (232.1463): 232.1457. 
IR (ATR) υ (cm-1) = 2983, 2906, 2853, 2226, 1702, 1665, 1474, 1453, 1366, 1317, 1300, 
1248, 1184, 1144, 1114, 1100, 1025, 989, 856, 812, 791, 752. 
 
Preparation of adamantan-1-yl(phenyl)sulfane (53c) 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with the adamantyl zinc reagent 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) 
and cooled to 0 °C. S-phenyl benzenesulfonothioate (52c, 225 mg, 0.9 mmol) was added 
and the reaction mixture was stirred for 2 h at at room temperature. The reaction was 
quenched with sat. NH4Cl solution (10 mL) and extracted with EtOAc (3x20 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. The crude 
residue obtained was purified by flash column chromatography (silica, pentane pur) to 
give 53c as a pale brown solid (216 mg, 98 %). 
 
m.p.: 73.9-74.9 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.48-7.57 (m, 2H), 7.40-7.55 (m, 2H), 7.26-7.42 
(m, 3H), 2.01 (bs, 3H), 1.82 (d, J=2.8Hz, 6H), 1.50-1.71 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 137.6, 130.5, 128.5, 128.2, 47.8, 43.6, 36.2, 30.0.  
MS (70 eV, EI), m/z (%) = 244 (M+, 9), 136 (13), 135 (100), 107 (7), 93 (14), 79 (15),  
61 (9), 43 (49). 
HRMS (EI), m/z calc. for C16H20S (244.1286): 244.1292. 
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IR (ATR) υ (cm-1) = 3059, 2901, 2848, 1583, 1574, 1474, 1450, 1442, 1400, 1340, 1296, 
1252, 1207, 1140, 1084, 1068, 1050, 1036, 976, 959, 920, 885, 826, 810, 752, 693, 684. 
 
Preparation of 3-(adamantan-1-yl)cyclohexanone (53d) 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with the adamanyl zinc reagent 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) and 
cooled to -40 °C. CuCN·2LiCl (1.0 mL, 1.0 mmol, 1.0 M in THF) was added, followed 
by a solution of cyclohexenone (52d, 87 mg, 0.9 mmol) and chlorotrimethylsilane  
(0.4 mL, 2.5 mmol) in THF (1 mL) and the reaction mixture was stirred over night 
slowly warming up to room temperature. The reaction was quenched with sat. 
NH4Cl/NH3 (9:1) solution (10 mL) and extracted with EtOAc (3x20 mL). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. The crude residue 
obtained was purified by flash column chromatography (silica, pentane:Et2O 8:2) to give 
53d as a white solid (190 mg, 91 %). 
 
m.p.: 67.0-67.4 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 2.27-2.48 (m, 2H), 2.02-2.27 (m, 3H), 1.87-2.01 
(m, 4H), 1.65-1.75 (m, 3H), 1.55-1.65 (m, 3H), 1.39-1.54 (m, 7H), 1.23-1.37 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 213.4, 49.7, 42.1, 41.5, 39.4, 37.2, 34.4, 28.6, 
25.7, 24.6.  
MS (70 eV, EI), m/z (%) = 232 (M+, 3), 136 (10), 135 (100), 96 (6), 93 (9), 79 (10),  
42 (32), 41 (6). 
HRMS (EI), m/z calc. for C16H24O (232.1827): 232.1821. 
IR (ATR) υ (cm-1) = 2965, 2942, 2896, 2862, 2844, 1709, 1449, 1424, 1418, 1360, 1347, 
1322, 1316, 1304, 1277, 1268, 1238, 1228, 1216, 1168, 1102, 1058, 1034, 998, 967, 927, 
899, 862, 814, 760, 722, 661. 
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Preparation of N-phenyladamantan-1-amine (55a) 
 
The amine synthesis was performed according to TP4 in 2 h with 46a (3.2 mL,  
1.0 mmol, 0.32 M in THF), nitrosobenzene (54a, 96 mg, 0.9 mmol), FeCl2 (254 mg,  
2 mmol) and NaBH4 (42 mg, 1.1 mmol). Flash column chromatography (silica, 
pentane:EtOAc 7:1) furnished 55a as a pale yellow solid (182 mg, 89 %). 
 
m.p.: 73.3-75.7 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.07-7.25 (m, 2H), 6.59-6.93 (m, 3H), 3.40 (bs, 
1H), 2.12 (bs, 3H), 1.89 (d, J=2.8Hz, 6H), 1.58-1.82 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 145.9, 128.7, 119.3, 119.2, 52.3, 43.5, 36.5, 29.7.  
MS (70 eV, EI), m/z (%) = 227 (M+, 33), 170 (50), 136 (10), 135 (100), 93 (24), 91 (9),  
79 (21), 43 (39). 
HRMS (EI), m/z calc. for C16H21N (227.1674): 227.1664. 
IR (ATR) υ (cm-1) = 3414, 3089, 3050, 3014, 2902, 2847, 1597, 1503, 1494, 1472, 1448, 
1432, 1356, 1344, 1324, 1306, 1286, 1270, 1236, 1181, 1131, 1096, 1081, 992, 978, 861, 
818, 741, 690. 
 
Preparation of N1-(adamantan-1-yl)-N4,N4-dimethylbenzene-1,4-diamine (55b) 
 
The amine synthesis was performed according to TP4 in 2 h with 46a (3.2 mL,  
1.0 mmol, 0.32 M in THF), N,N-dimethyl-4-nitrosoaniline (54b, 135 mg, 0.9 mmol), 
FeCl2 (254 mg, 2 mmol) and NaBH4 (42 mg, 1.1 mmol). Flash column chromatography 
(silica, pentane:EtOAc 1:1) furnished 55b as a brown solid (172 mg, 71 %). 
 
m.p.: 105.2-107.4 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 6.83 (d, J=8.3Hz, 2H), 6.66 (d, J=8.3Hz, 2H), 
2.64-3.11 (m, 7H), 1.95-2.22 (m, 3H), 1.46-1.88 (m, 12H). 
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13C NMR (100 MHz, CDCl3) δ (ppm) = 146.6, 135.1, 125.0, 113.5, 52.6, 43.8, 41.3, 
36.5, 29.8.  
MS (70 eV, EI), m/z (%) = 270 (M+, 100), 213 (14), 136 (13), 135 (34), 121 (12), 93 (7),  
79 (6). 
HRMS (EI), m/z calc. for C18H26N2 (270.2096): 270.2090. 
IR (ATR) υ (cm-1) = 3296, 3036, 2985, 2901, 2842, 2790, 1616, 1511, 1479, 1443, 1354, 
1340, 1326, 1309, 1282, 1243, 1212, 1177, 1163, 1124, 1107, 1101, 1094, 1054, 944, 
934, 922, 818, 806, 788, 773, 722, 689. 
 
Preparation of ethyl 3-(4-(methylthio)phenyl)adamantane-1-carboxylate (56a) 
 
The cross-coupling reaction of 46b (4.2 mL, 1.0 mmol, 0.24 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and (4-bromophenyl)(methyl)-sulfane (47f, 
183 mg, 0.9 mmol) was performed according to TP2 in 2 h. Flash column 
chromatography (silica, pentane:Et2O 7:3) furnished 56a as a colorless oil (259 mg,  
87 %). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.17-7.35 (m, 4H), 4.12 (q, J=7.2Hz, 2H), 2.47 
(s, 3H), 2.22 (bs, 2H), 2.00 (s, 2H), 1.83-1.97 (m, 8H), 1.73 (bs, 2H), 1.24 (t, J=7.0Hz, 
3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 177.3, 147.2, 135.4, 126.9, 125.4, 60.2, 44.2, 
42.1, 41.7, 38.1, 36.2, 35.6, 28.7, 16.2, 14.2.  
MS (70 eV, EI), m/z (%) = 330 (M+, 100), 257 (16), 201 (16), 164 (9), 137 (12). 
HRMS (EI), m/z calc. for C20H26O2S (330.1654): 330.1653. 
IR (ATR) υ (cm-1) = 3079, 3024, 2979, 2904, 2853, 1720, 1569, 1497, 1448, 1400, 1364, 
1343, 1320, 1242, 1200, 1173, 1149, 1104, 1097, 1067, 1022, 1013, 970, 958, 915, 824, 
808, 736, 720, 690. 
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Preparation of ethyl 3-(4-(ethoxycarbonyl)phenyl)adamantane-1-carboxylate (56b) 
 
The cross-coupling reaction of 46b (4.2 mL, 1.0 mmol, 0.24 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and ethyl 4-bromobenzoate (47b, 206 mg, 
0.9 mmol) was performed according to TP2 in 2 h. Flash column chromatography (silica, 
pentane:Et2O 7:3) furnished 56b as a colorless solid (269 mg, 84 %). 
 
m.p.: 27.1-28.3 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.84-8.11 (m, 2H), 7.33-7.58 (m, 2H), 4.36 (q, 
J=7.2Hz, 2H), 4.12 (q, J=7.1Hz, 2H), 2.15-2.34 (m, 2H), 2.03 (s, 2H), 1.83-1.97 (m, 7H), 
1.74 (bs, 3H), 1.37 (t, J=7.2Hz, 3H), 1.24 (t, J=7.2Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 177.1, 166.6, 155.1, 129.5, 128.1, 124.9, 60.7, 
60.3, 43.8, 41.9, 41.6, 38.0, 36.9, 35.5, 28.6, 14.3, 14.2.  
MS (70 eV, EI), m/z (%) = 356 (M+, 37), 311 (13), 284 (20), 283 (100), 255 (6), 227 (8),  
163 (6), 155 (12), 93 (10), 91 (6). 
HRMS (EI), m/z calc. for C22H28O4 (356.1988): 356.1981. 
IR (ATR) υ (cm-1) = 3092, 3053, 2986, 2927, 2903, 2855, 1710, 1608, 1447, 1409, 1389, 
1365, 1271, 1250, 1241, 1197, 1172, 1103, 1067, 1017, 978, 912, 859, 842, 775, 766, 
749, 730, 707. 
 
Preparation of ethyl 3-(2-methylbenzothiazol-5-yl)adamantane-1-carboxylate (56c) 
 
The cross-coupling reaction of 46b (4.2 mL, 1.0 mmol, 0.24 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and 5-bromo-2-methylbenzothiazole (49c, 
205 mg, 0.9 mmol) was performed according to TP2 in 2 h. Flash column 
chromatography (silica, pentane:Et2O 6.5:3.5) furnished 56c as a white solid (224 mg,  
70 %). 
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m.p.: 83.6-84.5 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.95 (d, J=1.9Hz, 1H), 7.75 (d, J=8.6Hz, 1H), 
7.40 (dd, J=8.6Hz, 1.9Hz, 1H), 4.11 (q, J=7.2Hz, 2H), 2.82 (s, 3H), 2.16-2.35 (m, 2H), 
2.08 (s, 2H), 1.95 (d, J=3.3Hz, 8H), 1.65-1.81 (m, 2H), 1.24 (t, J=7.0Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 177.2, 167.1, 153.5, 148.7, 132.8, 122.3, 120.9, 
118.6, 60.2, 44.4, 42.3, 41.7, 38.1, 36.6, 35.6, 28.7, 20.0, 14.2.  
MS (70 eV, EI), m/z (%) = 355 (M+, 100), 283 (16), 282 (76), 240 (11), 227 (11),  
226 (51), 190 (13), 189 (16), 162 (25), 93 (14), 61 (11), 45 (12), 44 (16), 43 (95). 
HRMS (EI), m/z calc. for C21H25NO2S (355.1606): 355.1609. 
IR (ATR) υ (cm-1) = 3053, 3032, 2981, 2930, 2918, 2905, 2853, 1716, 1548, 1530, 1458, 
1450, 1417, 1389, 1367, 1341, 1266, 1256, 1248, 1230, 1170, 1164, 1149, 1101, 1074, 
1057, 1022, 1002, 974, 954, 935, 901, 878, 863, 815, 775, 734, 699, 681. 
 
Preparation of ethyl 3-(4-chlorobenzoyl)adamantane-1-carboxylate (57a) 
 
The acylation reaction of 46b (4.2 mL, 1.0 mmol, 0.24 M in THF) with CuCN·2LiCl  
(0.2 mL, 0.2 mmol, 1 M in THF) and 4-chlorobenzoyl chloride (50b, 158 mg, 0.9 mmol) 
was performed according to TP3 over night. Flash column chromatography (silica, 
pentane:Et2O 8:2) furnished 57a as a colorless oil (256 mg, 82 %). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.46-7.61 (m, 2H), 7.30-7.42 (m, 2H), 4.02-4.19 
(m, 2H), 2.16-2.25 (m, 2H), 2.10 (s, 2H), 1.85-2.04 (m, 8H), 1.64-1.84 (m, 4H), 1.18-
1.29 (m, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 207.4, 176.7, 137.1, 136.8, 128.9, 128.3, 60.4, 
47.1, 41.0, 40.0, 38.3, 37.9, 35.4, 28.0, 14.2.  
MS (70 eV, EI), m/z (%) = 346 (M+, 4), 273 (5), 208 (12), 207 (100), 161 (15), 139 (9),  
134 (5), 133 (33), 91 (6), 79 (6). 
HRMS (EI), m/z calc. for C20H23ClO3 (346.1336): 346.1326. 
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IR (ATR) υ (cm-1) = 3069, 2978, 2907, 2857, 1720, 1670, 1591, 1487, 1450, 1393, 1366, 
1344, 1324, 1263, 1243, 1227, 1208, 1175, 1117, 1103, 1091, 1076, 1038, 1011, 952, 
905, 839, 828, 740, 684, 670. 
 
Preparation of ethyl 3-(furan-2-carbonyl)adamantane-1-carboxylate (57b) 
 
The acylation reaction of 46b (4.2 mL, 1.0 mmol, 0.24 M in THF) with CuCN·2LiCl  
(0.2 mL, 0.2 mmol, 1 M in THF) and furan-2-carbonyl chloride (50e, 118 mg, 0.9 mmol) 
was performed according to TP3 over night Flash column chromatography (silica, 
pentane:Et2O 7:3) furnished 57b as a colorless oil (147 mg, 54 %). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.53 (d, J=1.1Hz, 1H), 7.21 (d, J=3.6Hz, 1H), 
6.48 (dd, J=3.6Hz, 1.7Hz, 1H), 4.10 (q, J=7.2Hz, 2H), 2.14-2.28 (m, 4H), 2.03 (bs, 4H), 
1.91 (d, J=3.0Hz, 4H), 1.74 (bs, 2H), 1.23 (t, J=7.0Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 193.4, 176.9, 152.7, 145.0, 118.3, 111.7, 60.3, 
45.9, 41.0, 39.1, 38.1, 37.3, 35.6, 28.0, 14.2.  
MS (70 eV, EI), m/z (%) = 302 (M+, 37), 229 (12), 208 (13), 207 (100), 161 (22),  
133 (52), 91 (11), 91 (11), 79 (10). 
HRMS (EI), m/z calc. for C18H22O4 (302.1518): 302.1513. 
IR (ATR) υ (cm-1) = 3125, 2975, 2908, 2857, 1721, 1658, 1560, 1462, 1386, 1366, 1297, 
1278, 1235, 1162, 1123, 1104, 1078, 1053, 1040, 1014, 956, 921, 883, 864, 815, 760, 
732, 696, 673. 
 
Preparation of 5-(4-(methylthio)phenyl)spiro[adamantane-2,2'-[1,3]dioxolane] (58a) 
 
The cross-coupling reaction of 46c (4.5 mL, 1.0 mmol, 0.22 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and (4-bromophenyl)(methyl)-sulfane (47f, 
183 mg, 0.9 mmol) was performed according to TP2 in 2 h. Flash column 
chromatography (silica, pentane:Et2O 9:1) furnished 58a as a white solid (208 mg,  
73 %). 
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m.p.: 89.1-89.9 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.15-7.36 (m, 4H), 3.97 (s, 4H), 2.47 (s, 3H), 
1.98-2.33 (m, 6H), 1.95 (bs, 2H), 1.88 (bs, 2H), 1.62-1.81 (m, 4H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 147.3, 135.0, 126.8, 125.5, 110.8, 64.3, 64.2, 
42.4, 40.5, 36.9, 35.1, 34.0, 27.5, 16.2.  
MS (70 eV, EI), m/z (%) = 316 (M+, 100), 201 (7), 137 (7), 113 (17), 99 (15), 73 (8),  
55 (8). 
HRMS (EI), m/z calc. for C19H24O2S (316.1497): 316.1483. 
IR (ATR) υ (cm-1) = 3075, 3017, 2991, 2921, 2906, 2856, 1718, 1594, 1495, 1443, 1393, 
1384, 1245, 1223, 1181, 1123, 1096, 1063, 1036, 1006, 966, 952, 924, 904, 883, 816, 
808, 796, 761, 738, 719, 677. 
 
Preparation of 4-(spiro[adamantane-2,2'-[1,3]dioxolan]-5-yl)benzonitrile (58b) 
 
The cross-coupling reaction of 46c (4.5 mL, 1.0 mmol, 0.22 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and 4-bromobenzonitrile (47d, 164 mg,  
0.9 mmol) was performed according to TP2 in 2 h. Flash column chromatography (silica, 
pentane:Et2O 6.5:3.5) furnished 58b as a white solid (204 mg, 77 %). 
 
m.p.: 85.3-87.6 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.53-7.63 (m, 2H), 7.40-7.49 (m, 2H), 3.91-4.05 
(m, 4H), 2.16-2.28 (m, 2H), 1.66-2.15 (m, 12H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 155.5, 132.0, 125.9, 119.1, 110.4, 109.5, 64.4, 
64.3, 42.0, 40.2, 36.7, 36.0, 33.8, 27.3.  
MS (70 eV, EI), m/z (%) = 295 (M+, 100), 252 (27), 193 (44), 180 (15), 113 (46),  
99 (61), 73 (24), 55 (18), 45 (11), 43 (50). 
HRMS (EI), m/z calc. for C19H21NO2 (295.1572): 295.1569. 
IR (ATR) υ (cm-1) = 3066, 3042, 2975, 2928, 2907, 2857, 2223, 1726, 1503, 1469, 1446, 
1385, 1252, 1228, 1188, 1137, 1123, 1097, 1091, 1064, 1038, 1018, 1004, 945, 924, 905, 
832, 824, 797, 731, 682. 
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Preparation of 5-(3,4-dimethoxyphenyl)spiro[adamantane-2,2'-[1,3]dioxolane] (58c) 
 
The cross-coupling reaction of 46c (4.5 mL, 1.0 mmol, 0.22 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and 4-bromo-1,2-dimethoxybenzene (47n, 
195 mg, 0.9 mmol) was performed according to TP2 in 2 h. Flash column 
chromatography (silica, pentane:Et2O 4:6) furnished 58c as a white solid (211 mg, 71 %). 
 
m.p.: 94.6-96.1 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 6.84-6.94 (m, 2H), 6.75-6.84 (m, 1H), 3.97 (d, 
J=1.1Hz, 4H), 3.88 (s, 3H), 3.85 (s, 3H), 2.24-2.20 (m, 2H), 1.99-2.08 (m, 3H), 1.95 (bs, 
2H), 1.88 (bs, 2H), 1.58-1.83 (m, 5H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 148.5, 147.0, 143.0, 116.9, 110.8, 108.8, 64.3, 
64.2, 55.9, 55.8, 42.7, 40.8, 36.9, 35.1, 34.0, 27.6.  
MS (70 eV, EI), m/z (%) = 330 (M+, 100), 215 (6), 193 (5), 151 (4), 113 (13), 99 (9),  
55 (4), 43 (8). 
HRMS (EI), m/z calc. for C20H26O4 (330.1831): 330.1831. 
IR (ATR) υ (cm-1) = 3074, 3002, 2992, 2932, 2906, 2852, 2838, 1602, 1585, 1517, 1462, 
1444, 1408, 1385, 1364, 1323, 1255, 1238, 1224, 1186, 1163, 1155, 1135, 1123, 1095, 
1053, 1027, 1005, 955, 932, 902, 843, 797, 767, 754. 
 
6.5 PREPARATION OF α,α’-DIADAMANTYL-SEXITHIOPHENE 
Preparation of 5-(adamantan-1-yl)-2,2':5',2''-terthiophene (48s) 
 
The cross-coupling reaction of 46a (3.2 mL, 1.0 mmol, 0.32 M in THF) with Pd(OAc)2  
(2 mg, 0.01 mmol), SPhos (8 mg, 0.02 mmol) and 5-bromo-2,2':5',2''-terthiophene (49h, 
295 mg, 0.9 mmol) was performed according to TP2 in 2 h. Flash column 
chromatography (silica, pentane:Et2O 100:1) furnished 48s as a yellow solid (220 mg,  
64 %). 
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m.p.: 171.0-173.0 °C. 
1H NMR (600 MHz, CDCl3) δ (ppm) = 7.13-7.25 (m, 2H), 6.96-7.10 (m, 4H), 6.67-6.76 
(m, 1H), 2.10 (bs, 3H), 1.99 (d, J=2.7Hz, 6H), 1.70-1.84 (m, 6H). 
13C NMR (150 MHz, CDCl3) δ (ppm) = 157.9, 137.4, 137.0, 135.5, 133.6, 127.8, 124.3, 
124.2, 123.4, 123.4, 123.1, 121.1, 44.8, 36.6, 36.5, 28.8.  
MS (70 eV, EI), m/z (%) = 382 (M+, 100), 327 (5), 326 (6), 325 (27), 292 (5), 288 (6),  
261 (5), 248 (22), 42 (5), 41 (6). 
HRMS (EI), m/z calc. for C22H22S3 (382.0884): 382.0870. 
IR (ATR) υ (cm-1) = 3072, 3063, 2954, 2902, 2847, 1514, 1495, 1460, 1447, 1423, 1377, 
1364, 1342, 1315, 1232, 1207, 1193, 1159, 1099, 1058, 1004, 965, 912, 831, 790, 675. 
 
Preparation of 5-(adamantan-1-yl)-5''-bromo-2,2':5',2''-terthiophene (59) 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with 48s (180 mg, 0.4 mmol) and dissolved in 2 mL CHCl3. Then, N-
bromo-succinimide (75 mg, 0.42 mmol) was added and the reaction mixture was stirred 
over night at room temperature. The reaction was quenched with water (5 mL) and 
extracted with EtOAc (3x10 mL). The combined organic phases were dried over Na2SO4 
and concentrated in vacuo. The pure product 59 was obtained without further purification 
as a colorless solid (181 mg, 98 %). 
 
m.p.: 154.6-157.3 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 6.81-7.14 (m, 5H), 6.72 (d, J=3.6Hz, 1H), 2.09 
(bs, 3H), 1.89-2.04 (m, 6H), 1.67-1.89 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 192.4, 158.2, 138.8, 137.5, 134.3, 133.3, 130.6, 
124.5, 123.4, 123.4, 121.2, 110.7, 44.8, 36.6, 36.5, 28.8.  
MS (70 eV, EI), m/z (%) = 461 (M+, 100), 459 (M+, 90), 406 (7), 405 (25), 404 (8),  
403 (23), 368 (5), 366 (6), 203 (6). 
HRMS (EI), m/z calc. for C22H21BrS3 (461.9968): 461.9951. 
IR (ATR) υ (cm-1) = 3079, 3063, 2900, 2846, 1506, 1445, 1426, 1343, 1315, 1248, 1225, 
1194, 1101, 1064, 1052, 1003, 969, 892, 853, 788, 692, 684, 654. 
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Preparation of 5,5'''''-diadamantan-1-yl)-2,2':5',2'':5'',2''':5''',2'''':5'''',2'''''-sexi-
thiophene (60) 
S SS 4
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with magnesium turnings (24 mg, 1 mmol), LiCl (22 mg, 0.5 mmol) and 59 
(153 mg, 0.39 mmol) and dissolved in 2 mL THF. Then, the reaction mixture was cold to 
0 °C and the reaction was initiated by adding a catalytic amount of iodine. The reaction 
mixture was stirred for 1 h slowly warming up to room temperature. After addition of 
Ni(dppp)Cl2 (22 mg, 0.04 mmol) in 1 mL THF, the reaction mixture was refluxed over 
night. The reaction was quenched with sat. NH4Cl solution (10 mL) and extracted with 
EtOAc (3x20 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. The crude residue obtained was purified by flash column 
chromatography (silica, pentane:Et2O 97:3) to give 60 as a yellow solid (229 mg, 77 %). 
 
m.p.: 115.3-117.0 °C. 
1H NMR (600 MHz, CDCl3) δ (ppm) = 7.15-7.22 (m, 2H), 6.92-7.12 (m, 8H), 6.64-6.77 
(m, 2H), 2.09 (bs, 6H), 1.98 (d, J=2.7Hz, 12H), 1.72-1.85 (m, 12H). 
13C NMR (150 MHz, CDCl3) δ (ppm) = 157.9, 137.3, 137.0, 135.4, 133.6, 127.8, 124.3, 
124.2, 123.4, 123.4, 123.1, 121.1, 44.8, 36.6, 36.5, 28.8.  
MS (70 eV, EI), m/z (%) = 762 (M+, 1), 518 (12), 517 (22), 516 (51), 384 (17), 383 (26),  
382 (100), 326 (7), 325 (28), 292 (5), 288 (6). 
HRMS (EI), m/z calc. for C44H42S6 (762.1611): 762.1599. 
IR (ATR) υ (cm-1) = 3064, 2901, 2846, 1738, 1714, 1506, 1446, 1425, 1343, 1315, 1256, 
1225, 1195, 1100, 1063, 1051, 1003, 969, 892, 868, 837, 790, 689, 683, 654. 
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7. FULL FUNCTIONALIZATION OF THE IMIDAZOLE SCAFFOLD BY 
SELECTIVE METALATION AND SULFOXIDE/MAGNESIUM 
EXCHANGE 
7.1 PREPARATION OF STARTING MATERIALS 
All reagents were obtained from commercial sources. Compounds 61259 and 68a254 were 
prepared according to literature-known procedures. 
 
Preparation of 2-(tert-butyldimethylsilyl)-5-((4-methoxy-3,5-dimethylphenyl)-
sulfinyl)-N,N-dimethyl-imidazole-1-sulfonamide (67) 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with 61 (5.79 g, 20 mmol) and dissolved in 20 mL THF. TMPMgCl·LiCl 
(62, 20 mL, 22 mmol, 1.1 M in THF) was added and the resulting mixture was stirred for 
2 h at room temperature. After cooling to -20 °C, a solution of 68a (3,94 g, 18 mmol) in 
20 mL THF was added dropwise and stirred for 4 h while slowly warming up to room 
temperature. The reaction was quenched with sat. NH4Cl solution (50 mL) and extracted 
with EtOAc (3x50 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. The crude residue obtained was purified by flash column 
chromatography (silica, pentane:EtOAc 6.5:3.5) to give 67 as a white solid (7.30 g,  
86 %). 
 
m.p.: 116.3-117.2 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.37 (s, 2H),  7.02 (s, 1H), 3.74 (s, 3H), 3.04 (s, 
6H), 2.31 (s, 6H), 0.97 (s, 9H), 0.38 (d, J=1.11Hz, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 159.9, 159.5, 138.2, 136.1, 135.9, 132.5, 125.6, 
59.8, 37.9, 27.0, 18.3, 16.3, -4.0, -4.0.  
MS (70 eV, EI), m/z (%) = 456 ([M-CH3]+, 3), 416 (14), 415 (24), 414 (100), 168 (11),  
167 (26), 166 (87), 102 (21), 73 (20). 
HRMS (EI), m/z calc. for C19H30N3O4S2Si (456.1447 ([M-CH3])): 456.1442 ([M-CH3]). 
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IR (ATR) υ (cm-1) = 3124, 2981, 2953, 2930, 2885, 2853, 1472, 1457, 1364, 1250, 1178, 
1146, 1138, 1095, 1058, 1005, 976, 930, 834, 823, 814, 775, 736, 667. 
7.2 TYPICAL PROCEDURES 
Typical procedure 1 (TP1): Deprotonation at position 4 with TMPMgCl·LiCl  
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with 67 and dissolved in THF (1 mL/mmol). After cooling to -30 °C, 
TMPMgCl·LiCl (62, 1.1 equiv) was added dropwise and the reaction mixture was stirred 
for 1 h at -30 °C until GC-analysis of iodolyzed reaction aliquot showed full 
consumption of the starting material. 
 
Typical procedure 2 (TP2):  Sulfoxide-Magnesium Exchange at position 5 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with the sulfoxide and dissolved in THF (1 mL/mmol). After cooling to  
-78 °C, iPrMgCl·LiCl (63, 1.2 equiv) was added dropwise and the reaction mixture was 
stirred for 1 h at -78 °C until GC-analysis of iodolyzed reaction aliquot showed full 
consumption of the starting material. 
 
Typical procedure 3 (TP3): Deprotonation at position 2 with TMP2Zn·2MgCl·2LiCl 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with the imidazol derivative and dissolved in THF (1 mL/mmol). After 
cooling to -20 °C, TMP2Zn·2MgCl·2LiCl (65, 1.2 equiv) was added dropwise and the 
reaction mixture was stirred for 1 h at -20 °C until GC-analysis of iodolyzed reaction 
aliquot showed full consumption of the starting material. 
 
Typical procedure 4 (TP4): Deprotonation at position 2 with TMPMgCl·LiCl 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with the imidazol derivative and dissolved in THF (1 mL/mmol). After 
cooling to -78 °C, TMPMgCl·LiCl (62, 1.2 equiv) was added dropwise and the reaction 
mixture was stirred for 1 h at -78 °C until GC-analysis of iodolyzed reaction aliquot 
showed full consumption of the starting material. 
 
Typical procedure 5 (TP5): Deprotection at position 2 with TBAF 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with the protected imidazol derivative and dissolved in THF (10 mL/mmol). 
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After cooling down to 0 °C, TBAF·3H2O (64, 1 equiv, 0.1 M in THF) was added 
dropwise and the reaction mixture was stirred for 5 min. The reaction mixture was 
quenched with sat. NH4Cl solution and extracted with EtOAc (3x). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. The crude residue 
obtained was purified by flash column chromatography to give the analytically pure 
product. 
 
Typical procedure 6 (TP6): Cross-coupling reactions of imidazol zinc reagents  
To the freshly prepared imidazol magnesium reagent was added ZnCl2 (1.0M in THF,  
1.1 equiv) and the reaction mixture was stirred for 15 min at the indicated temperature. 
Pd(PPh3)4 (5 mol %) and the aryl iodide (0.9 or 1.1 equiv) were added and the reaction 
mixture was stirred for the given time at 50 °C. The reaction mixture was quenched with 
sat. NH4Cl solution (10 mL) and extracted with EtOAc (3x20 mL). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. The crude residue 
obtained was purified by flash column chromatography to give the analytically pure 
product. 
 
Typical procedure 7 (TP7):  Allylation of imidazol zinc reagents 
To the freshly prepared imidazol magnesium reagent was added ZnCl2 (1.0M in THF,  
1.1 equiv) and the reaction mixture was stirred for 15 min at the indicated temperature. 
CuCN·2LiCl (1.0M in THF, 1.1 equiv) and the allyl bromide (0.9 or 1.1 equiv) were 
added and the reaction mixture was warmed to 25 °C. After stirring for the given time, 
the reaction mixture was quenched with sat. NH4Cl/NH3 (9:1) solution (10 mL) and 
extracted with EtOAc (3x10 mL). The combined organic phases were dried over Na2SO4 
and concentrated in vacuo. The crude residue obtained was purified by flash column 
chromatography to give the analytically pure product. 
 
Typical procedure 8 (TP8):  Acylation of imidazol zinc reagents 
To the freshly prepared imidazol magnesium reagent was added ZnCl2 (1.0M in THF,  
1.1 equiv) and the reaction mixture was stirred for 15 min at the indicated temperature. 
CuCN·2LiCl (1.0M in THF, 1.1 equiv) and the acyl chloride (0.9 or 1.1 equiv) were 
added and the reaction mixture was warmed to 25 °C. After stirring for the given time, 
the reaction mixture was quenched with sat. NH4Cl/NH3 (9:1) solution (10 mL) and 
extracted with EtOAc (3x10 mL). The combined organic phases were dried over Na2SO4 
and concentrated in vacuo. The crude residue obtained was purified by flash column 
chromatography to give the analytically pure product. 
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Typical procedure 9 (TP9):  Pd-catalyzed acylation of imidazol zinc reagents 
To the freshly prepared imidazol magnesium reagent was added ZnCl2 (1.0M in THF,  
1.1 equiv) and the reaction mixture was stirred for 15 min at the indicated temperature. 
Pd(PPh3)4 (5 mol %) and the acyl chloride (0.9 or 1.1 equiv) were added and the reaction 
mixture was stirred for the given time at room temperature. The reaction mixture was 
quenched with sat. NH4Cl solution (10 mL) and extracted with EtOAc (3x20 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. The crude 
residue obtained was purified by flash column chromatography to give the analytically 
pure product. 
 
Typical procedure 10 (TP10): Deprotection/Reprotection  
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum 
was charged with the protected imidazol derivative and dissolved in DCM (2 mL/mmol). 
Trimethyloxonium tetrafluoroborate (1 equiv) was added at room temperature and the 
reaction mixture was stirred over night. After removing the solvent in high vacuum, the 
remaining solid was dissolved in EtOH (10 mL/mmol), conc. HCl (5 ml/mmol) was 
added and the reaction mixture was stirred at 60 °C for 30 min. The reaction was 
quenched with sat. NaHCO3 solution and extracted with EtOAc (3x). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. The crude residue 
obtained was purified by flash column chromatography to give the analytically pure 
product. 
 
7.3 SELECTIVE FUNCTIONALIZATION ON POSITION 4 OF THE IMIDAZOLE RING 
Preparation of ethyl 4-(2-(tert-butyldimethylsilyl)-1-(N,N-dimethylsulfamoyl)-5-((4-
methoxy-3,5-dimethylphenyl)sulfinyl)imidazol-4-yl)benzoate (70a) 
 
Prepared according to TP1 from 2-(tert-butyldimethylsilyl)-5-((4-methoxy-3,5-
dimethylphenyl)sulfinyl)-N,N-dimethyl-imidazole-1-sulfonamide (67, 236 mg,  
0.5 mmol) and TMPMgCl·LiCl (62, 0.5 mL, 0.55 mmol, 1.1M in THF) at -30 °C in 1 h. 
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Subsequently, the cross-coupling was accomplished according to TP6 with ZnCl2  
(0.6 mL, 0.6 mmol, 1.0M in THF), Pd(PPh3)4 (29 mg, 0.025 mmol) and ethyl 4-
iodobenzoate (68b, 124 mg, 0.45 mmol) in 2 h. Flash column chromatographical 
purification on silica gel (pentane/EtOAc, 8:2) afforded 70a as a orange solid (234 mg, 
84%). 
 
m.p.: 132.7-133.9 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.84 (d, J=8.0Hz, 2H), 7.66 (d, J=8.0 Hz, 2H),  
6.92 (s, 2H), 4.27-4.43 (m, 2H), 3.49 (s, 3H), 3.13 (s, 6H), 2.03-2.11 (m, 6H), 1.37 (t, 
J=7.2Hz, 3 H), 1.08 (s, 9H), 0.46 (d, J=11.9Hz, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.2, 158.4, 157.7, 147.8, 136.4, 133.7, 132.9, 
131.2, 130.2, 130.0, 128.3, 125.4, 60.9, 59.4, 37.9, 27.1, 18.7, 15.8, 14.3, -4.1, -4.2.  
MS (70 eV, EI), m/z (%) = 604 ([M-CH3]+, 3), 564 (22), 563 (40), 562 (100), 328 (18),  
183 (15), 167 (25), 166 (20), 102 (17), 92 (11), 73 (49). 
HRMS (EI), m/z calc. for C28H38N3O6S2Si (604.1971 ([M-CH3])): 604.1961 ([M-CH3]). 
IR (ATR) υ (cm-1) = 3056, 2980, 2936, 2853, 1716, 1474, 1376, 1282, 1272, 1171, 1130, 
1109, 1097, 1050, 1012, 964, 843, 822, 779, 726, 669. 
 
Preparation of 2-(tert-butyldimethylsilyl)-5-((4-methoxy-3,5-dimethylphenyl)-
sulfinyl)-N,N-dimethyl-4-(4-(trifluoromethyl)phenyl)-imidazole-1-sulfonamide (70b) 
 
Prepared according to TP1 from 2-(tert-butyldimethylsilyl)-5-((4-methoxy-3,5-
dimethylphenyl)sulfinyl)-N,N-dimethyl-imidazole-1-sulfonamide (67, 236 mg,  
0.5 mmol) and TMPMgCl·LiCl (62, 0.5 mL, 0.55 mmol, 1.1M in THF) at -30 °C in 1 h. 
Subsequently, the cross-coupling was accomplished according to TP6 with ZnCl2  
(0.55 mL, 0.55 mmol, 1.0M in THF), Pd(PPh3)4 (29 mg, 0.025 mmol) and 1-iodo-4-
(trifluoromethyl)benzene (68c, 122 mg, 0.45 mmol) in 2 h. Flash column 
chromatographical purification on silica gel (pentane/EtOAc, 8:2) afforded 70b as a pale 
orange solid (201 mg, 72%). 
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m.p.: 149.5-151.9 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.72 (d, J=8.6Hz, 2H), 7.43 (d, J=8.9Hz, 2H), 
6.91 (s, 2H), 3.50 (s, 3H), 3.15 (s, 6H), 2.08 (s, 6H), 1.08 (s, 9H), 0.48 (s, 3H), 0.45 (s, 
3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 158.5, 157.7, 147.4, 135.6, 133.6, 133.1, 131.2, 
130.4, 130.3 (q, J=32.3Hz), 125.4, 124.0 (q, J=3,7Hz), 124.0 (q, J=272.1Hz), 59.4, 37.9, 
27.0, 18.6, 15.8, -4.1, -4.1.  
MS (70 eV, EI), m/z (%) = 614 ([M-H]+, 3), 560 (17), 559 (31), 558 (100), 167 (10),  
73 (11). 
HRMS (EI), m/z calc. for C27H35F3N3O4S2Si (614.1790 ([M-H])): 614.1781 ([M-H]). 
IR (ATR) υ (cm-1) = 3061, 2954, 2926, 2888, 2853, 1737, 1620, 1474, 1380, 1322, 1224, 
1172, 1159, 1118, 1093, 1072, 1054, 1011, 959, 857, 841, 823, 817, 780, 722, 716, 668. 
 
Preparation of 2-(tert-butyldimethylsilyl)-4-(4-chlorophenyl)-5-((4-methoxy-3,5-di-
methylphenyl)sulfinyl)-N,N-dimethyl-imidazole-1-sulfonamide (70c) 
 
Prepared according to TP1 from 2-(tert-butyldimethylsilyl)-5-((4-methoxy-3,5-
dimethylphenyl)sulfinyl)-N,N-dimethyl-imidazole-1-sulfonamide (67, 236 mg,  
0.5 mmol) and TMPMgCl·LiCl (62, 0.5 mL, 0.55 mmol, 1.1M in THF) at -30 °C in 1 h. 
Subsequently, the cross-coupling was accomplished according to TP6 with ZnCl2  
(0.55 mL, 0.55 mmol, 1.0M in THF), Pd(PPh3)4 (29 mg, 0.025 mmol) and 1-chloro-4-
iodobenzene (68d, 107 mg, 0.45 mmol) in 2 h. Flash column chromatographical 
purification on silica gel (pentane/EtOAc, 8.5:1.5) afforded 70c as a pale yellow solid  
(186 mg, 71%). 
 
m.p.: 144.8-146.1 °C. 
1H NMR (600 MHz, CDCl3) δ (ppm) = 7.51 (d, J=8.5Hz, 2H), 7.12 (d, J=8.5Hz, 2H), 
6.90 (s, 2H), 3.55 (s, 3H), 3.12 (s, 6H), 2.10 (s, 6H), 1.06 (s, 9H), 0.46 (s, 3H), 0.42 (s, 
3H). 
C. EXPERIMENTAL SECTION 
304 
13C NMR (150 MHz, CDCl3) δ (ppm) = 158.4, 157.6, 147.8, 134.5, 133.7, 132.1, 131.4, 
131.2, 130.6, 127.3, 125.4, 59.5, 37.9, 27.1, 18.6, 15.9, -4.1, -4.2.  
MS (70 eV, EI), m/z (%) = 566 ([M-CH3]+, 3), 527 (14), 526 (49), 525 (31), 524 (100),  
290 (18), 232 (12), 193 (10), 183 (13), 167 (25), 166 (20), 102 (19), 92 (11), 73 (44). 
HRMS (EI), m/z calc. for C25H33ClN3O4S2Si (566.1370 ([M-CH3])): 566.1368 ([M-
CH3]). 
IR (ATR) υ (cm-1) = 3074, 3052, 2956, 2932, 2888, 2856, 1740, 1603, 1533, 1473, 1417, 
1380, 1290, 1254, 1218, 1193, 1170, 1131, 1097, 1088, 1053, 1012, 976, 965, 934, 854, 
838, 822, 813, 779, 738, 726, 710, 668. 
 
Preparation of 2-(tert-butyldimethylsilyl)-5-((4-methoxy-3,5-dimethylphenyl)-
sulfinyl)-4-(4-methoxyphenyl)-N,N-dimethyl-imidazole-1-sulfonamide (70d) 
 
Prepared according to TP1 from 2-(tert-butyldimethylsilyl)-5-((4-methoxy-3,5-
dimethylphenyl)sulfinyl)-N,N-dimethyl-imidazole-1-sulfonamide (67, 236 mg,  
0.5 mmol) and TMPMgCl·LiCl (62, 0.5 mL, 0.55 mmol, 1.1M in THF) at -30 °C in 1 h. 
Subsequently, the cross-coupling was accomplished according to TP6 with ZnCl2  
(0.55 mL, 0.55 mmol, 1.0M in THF), Pd(PPh3)4 (29 mg, 0.025 mmol) and 1-iodo-4-
methoxybenzene (68e, 105 mg, 0.45 mmol) in 2 h. Flash column chromatographical 
purification on silica gel (pentane/EtOAc, 7:3) afforded 70d as a orange solid (157 mg, 
60%). 
 
m.p.: 124.4-126.3 °C. 
1H NMR (600 MHz, CDCl3) δ (ppm) =  7.57 (d, J=8.78Hz, 2H), 6.94 (s, 2H), 6.71 (d, 
J=8.78Hz, 2H), 3.76 (s, 3H), 3.55 (s, 3H), 3.11 (s, 6H), 2.10 (s, 6H), 1.08 (s, 9H), 0.47 (s, 
3H), 0.43 (s, 3H). 
13C NMR (150 MHz, CDCl3) δ (ppm) = 160.0, 158.3, 157.5, 149.1, 134.1, 131.4, 131.0, 
130.5, 125.4, 124.7, 112.6, 59.5, 55.1, 37.9, 27.1, 18.7, 15.9, -4.1, -4.1.  
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MS (70 eV, EI), m/z (%) = 577 (M+, 2), 522 (15), 521 (26), 520 (77), 383 (18),  
382 (63), 287 (26), 286 (100), 189 (20), 183 (11), 167 (34), 166 (19), 145 (18), 102 (12),  
73 (44). 
HRMS (EI), m/z calc. for C27H39N3O5S2Si (577.2100): 577.2093. 
IR (ATR) υ (cm-1) = 3117, 2981, 2952, 2936, 2910, 2857, 1707, 1634, 1616, 1474, 1373, 
1292, 1271, 1249, 1182, 1171, 1154, 1128, 1110, 1097, 1022, 975, 951, 864, 838, 820, 
813, 775, 734, 725, 710, 696, 673. 
 
Preparation of 2-(tert-butyldimethylsilyl)-5-((4-methoxy-3,5-dimethylphenyl)-
sulfinyl)-N,N-dimethyl-4-(pyridin-4-yl)imidazole-1-sulfonamide (70e) 
 
Prepared according to TP1 from 2-(tert-butyldimethylsilyl)-5-((4-methoxy-3,5-
dimethylphenyl)sulfinyl)-N,N-dimethyl-imidazole-1-sulfonamide (67, 236 mg,  
0.5 mmol) and TMPMgCl·LiCl (62, 0.5 mL, 0.55 mmol, 1.1M in THF) at -30 °C in 1 h. 
Subsequently, the cross-coupling was accomplished according to TP6 with ZnCl2  
(0.55 mL, 0.55 mmol, 1.0M in THF), Pd(PPh3)4 (29 mg, 0.025 mmol) and 4-iodopyridine 
(68f, 92 mg, 0.45 mmol) in 2 h. Flash column chromatographical purification on silica 
gel (pentane/EtOAc, 3:7) afforded 70e as a yellow oil (147 mg, 60%). 
 
1H NMR (400 MHz, CDCl3) δ (ppm) = 8.34-8.50 (m, 2H), 7.52-7.67 (m, 2H), 6.97 (s, 
2H), 3.55 (s, 3H), 3.13 (s, 6H), 2.12 (s, 6H), 1.08 (s, 9H), 0.47 (s, 3H), 0.44 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 158.7, 157.9, 149.6, 148.8, 146.0, 133.9, 133.7, 
128.5, 128.4, 124.1, 59.6, 38.0, 27.0, 18.7, 16.0, -4.2, -4.2.  
MS (70 eV, EI), m/z (%) = 548 (M+, 1), 493 (15), 492 (25), 491 (100), 311 (10),  
310 (19), 309 (94), 278 (21), 277 (47), 201 (11), 183 (17), 167 (13), 166 (11), 102 (11),  
92 (16), 43 (27). 
HRMS (EI), m/z calc. for C25H36N4O4S2Si (548.1947): 548.1927. 
IR (ATR) υ (cm-1) = 3053, 3035, 2953, 2931, 2892, 2857, 1736, 1604, 1474, 1413, 1378, 
1274, 1251, 1219, 1190, 1171, 1133, 1119, 1097, 1053, 1007, 969, 823, 781, 725, 712, 
696. 
C. EXPERIMENTAL SECTION 
306 
Preparation of (E)-2-(tert-butyldimethylsilyl)-5-((4-methoxy-3,5-dimethylphenyl)-
sulfinyl)-N,N-dimethyl-4-(oct-1-en-1-yl)-imidazole-1-sulfonamide (70f) 
 
Prepared according to TP1 from 2-(tert-butyldimethylsilyl)-5-((4-methoxy-3,5-
dimethylphenyl)sulfinyl)-N,N-dimethyl-imidazole-1-sulfonamide (67, 236 mg,  
0.5 mmol) and TMPMgCl·LiCl (62, 0.5 mL, 0.55 mmol, 1.1M in THF) at -30 °C in 1 h. 
Subsequently, the cross-coupling was accomplished according to TP6 with ZnCl2  
(0.55 mL, 0.55 mmol, 1.0M in THF), Pd(PPh3)4 (29 mg, 0.025 mmol) and (E)-1-iodooct-
1-ene (68g, 107 mg, 0.45 mmol) in 2 h. Flash column chromatographical purification on 
silica gel (pentane/EtOAc, 8:2) afforded 70f as a brown solid (216 mg, 83%). 
 
m.p.: 98.9-101.2 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.31 (s, 2H), 6.57-6.77 (m, 1H), 6.26-6.39 (m, 
1H), 3.72 (s, 3H), 3.01 (s, 6H), 2.31 (s, 6H), 2.00-2.15 (m, 2H), 1.21-1.32 (m, 8H),  
1.05 (s, 9H), 0.82-0.93 (m, 3H), 0.40 (s, 3H), 0.39 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.2, 158.4, 157.7, 147.8, 136.4, 133.7, 132.9, 
131.2, 130.2, 130.0, 128.3, 125.4, 60.9, 59.4, 37.9, 27.1, 18.7, 15.8, 14.3, -4.1, -4.2.  
MS (70 eV, EI), m/z (%) = 581 (M+, 2), 547 (10), 526 (18), 525 (31), 524 (96),  
474 (15), 473 (38), 398 (17), 291 (27), 290 (100), 257 (10), 193 (28), 183 (11), 167 (43),  
166 (18). 
HRMS (EI), m/z calc. for C28H47N3O4S2Si (581.2777): 581.2766. 
IR (ATR) υ (cm-1) = 3062, 2992, 2959, 2923, 2902, 2858, 1741, 1654, 1458, 1372, 1359, 
1248, 1220, 1178, 1157, 1091, 1049, 1010, 944, 841, 824, 779, 725, 673, 660. 
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Preparation of ethyl 2-((2-(tert-butyldimethylsilyl)-1-(N,N-dimethylsulfamoyl)-5-((4-
methoxy-3,5-dimethylphenyl)sulfinyl)-imidazol-4-yl)methyl)acrylate (70g) 
 
Prepared according to TP1 from 2-(tert-butyldimethylsilyl)-5-((4-methoxy-3,5-
dimethylphenyl)sulfinyl)-N,N-dimethyl-imidazole-1-sulfonamide (67, 236 mg,  
0.5 mmol) and TMPMgCl·LiCl (62, 0.5 mL, 0.55 mmol, 1.1M in THF) at -30 °C in 1 h. 
Subsequently, the allylation reaction was accomplished according to TP7 with ZnCl2  
(0.55 mL, 0.55 mmol, 1.0M in THF), CuCN·2LiCl (0.55 mL, 0.55 mmol, 1.0M in THF) 
and ethyl 2-(bromomethyl)acrylate (68h, 235 mg, 0.45 mmol) over night. Flash column 
chromatographical purification on silica gel (pentane/EtOAc, 7:3) afforded 70g as a 
colorless solid (256 mg, 98%). 
 
m.p.: 97.7-99.9 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.24 (s, 2H), 5.88 (d, J=1.1Hz, 1H), 4.85 (d, 
J=1.4Hz, 1H), 4.08-4.16 (m, 2H), 3.71 (s, 3H), 3.04 (s, 6H), 2.26 (s, 6H), 1.22-1.26 (m, 
3H), 0.98 (s, 9H), 0.27-0.47 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.4, 158.9, 156.9, 146.4, 136.7, 136.1, 132.3, 
131.0, 124.9, 124.8, 60.6, 59.7, 37.9, 29.5, 26.9, 18.5, 16.2, 14.1, -4.1, -4.2.  
MS (70 eV, EI), m/z (%) = 583 (M+, 1), 528 (16), 527 (29), 526 (100), 345 (16),  
344 (11), 183 (21), 168 (10), 167 (30), 166 (33), 102 (14), 73 (29). 
HRMS (EI), m/z calc. for C26H41N6O6S2Si (583.2206): 583.2212. 
IR (ATR) υ (cm-1) = 3112, 2983, 2950, 2928, 2911, 2888, 2855, 1717, 1636, 1474, 1376, 
1272, 1244, 1220, 1180, 1152, 1119, 1094, 1054, 1040, 1020, 1006, 960, 842, 823, 780, 
726. 
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Preparation of 2-(tert-butyldimethylsilyl)-4-(4-chlorobenzoyl)-5-((4-methoxy-3,5-
dimethylphenyl)sulfinyl)-N,N-dimethyl-imidazole-1-sulfonamide (70h) 
 
Prepared according to TP1 from 2-(tert-butyldimethylsilyl)-5-((4-methoxy-3,5-
dimethylphenyl)sulfinyl)-N,N-dimethyl-imidazole-1-sulfonamide (67, 236 mg,  
0.5 mmol) and TMPMgCl·LiCl (62, 0.5 mL, 0.55 mmol, 1.1M in THF) at -30 °C in 1 h. 
Subsequently, the acylation reaction was accomplished according to TP8 with ZnCl2  
(0.55 mL, 0.55 mmol, 1.0M in THF), CuCN·2LiCl (0.55 mL, 0.55 mmol, 1.0M in THF) 
and 4-chlorobenzoyl chloride (68i, 79 mg, 0.45 mmol) over night. Flash column 
chromatographical purification on silica gel (pentane/EtOAc, 7:3) afforded 70h as a pale 
yellow solid (225 mg, 82%). 
 
m.p.: 139.0-140.6 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.68 (d, J=8.9Hz, 2H), 7.30 (d, J=8.9Hz, 2H), 
7.16 (s, 2H), 3.53 (s, 3H), 3.07 (s, 6H), 2.14 (s, 6H), 1.00 (s, 9H), 0.38-0.47 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 186.7, 159.0, 157.5, 144.2, 139.7, 137.9, 134.8, 
134.3, 131.8, 131.4, 128.2, 125.9, 59.6, 38.1, 26.9, 18.6, 16.1, -4.0, -4.1.  
MS (70 eV, EI), m/z (%) = 594 ([M-CH3]+, 4), 555 (20), 554 (66), 553 (43), 552 (100),  
454 (21), 183 (46), 168 (28), 167 (100), 166 (78), 139 (78), 111 (25), 108 (37), 102 (46),  
75 (35), 73 (74), 43 (29). 
HRMS (EI), m/z calc. for C26H33ClN3O5S2Si (594.1319 ([M-CH3])): 594.1329 ([M-
CH3]). 
IR (ATR) υ (cm-1) = 3125, 2952, 2931, 2900, 2857, 1730, 1676, 1586, 1473, 1417, 1381, 
1274, 1250, 1217, 1176, 1156, 1091, 1065, 1022, 1011, 971, 902, 844, 822, 814, 781, 
762, 726, 686, 670. 
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Preparation of ethyl 3-(2-(tert-butyldimethylsilyl)-1-(N,N-dimethylsulfamoyl)-5-((4-
methoxy-3,5-dimethylphenyl)sulfinyl)-imidazol-4-yl)propiolate (70i) 
 
Prepared according to TP1 from 2-(tert-butyldimethylsilyl)-5-((4-methoxy-3,5-
dimethylphenyl)sulfinyl)-N,N-dimethyl-imidazole-1-sulfonamide (67, 236 mg,  
0.5 mmol) and TMPMgCl·LiCl (62, 0.5 mL, 0.55 mmol, 1.1M in THF) at -30 °C in 1 h. 
Subsequently, ZnCl2 (0.55 mL, 0.55 mmol, 1.0M in THF) was added and stirred for  
15 min at -30 °C. CuCN·2LiCl (0.55 mL, 0.55 mmol, 1.0M in THF) and ethyl 3-
bromopropiolate (68j, 80 mg, 0.45 mmol) were added and the reaction mixture was 
stirred over night while warming up to room temperature. The reaction was quenched 
with sat. NH4Cl/NH3 (9:1) solution (10 mL) and extracted with EtOAc (3x10 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. The crude 
residue obtained was purified by flash column chromatography (silica, pentane:EtOAc 
7:3) to give 70i as a yellow oil (133 mg, 53 %). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.42 (s, 2H), 4.24 (q, J=6.8Hz, 2H), 3.73 (s, 3H),  
3.09 (s, 6H), 2.32 (s, 6H), 1.31 (t, J=6.8Hz, 3H), 1.00 (s, 9H), 0.33-0.45 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 159.6, 158.2, 153.0, 141.6, 134.3, 132.4, 125.4, 
125.0, 86.7, 76.3, 62.1, 59.7, 38.1, 27.0, 18.4, 16.3, 14.1, -4.0, -4.0.  
MS (70 eV, EI), m/z (%) = 552 ([M-CH3]+, 1), 412 (38), 356 (32), 334 (36), 298 (57),  
269 (58), 189 (27), 183 (44), 182 (65), 167 (91), 147 (71), 102 (87), 75 (37), 73 (100). 
HRMS (EI), m/z calc. for C24H34N3O6S2Si (552.1658 ([M-CH3])): 552.1654 ([M-CH3]). 
IR (ATR) υ (cm-1) = 3114, 2954, 2931, 2906, 2858, 2232, 1710, 1472, 1418, 1383, 1288, 
1275, 1245, 1217, 1176, 1165, 1096, 1066, 1033, 1010, 971, 844, 822, 813, 781, 748, 
725. 
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7.4 SELECTIVE FUNCTIONALIZATION ON POSITION 5 OF THE IMIDAZOLE RING 
Preparation of ethyl 4-(2-(tert-butyldimethylsilyl)-1-(N,N-dimethylsulfamoyl)-4-(2-
(ethoxycarbonyl)allyl)- imidazol-5-yl)benzoate (72a) 
 
Prepared according to TP2 from ethyl 2-((2-(tert-butyldimethylsilyl)-1-(N,N-
dimethylsulfamoyl)-5-((4-methoxy-3,5-dimethylphenyl)sulfinyl)-imidazol-4-yl)methyl)-
acrylate (70g, 292 mg, 0.5 mmol) and iPrMgCl·LiCl (63, 0.5 mL, 0.6 mmol, 1.2M in 
THF) at -78 °C in 1 h. Subsequently, the cross-coupling was accomplished according to 
TP6 with ZnCl2 (0.6 mL, 0.6 mmol, 1.0M in THF), Pd(PPh3)4 (29 mg, 0.025 mmol) and 
ethyl 4-iodobenzoate (68b, 124 mg, 0.45 mmol) in 2 h. Flash column chromatographical 
purification on silica gel (pentane/EtOAc, 8.5:1.5) afforded 72a as a pale yellow solid  
(173 mg, 71%). 
 
m.p.: 83.8-85.1 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.10 (d, J=8.0Hz, 2 H), 7.47 (d, J=8.0Hz, 2H),  
6.18 (s, 1H), 5.41 (s, 1H), 4.39 (q, J=7.2Hz, 2H), 4.13 (q, J=7.0Hz, 2H), 3.37 (s, 2H), 
2.28 (s, 6H), 1.40 (t, J=6.9Hz, 3H), 1.23 (t, J=7.1Hz, 3H), 1.06 (s, 6H), 0.39 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.8, 166.0, 155.0, 140.1, 138.4, 134.0, 131.0, 
130.7, 129.2, 128.4, 125.8, 61.2, 60.6, 36.6, 29.1, 27.0, 18.6, 14.3, 14.1, -4.0.  
MS (70 eV, EI), m/z (%) = 548 ([M-H]+, 1), 534 (4), 504 (5), 494 (15), 493 (30),  
492 (100), 344 (6), 103 (8). 
HRMS (EI), m/z calc. for C26H38N3O6SSi (548.2251 ([M-H])): 548.2239 ([M-H]). 
IR (ATR) υ (cm-1) = 3118, 2981, 2947, 2937, 2910, 2857, 1708, 1634, 1617, 1474, 1373, 
1293, 1271, 1254, 1249, 1183, 1153, 1128, 1111, 1099, 1022, 976, 951, 864, 826, 821, 
776, 735, 724, 710, 697, 673. 
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Preparation of ethyl 2-((2-(tert-butyldimethylsilyl)-5-(4-cyanophenyl)-1-(N,N-
dimethyl-sulfamoyl)- imidazol-4-yl)methyl)acrylate (72b) 
 
Prepared according to TP2 from ethyl 2-((2-(tert-butyldimethylsilyl)-1-(N,N-
dimethylsulfamoyl)-5-((4-methoxy-3,5-dimethylphenyl)sulfinyl)-imidazol-4-yl)methyl)-
acrylate (70g, 292 mg, 0.5 mmol) and iPrMgCl·LiCl (63, 0.5 mL, 0.6 mmol, 1.2M in 
THF) at -78 °C in 1 h. Subsequently, the cross-coupling was accomplished according to 
TP6 with ZnCl2 (0.6 mL, 0.6 mmol, 1.0M in THF), Pd(PPh3)4 (29 mg, 0.025 mmol) and  
4-iodobenzonitrile (68k, 103 mg, 0.45 mmol) in 1 h. Flash column chromatographical 
purification on silica gel (pentane/EtOAc, 8:2) afforded 72b as a brown solid (202 mg, 
90%). 
 
m.p.: 98.3-99.7 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.72 (d, J=8.6Hz, 2H), 7.54 (d, J=8.6Hz, 2H), 
6.21 (d, J=1.1Hz, 1H), 5.46 (d, J=1.4Hz, 1H), 4.14 (q, J=7.0Hz, 2H), 3.36 (s, 2H),  
2.31 (s, 6H), 1.24 (t, J=7.2Hz, 3H), 1.05 (s, 9H), 0.39 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.6, 155.7, 140.6, 138.1, 134.4, 131.7, 131.7, 
127.5, 126.1, 118.3, 112.6, 60.7, 36.7, 29.2, 27.0, 18.6, 14.1, -4.1.  
MS (70 eV, EI), m/z (%) = 501 ([M-H]+, 1), 447 (11), 446 (28), 445 (100), 103 (17),  
92 (19), 76 (10), 75 (28), 73 (14). 
HRMS (EI), m/z calc. for C24H33N4O4SSi (501.1992 ([M-H])): 501.1992 ([M-H]). 
IR (ATR) υ (cm-1) = 3060, 2978, 2956, 2929, 2908, 2854, 2229, 1715, 1640, 1612, 1466, 
1372, 1302, 1250, 1190, 1179, 1152, 1135, 1108, 1096, 1043, 1020, 972, 848, 838, 823, 
813, 776, 729, 694, 665. 
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Preparation of 2-(tert-butyldimethylsilyl)-N,N-dimethyl-4,5-di((E)-oct-1-en-1-yl)-
imidazole-1-sulfonamide (72c) 
 
Prepared according to TP2 from (E)-2-(tert-butyldimethylsilyl)-5-((4-methoxy-3,5-
dimethylphenyl)-sulfinyl)-N,N-dimethyl-4-(oct-1-en-1-yl)-imidazole-1-sulfonamide (70f,  
291 mg, 0.5 mmol) and iPrMgCl·LiCl (63, 0.5 mL, 0.6 mmol, 1.2M in THF) at  
-78 °C in 1 h. Subsequently, the cross-coupling was accomplished according to TP6 with 
ZnCl2 (0.6 mL, 0.6 mmol, 1.0M in THF), Pd(PPh3)4 (29 mg, 0.025 mmol) and (E)-1-
iodooct-1-ene (68g, 107 mg, 0.45 mmol) in 1 h. Flash column chromatographical 
purification on silica gel (pentane/EtOAc, 75:1) afforded 72c as a colorless oil (202 mg, 
88%). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 6.56-6.71 (m, 1H), 6.21-6.46 (m, 2H), 5.85-5.98 
(m, 1H), 2.79 (s, 6H), 2.13-2.31 (m, 4H), 1.23-1.40 (m, 16H), 1.08 (s, 9H), 0.82-0.96 (m, 
6H), 0.37 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 153.6, 139.2, 138.1, 132.8, 126.9, 120.1, 117.5, 
37.8, 33.4, 33.0, 31.7, 31.7, 29.2, 29.2, 29.0, 28.9, 27.1, 22.6, 22.6, 18.6, 14.1, 14.0, -4.2.  
MS (70 eV, EI), m/z (%) = 509 (M+, 1), 454 (15), 453 (36), 452 (100), 389 (12),  
388 (31), 377 (33), 287 (22), 262 (33), 76 (12), 73 (25), 57 (14), 43 (20), 41 (11). 
HRMS (EI), m/z calc. for C27H51N3O2SSi (509.3471): 509.3456. 
IR (ATR) υ (cm-1) = 3037, 2955, 2926, 2855, 1646, 1463, 1376, 1286, 1248, 1183, 1162, 
1143, 1123, 1022, 962, 840, 823, 813, 777, 763, 749, 722, 668. 
 
Preparation of (E)-2-(tert-butyldimethylsilyl)-N,N-dimethyl-5-(4-nitrophenyl)-4-
(oct-1-en-1-yl)- imidazole-1-sulfonamide (72d) 
 
Prepared according to TP2 from (E)-2-(tert-butyldimethylsilyl)-5-((4-methoxy-3,5-
dimethylphenyl)-sulfinyl)-N,N-dimethyl-4-(oct-1-en-1-yl)-imidazole-1-sulfonamide (70f,  
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291 mg, 0.5 mmol) and iPrMgCl·LiCl (63, 0.5 mL, 0.6 mmol, 1.2M in THF) at  
-78 °C in 1 h. Subsequently, the cross-coupling was accomplished according to TP6 with 
ZnCl2 (0.6 mL, 0.6 mmol, 1.0M in THF), Pd(PPh3)4 (29 mg, 0.025 mmol) and 1-iodo-4-
nitrobenzene (68l, 112 mg, 0.45 mmol) in 1 h. Flash column chromatographical 
purification on silica gel (pentane/EtOAc, 9.5:0.5) afforded 72d as a yellow solid (232 
mg, 100%). 
 
m.p.: 120.2-123.1 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) =  8.31 (d, J=8.8Hz, 2H), 7.61 (d, J=8.8Hz, 2H), 
6.60-6.73 (m, 1H), 5.82-5.95 (m, 1H), 2.33 (s, 6H), 2.04-2.18 (m, 2H), 1.22-1.40 (m, 
8H), 1.13 (s, 9H), 0.81-0.92 (m, 3H), 0.42 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 156.4, 147.7, 141.2, 136.3, 135.1, 132.2, 125.2, 
123.1, 118.4, 36.7, 33.0, 31.6, 29.1, 28.9, 27.1, 22.6, 18.7, 14.0, -4.3.  
MS (70 eV, EI), m/z (%) = 505 ([M-CH3]+, 3), 465 (14), 464 (31), 463 (100), 420 (7),  
399 (9), 388 (19), 298 (8), 277 (13), 274 (9). 
HRMS (EI), m/z calc. for C24H37N4O4SSi (505.2305 ([M-CH3])): 505.2305 ([M-CH3]). 
IR (ATR) υ (cm-1) = 3106, 2953, 2928, 2857, 1700, 1662, 1602, 1515, 1468, 1377, 1341, 
1249, 1156, 1103, 1045, 1014, 969, 862, 854, 836, 822, 812, 776, 731, 713, 668. 
 
Preparation of (E)-ethyl 4-(2-(tert-butyldimethylsilyl)-1-(N,N-dimethylsulfamoyl)-5-
(oct-1-en-1-yl)-imidazol-4-yl)benzoate (72e) 
 
Prepared according to TP2 from ethyl 4-(2-(tert-butyldimethylsilyl)-1-(N,N-
dimethylsulfamoyl)-5-((4-methoxy-3,5-dimethylphenyl)sulfinyl)-imidazol-4-yl)benzoate 
(70a, 310 mg, 0.5 mmol) and iPrMgCl·LiCl (63, 0.5 mL, 0.6 mmol, 1.2M in THF) at  
-78 °C in 1 h. Subsequently, the cross-coupling was accomplished according to TP6 with 
ZnCl2 (0.6 mL, 0.6 mmol, 1.0M in THF), Pd(PPh3)4 (29 mg, 0.025 mmol) and (E)-1-
iodooct-1-ene (68g; 107 mg, 0.45 mmol) in 1 h. Flash column chromatographical 
purification on silica gel (pentane/EtOAc, 9.5:0.5) afforded 72e as a pale yellow solid 
(147 mg, 60%). 
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m.p.: 68.9-70.4 °C. 
1H NMR (400 MHz, CDCl3) δ (ppm) =  8.01 (d, J=8.7Hz, 2H), 7.90 (d, J=8.7Hz, 2H), 
6.38-6.50 (m, 1H), 5.89-6.03 (m, 1H), 4.37 (q, J=7.1Hz, 2H), 2.85 (s, 6H), 2.14-2.23 (m, 
2H), 1.19-1.48 (m, 11H), 1.09 (s, 6H), 0.84-0.94 (m, 3H), 0.40 (s, 6H). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 166.6, 154.0, 140.5, 139.1, 139.0, 129.4, 128.7, 
128.5, 127.6, 117.0, 60.8, 37.8, 33.4, 31.7, 29.0, 28.5, 27.1, 22.6, 18.7, 14.3, 14.1, -4.2.  
MS (70 eV, EI), m/z (%) = 546 ([M-H]+, 1), 504 (11), 492 (14), 491 (33), 490 (100),  
426 (7), 416 (5), 415 (16), 330 (5). 
HRMS (EI), m/z calc. for C28H44N3O4SSi (546.2822 ([M-H])): 546.2835 ([M-H]). 
IR (ATR) υ (cm-1) = 3084, 3058, 2981, 2950, 2929, 2856, 1715, 1608, 1470, 1455, 1375, 
1270, 1246, 1222, 1176, 1146, 1121, 1106, 1072, 998, 977, 862, 822, 776, 731, 713, 694, 
666. 
 
Preparation of ethyl 4-(2-(tert-butyldimethylsilyl)-5-(4-chlorophenyl)-1-(N,N-
dimethyl-sulfamoyl)-imidazol-4-yl)benzoate (72f) 
 
Prepared according to TP2 from ethyl 4-(2-(tert-butyldimethylsilyl)-1-(N,N-
dimethylsulfamoyl)-5-((4-methoxy-3,5-dimethylphenyl)sulfinyl)-imidazol-4-yl)benzoate 
(70a, 310 mg, 0.5 mmol) and iPrMgCl·LiCl (63, 0.5 mL, 0.6 mmol, 1.2M in THF) at  
-78 °C in 1 h. Subsequently, the cross-coupling was accomplished according to TP6 with 
ZnCl2 (0.6 mL, 0.6 mmol, 1.0M in THF), Pd(PPh3)4 (29 mg, 0.025 mmol) and 1-chloro-
4-iodobenzene (68d, 131 mg, 0.55 mmol) in 1 h. Flash column chromatographical 
purification on silica gel (pentane/EtOAc, 9.5:0.5) afforded 72f as a white solid (191 mg, 
70%). 
 
m.p.: 197.7-199.3 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) =  7.88 (d, J=8.3Hz, 2H), 7.33-7.52 (m, 6H), 4.33 
(q, J=7.2Hz, 2H), 2.38 (s, 6H), 1.35 (t, J=7.2Hz, 3H), 1.17 (s, 9H), 0.45 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.4, 155.0, 139.9, 137.6, 135.7, 132.8, 129.4, 
129.1, 128.8, 128.4, 127.9, 126.6, 60.8, 36.5, 27.1, 18.8, 14.3, -4.2.  
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MS (70 eV, EI), m/z (%) = 546 ([M-H]+, 1), 504 (7), 493 (13), 492 (42), 491 (30),  
490 (100), 398 (11), 372 (7), 107 (9), 102 (8), 76 (17). 
HRMS (EI), m/z calc. for C26H33ClN3O4SSi (546.1650 ([M-H])): 546.1634 ([M-H]). 
IR (ATR) υ (cm-1) = 3092, 2991, 2976, 2956, 2934, 2904, 2886, 2854, 1707, 1612, 1472, 
1384, 1272, 1246, 1162, 1108, 1084, 1044, 1015, 981, 844, 823, 816, 779, 731, 724, 669. 
 
Preparation of ethyl 4-(2-(tert-butyldimethylsilyl)-1-(N,N-dimethylsulfamoyl)-4-(4-
(trifluoromethyl)phenyl)-imidazol-5-yl)benzoate (72g) 
 
Prepared according to TP2 from 2-(tert-butyldimethylsilyl)-5-((4-methoxy-3,5-
dimethylphenyl)sulfinyl)-N,N-dimethyl-4-(4-(trifluoromethyl)phenyl)-imidazole-1-
sulfonamide (70b, 308 mg, 0.5 mmol) and iPrMgCl·LiCl (63, 0.5 mL, 0.6 mmol, 1.2M in 
THF) at -78 °C in 1 h. Subsequently, the cross-coupling was accomplished according to 
TP6 with ZnCl2 (0.6 mL, 0.6 mmol, 1.0M in THF), Pd(PPh3)4 (29 mg, 0.025 mmol) and 
ethyl 4-iodobenzoate (68b, 124 mg, 0.45 mmol) in 1 h. Flash column chromatographical 
purification on silica gel (pentane/EtOAc, 9.5:0.5) afforded 72g as a brown solid  
(223 mg, 80%). 
 
m.p.: 110.8-112.4 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) =  8.17 (d, J=8.0Hz, 2H), 7.53 (d, J=8.0Hz, 2H), 
7.37-7.49 (m, 4H), 4.43 (q, J=7.2Hz, 2H), 2.33 (s, 6H), 1.44 (t, J=7.2Hz, 3H), 1.17 (s, 
9H), 0.45 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 165.9, 155.1, 139.6, 136.7, 134.6, 131.5, 131.4, 
129.9 (q, J=32.3Hz), 128.8, 128.0, 127.0, 125.1 (q, J=3.7Hz), 124.2 (q, J=271.8Hz), 
61.4, 36.5, 27.1, 18.8, 14.3, -4.2.  
MS (70 eV, EI), m/z (%) = 580 ([M-H]+, 2), 538 (9), 526 (11), 525 (31), 524 (100),  
107 (13), 92 (20), 76 (20). 
HRMS (EI), m/z calc. for C28H38N3O6S2Si (580.1913 ([M-H])): 580.1905 ([M-H]). 
IR (ATR) υ (cm-1) = 2954, 2935, 2901, 2857, 1718, 1619, 1475, 1464, 1378, 1323, 1284, 
1273, 1250, 1160, 1119, 1107, 1086, 1064, 1043, 1017, 973, 847, 823, 814, 782, 776, 
733, 725, 712, 697, 669. 
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Preparation of 2-(tert-butyldimethylsilyl)-5-(4-chlorophenyl)-N,N-dimethyl-4-(4-(tri-
fluoromethyl)phenyl)-imidazole-1-sulfonamide (72h) 
 
Prepared according to TP2 from 2-(tert-butyldimethylsilyl)-5-((4-methoxy-3,5-
dimethylphenyl)sulfinyl)-N,N-dimethyl-4-(4-(trifluoromethyl)phenyl)-imidazole-1-
sulfonamide (70b, 308 mg, 0.5 mmol) and iPrMgCl·LiCl (63, 0.5 mL, 0.6 mmol, 1.2M in 
THF) at -78 °C in 1 h. Subsequently, the cross-coupling was accomplished according to 
TP6 with ZnCl2 (0.6 mL, 0.6 mmol, 1.0M in THF), Pd(PPh3)4 (29 mg, 0.025 mmol) and 
1-chloro-4-iodobenzene (68d, 131 mg, 0.55 mmol) in 1 h. Flash column 
chromatographical purification on silica gel (pentane/EtOAc, 9.5:0.5) afforded 72h as a 
white solid (217 mg, 80%). 
 
m.p.: 175.5-177.0 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.42-7.55 (m, 6H), 7.34-7.41 (m, 2H), 2.39 (s, 
6H), 1.17 (s, 9H), 0.45 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 155.0, 139.5, 136.8, 135.8, 132.8, 129.2, 128.9 
(q, J=32.3Hz), 128.3, 127.8, 126.9, 125.1 (q, J=3.9Hz), 124.2 (q, J=272.1Hz), 36.5, 27.1, 
18.8, -4.2.  
MS (70 eV, EI), m/z (%) = 543 (M+, 1), 489 (11), 488 (40), 487 (26), 486 (100), 379 (6),  
107 (10), 92 (14), 76 (12). 
HRMS (EI), m/z calc. for C24H29ClF3N3O2SSi (543.1390): 543.1399. 
IR (ATR) υ (cm-1) = 3060, 2978, 2959, 2937, 2890, 2855, 1620, 1486, 1377, 1325, 1248, 
1159, 1126, 1108, 1086, 1065, 1043, 1016, 977, 844, 837, 822, 815, 779, 746, 728, 719. 
 
 
 
 
 
 
 
C. EXPERIMENTAL SECTION 
317 
Preparation of 2-(tert-butyldimethylsilyl)-4-(4-chlorophenyl)-N,N-dimethyl-5-(4-(tri-
fluoromethyl)phenyl)-imidazole-1-sulfonamide (72i) 
 
Prepared according to TP2 from 2-(tert-butyldimethylsilyl)-4-(4-chlorophenyl)-5-((4-
methoxy-3,5-dimethylphenyl)sulfinyl)-N,N-dimethyl-imidazole-1-sulfonamide (70c,  
291 mg, 0.5 mmol) and iPrMgCl·LiCl (63, 0.5 mL, 0.6 mmol, 1.2M in THF) at -78 °C in 
1 h. Subsequently, the cross-coupling was accomplished according to TP6 with ZnCl2  
(0.6 mL, 0.6 mmol, 1.0M in THF), Pd(PPh3)4 (29 mg, 0.025 mmol) and 1-iodo-4-
(trifluoromethyl)benzene (68c, 123 mg, 0.45 mmol) in 2 h. Flash column 
chromatographical purification on silica gel (pentane/EtOAc, 9.5:0.5) afforded 72i as a 
white solid (166 mg, 68%). 
 
m.p.: 199.3-200.5 °C. 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.75 (d, J=8.1Hz, 2H), 7.58 (d, J=8.2Hz, 2H), 
7.23-7.33 (m, 2H), 7.09-7.21 (m, 2H), 2.33 (s, 6H), 1.17 (s, 9H), 0.45 (s, 6H). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 155.1, 140.1, 134.1, 133.1, 132.0, 131.5, 131.4 
(q, J=33.0Hz), 128.4, 128.2, 126.5, 125.6 (q, J=3.8Hz), 123.8 (q, J=272.6Hz), 36.4, 27.1, 
18.8, -4.2. 
MS (70 eV, EI), m/z (%) = 528 ([M-CH3]+, 4), 489 (12), 488 (51), 487 (33), 486 (100),  
394 (11), 107 (15), 102 (11), 92 (21), 43 (12). 
HRMS (EI), m/z calc. for C23H26ClF3N3O2SSi (528.1156 ([M-CH3])): 528.1155 ([M-
CH3]). 
IR (ATR) υ (cm-1) = 3087, 3056, 2982, 2958, 2937, 2910, 2895, 2858, 1621, 1516, 1486, 
1408, 1374, 1327, 1295, 1263, 1249, 1204, 1190, 1156, 1120, 1107, 1092, 1080, 1068, 
1041, 1016, 976, 956, 935, 854, 847, 837, 828, 819, 778, 732, 698, 674. 
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Preparation of ethyl 4-(2-(tert-butyldimethylsilyl)-1-(N,N-dimethylsulfamoyl)-5-((4-
fluorophenyl)(hydroxy)methyl)-imidazol-4-yl)benzoate (72j) 
 
Prepared according to TP2 from ethyl 4-(2-(tert-butyldimethylsilyl)-1-(N,N-
dimethylsulfamoyl)-5-((4-methoxy-3,5-dimethylphenyl)sulfinyl)-imidazol-4-yl)benzoate 
(70a, 310 mg, 0.5 mmol) and iPrMgCl·LiCl (63, 0.5 mL, 0.6 mmol, 1.2M in THF) at  
-78 °C in 1 h. Subsequently, 4-fluorobenzaldehyde (68m, 56 mg, 0.45 mmol) was added 
and the reaction mixture was allowed to slowly warm to 25 °C and continuously stirred 
over night. The reaction was quenched with sat. NH4Cl solution (10 mL) and extracted 
with EtOAc (3x10 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. The crude residue obtained was purified by flash column 
chromatography (silica, pentane:EtOAc 7:3) to give 72j as a yellow solid (250 mg,  
100 %). 
 
m.p.: 143.4-146.0 °C. 
1H NMR (400 MHz, d6-DMSO) δ (ppm) = 7.79-7.91 (m, 2H), 7.74 (d, J=8.5Hz, 2H), 
7.08-7.21 (m, 2H), 6.87-7.04 (m, 2H), 6.57 (d, J=4.4Hz, 1H), 6.34 (d, J=4.4Hz, 1H), 4.23 
(q, J=7.1Hz, 2H), 2.80 (s, 6H), 1.26 (t, J=7.1Hz, 3H), 1.05 (s, 9H), 0.23-0.50 (m, 6H). 
13C NMR (100 MHz, d6-DMSO) δ (ppm) = 165.9, 161.4 (d, J=242.7Hz), 153.6, 141.2, 
138.3, 138.1 (d, J=2.9Hz), 133.5, 129.0, 128.7, 128.6, 128.1 (d, J=8.2Hz), 114.9 (d, 
J=21.4Hz), 63.7, 61.0, 37.6, 27.6, 18.9, 14.5, -3.5, -3.6.  
MS (70 eV, EI), m/z (%) = 561 (M+, 1), 506 (15), 505 (32), 504 (100), 123 (11),  
102 (12), 92 (35), 75 (24), 73 (20). 
HRMS (EI), m/z calc. for C27H36FN3O5SSi (561.2129): 561.2122. 
IR (ATR) υ (cm-1) = 3408, 3068, 2987, 2951, 2933, 2909, 2856, 1683, 1609, 1510, 1474, 
1417, 1380, 1366, 1278, 1256, 1250, 1220, 1178, 1164, 1148, 1133, 1110, 1069, 1032, 
1019, 968, 858, 835, 821, 812, 794, 778, 721, 696, 670. 
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Preparation of (E)-2-(tert-butyldimethylsilyl)-5-(4-chlorobenzoyl)-N,N-dimethyl-4-
(oct-1-en-1-yl)- imidazole-1-sulfonamide (72k) 
 
Prepared according to TP2 from (E)-2-(tert-butyldimethylsilyl)-5-((4-methoxy-3,5-
dimethylphenyl)-sulfinyl)-N,N-dimethyl-4-(oct-1-en-1-yl)-imidazole-1-sulfonamide (70f,  
291 mg, 0.5 mmol) and iPrMgCl·LiCl (63, 0.5 mL, 0.6 mmol, 1.2M in THF) at  
-78 °C in 1 h. Subsequently, the Pd-catalyzed acylation was accomplished according to 
TP9 with ZnCl2 (0.6 mL, 0.6 mmol, 1.0M in THF), Pd(PPh3)4 (29 mg, 0.025 mmol) and  
4-chlorobenzoyl chloride (68i, 96 mg, 0.55 mmol) over night at room temperature. Flash 
column chromatographical purification on silica gel (pentane/EtOAc, 9.5:0.5) afforded 
72k as a yellow oil (212 mg, 79%). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) =  7.76 (d, J=8.3Hz, 2H), 7.45 (d, J=8.6Hz, 2H), 
6.56-6.74 (m, 1H), 5.77-5.92 (m, 1H), 2.72 (s, 6H), 1.94-2.14 (m, 2H), 1.18-1.37 (m, 
8H), 1.10 (s, 9H), 0.81-0.93 (m, 3H), 0.44 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 186.4, 157.7, 143.8, 140.4, 136.8, 136.2, 131.2, 
129.0, 125.5, 118.9, 37.9, 32.8, 31.6, 28.8, 28.7, 27.1, 22.5, 18.6, 14.0, -4.2.  
MS (70 eV, EI), m/z (%) = 522 ([M-CH3]+, 3), 483 (12), 482 (46), 481 (28), 480 (100),  
389 (17), 287 (11), 140 (13), 139 (35), 92 (43), 76 (16), 75 (13), 73 (45), 56 (10),  
41 (11). 
HRMS (EI), m/z calc. for C25H37ClN3O3SSi 522.2013 ([M-CH3])): 522.2131 ([M-CH3]). 
IR (ATR) υ (cm-1) = 3031, 2955, 2928, 2856, 1659, 1587, 1464, 1373, 1250, 1218, 1169, 
1157, 1090, 1014, 967, 924, 842, 823, 814, 780, 762, 736, 724, 683, 670. 
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Preparation of ethyl 4-(2-(tert-butyldimethylsilyl)-5-(4-chlorobenzoyl)-1-(N,N-
dimethyl-sulfamoyl)- imidazol-4-yl)benzoate (72l) 
 
Prepared according to TP2 from ethyl 4-(2-(tert-butyldimethylsilyl)-1-(N,N-
dimethylsulfamoyl)-5-((4-methoxy-3,5-dimethylphenyl)sulfinyl)-imidazol-4-yl)benzoate 
(70a, 310 mg, 0.5 mmol) and iPrMgCl·LiCl (63, 0.5 mL, 0.6 mmol, 1.2M in THF) at  
-78 °C in 1 h. Subsequently, the Pd-catalyzed acylation was accomplished according to 
TP9 with ZnCl2 (0.6 mL, 0.6 mmol, 1.0M in THF), Pd(PPh3)4 (29 mg, 0.025 mmol) and  
4-chlorobenzoyl chloride (68i, 96 mg, 0.55 mmol) over night at room temperature. Flash 
column chromatographical purification on silica gel (pentane/EtOAc, 9:1) afforded 72l as 
a white solid (190 mg, 66%). 
 
m.p.: 143.4-146.0 °C. 
1H NMR (400 MHz, CDCl3) δ (ppm) =  7.90 (d, J=8.8Hz, 2H), 7.71 (d, J=9.0Hz, 2H), 
7.62 (d, J=8.8Hz, 2H), 7.36 (d, J=8.8Hz, 2H), 4.32 (q, J=7.0Hz, 2H), 2.73 (s, 6H),  
1.34 (t, J=7.1Hz, 3H), 1.13 (s, 9H), 0.47 (s, 6H). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 188.3, 166.2, 155.8, 141.5, 141.1, 136.3, 135.1, 
131.0, 129.8, 129.7, 129.3, 127.1, 126.2, 61.0, 37.9, 27.1, 18.6, 14.3, -4.1.  
MS (70 eV, EI), m/z (%) = 560 ([M-CH3]+, 1), 463 (20), 461 (51), 354 (43), 325 (18),  
309 (33), 138 (62), 111 (28), 108 (100), 44 (28), 43 (31). 
HRMS (EI), m/z calc. for C26H31ClN3O5SSi (560.1442 ([M-CH3])): 560.1459 ([M-
CH3]). 
IR (ATR) υ (cm-1) = 3085, 3066, 2978, 2954, 2928, 2852, 1784, 1720, 1659, 1586, 1379, 
1355, 1273, 1245, 1231, 1183, 1167, 1140, 1100, 1092, 1073, 1019, 995, 976, 902, 841, 
822, 780, 771, 743, 733, 726, 698, 671. 
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7.5 SELECTIVE FUNCTIONALIZATION ON POSITION 2 OF THE IMIDAZOLE RING 
7.5.1 SELECTIVE DEPROTECTION ON POSITION 2 
Preparation of ethyl 4-(5-(4-chlorophenyl)-1-(N,N-dimethylsulfamoyl)-imidazol-4-
yl)-benzoate (73a) 
 
Prepared according to TP5 from ethyl 4-(2-(tert-butyldimethylsilyl)-5-(4-chlorophenyl)-
1-(N,N-dimethyl-sulfamoyl)-imidazol-4-yl)benzoate (72f, 619 mg, 1.13 mmol) and 
TBAF·3H2O (64, 357 mg, 1.13 mmol, 0.1M in THF) at 0 °C in 5 min. Flash column 
chromatographical purification on silica gel (pentane/EtOAc, 1:1) afforded 73a as a pale 
yellow solid (456 mg, 93%).  
 
m.p.: 165.4-167.3 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.13 (s, 1H), 7.90 (d, J=8.3Hz, 2H), 7.35-7.50 
(m, 6H), 4.33 (q, J=7.2Hz, 2H), 2.52 (s, 6H), 1.36 (t, J=7.0Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.3, 140.0, 139.1, 137.0, 136.2, 133.2, 129.6, 
129.3, 129.2, 127.1, 126.8, 126.0, 60.9, 37.2, 14.3.  
MS (70 eV, EI), m/z (%) = 433 (M+, 100), 325 (42), 253 (18), 252 (26), 218 (22),  
133 (17), 123 (40), 108 (28), 57 (19). 
HRMS (EI), m/z calc. for C20H20ClN3O4S (433.0863): 433.0856. 
IR (ATR) υ (cm-1) = 3147, 3088, 3071, 2957, 2923, 2866, 2854, 1707, 1612, 1484, 1474, 
1382, 1364, 1268, 1254, 1246, 1185, 1169, 1135, 1100, 1092, 1081, 1018, 1005, 977, 
966, 938, 863, 835, 780, 742, 722, 696. 
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Preparation of 5-(4-chlorophenyl)-N,N-dimethyl-4-(4-(trifluoromethyl)phenyl)- 
imidazole-1-sulfonamide (73b) 
 
Prepared according to TP5 from 2-(tert-butyldimethylsilyl)-5-(4-chlorophenyl)-N,N-
dimethyl-4-(4-(tri-fluoromethyl)phenyl)-imidazole-1-sulfonamide (72h, 1.43 g,  
2.63 mmol) and TBAF·3H2O (64, 829 mg, 2.63 mmol, 0.1M in THF) at 0 °C in 5 min. 
Flash column chromatographical purification on silica gel (pentane/EtOAc, 6.5:3.5) 
afforded 73b as a white solid (1.06 g, 94%). 
 
m.p.: 157.7-159.2 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.13 (s, 1H), 7.43-7.52 (m, 6H), 7.36-7.43 (m, 
2H), 2.53 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 139.6, 139.1, 136.3, 136.2, 133.1, 129.3 (q, 
J=32.5Hz), 129.2, 127.2, 127.0, 126.0, 125.3 (q, J=3.7Hz), 124.1 (q, J=272.1Hz), 37.2.  
MS (70 eV, EI), m/z (%) = 429 (M+, 100), 323 (28), 322 (21), 321 (75), 286 (46),  
157 (27), 152 (12), 150 (27), 137 (11), 123 (57), 108 (72), 57 (19), 44 (12). 
HRMS (EI), m/z calc. for C18H15ClF3N3O2S (429.0526): 429.0522. 
IR (ATR) υ (cm-1) = 3138, 3122, 2956, 2930, 2856, 1618, 1479, 1390, 1325, 1240, 1206, 
1166, 1141, 1117, 1106, 1084, 1062, 1022, 1014, 1003, 960, 940, 846, 832, 742, 725, 
715. 
 
Preparation of 4-(4-chlorophenyl)-N,N-dimethyl-5-(4-(trifluoromethyl)phenyl)- 
imidazole-1-sulfonamide (73c) 
 
Prepared according to TP5 from 2-(tert-butyldimethylsilyl)-4-(4-chlorophenyl)-N,N-
dimethyl-5-(4-(trifluoromethyl)phenyl)-imidazole-1-sulfonamide (72i, 544 mg,  
1.0 mmol) and TBAF·3H2O (64, 316 mg, 1.0 mmol, 0.1M in THF) at 0 °C in 5 min. 
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Flash column chromatographical purification on silica gel (pentane/EtOAc, 6.5:3.5) 
afforded 73c as a white solid (430 mg, 100%). 
 
m.p.: 201.7-203.2 °C. 
1H NMR (400 MHz, CDCl3) δ (ppm) = 8.13 (s, 1H), 7.72 (d, J=8.0Hz, 2H), 7.59 (d, 
J=8.0Hz, 2H), 7.23-7.32 (m, 2H), 7.16-7.23 (m, 2H), 2.50 (s, 6H). 
13C NMR (150 MHz, CDCl3) δ (ppm) = 140.3, 139.2, 133.6, 132.7, 132.4, 131.8 (q, 
J=33.0Hz), 130.9, 128.6, 128.5, 125.6 (q, J=3.5Hz), 124.7, 123.7 (q, J=272.6Hz), 37.2. 
MS (70 eV, EI), m/z (%) = 429 (M+, 100), 323 (25), 322 (19), 321 (67), 286 (41),  
122 (59), 108 (73), 57 (17), 44 (13), 43 (19). 
HRMS (EI), m/z calc. for C18H15ClF3N3O2S (429.0526): 429.0520. 
IR (ATR) υ (cm-1) = 3150, 3127, 3066, 2976, 2937, 1701, 1622, 1493, 1461, 1412, 1392, 
1330, 1270, 1240, 1207, 1171, 1161, 1140, 1118, 1106, 1094, 1081, 1070, 1052, 1024, 
1014, 1004, 959, 940, 859, 844, 836, 827, 754, 737, 726, 696, 656. 
 
7.5.2 SELECTIVE FUNCTIONALIZATION ON POSITION 2 
Preparation of ethyl 4-(5-(4-chlorophenyl)-1-(N,N-dimethylsulfamoyl)-2-(2-(ethoxy-
carbonyl)allyl)- imidazol-4-yl)benzoate (76a) 
 
Prepared according to TP3 from ethyl 4-(5-(4-chlorophenyl)-1-(N,N-dimethylsulfamoyl)-
imidazol-4-yl)-benzoate (73a, 109 mg, 0.25 mmol) and TMP2Zn·2MgCl·2LiCl (65, 0.28 
mL, 0.14 mmol, 0.5M in THF) at -20 °C in 1 h. Subsequently, the allylation reaction was 
accomplished according to TP7 with CuCN·2LiCl (0.25 mL, 0.25 mmol, 1.0M in THF) 
and ethyl 2-(bromomethyl)acrylate (68h, 53 mg, 0.275 mmol) in 1.5 h. Flash column 
chromatographical purification on silica gel (pentane/EtOAc, 7.5:2.5) afforded 76a as a 
yellow oil (121 mg, 81%). 
 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.84 (d, J=8.8Hz, 2H), 7.38-7.51 (m, 2H), 7.29-
7.38 (m, 4H), 6.33 (s, 1H), 5.60 (s, 1H), 4.19-4.37 (m, 4H), 4.11 (s, 2H), 2.49 (s, 6H), 
1.27-1.37 (m, 6H). 
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13C NMR (75 MHz, CDCl3) δ (ppm) = 166.7, 166.4, 148.8, 137.4, 137.2, 137.1, 135.8, 
133.3, 129.4, 129.4, 129.0, 128.9, 128.2, 127.0, 126.9, 126.0, 60.9, 60.9, 37.0, 14.3, 14.3.  
MS (70 eV, EI), m/z (%) = 545 (M+, 9), 440 (18), 439 (45), 438 (51), 437 (100),  
409 (14), 366 (17), 365 (14), 364 (19), 43 (42). 
HRMS (EI), m/z calc. for C26H28ClN3O6S (545.1387): 545.1374. 
IR (ATR) υ (cm-1) = 2979, 2935, 2912, 2873, 1712, 1611, 1482, 1450, 1380, 1273, 1168, 
1124, 1092, 1079, 1017, 975, 838, 825, 780, 722. 
 
Preparation of ethyl 4-(5-(4-chlorophenyl)-1-(N,N-dimethylsulfamoyl)-2-(4-nitro-
phenyl)imidazol-4-yl)benzoate (76b) 
 
Prepared according to TP3 from ethyl 4-(5-(4-chlorophenyl)-1-(N,N-dimethylsulfamoyl)-
imidazol-4-yl)-benzoate (73a, 109 mg, 0.25 mmol) and TMP2Zn·2MgCl·2LiCl (65, 0.28 
mL, 0.14 mmol, 0.5M in THF) at -20 °C in 1 h. Subsequently, the cross-coupling was 
accomplished according to TP6 with Pd(PPh3)4 (14 mg, 0.0125 mmol) and 1-iodo-4-
nitrobenzene (68l, 56 mg, 0.225 mmol) in 1 h. Flash column chromatographical 
purification on silica gel (pentane/EtOAc, 7.5:2.5) afforded 76b as a yellow solid (91 mg, 
76%). 
 
m.p.: 131.0-133.6 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.27-8.37 (m, 2H), 7.84-7.98 (m, 4H), 7.37-7.56 
(m, 6H), 4.34 (q, J=7.2Hz, 2H), 2.39 (s, 6H), 1.36 (t, J=7.2Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.2, 148.5, 148.3, 138.7, 137.8, 136.6, 136.1, 
132.6, 130.9, 129.6, 129.6, 129.3, 129.1, 127.6, 127.2, 123.0, 61.0, 37.1, 14.3.  
MS (70 eV, EI), m/z (%) = 554 (M+, 2), 449 (44), 448 (33), 447 (100), 419 (17),  
417 (25), 402 (15), 373 (11), 340 (22), 177 (18), 150 (11), 139 (16). 
HRMS (EI), m/z calc. for C26H23ClN4O6S (554.1027): 554.1015. 
IR (ATR) υ (cm-1) = 3095, 2983, 2947, 2924, 2911, 2860, 1719, 1604, 1519, 1483, 1383, 
1351, 1267, 1240, 1168, 1134, 1125, 1107, 1098, 1091, 1078, 1018, 1006, 974, 953, 856, 
832, 780, 760, 737, 728, 718, 696. 
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Preparation of ethyl 2-((5-(4-chlorophenyl)-1-(N,N-dimethylsulfamoyl)-4-(4-(tri-
fluoromethyl)phenyl)-imidazol-2-yl)methyl)acrylate (76c) 
 
Prepared according to TP3 from 5-(4-chlorophenyl)-N,N-dimethyl-4-(4-
(trifluoromethyl)phenyl)-imidazole-1-sulfonamide (73b, 109 mg, 0.25 mmol) and 
TMP2Zn·2MgCl·2LiCl (65, 0.28 mL, 0.14 mmol, 0.5M in THF) at -20 °C in 1 h. 
Subsequently, the allylation reaction was accomplished according to TP7 with 
CuCN·2LiCl (0.25 mL, 0.25 mmol, 1.0M in THF) and ethyl 2-(bromomethyl)acrylate 
(68h, 44 mg, 0.225 mmol) over night. Flash column chromatographical purification on 
silica gel (pentane/EtOAc, 8:2) afforded 76c as a white solid (105 mg, 86%). 
 
m.p.: 86.3-89.3 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) =  7.28-7.55 (m, 8H), 6.34 (s, 1H), 5.61 (s, 1H), 
4.26 (q, J=7.2 Hz, 2H), 4.11 (s, 2H), 2.51 (s, 6H), 1.31 (t, J=7.0Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.7, 148.8, 137.1, 137.0, 136.3, 135.9, 133.3, 
129.0 (q, J=32.5Hz), 129.0, 128.1, 127.1, 126.9, 126.0, 125.0 (q, J=3.7Hz), 124.1 (q, 
J=272.1Hz), 60.9, 37.0, 33.4, 14.2.  
MS (70 eV, EI), m/z (%) = 541 (M+, 5), 436 (13), 435 (40), 434 (38), 433 (100),  
405 (15), 389 (14), 388 (14), 387 (19), 362 (20), 361 (22), 360 (24), 359 (20), 108 (14), 
43 (27). 
HRMS (EI), m/z calc. for C24H23ClF3N3O4S (541.1050): 541.1043. 
IR (ATR) υ (cm-1) = 3096, 3003, 2984, 2928, 2882, 2855, 1724, 1618, 1423, 1391, 1324, 
1306, 1204, 1169, 1155, 1118, 1108, 1091, 1079, 1064, 1017, 969, 960, 948, 850, 832, 
822, 808, 744, 724, 714. 
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Preparation of ethyl 4-(5-(4-chlorophenyl)-1-(N,N-dimethylsulfamoyl)-4-(4-(tri-
fluoromethyl)phenyl)-imidazol-2-yl)benzoate (76d) 
 
Prepared according to TP3 from 5-(4-chlorophenyl)-N,N-dimethyl-4-(4-
(trifluoromethyl)phenyl)-imidazole-1-sulfonamide (73b, 109 mg, 0.25 mmol) and 
TMP2Zn·2MgCl·2LiCl (65, 0.28 mL, 0.14 mmol, 0.5M in THF) at -20 °C in 1 h. 
Subsequently, the cross-coupling was accomplished according to TP6 with Pd(PPh3)4 (14 
mg, 0.0125 mmol) and ethyl 4-iodobenzoate (68b, 76 mg, 0.275 mmol) in 1 h. Flash 
column chromatographical purification on silica gel (pentane/EtOAc, 8:2) afforded 76d 
as a pale yellow solid (104 mg, 72%). 
 
m.p.: 157.8-159.3 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.10-8.22 (m, 2H), 7.77-7.88 (m, 2H), 7.40-7.54 
(m, 8H), 4.41 (q, J=7.2Hz, 2H), 2.38 (s, 6H), 1.42 (t, J=7.0Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 166.0, 149.4, 137.8, 136.1, 136.1, 135.8, 135.6, 
132.6, 131.5, 129.9, 129.4 (q, J=32.5Hz), 129.2, 129.1, 128.1, 127.5, 125.2 (q, J=3.9Hz), 
124.1 (q, J=271.8Hz), 61.3, 37.1, 14.3.  
MS (70 eV, EI), m/z (%) = 577 (M+, 5), 472 (29), 471 (52), 470 (92), 469 (100),  
161 (13), 157 (12), 133 (12), 122 (12). 
HRMS (EI), m/z calc. for C27H23ClF3N3O4S (577.1050): 577.1043. 
IR (ATR) υ (cm-1) = 3087, 3062, 2984, 2972, 2956, 2934, 2904, 2872, 2855, 1721, 1618, 
1489, 1389, 1326, 1288, 1277, 1167, 1125, 1106, 1090, 1081, 1064, 1018, 1005, 971, 
850, 833, 778, 740, 729, 718. 
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Preparation of 5-(4-chlorophenyl)-2-(4-cyanophenyl)-N,N-dimethyl-4-(4-(trifluoro-
methyl)phenyl)- imidazole-1-sulfonamide (76e) 
 
Prepared according to TP3 from 5-(4-chlorophenyl)-N,N-dimethyl-4-(4-
(trifluoromethyl)phenyl)-imidazole-1-sulfonamide (73b, 109 mg, 0.25 mmol) and 
TMP2Zn·2MgCl·2LiCl (65, 0.28 mL, 0.14 mmol, 0.5M in THF) at -20 °C in 1 h. 
Subsequently, the cross-coupling was accomplished according to TP6 with Pd(PPh3)4 (14 
mg, 0.0125 mmol) and 4-iodobenzonitrile (68k, 52 mg, 0.225 mmol) in 2 h. Flash 
column chromatographical purification on silica gel (pentane/EtOAc, 7:3) afforded 76e 
as a pale brown solid (113 mg, 95%). 
 
m.p.: 142.4-144.3 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.82-7.91 (m, 2H), 7.71-7.81 (m, 2H), 7.45-7.52 
(m, 8H), 2.38 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 148.7, 138.2, 136.2, 136.0, 135.9, 132.6, 131.6, 
130.6, 129.8 (q, J=32.3Hz), 129.4, 128.9, 127.6, 127.5, 125.2 (q, J=3.9Hz), 124.0 (q, 
J=271.8Hz), 118.4, 113.3, 37.1.  
MS (70 eV, EI), m/z (%) = 530 (M+, 8), 425 (33), 424 (58), 423 (86), 422 (100),  
267 (15), 157 (17), 123 (22), 114 (42), 108 (16), 43 (12). 
HRMS (EI), m/z calc. for C25H18ClF3N4O2S (530.0791): 530.0785. 
IR (ATR) υ (cm-1) = 3094, 3056, 2983, 2955, 2929, 2858, 2229, 1926, 1720, 1612, 1605, 
1520, 1384, 1351, 1324, 1312, 1297, 1270, 1203, 1169, 1135, 1118, 1109, 1096, 1082, 
1063, 1017, 1008, 974, 956, 853, 848, 832, 748, 729, 722, 696. 
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Preparation of 5-(4-chlorophenyl)-2-((4-fluorophenyl)(hydroxy)methyl)-N,N-
dimethyl-4-(4-(trifluoromethyl)phenyl)-imidazole-1-sulfonamide (76f) 
 
Prepared according to TP4 from 5-(4-chlorophenyl)-N,N-dimethyl-4-(4-(trifluoro-
methyl)phenyl)-imidazole-1-sulfonamide (73b, 109 mg, 0.25 mmol) and TMPMgCl·LiCl 
(62, 0.27 mL, 0.3 mmol, 1.1M in THF) at -78 °C in 1 h. Subsequently,  
4-fluorobenzaldehyde (68m, 34 mg, 0.275 mmol) was added and the reaction mixture 
was allowed to slowly warm to 25 °C and continuously stirred for 6 h. The reaction was 
quenched with sat. NH4Cl solution (10 mL) and extracted with EtOAc (3x10 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. The crude 
residue obtained was purified by flash column chromatography (silica, pentane:EtOAc 
7:3) to give 76f as a white solid (127 mg, 92 %). 
 
m.p.: 155.1-157.8 °C. 
1H NMR (600 MHz, CDCl3) δ (ppm) = 7.44-7.52 (m, 6H), 7.33-7.44 (m, 4H), 7.06 (t, 
J=8.6Hz, 2H), 6.28 (d, J=6.7Hz, 1H), 4.47 (d, J=7.9Hz, 1H), 2.23 (s, 6H). 
13C NMR (150 MHz, CDCl3) δ (ppm) = 162.5 (d, J=246.8Hz), 152.4, 137.3 (d, 
J=3.1Hz), 136.7, 136.4, 135.7, 133.3, 133.3, 129.5 (d, J=8.1Hz), 129.4 (q, J=32.5Hz), 
129.2, 127.6, 127.1, 125.2 (q, J=3.9Hz), 124.0 (q, J=271.5Hz), 115.4 (d, J=21.3Hz), 
70.1, 36.6.  
MS (70 eV, EI), m/z (%) = 553 (M+, 12), 431 (35), 430 (48), 429 (100), 428 (71), 417 
(21), 323 (17), 321 (41), 286 (24), 156 (17), 123 (64), 120 (24), 108 (56), 61 (15),  
57 (21), 44 (18), 43 (31). 
HRMS (EI), m/z calc. for C25H20ClF4N3O3S (553.0850): 553.0841. 
IR (ATR) υ (cm-1) = 3387, 3003, 2960, 2929, 2857, 1619, 1604, 1508, 1382, 1327, 1222, 
1170, 1120, 1111, 1086, 1064, 1016, 977, 962, 854, 838, 747, 724. 
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Preparation of 5-(4-chlorophenyl)-2-((3,4-dichlorophenyl)thio)-N,N-dimethyl-4-(4-
(trifluoromethyl)phenyl)-imidazole-1-sulfonamide (76g) 
 
Prepared according to TP4 from 5-(4-chlorophenyl)-N,N-dimethyl-4-(4-(trifluoro-
methyl)phenyl)-imidazole-1-sulfonamide (73b, 109 mg, 0.25 mmol) and TMPMgCl·LiCl 
(62, 0.27 mL, 0.3 mmol, 1.1M in THF) at -78 °C in 1 h. Subsequently,  
S-(3,4-dichlorophenyl) benzenesulfonothioate (68n, 72 mg, 0.225 mmol) was added and 
the reaction mixture was allowed to slowly warm to 25 °C and continuously stirred over 
night. The reaction was quenched with sat. NH4Cl solution (10 mL) and extracted with 
EtOAc (3x10 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. The crude residue obtained was purified by flash column 
chromatography (silica, pentane:EtOAc 8.5:1.5) to give 76g as a white solid (127 mg,  
93 %). 
 
m.p.: 131.1-133.0 °C. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.83 (d, J=1.7Hz, 1H), 7.32-7.53 (m, 8H), 7.23-
7.31 (m, 2H), 2.65 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 145.5, 138.4, 136.2, 136.0, 135.8, 133.8, 133.7, 
133.3, 132.9, 130.8, 129.9, 129.4 (q, J=32.5Hz), 129.1, 128.6, 127.6, 126.9, 125.1 (q, 
J=3.7Hz), 124.0 (q, J=272.1Hz), 37.5.  
MS (70 eV, EI), m/z (%) = 605 (M+, 23), 502 (21), 501 (47), 500 (67), 498 (57),  
497 (100), 465 (17), 464 (61), 462 (82), 461 (23), 439 (46), 191 (17), 189 (24), 154 (17), 
43 (49). 
HRMS (EI), m/z calc. for C24H17Cl3F3N3O2S2 (604.9780): 604.9778. 
IR (ATR) υ (cm-1) = 3092, 2994, 2956, 2920, 2851, 1618, 1487, 1455, 1410, 1379, 1322, 
1250, 1223, 1190, 1165, 1122, 1108, 1094, 1082, 1062, 1045, 1033, 1016, 972, 951, 851, 
834, 815, 747, 728, 710. 
 
C. EXPERIMENTAL SECTION 
330 
Preparation of 2-(4-chlorobenzoyl)-5-(4-chlorophenyl)-N,N-dimethyl-4-(4-(tri-
fluoromethyl)phenyl)-imidazole-1-sulfonamide (76h) 
 
Prepared according to TP4 from 5-(4-chlorophenyl)-N,N-dimethyl-4-(4-(trifluoro-
methyl)phenyl)-imidazole-1-sulfonamide (73b, 109 mg, 0.25 mmol) and TMPMgCl·LiCl 
(62, 0.27 mL, 0.3 mmol, 1.1M in THF) at -78 °C in 1 h. Subsequently, the Pd-catalyzed 
acylation was accomplished according to TP9 with ZnCl2 (0.3 mL,  
0.3 mmol, 1.0M in THF), Pd(PPh3)4 (14 mg, 0.0125 mmol) and 4-chlorobenzoyl chloride 
(68i, 48 mg, 0.275 mmol) over night at room temperature. Flash column 
chromatographical purification on silica gel (pentane/EtOAc, 8.5:1.5) afforded 76h as a 
pale yellow solid (83 mg, 58%). 
 
m.p.: 245.4-246.2 °C. 
1H NMR (400 MHz, d8-THF) δ (ppm) = 8.03 (d, J=8.4Hz, 2H), 7.51-7.60 (m, 10H), 
2.65 (s, 6H). 
13C NMR (100 MHz, d8-THF) δ (ppm) = 185.5, 146.9, 141.2, 138.6, 137.6, 137.1, 
135.6, 134.9, 132.6, 130.1 (q, J=32.1Hz), 130.0, 129.8, 129.5, 128.6, 128.2, 126.0 (q, 
J=3.9Hz), 125.4 (q, J=271.7Hz).  
MS (70 eV, EI), m/z (%) = 567 (M+, 39), 460 (15), 433 (20), 431 (32), 146 (22),  
139 (60), 122 (36), 111 (45), 108 (100), 44 (18), 42 (16). 
HRMS (EI), m/z calc. for C25H18Cl2F3N3O3S (567.0398): 567.0384. 
IR (ATR) υ (cm-1) = 3088, 2961, 2920, 2852, 1678, 1617, 1583, 1482, 1380, 1324, 1211, 
1204, 1164, 1126, 1109, 1096, 1083, 1063, 1014, 981, 962, 912, 856, 846, 836, 764, 734, 
720. 
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Preparation of 4-(4-chlorophenyl)-2-(4-cyanophenyl)-N,N-dimethyl-5-(4-(trifluoro-
methyl)phenyl)-imidazole-1-sulfonamide (76i) 
 
Prepared according to TP4 from 4-(4-chlorophenyl)-N,N-dimethyl-5-(4-(trifluoro-
methyl)phenyl)-imidazole-1-sulfonamide (73c, 109 mg, 0.25 mmol) and TMPMgCl·LiCl 
(62, 0.27 mL, 0.3 mmol, 1.1M in THF) at -78 °C in 1 h. Subsequently, the cross-coupling 
was accomplished according to TP6 with ZnCl2 (0.3 mL, 0.3 mmol, 1.0M in THF), 
Pd(PPh3)4 (14 mg, 0.0125 mmol) and 4-iodobenzonitrile (68k, 52 mg,  
0.225 mmol) in 2 h. Flash column chromatographical purification on silica gel 
(pentane/EtOAc, 7:3) afforded 76i as a white solid (90 mg, 75%). 
 
m.p.: 208.3-209.5 °C. 
1H NMR (600 MHz, CDCl3) δ (ppm) = 7.82-7.91 (m, 2H), 7.71-7.79 (m, 4H), 7.63 (d, 
J=8.0Hz, 2H), 7.23-7.29 (m, 2H), 7.16-7.23 (m, 2H), 2.34 (s, 6H). 
13C NMR (150 MHz, CDCl3) δ (ppm) = 148.8, 138.9, 135.8, 133.9, 133.2, 131.7, 131.6, 
131.6 (q, J=32.8Hz), 130.6, 130.5, 128.7, 128.6, 127.9, 125.7 (q, J=3.7Hz), 124.6 (q, 
J=272.4Hz), 118.3, 113.3, 37.0.  
MS (70 eV, EI), m/z (%) = 530 (M+, 6), 425 (37), 424 (49), 423 (100), 422 (81),  
267 (13), 123 (13), 114 (28), 108 (10), 43 (11). 
HRMS (EI), m/z calc. for C25H18ClF3N4O2S (530.0791): 530.0790. 
IR (ATR) υ (cm-1) = 3098, 3071, 2982, 2948, 2238, 1620, 1544, 1490, 1403, 1383, 1330, 
1315, 1294, 1240, 1200, 1172, 1161, 1136, 1122, 1106, 1091, 1078, 1068, 1022, 1008, 
977, 852, 838, 733, 696, 658. 
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Preparation of 4-(4-chlorophenyl)-2-((3,4-dichlorophenyl)thio)-N,N-dimethyl-5-(4-
(trifluoromethyl)phenyl)-imidazole-1-sulfonamide (76j) 
 
Prepared according to TP4 from 4-(4-chlorophenyl)-N,N-dimethyl-5-(4-(trifluoro-
methyl)phenyl)-imidazole-1-sulfonamide (73c, 109 mg, 0.25 mmol) and TMPMgCl·LiCl 
(62, 0.27 mL, 0.3 mmol, 1.1M in THF) at -78 °C in 1 h. Subsequently,  
S-(3,4-dichlorophenyl) benzenesulfonothioate (68n, 72 mg, 0.225 mmol) was added and 
the reaction mixture was allowed to slowly warm to 25 °C and continuously stirred over 
night. The reaction was quenched with sat. NH4Cl solution (10 mL) and extracted with 
EtOAc (3x10 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. The crude residue obtained was purified by flash column 
chromatography (silica, pentane:EtOAc 8.5:1.5) to give 76j as a white solid (96 mg,  
70 %). 
 
m.p.: 155.4-156.4 °C. 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.82 (d, J=1.9Hz, 1H), 7.73 (d, J=8.1Hz, 2H), 
7.49-7.57 (m, 4H), 7.09-7.14 (m, 2H), 7.02-7.08 (m, 2H), 2.64 (s, 6H). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 145.4, 139.1, 135.8, 133.7, 133.6, 133.6, 133.4, 
132.9, 132.5, 131.7 (q, J=32.6Hz), 130.8, 130.5, 129.9, 128.5, 128.2, 127.4, 125.5 (q, 
J=3.8Hz), 123.7 (q, J=272.9Hz), 37.5.  
MS (70 eV, EI), m/z (%) = 605 (M+, 23), 502 (22), 501 (51), 500 (54), 497 (100),  
466 (14), 465 (20), 464 (56), 463 (34), 462 (78), 461 (19), 440 (11), 439 (43), 191 (11), 
189 (15), 154 (11), 108 (10), 43 (10). 
HRMS (EI), m/z calc. for C24H17Cl3F3N3O2S2 (604.9780): 604.9767. 
IR (ATR) υ (cm-1) = 3099, 3068, 2986, 2927, 2859, 1487, 1452, 1421, 1394, 1363, 1330, 
1283, 1244, 1225, 1185, 1173, 1161, 1124, 1106, 1091, 1080, 1067, 1035, 1014, 969, 
952, 858, 844, 832, 810, 725, 698, 676. 
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7.6 SELECTIVE N-3-ALKYLATION AND SUBSEQUEBT N-1 DEPROTECTION 
Preparation of 4-(4-(4-chlorophenyl)-1-methyl-5-(4-(trifluoromethyl)phenyl)-
imidazol-2-yl)benzonitrile (78a) 
 
The reaction was performed according to TP10 with 5-(4-chlorophenyl)-2-(4-
cyanophenyl)-N,N-dimethyl-4-(4-(trifluoromethyl)phenyl)-imidazole-1-sulfonamide 
(76e, 265 mg, 0.5 mmol), trimethyloxonium tetrafluoroborate (66, 74 mg, 0.5 mmol) and 
conc. HCl (2.5 mL). Flash column chromatographical purification on silica gel 
(pentane/EtOAc, 8:2) afforded 78a as a white solid (158 mg, 72%).  
 
m.p.: 204.4-207.3 °C. 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.88 (d, J=7.8Hz, 2H), 7.76 (dd, J=11.1Hz, 
8.1Hz, 4H), 7.51 (d, J=7.8Hz, 2H), 7.39 (d, J=7.8Hz, 2H), 7.20 (d, J=7.8Hz, 2H), 3.55 (s, 
3H). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 146.5, 138.3, 134.4, 133.8, 133.0, 132.4, 132.0, 
131.1 (q, J=32.9Hz), 131.0, 130.2, 129.3, 128.6, 128.3, 126.2 (q, J=3.7Hz), 123.8 (q, 
J=272.3Hz), 118.3, 112.6, 33.6.  
MS (70 eV, EI), m/z (%) = 437 (M+, 100), 436 (35), 421 (6), 401 (3), 267 (3), 190 (4),  
186 (3), 123 (3). 
HRMS (EI), m/z calc. for C24H15ClF3N3 (437.0907): 437.0902. 
IR (ATR) υ (cm-1) = 3097, 3072, 2956, 2925, 2872, 2856, 2226, 1730, 1608, 1513, 1486, 
1465, 1407, 1381, 1326, 1294, 1284, 1275, 1244, 1167, 1130, 1106, 1092, 1069, 1032, 
1018, 1010, 959, 848, 837, 825, 792, 739, 716, 705, 690, 652. 
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Preparation of 4-(5-(4-chlorophenyl)-1-methyl-4-(4-(trifluoromethyl)phenyl)-
imidazol-2-yl)benzonitrile (78b) 
 
The reaction was performed according to TP10 with 4-(4-chlorophenyl)-2-(4-
cyanophenyl)-N,N-dimethyl-5-(4-(trifluoromethyl)phenyl)-imidazole-1-sulfonamide (76i, 
265 mg, 0.5 mmol), trimethyloxonium tetrafluoroborate (66, 74 mg, 0.5 mmol) and conc. 
HCl (2.5 mL). Flash column chromatographical purification on silica gel 
(pentane/EtOAc, 8:2) afforded 78b as a white solid (162 mg, 72%).  
 
m.p.: 176.1-178.0 °C. 
1H NMR (600 MHz, CDCl3) = 7.88 (d, J=8.5Hz, 2H), 7.74-7.82 (m, 2H), 7.60 (d, 
J=8.0Hz, 2H), 7.42-7.53 (m, 4H), 7.29-7.38 (m, 2H), 3.54 (s, 3H). 
13C NMR (150 MHz, CDCl3) δ (ppm) = 146.3, 137.5, 137.2, 135.7, 134.5, 132.5, 132.0, 
131.4, 129.8, 129.3, 128.7 (q, J=32.3Hz), 128.4, 126.9, 125.2 (q, J=3.9Hz), 123.3 (q, 
J=271.8Hz), 118.4, 112.6, 33.4. 
MS (70 eV, EI), m/z (%) = 437 (M+, 100), 436 (36), 425 (5), 424 (5), 423 (16), 422 (5),  
421 (7), 267 (5), 190 (6). 
HRMS (EI), m/z calc. for C24H15ClF3N3 (437.0907): 437.0903. 
IR (ATR) υ (cm-1) = 3067, 2959, 2928, 2871, 2228, 1739, 1608, 1515, 1484, 1412, 1378, 
1321, 1246, 1162, 1132, 1108, 1090, 1064, 1035, 1014, 960, 852, 837, 737, 716, 699, 
676. 
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Preparation of 4-(4-chlorophenyl)-2-((3,4-dichlorophenyl)thio)-1-methyl-5-(4-
(trifluoro-methyl)phenyl)- imidazole (78c) 
 
The reaction was performed according to TP10 with 5-(4-chlorophenyl)-2-((3,4-
dichloro-phenyl)thio)-N,N-dimethyl-4-(4-(trifluoromethyl)phenyl)-imidazole-1-sulfon-
amide (76g, 303 mg, 0.5 mmol), trimethyloxonium tetrafluoroborate (66, 74 mg,  
0.5 mmol) and conc. HCl (2.5 mL). Flash column chromatographical purification on 
silica gel (pentane/EtOAc, 8.5:1.5) afforded 78c as a white solid (167 mg, 65%).  
 
m.p.: 158.4-160.9 °C. 
1H NMR (600 MHz, CDCl3) δ (ppm) = 7.73 (d, J=8.3Hz, 6H), 7.41-7.47 (m, 3H), 7.33-
7.39 (m, 3H), 7.18-7.22 (m, 2H), 7.15 (dd, J=8.5Hz, 2.1Hz, 1H), 3.48 (s, 3H). 
13C NMR (150 MHz, CDCl3) δ (ppm) = 139.3, 137.8, 134.0, 133.8, 133.5, 133.1, 131.6, 
131.5, 131.3 (q, J=32.8Hz), 131.1, 131.0, 130.9, 129.9, 128.6, 128.3, 127.7, 126.3 (q, 
J=3.7Hz), 124.6 (q, J=272.4Hz), 32.6.   
MS (70 eV, EI), m/z (%) = 512 (M+, 100), 511 (41), 479 (11), 295 (14), 246 (11), 186 
(29), 145 (10), 43 (32). 
HRMS (EI), m/z calc. for C23H14Cl3F3N2S (511.9895): 511.9890. 
IR (ATR) υ (cm-1) = 3080, 3060, 2925, 2852, 1738, 1617, 1569, 1513, 1484, 1458, 1406, 
1367, 1322, 1297, 1263, 1164, 1121, 1107, 1090, 1068, 1030, 1014, 960, 875, 851, 836, 
816, 807, 776, 735, 713, 692, 674. 
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Preparation of 5-(4-chlorophenyl)-2-((3,4-dichlorophenyl)thio)-1-methyl-4-(4-
(trifluoro-methyl)phenyl)-imidazole (78d) 
 
The reaction was performed according to TP10 with 4-(4-chlorophenyl)-2-((3,4-
dichlorophenyl)thio)-N,N-dimethyl-5-(4-(trifluoromethyl)phenyl)-imidazole-1-sulfon-
amide (76j, 303 mg, 0.5 mmol), trimethyloxonium tetrafluoroborate (66, 74 mg,  
0.5 mmol) and conc. HCl (2.5 mL). Flash column chromatographical purification on 
silica gel (pentane/EtOAc, 9.5:0.5) afforded 78d as a white solid (185 mg, 72%).  
 
m.p.: 168.3-169.6 °C. 
1H NMR (600 MHz, CDCl3) δ (ppm) = 7.58 (d, J=8.2Hz, 2H), 7.47 (d, J=8.5Hz, 4H), 
7.42 (d, J=2.2Hz, 1H), 7.36 (d, J=8.5Hz, 1H), 7.26 (d, J=8.5Hz, 2H), 7.14 (dd, J=8.2Hz, 
2.2Hz, 1H), 3.46 (s, 3H). 
13C NMR (150 MHz, CDCl3) δ (ppm) = 138.5, 137.6, 136.9, 135.8, 134.1, 133.4, 132.3, 
131.7, 131.4, 131.1, 129.8, 129.8, 128.8 (q, J=32.5Hz), 128.3, 127.6, 126.8, 125.2 (q, 
J=3.9Hz), 124.2 (q, J=271.8Hz), 32.4.  
MS (70 eV, EI), m/z (%) = 512 (M+, 98), 511 (51), 479 (12), 295 (13), 152 (29), 61 (11), 
45 (11), 44 (15), 43 (51). 
HRMS (EI), m/z calc. for C23H14Cl3F3N2S (511.9895): 511.9904. 
IR (ATR) υ (cm-1) = 3078, 3056, 2956, 2925, 2854, 1617, 1515, 1482, 1450, 1366, 1325, 
1305, 1246, 1166, 1134, 1112, 1104, 1093, 1066, 1032, 1015, 961, 881, 847, 835, 821, 
808, 753, 746, 700, 675. 
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1.  LIST OF ABBREVIATIONS 
 
Ac  acetyl 
Ad  adamanyl 
Alk  alkyl 
aq.  aqueous 
Ar  aryl  
ATR  attenuated total reflection (IR) 
9-BBN  9-borabicyclo[3.3.1]nonane 
Boc  tert-butyloxycarbonyl 
br  broad (NMR) 
Bu  butyl 
cal.  calculated 
Cbz  carboxybenzyl 
conc.  concentrated 
d  doublet (NMR) / day 
dba  trans,trans-dibenzylideneacetone 
dist.   distilled 
DCM  dichloromethane 
DMAP  4-(dimethylamino)pyridine 
DMF  N,N-dimethylformamide 
dppe  1,2-bis(diphenylphosphino)ethane 
dppf  1,1'-bis(diphenylphosphino)ferrocene 
dppp  1,2-bis(diphenylphosphino)propane 
equiv  equivalent 
E  electrophile 
EI  electron ionization 
Et  ethyl 
EWG  electron-withdrawing group 
FG  functional group 
GC  gas chromatography 
h  hour 
Hal  halogene 
Het  hetero 
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Hex  hexyl 
HRMS high resolution mass spectroscopy 
Hz Hertz 
iPr  iso-propyl 
IR  infrared 
isityl  2,4,6-triisopropylphenyl 
J  coupling constant (NMR) 
L  ligand 
LDA  lithium N,N-diisopropylamide 
M  mol/L 
m  meta 
Me  methyl 
min  minute  
mp.  melting point 
MS  mass spectroscopy 
MHz  Megahertz 
nBu  n-butyl 
nPr  n-propyl 
NBS  N-bromosuccinimide 
NCS  N-chlorosuccinimide 
Nf  nonaflate 
NHC  N-heterocyclic carbene 
NIS  N-iodosuccinimide 
NMR  nuclear magnetic resonance 
NMP  N-methylpyrrolidin-2-one 
NP  naphthalide 
o  ortho 
p  para 
PEPPSI-IPr [1,3-Bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-
chloropyridyl)palladium(II) dichloride 
PG protecting group 
Ph  phenyl 
Piv  pivalyl 
ppm  parts per million 
Py  pyridyl 
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R  organic substituent 
rpm  revolutions per minute 
sat.  saturated 
SEM  2-(Ttrimethylsilyl)ethoxymethyl 
SPhos  2-dicyclohexylphosphino-2’,6’-dimethoxybiphenyl 
tBu  tert-butyl 
T  temperature 
t  reaction time 
TBAF  tetra-n-butylammonium fluoride 
TBDMS tert-butyldimethylsilyl 
TLC  thin layer chromatography 
Tf  triflate 
THF  tetrahydrofuran 
TIPS  triisopropylsilyl 
TMP  2,2,6,6-tetramethylpiperidyl 
TMS  trimethylsilyl 
Tol  tolyl 
Ts  4-toluenesulfonyl 
TP  typical procedure 
 
 
  
